Final Program - American Society for Radiation Oncology

Transcription

Final Program
ASTRO 54th Annual Meeting
Meeting Dates: October 28-31, 2012 | Exhibit Dates: October 28-30, 2012
BOSTON CONVENTION AND EXHIBITION CENTER | BOSTON
Advancing Patient Care
through iNNOVATiON
ANNUAL MEE TING
S C I E N C E B A S E D, PAT I E N T D R I V E N
d
nloa bile –
w
o
D
Omo
ASTR cial
ffi
the o ng app. .
i
ils
t
mee 17 for deta
age
S ee p
HELD IN CONJUNCTION WITH:
AMERICAN SOCIETY OF RADIOLOGIC TECHNOLOGISTS (ASRT)
ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY (ARRO)
SOCIETY FOR RADIATION ONGOLOGY ADMINISTRATORS (SROA)
The power of two
O-MAR and iDose 4 off.
O-MAR and iDose 4 on.
Images courtesy of Az Ospedaliera University.
Brilliance CT Big Bore
O-MAR and iDose4
Just one glance at the images above tells
the story. Philips O-MAR reduces artifacts
caused by large orthopedic implants.
iDose4 improves image quality* through
artifact prevention and increased spatial
resolution. Together they produce high
image quality with reduced artifacts.
These two powerful technologies can
enhance many aspects of Radiation
Oncology and are now available on the
Brilliance CT Big Bore.
Images courtesy of Udine – Santa Maria Hospital Radioterapia.
To learn more, visit www.philips.com/astro.
*Improvedimagequalityisdefinedbyimprovementsinspatial
resolution and/or noise reduction as measured in phantom studies.
54th ANNUAL MEETING | MEETING DATES: OCTOBER 28-31, 2012 | EXHIBIT DATES: OCTOBER 28-30, 2012
BOSTON CONVENTION AND EXHIBITION CENTER | BOSTON
through iNNOVATiON
Final Program
d
–
nloa
Dow mobile
O
ASTR cial
ffi
the o ng app. .
ils
ti
mee 17 for deta
age
S ee p
ANNUAL MEE TING
HELD IN CONJUNCTION WITH:
AMERICAN SOCIETY OF RADIOLOGIC TECHNOLOGISTS (ASRT)
ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY (ARRO)
SOCIETY FOR RADIATION ONGOLOGY ADMINISTRATORS (SROA)
Welcome
TO THE 54TH ANNUAL MEETING OF
THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY
“Advancing Patient Care Through Innovation”
Dear Colleagues,
It is my pleasure to welcome you to ASTRO’s 54th Annual Meeting,
the premier forum for advancing the discipline of radiation oncology.
Leading radiation oncologists, radiation physicists, radiation biologists,
medical dosimetrists, radiation therapists and radiation oncology nurses
from around the world have come together to interact and share the
latest scientific research.
A highlight of this year’s meeting will be the exploration of the concept that innovation in
health care delivery systems will result in better care at a lower cost. The Presidential Symposium “Transforming Care Through Innovation” will kick off the meeting on Sunday morning. This
symposium brings together distinguished experts to discuss and explore a topic that is becoming
increasingly more important to clinicians and scientists alike.
The Annual Meeting Scientific and Education committees, under the leadership of Lynn D. Wilson,
MD, MPH, have organized an exceptional program. A record number of abstracts make up the
more than 48 scientific sessions and 1,700+ poster presentations – making it the largest
scientific program ever! This, combined with the educational program developed based on
practice gaps, will give attendees the opportunity to increase their knowledge, skills and
competence in a variety of learning formats.
The keynote addresses will feature Dr. Arthur Kellermann, Rand Health; Mr. Edward Kennedy Jr.,
Marwood Group; and Professor Michael Porter, Harvard Business School. (see pages 40-41 for full
details)
Please join me in recognizing the 2012 Gold Medalists, Honorary Member and ASTRO Fellows
during the Awards Ceremony on Tuesday beginning at 9:45 a.m. in the Grand Ballroom. We are all
the beneficiaries of their achievements, and welcome this occasion to express our appreciation
and gratitude.
Be sure to take time this week to visit the Exhibit Hall featuring more than 200 companies
showcasing the latest equipment and technology. Back this year, is the Industry-Expert Theater.
Located in the Exhibit Hall, the Industry-Expert Theater provides attendees with an opportunity to
enjoy a complimentary lunch while learning more about the featured exhibitors’ specific products.
I hope you enjoy the meeting, and all that the city of Boston has to offer with its arts, culture and
history.
Michael L. Steinberg, MD, FASTRO
President, ASTRO
Chairman, Annual Meeting Steering Committee
2
ASTRO 2012 / 54TH ANNUAL MEE TING
Table of Contents
WELCOME TO THE 54TH ANNUAL MEETING Board of Directors Continuing Medical Education Annual Meeting Committee Members Abstract Reviewers Gold Medal and Honorary Member Recipients Fellow Recipients
Awards
2
4
5
7
8
9
11
12
GENERAL INFORMATION 15
ASTROmobile
17
Concessions
19
Industry-Expert Theater
20
Industry Satellite Symposia21
Shuttle Service24
Boston Convention and Exhibition Center Floor Plans
27
SCHEDULE OF EVENTS eContouring Learning Lab
33
Live Self-Assessment Modules (SAMS)
34
Presidential Symposium
36
ARRO Program
38
Meeting Highlights40
Nurses’ Program42
Schedule by Day
Saturday 43
Sunday 45
Monday 56
Tuesday 68
Wednesday 86
POSTER PRESENTATIONS 107
INDEXES By Author 169
By Topic 179
EXHIBITOR LISTINGS
Exhibitor List
191
Exhibitor List by Product/Service Category
199
Exhibit Hall Floor Plan
203
3
Board of Directors
Leonard L. Gunderson, MD, MS, FASTRO
Chairman
Michael L. Steinberg, MD, FASTRO
President
Colleen A. Lawton, MD, FASTRO
President-elect
Phillip M. Devlin, MD
Secretary/Treasurer
Anthony L. Zietman, MD, FASTRO
Immediate Past Chairman
Bruce G. Haffty, MD, FASTRO
Education Council Chairman
Laura A. Dawson, MD
Education Council Vice-chairman
C. Leland Rogers, MD
Government Relations Council Chairman
Bharat B. Mittal, MD, FASTRO
Government Relations Council Vice-chairman
Najeeb Mohideen, MD
Health Policy Council Chairman
Brian Kavanagh, MD
Health Policy Council Vice-chairman
Jacqueline P. Williams, PhD, FASTRO
Research Council Chairman
Mary K. Martel, PhD, FASTRO
Research Council Vice-chairman
Laura I. Thevenot, CAE
Chief Executive Officer
4
Continuing Medical Education
NEEDS STATEMENT
Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO),
cancer deaths worldwide are projected to continue
to rise to more than 11 million in 2030. Nearly twothirds of these patients will receive radiation therapy
during their illness – most with the intent to cure the
cancer. Advances in the applications, technologies
and methodologies of radiation oncology continue
to evolve rapidly and the delivery of radiation therapy
has become more complex, making it imperative that
the radiation oncology professional remain current in
the state-of-the-art techniques. The American Society
for Radiation Oncology is committed to providing
educational programming that creates a forum for
global collaboration on issues in radiation oncology
to improve professional practice by increasing their
level of knowledge, as required to improve competency in the field of oncology.
PROGRAM DESCRIPTION AND OBJECTIVES
ASTRO’S Annual Meeting is the premier radiation
oncology scientific event in the world and draws more
than 11,000 attendees each year. During the 2012
Annual Meeting, we will look at how innovation is fast
becoming society’s response to our impending health
care crisis. The effectors of change see innovation – not
only technological innovations but also innovations in
how care is delivered to improve outcomes and drive
down cost – as the solution.
The scientific program will continue to be the
ideal platform to bring together clinicians, scientists
and researchers from all of the oncologic disciplines
to exchange ideas, promote multidisciplinary care
and address the educational and professional
development interests of our attendees. Scientific and
educational sessions will cover specific clinical areas
including breast, central nervous system, gastrointestinal, genitourinary, gynecological, head and
neck, lymphoma, musculoskeletal, pediatric, sarcoma
and thoracic cancers. Radiation biology and radiation
physics concepts will also be explored.
The Annual Meeting will feature a continued
emphasis on quality and safety issues in the delivery
of radiation therapy in the areas of treatment techniques, equipment, terminology and professional responsibilities. Program content has been designed
to address specific documented and clinically
important practice gaps in physician knowledge and
competence.
ELEMENTS OF COMPETENCE
The Annual Meeting program has been designed to
narrow the competency gaps of patient/patientcentered care, medical knowledge, cognitive expertise,
evidence-based practice, evaluation of performance
in practice, interpersonal skills and communication,
practice-based learning and improvement, utilization
of informatics, work in interdisciplinary teams, quality
improvement, professional standing and commitment
to lifelong learning, thirteen of the fifteen core competencies embraced by the American Board of Medical
Specialties, Accreditation Council for Graduate Medical
Education and the Institute of Medicine.
TARGET AUDIENCE
The Annual Meeting program is intended for all
health professionals in the field of oncology, with
particular emphasis on radiation oncologists, radiation oncology residents, radiation biologists, radiation
physicists, medical dosimetrists, radiation therapists
and radiation oncology nurses.
CONTINUING MEDICAL EDUCATION
PHYSICIANS
The American Society for Radiation Oncology is
accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical
education for physicians.
CREDIT DESIGNATION
ASTRO designated this live activity for a maximum of
33.75 AMA PRA Category 1 Credits™. Physicians should
claim only the credit commensurate with the extent
of their participation in the activity.
PHYSICISTS
CAMPEP approval is pending for medical physics
continuing education credit (MPCEC) hours.
DOSIMETRISTS
An application has been submitted to the Medical
Dosimetrist Certification Board for designation of
MDCB credit.
NURSES
This activity has been submitted to the Oncology
Nursing Society (ONS) for approval to award contact
hours. ONS is accredited as an approver of continuing nursing education by the American
Nurses Credentialing Center’s Commission on
Accreditation.
5
PROGRAM EVALUATION PROCESS AND
CONTINUING EDUCATION CREDITS
You must be a full-conference or one-day only
registrant to receive continuing education credit.
To receive continuing education credits, you
must submit an evaluation indicating the sessions
that you attended no later than 30 days post meeting.
All attendees will have the opportunity to complete
the evaluation online at the meeting or in the comfort
of your home or office once you return. When the
evaluation has been completed, you will be able to
print your certificate or email it to yourself for your
records.
Keep track of the sessions you attended
throughout the meeting to save time in the evaluation process. For questions regarding
continuing education credits, please visit CE
Central located in the North Lobby at the Boston
Convention and Exhibition Center.
Visit CE Central or the Cyber Café to complete
your online evaluation form and obtain your
certificate. CE Central is located in the North Lobby
and the Cyber Café is located in the Exhibit Hall. You
will need your badge number to complete the
evaluation form. Please write your badge number
here for future reference.
ASTRO is an accredited provider of continuing medical education. Since our accreditation is important to us, we plan activities that are compliant with the ACCME and the content or
format of CME activities and related materials will
promote improvements or quality in health care
and not a specific proprietary business interest or
commercial bias. Planning Committee members
and speakers are required to disclose the existence
of any financial or other relationship with the
manufacturer(s) of any commercial product(s) or
provider(s) of any commercial services discussed in
an educational presentation.
Any conflicts of interest are resolved prior
to participation. In addition to written disclosure,
presenters will disclose any vested interest
or their intention to discuss off‐label use of pharmaceuticals or devices, if applicable, to the
audience at the beginning of their presentation and in accordance with the Accreditation Council
for Continuing Medical Education standards and the
Food and Drug Administration requirements.
In an effort to increase transparency and
easy access to all disclosures, ASTRO’s Faculty,
Committee and Planner disclosure information will
be available online for the 2012 Annual Meeting. Go
to the ASTRO Annual Meeting Program Web page
https://www.astro.org/Meetings-and-Events/
2012-Annual-Meeting/Meeting-Program/Index.
aspx. In addition, disclosure slides will be shown at
the beginning of each session and every presenter is
also required to display their disclosure. Disclosure
information will not be printed in paper versions of
the meeting materials.
DISCLAIMER
Ann Smith, MD
ASTRO
Fairfax, VA
ASTRO is committed to the free exchange of medical education. Inclusion of any presentation in
this program, including presentations of off-label
uses, does not imply an endorsement by ASTRO of
the uses, products or techniques presented.
123456
Your badge number
6
DISCLOSURE OF VESTED INTEREST
The information contained in this program is
current as of September 21, 2012, and is subject to
change. Program changes will be provided in an
addendum and posted online.
2012 Committee Members
2011-2012 Annual Meeting Steering Committee
Michael L. Steinberg, MD, FASTRO, Chairman
Colleen A. Lawton, MD, FASTRO, Vice-chairman
Lynn D. Wilson, MD, MPH, FASTRO, Chairman, Scientific Committee
Benjamin Movsas, MD, Vice-chairman, Scientific Committee
Andrea Ng, MD, Chairman, Education Committee
Catherine C. Park, MD, Vice- chairman, Education Committee
Lynn D. Wilson, MD, MPH, FASTRO
2011-2012 Annual Meeting Scientific Committee
Lynn Wilson, MD, MPH, FASTRO,
Chairman
Benjamin Movsas, MD,
Vice-chairman
May Abdel-Wahab, MD, PhD
Ross A. Abrams, MD, FASTRO
Sanjeev Aggarwal, MD
Kevin A. Camphausen, MD
Eric Lin Chang, MD
Indrin Julian Chetty, PhD
Louis S. Constine, MD, FASTRO
Prajnan Das, MD, MPH
Theodore L. DeWeese, MD
Susan Higgins, MD
W. Robert Lee, MD
Alexander Lin, MD
Nina A. Mayr, MD, FASTRO
Radhe Mohan, PhD, FASTRO
Arnold C. Paulino, MD
Timothy D. Solberg, PhD
Mohan Suntharalingam, MD
Katherine S. Tzou, MD
Julia Compton, MD
Stephanie E. Weiss, MD
Christopher G. Willett, MD, FASTRO
Theodore E. Yaeger, MD
Gary Yang, MD
2011-2012 Annual Meeting Education Committee
Andrea K. Ng, MD, MPH,
Chairman
Catherine C. Park, MD,
Vice-chairman
A. William Blackstock, MD,
Immediate Past Chairman
Mansoor M. Ahmed, PhD
Changhu Chen, MD
Brian Czito, MD
Vinai Gondi, MD
Sharad Goyal, MD
Kun (Kim) Huang, MD
Krystyna D. Kiel, MD
Joshua D. Lawson, MD
W. Robert Lee, MD, MEd
Brian Marples, PhD
Loren K. Mell, MD
Joanne M. Moar, RN, OCN
Arno J. Mundt III, MD
Christopher F. Njeh, PhD
Catherine C. Park, MD
Baldev Patyal, PhD
Narayan Sahoo, PhD
Roy B. Tishler, MD, PhD
Akila N. Viswanathan, MD, MPH
Andrew Z. Wang, MD
George D. Wilson, PhD
Suzanne L. Wolden, MD
Min Yao, MD
7
2012 Abstract Reviewers
Thank You
May Abdel-Wahab
Ross Abrams *
Sanjeev Aggarwal *
Peter Ahn
Kevin Albuquerque
Kaled Alektiar *
Berthe Aleman
Brian Alexander
Michelle Alonso-Basanta
Jonathan Ashman
Elizabeth Baldini
James Balter
Christopher Barker
Glenn Stuart Bauman
Beth Beadle
Justin Bekelman
Stanley Benedict
Ranjit Bindra
Slawomir Blamek
Jeffrey Bogart
James Bonner
Kristy Brock
Stephen Brown
Mark Buyyounouski
Kevin Camphausen *
David J. Carlson
Jimmy Caudell
A. Bapsi Chakravarthy
Arnab Chakravarti
Annie Chan
Bryan Chang
Daniel Chang
Joe Y. Chang
Samuel T. Chao
Allen Chen
Changhu Chen
Ronald Chen
Bhisham Chera
Indrin Chetty
Steven Chmura
Hak Choy
Richard Chung
Jay Ciezki
Deborah Citrin
John Coen
C Norman Coleman
Louis S. Constine *
Joseph Contessa
Bouthaina Dabaja
Shari Damast
Laura Dawson
Jennifer De Los Santos
Joseph Deasy
Roy Decker
Andre Dekker
Thomas Delaney
John DeMarco
Robert Den
Jun Deng
Theodore DeWeese
Adam Dicker *
Thomas Dilling
Corinne Doll
Lei Dong
Jason Efstathiou *
Hans Eich
John Einck
Issam El Naqa
Mohamed Elshaikh
Ronald Ennis
Steven Feigenberg
Felix Feng
Robert Foote
Eric Ford
Benedick Fraass
Gary Freedman *
Martin Fuss
David Gaffney
Adam Garden
Laurie Gaspar *
David Gius
Elizabeth Gore
Alexander Gottschalk
Edward Graves
Michael Haddock
Karl Haglund
Paul Harari
Mark Henderson
Christopher Herbert
Joseph Herman
Gilda Hillman
Alice Y. Ho
David Hodgson
Sarah Hoffe
Karen Hoffman
Brad Hoppe
Peter Hoskin
David Howell
Dimitre Hristov
I-Chow Hsu
Geoffrey Hugo
Arthur Hung
Tim Illidge
Salma Jabbour
David Jaffray *
Nora Janjan
Ryan Jensen
Steve Jiang
William Jones III
Mitchell Kamrava
Paul Keall *
Paul J. Kelly
Youlia Kirova
Eric Klein
Ann Klopp
Wui-Jin Koh
Marisa Kollmeier
Kevin Kozak
Jon Kruse
Greg Kubicek
Charles Kunos
Patrick Kupelian *
Nadia Laack
to the 2012 Abstract Reviewers
Katja Langen
Joshua Lawson
Quynh Le
Andrew Lee
Peter Levendag
Stanley Liauw
Alexander Lin *
Arthur Liu
Fei-Fei Liu
Billy Loo
Daniel Low
Andrew Lowy
Join Luh
Stephen Lutz *
C-M Charlie Ma
Shannon MacDonald
Mitchell Machtay
Gikas Mageras
Anand Mahadevan
Sheida Mani
Rufus Mark
Mary K. Martel
Nina Mayr *
Susie McCloskey
Vivek Mehta
Loren Mell
Moyed Miften
Michael Milano
Drew Moghanaki
Radhe Mohan
Jean Moran
Benjamin Movsas *
Sasa Mutic
Ashwatha Narayana
Paul Nguyen
Mark Oldham
Kenneth Olivier
Jatinder Palta
Catherine Park
Upendra Parvathaneni
Abhijit Patel
Shilpen Patel
Arnold Paulino *
Todd Pawlicki
Mark Phillips
Jean-Philippe Pignol
Alan Pollack
Lorraine Portelance
Louis Potters
Jean Pouliot
Robert Prosnitz
Rachel Rabinovitch
Abram Recht
Ramesh Rengan
Mark Rivard
Kenneth Roberts
Cliff G. Robinson
Ken Rosenzweig
Mihaela Rosu
Christian Rübe
Samuel Ryu
Amit Sawant
David Sebag-Montefiore
Suresh Senan
Jan Seuntjens
Michael Sharpe
Xinglei Shen
Ke Sheng
David Sher
Helen Shih
Tim Showalter
Farzan Siddiqui
Nicole Simone
Ben Slotman
William Small Jr.
Ben Smith *
Timothy Solberg
William Song
Jan-Jakob Sonke
Lena Specht
Baldassarre Stea
Jonathan Strauss
Mohan Suntharalingam *
Alphonse Taghian
Michael Tee
Stephanie Terezakis
Charles Thomas
Wade Thorstad
Robert Timmerman
Roy Tishler
Wolfgang Tome
Phuoc Tran
Prabhakar Tripuraneni *
Alexei Trofimov
Andrew Vassil
Greg Videtic
Akila Viswanathan
Zeljko Vujaskovic
Eleanor Walker
Andrew Wang
Joanne Weidhaas
Stephanie Weiss
Maria Werner-Wasik
Julia White
Karen Winkfield
Aaron Wolfson
Gayle Woloschak
Rebecca Wong
John Wong
Ping Xia
Ying Xiao
Lei Xing
Di Yan
Fang-Fang Yin
Torunn Yock
Sue Yom
James Yu
(Weining) Ken Zhen
Key
* Track Chairman
Gold Medal Recipients
The Gold Medal is ASTRO’s highest honor bestowed
on revered members who have made outstanding
contributions to the field of radiation oncology.
2012 GOLD MEDALISTS
J. ROBERT CASSADY, MD, FASTRO
Dr. Cassady recently retired from his position as
professor and chairman of the department of
radiation oncology at the Lahey Clinic in Burlington,
Mass. An esteemed educator and clinician, his
service spans over four decades and has had a major
influence in the fields of pediatric oncology, prostate
cancer and hyperthermia.
GEORGE T.Y. CHEN, PHD, FASTRO
Dr. Chen is a medical physicist at the Massachusetts
General Hospital, where he served as head of the
radiation physics division from 1999-2008. A former
member of the ASTRO Board of Directors, he is
recognized for his work in multimodality image
registration.
MARK W. DEWHIRST, DVM, PHD, FASTRO
Dr. Dewhirst serves as the Gustavo S. Montana professor
in the department of radiation oncology at Duke
University in Durham, N.C., with joint appointments in
pathology and biomedical engineering. A veterinary
clinician and former member of the ASTRO Board of
Directors, he is recognized for his contributions to the
research of hypoxia, angiogenesis and the development
of heat activated drug delivery using liposomes.
9
Honorary Member Recipient
Honorary Membership is awarded annually to a distinguished cancer
researcher or leader in a discipline other than radiation oncology, radiation
physics or radiobiology.
2012 HONORARY MEMBER
MARK P. CAROL, MD
Dr. Carol is a neurosurgeon with more than 30 years of experience
in the medical device and health care services arenas and is widely
viewed as the “father of IMRT” and a pioneer in radiation oncology.
His work with IMRT and IGRT has advanced the specialty and role of
radiation oncology in the treatment of cancer and allied diseases.
10
Fellow Recipients
PLEASE JOIN US IN CONGRATULATING THE 2012 FELLOWS:
Thomas A. Buchholz, MD
The University of Texas, MD Anderson
Cancer Center
Beth Erickson, MD
Medical College of Wisconsin
Francine Halberg, MD
Marin Cancer Institute
A. Robert Kagan, MD
Southern California Kaiser Permanente
Medical Group
Maria D. Kelly, MB, BCh
Veterans Healthcare Administration
Eric E. Klein, PhD
Washington University, St. Louis
Benjamin Movsas, MD
Henry Ford Health System
Arno J. Mundt III, MD
University of California, San Diego
Subir Nag, MD
Kaiser Permanente
Jatinder R. Palta, PhD
University of Florida
Timothy Whelan, BM, BCH
McMaster University and Juravinski
Cancer Center
Joachim Yahalom, MD
Memorial Sloan-Kettering Cancer Center
11
Awards
2012 ASTRO ANNUAL MEETING AWARD RECIPIENTS
RESIDENT CLINICAL/BASIC SCIENCE
RESEARCH AWARD
Richard L. Bakst, MD (Radiation and Cancer Biology)
Tracy S. Bray, MD (Radiation Physics)
Nitin Ohri, MD (Clinical)
BASIC SCIENCE ABSTRACT AWARD
Radiation Physics
Catherine Coolens, PhD, CIPEM
Yuan Yuan Ge, PhD
Yu Kuang, PhD
Radiation and Cancer Biology
RESIDENT DIGITAL POSTER RECOGNITION
AWARD
Mohamed Abazeed, MD, PhD (Radiation and Cancer Biology)
Nathan Becker, PhD (Radiation Physics)
Maha Jawad, MD (Clinical)
RESIDENT POSTER VIEWING RECOGNITION
AWARD
Clinical
Charles R. Woods, MD (1st place)
Jason Sun, MD (2nd place)
Jessica Wobb, MD (3rd place)
Radiation and Cancer Biology
Joshua Dilworth, MD, PhD (1st place)
Yuya Yoshimoto, MD, PhD (2nd place)
Ikuno Nishibuchi, MD (3rd place)
Radiation Physics
Gaurav Marwaha, MD (1st place)
Daniel Habermehl, MD (2nd place)
Georges Hobeika, MD (3rd place)
Kazi Ahmed, PhD
Tina Dasgupta, MD, PhD
Felix Y. Feng, MD
Eddy S. Yang MD, PhD
ANNUAL MEETING SCIENTIFIC ABSTRACT
TRAVEL AWARD
Bryan G. Allen, MD, PhD
Natalie Ausborn, BS
Nataniel Lester-Coll, MD
Pierre Graff, MD, PhD, MS
Chaitanya G. Joshi
Zachary Kohutek, MD, PhD
Kiran Kumar, BS
Bowen Meng
Takahiro Oike
Gabriele Reinartz, MD
Philipp Seidel, MS
Kumara Swamy, MD
Robert B. Taylor, MD, PhD
Sean Vance, MS
Joanna Yang
International – U.S. Annual Meeting Scientific
Abstract Award
Songbing Qin, MD
Nurse Excellence Award
Michelle Wallace, RN, BSN
Annual Meeting Nurse Abstract Award
Laura L. Ochoa, PhD, RN
12
INSIDE:
General Information and Highlights
ASTROmobile – Official Meeting App
Shuttle Bus Schedule/Routes
Boston Convention and Exhibition Center
Floor Plans
You need accuracy when integrating molecular
imaging with radiation therapy. That’s what
you get with the GEMINI TF Big Bore.
When using functional and biological information to plan or adapt radiation treatment,
accuracy is vital. The GEMINI TF Big Bore PET/CT helps you keep patient positioning
consistent, to improve the precision of radiation therapy. It allows you to streamline
your workf low and offers the potential for more accurate tumor delineation
and evaluation of treatment response, because it’s
designed speciﬁcally to meet your needs. To learn more,
visit www.philips.com/geminitfbigbore.
General Information
BOSTON CONVENTION AND EXHIBITION
CENTER
415 Summer Street
Boston, MA 02210
617-954-2000
www.advantageboston.com/bcec
All activities take place at Boston Convention and
Exhibition Center unless specifically stated otherwise. All information is as current as of
September 21, 2012, and is subject to change.
ATTENDEE REGISTRATION
North Lobby, Level 1
Attendee registration counters will be located in
the North Lobby of the Boston Convention and
Exhibition Center.
ATTENDEE REGISTRATION HOURS
Saturday, October 27
Sunday, October 28
Monday, October 29
Tuesday, October 30
Wednesday, October 31
7:00 a.m. - 5:00 p.m.
6:30 a.m. - 5:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 2:00 p.m.
EXHIBITOR REGISTRATION
East Registration Lobby, Exhibit Level
Exhibitor registration counters will be located in the
East Registration Lobby on the Exhibit Level of the
Boston Convention and Exhibition Center.
EXHIBITOR REGISTRATION HOURS
Thursday, October 25
Friday, October 26
Sunday, October 28
Monday, October 29
Tuesday, October 30
8:00 a.m. - 5:00 p.m.
8:00 a.m. - 5:00 p.m.
7:00 a.m. - 5:00 p.m.
7:00 a.m. - 5:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 5:00 p.m.
AFFILIATED MEETINGS
36th ASRT RADIATION THERAPY CONFERENCE
October 28-30, 2012
Boston Marriott Copley Place
The 36th Annual ASRT Radiation Therapy Conference will take place at the Boston Marriott Copley Place. ASTRO registered attendees may attend ASRT sessions by paying a
reduced registration fee of $150. Proof of
registration (registration confirmation or badge)
is required to receive this reduced rate. If you
have not registered to attend the ASRT
conference but would like to do so, please
register on-site at the 4th Floor Registration
Desk.
29TH SROA ANNUAL MEETING
October 28-31, 2012
Hyatt Regency Cambridge
The 29th SROA Annual Meeting will take place
at the Hyatt Regency Cambridge. ASTRO
registered attendees may attend the SROA
general sessions by paying a reduced registration fee of $210. Proof of registration
(registration confirmation or badge) is required
to receive this reduced rate. If you have not
registered to attend the SROA conference but
would like to do so, please register on-site at the
Courtyard Reception Area.
15
ASTRO CAREER FAIR
ASTRO RESOURCE CENTER
Room 104 A-B, Level 1
Take advantage of the ASTRO Career Fair to connect
with candidates for employment. Equipped with
computers and printers for your convenience, the
Career Fair is available for employers to conduct
interviews with job applicants. Employers and
applicants must register through the online ASTRO
Radiation Oncology Career Center matching service
in order to schedule interviews in the on-site Career
Fair.
Booth 8043, Exhibit Hall
Visit the ASTRO Resource Center in the Exhibit Hall
to find out about products and services available to
ASTRO members. Not a member? Stop by and learn
about the benefits of membership. The Resource
Center is your one-stop shop to hear about the new
member benefits ASTRO is offering its members, as
well as learn about its initiatives for the coming year,
including the new PRQIwizard and a new error reporting system. Stop by and pick up updated patient brochures and join the new ASTRO private community –
ROhub. ASTRO’s knowledgeable staff will be on hand
to answer your questions about your membership.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
12:00 p.m. - 6:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 6:00 p.m.
Private interview rooms are also available. These
rooms are ideal if you have multiple interviews to
conduct, or just need more privacy. A limited number
of meeting rooms will be available to rent for
three-hour periods Saturday, October 27 through
Tuesday, October 30. For more information,
contact Todd Karstaedt at toddk@astro.org.
ASTRO PAC LOUNGE
Room 105, Level 1
ASTRO’s political action committee (ASTRO PAC)
is offering access to an exclusive lounge for all
ASTRO members who have donated to the ASTRO
PAC in 2012. The PAC lounge will feature Internet
access, coffee and beverages, food and a place to
rest between sessions. Donors will be automatically
entered into a raffle, including the opportunity to
win a new iPad and other great prizes. Members
who have not made their contribution will be able to
donate on-site. ASTRO PAC provides ASTRO with the
opportunity to more fully participate in government
and ensure our members’ voices are being heard
by key policy makers on Capitol Hill. Be sure to stop
by the lounge to get the most recent legislative and
election updates. For more information, please
email shandih@astro.org or visit
www.astro.org/astropac.
Hours of Operation:
Sunday, October 28
10:00 a.m. - 5:00 p.m.
Monday, October 29
10:00 a.m. - 5:30 p.m. Happy Hour 2012 Election Preview 4:30 p.m. - 5:30 p.m.
Tuesday, October 30
10:00 a.m. - 3:00 p.m.
16
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30 10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
BOSTON INFORMATION
North Lobby , Level 1
Attendees can stop by the Boston Information Desk
located in the North Lobby at the Boston Convention
and Exhibition Center to receive restaurant recommendations and make reservations, receive Boston
visitor guides, maps, destination information and
local directions.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
9:00 a.m. - 5:00 p.m.
9:00 a.m. - 5:30 p.m.
9:00 a.m. - 5:30 p.m.
9:00 a.m. - 5:30 p.m.
9:00 a.m. - 2:00 p.m.
BUSINESS CENTER
Located off of the North Lobby, Level 1
A FedEx Office and Print and Ship Center is conveniently located off of the North Lobby on Level 1 of
the Boston Convention and Exhibition Center. The
business center offers a variety of services including
packing and shipping, sign production, copying and
office supplies. For more information, please contact
FedEx directly at 617-954-2203.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
8:00 a.m. - 5:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 7:00 p.m.
8:00 a.m. - 5:00 p.m.
ASTROmobile Your Annual Meeting Guide
ASTROmobile gives you access to the
meeting program and the ability to
customize your meeting experience
with personalized maps and planners.
• Search engines for sessions by day, track or
speaker.
• Search engines for exhibitors by name,
booth number or product/service category.
• Session and exhibitor details with location maps.
• Search and view abstracts.
• General meeting information.
• Access your “My Plan” – your personal
Annual Meeting Schedule.
• Convention Center maps.
• Take notes during a session or about an
exhibitor and be able to access your notes from your mobile device.
ASTROmobile Login
An account has been created for all registered
attendees.
Please log in using the following login credentials:
User ID:
Badge Number
(found on front of your badge)
Password: Last Name
Start using ASTROmobile –
the official Annual Meeting app today!
iPhone Users
To access ASTROmobile using your
iPhone, simply download the
app, “ASTROmobile,”
from the Apple store.
Smart Phone Users
Go to www.astro.org/ASTROmobile
in your mobile Web browser to access
the 2012 ASTROmobile.
BUSINESS MEETING
Tuesday, October 30, 2012
12:00 p.m. - 1:15 p.m.
Room 210 A-C, Level 2
ASTRO voting members (Active, Affiliate, Allied or
International members) are invited to attend the
Business Meeting on Tuesday, October 30, from
12:00 p.m. - 1:15 p.m. Leaders of the Society will
present on important topics of interest to ASTRO
members. You should not miss this important
meeting. Lunch will be served.
CE CENTRAL
ASTRO and American Board of Radiology (ABR)
staff will be on hand to address specific attendee
questions about continuing education and MOC
requirements.
Are you current with your MOC requirements? ABR
staff at the booth can review your current status and
provide guidance on moving forward in your MOC
cycle.
Visit one of the CE Central access stations to
complete the continuing education and meeting
evaluations, print a session tracking form, search for
attendees using Find a Friend and search session,
abstract and exhibitor information with the Online
Conference Planner.
Attendees may also receive assistance with completing the online evaluation and can pick up details
on upcoming ASTRO events and details on ASTRO’s
online offerings that meet the requirements for MOC.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
1:00 p.m. - 5:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 6:00 p.m.
8:00 a.m. - 5:00 p.m.
CYBER CAFÉ
Booth 1055, Exhibit Hall
ASTRO attendees can browse the Internet and check,
retrieve and send email messages at the Cyber Café
in the Exhibit Hall.
Hours of Operation:
Sunday, October 28 Monday, October 29
Tuesday, October 30 18
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
ELECTRONIC BUSINESS CARD
Sponsored by ELEKTA
Included with your badge, you will receive an
electronic business card equipped with a magnetic
strip containing your contact information and other
demographic data. This card can be scanned in card
readers located in exhibitor booths throughout the
Exhibit Hall. Simply give your electronic business
card to the exhibitor and your contact information
will be recorded for follow-up by the exhibitor.
Note: Attendee email addresses will not be included in
the contact information given to exhibitors unless you
provided approval when registering.
EXHIBIT HALL
Halls A/B, Exhibit Level
Learn about the latest products in cancer treatment
and care in the Exhibit Hall.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30 10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
FACULTY/VIP OFFICE
Room 103, Level 1
Faculty members and VIPs should check in at the
Faculty/VIP Office, Room 103, to pick up registration
materials and receive last-minute updates and program changes. The Faculty/VIP Office is conveniently located next to the Speaker Ready
Room. Faculty and VIPs are welcome in the
Faculty/VIP Office throughout the meeting.
Faculty members include:
•
•
•
•
•
•
•
Educational Session lecturers.
Panel moderators and presenters.
Scientific program discussants.
eContouring Learning Lab presenters.
Presidential Symposium lecturers.
Keynote speakers and introducers.
Nursing program speakers.
Note: Presenters of abstracts are not classified as
faculty and should follow attendee registration instructions.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 5:00 p.m.
Concessions
WICKED GOOD MARKET FOOD COURT
STARBUCKS
Level 1, West Side
Food court that offers multiple restaurant options
with a wide variety of cuisines.
Westin Boston Waterfront Hotel, Lobby
Starbucks offers coffee, tea and other beverages as
well as pastries, sandwiches, salads and grab and go
items.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
11:00 a.m. - 3:00 p.m.
11:00 a.m. - 3:00 p.m.
11:00 a.m. - 3:00 p.m.
11:00 a.m. - 2:00 p.m.
OUTTAKES
Level 1, Off of North Lobby
Offers coffee, cold beverages, breakfast pastries and
grab and go salads and sandwiches.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
6:30 a.m. - 5:00 p.m.
7:00 a.m. - 5:00 p.m.
7:00 a.m. - 5:00 p.m.
7:00 a.m. - 4:00 p.m.
COFFEE KIOSK
Level 1, Off of North Lobby
Offers coffee, cold beverages and grab and go
snacks.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
7:00 a.m. - 3:00 p.m.
6:30 a.m. - 12:00 p.m.
7:00 a.m. - 12:00 p.m.
7:00 a.m. - 12:00 p.m.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
6:00 a.m. - 7:00 p.m.
6:00 a.m. - 7:00 p.m.
6:00 a.m. - 7:00 p.m.
6:00 a.m. - 7:00 p.m.
6:00 a.m. - 7:00 p.m.
SAUCIETY
Westin Boston Waterfront, Lobby
Sauciety is a modern American grill with a culinary
twist that builds off of high-quality regional cuisine,
and then focuses on a variety of unique and flavorful
sauces, spreads, dips and chutneys that the guest is
able to select from to customize each course of their
meal. Breakfast and lunch served daily.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
7:00 a.m. - 2:00 p.m.
7:00 a.m. - 2:00 p.m.
6:30 a.m. - 2:00 p.m.
6:30 a.m. - 2:00 p.m.
6:30 a.m. - 2:00 p.m.
EXHIBIT HALL FOOD COURTS
Halls A/B, Exhibit Hall
Two food court areas will be available in the Exhibit
Hall that will offer beverages, coffee and variety of
food options for breakfast and lunch. At this food
court, you will be able to redeem the $10 lunch
voucher you received with your registration
materials.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 4:00 p.m.
The concession schedule is subject to change.
19
FIRST AID
North Lobby First Aid Office, Level 1
First Aid is located in North Lobby at the Boston Convention and Exhibition Center.
The phone number is 617-954-2222, or dial ext. 2222 from a house phone.
In an emergency, please contact first aid or go to ASTRO Registration and have a
staff person contact security.
Hours of Operation:
Monday, October 22
Tuesday, October 23
Thursday, October 25
Friday, October 26
Sunday, October 28
Monday, October 29
Tuesday, October 30
Thursday, November 1
8:00 a.m. - 5:00 p.m.
8:00 a.m. - 5:00 p.m.
8:00 a.m. - 5:00 p.m.
8:00 a.m. - 5:00 p.m.
8:00 a.m. - 5:00 p.m.
7:00 a.m. - 6:00 p.m.
6:30 a.m. - 7:30 p.m.
7:00 a.m. - 7:30 p.m.
7:00 a.m. - 10:00 p.m.
7:00 a.m. - 8:00 p.m.
7:00 a.m. - 5:00 p.m.
INDUSTRY-EXPERT THEATER
Front of Hall A, Exhibit Hall
This activity allows companies to present their noteworthy products and
services through a live presentation in the Industry-Expert Theater located in the Exhibit Hall.
Seating is available on a first-come, first-served basis. A box lunch will be provided.
The Industry-Expert Theater content and views expressed therein are those of the exhibitor and not of ASTRO.
Sunday, October 28
Tuesday, October 30
Time: 12:45 p.m. - 1:45 p.m.
Time: 12:00 p.m. - 1:00 p.m.
Clinical Trial Update: Anchored Transponder in
Lung Cancer Patients
Goals and Objectives of the Trial, Current Status
and Future Potential
The Role of Zevalin in the Treatment of Lowgrade or Follicular Lymphoma
Presented by Varian Medical Systems
Contact: Shari Huffine
Phone: 650-424-5938
Monday, October 29
Time: 12:30 p.m. - 1:30 p.m.
Accuray Showcases Leading-edge Treatment
Solutions at ASTRO 2012 With New Clinical
Advancements in the Field of Radiosurgery
and Radiation Therapy
Presented by Accuray
Contact: sales@accuray.com
20
Presented by Spectrum Pharmaceuticals Inc.
Contact: Linda Azarbal
Phone: 949-743-9347
INDUSTRY SATELLITE SYMPOSIA
ASTRO has reviewed and approved these symposia as appropriate for presentation. These symposia
represent the content and views of the sponsors and are not part of the official ASTRO Annual Meeting.
Advances in Technology Clinical Forum
11:00 a.m. – 6:00 p.m.
Westin Boston Waterfront Hotel, Grand Ballroom
Accreditation: The Institute for Medical Education
is accredited by the Institute for Medical Quality/
California Medical Association (IMQ/CMA) to provide
continuing medical education for physicians. The
Institute for Medical Education takes responsibility
for the content, quality and scientific integrity of this
CME activity.
CME Credits: The Institute for Medical Education
designates this live activity for a maximum of 6 AMA
PRA Category 1 CreditsTM. Physicians should claim
only the credit commensurate with the extent of
their participation in the activity. MPCEC credits are
pending approval.
This activity is hosted by The Institute for Medical Education and is supported by an unrestricted
educational grant from Varian Medical Systems. To
register, visit www.regonline.com/2012CFBostonMA.
Prostate News Tonight
From Symptom Control to Survival: The Changing
Role of the Radiation Oncologist in the Management of mCRPC
Sunday, October 28
6:00 p.m. – 6:30 p.m. – Registration
6:30 p.m. – 8:00 p.m. –Prostate News Tonight
CME Dinner Symposium
Westin Copley Place, America Ballroom, 4th Floor
Accreditation: This live activity has been planned
and implemented in accordance with the essential
areas and policies of the Accreditation Council for
Continuing Medical Education through the joint
sponsorship of University of Hawaii at Hilo College of
Pharmacy and The Foundation for Men’s Health. The
University of Hawaii at Hilo College of Pharmacy is
accredited by the Hawaii Medical Association to provide continuing medical education for physicians.
CME Credits: The University of Hawaii Hilo College
of Pharmacy designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians
should claim only the credit commensurate with the
extent of their participation in the activity.
independent medical education grant from Bayer
HealthCare Pharmaceuticals. For more information,
visit www.FoundationforMensHealth.org. On-site
registration is available but space is limited; please
arrive by 6:00 p.m.
The Present and Future of Genomics in DCIS
Sunday, October 28
7:00 p.m. – 10:00 p.m.
Westin Boston Waterfront Hotel,
Commonwealth Ballroom
Accreditation: EXCEL Continuing Education is
accredited by the Accreditation Council for
Continuing Medical Education to provide
continuing medical education for physicians.
CME Credits: EXCEL Continuing Education designates this live activity for a maximum of 1 AMA PRA
Category 1 Credit™. Physicians should claim only
the credit commensurate with the extent of their
participation in the activity.
This live activity is supported by an educational
grant from Genomic Health. This activity is sponsored by EXCEL Continuing Education. To register, or
for more information, visit www.excelcme.com.
Advancing Patient Care Through Innovation:
The Role of Proton Therapy
Monday, October 29
6:00 p.m. – 7:30 p.m. with reception to follow
Institute of Contemporary Art
Accreditation: The University of Florida College of
Medicine is accredited by the Accreditation Council
for Continuing Medical Education to provide
continual medical education for physicians.
CME Credits: The University of Florida College of
Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians
should claim only the credit commensurate with the
extent of their participation in the activity.
This live activity is supported by an unrestricted
educational grant from IBA Particle Therapy. This
activity is hosted by The University of Florida
College of Medicine. Preregistration is REQUIRED to
attend. For more information and to register online,
please visit http://proton.cme.ufl.edu.
This program is jointly sponsored by the University of Hawaii at Hilo College of Pharmacy and The
Foundation for Men’s Health and supported by an
21
INFORMATION DESK
PARKING
Have a question? Stop by the Information Desk to
get your questions answered.
Both valet and self parking is available at the Boston
Convention and Exhibition Center. ASTRO does not validate for parking.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
Valet Parking
Valet parking is available at the Boston Convention
and Exhibition Center for $25 per day. From Summer
Street, turn onto East Side Drive and the valet area
will be immediately on your right.
7:00 a.m. - 5:00 p.m.
6:30 a.m. - 5:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 3:15 p.m.
LOST AND FOUND
To report a missing item, to check to see if an item
has been turned into security or to turn in a lost
item, please stop by the Information Desk located in
the North Lobby.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
7:00 a.m. - 5:00 p.m.
6:30 a.m. - 5:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 3:15 p.m.
LUNCH VOUCHER
Attendees will receive a lunch voucher valued at $10
that can be used at food outlets in the Exhibit Hall
only. This voucher was provided to all attendees
and exhibitors with their registration materials.
Duplicates will not be issued for lost vouchers.
LUGGAGE/COAT CHECK
Room 101, Level 1
Luggage and coat check will be available at the
Boston Convention and Exhibition Center for $3 per
item.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
22
6:30 a.m. - 6:00 p.m.
6:00 a.m. - 6:00 p.m.
7:00 a.m. - 7:00 p.m.
7:00 a.m. - 6:30 p.m.
7:00 a.m. - 5:30 p.m.
Self Parking
Self parking is available in the South parking lot at
the Boston Convention and Exhibition Center and
is $12 per day. From Summer Street, turn onto East
Side Drive and drive past the valet area. Continue
straight along the side of the Boston Convention
and Exhibition Center. At the end of the building,
make a right and go down the ramp. At the bottom
of the ramp, turn left and the entrance to the South
parking lot will be in front of you.
POSTER VIEWING
Hall C, Exhibit Hall
Poster Viewing Hours:
Sunday, October 28
Monday, October 29
Poster Reception
Tuesday, October 30
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 6:45 p.m.
5:30 p.m. - 6:45 p.m.
10:00 a.m. - 5:00 p.m.
Includes posters from the following categories:
•Breast
•Central Nervous System
•Gastrointestinal
•Genitourinary
•Gynecological
•Head and Neck
•Health Services Research
•History
•Informatics/Bioinformatics
•Lung
•Lymphoma/Hematologic Malignancies
•Nonmalignancies
•Palliative Care
•Pediatric Cancer
•Quality of Life
•Radiation and Cancer Biology
•Radiation Physics
•Sarcomas and Cutaneous Tumors
POSTER VIEWING SESSION AND
RECEPTION*
Monday, October 29
5:30 p.m. - 6:45 p.m.
Hall C, Exhibit Level
During this session, all poster presenters are asked
to stand by their poster to answer questions about
their research. New this year will be a presentation
area where the poster award winners will provide
highlights of their research and be available for
questions. The presentation schedule will be
available in the poster viewing area.
Each full-conference attendee, exhibitor and Monday one-day conference attendee will
receive one drink ticket that can be used for complimentary beverage at the Poster Viewing Session and Reception on Monday, October 29.
After your ticket has been redeemed, drinks will be available for purchase. You must be 21 years of age
to consume alcoholic beverages. Your drink ticket
will be included with your badge in your registration
materials.
PRESS ROOM
Abstract presenters are encouraged to bring press
releases promoting their presentation in Boston
to the Press Room. For more information or for assistance writing or distributing your release, please
contact ASTRO Media Relations at 1-800-962-7875
or press@astro.org, or visit the online press room at
www.astro.org.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
8:00 a.m. - 5:00 p.m.
7:00 a.m. - 4:00 p.m.
7:00 a.m. - 4:00 p.m.
7:00 a.m. - 12:00 p.m.
For Press Room guidelines, visit www.astro.org.
*This session is not accredited for continuing
medical education credits.
23
Shuttle Service
Complimentary shuttle service will be provided between the Boston Convention and Exhibition Center and
official ASTRO hotels. The shuttle drop-off and pick-up locations are on Level 1 on the east and west sides of
the Boston Convention and Exhibition Center. Please refer to signs in the convention center and your hotel
lobby for the most current information.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
7:00 a.m. - 6:00 p.m.*
6:30 a.m. - 7:00 p.m.*
6:30 a.m. - 7:30 p.m.*
6:30 a.m. - 7:15 p.m.*
6:30 a.m. - 6:00 p.m.*
*Indicates the last time shuttle buses depart the Boston Convention and Exhibition Center returning to official ASTRO hotels. The
last shuttle departs hotels approximately 45 minutes prior to this last time.
HOTELS AND BOARDING LOCATIONS
All travel times are approximate pending time of day, day of week and traffic conditions.
Route
1
2
3
4
5
6
Hotel
Boarding Location at Hotel
Hyatt Regency Boston Downtown
Curbside on Chauncey
Omni Parker House Hotel
NE corner of Tremont and Beacon
Hilton Boston Back Bay
At Sheraton Boston Hotel, on Dalton
Sheraton Boston Hotel
Curbside on Dalton
Boston Park Plaza
Curbside on Columbus
Courtyard by Marriott Boston Tremont
Curbside on Tremont
Doubletree Hotel Boston Downtown
At Courtyard by Marriott, on Tremont
W Boston
At Courtyard by Marriott, on Tremont
Boston Marriott Long Wharf
Curbside in front
InterContinental Boston
Curbside in front
Boston Marriott Copley Place
Curbside in front, on Huntington
Colonnade Hotel
At Boston Marriott Copley Place
Fairmont Copley Plaza
Westin Copley Place Boston
Embassy Suites Boston at Logan Airport
Curbside on Porter
Hilton Boston Logan Airport
Side of hotel
Hyatt Harborside
At Water Taxi Pickup
Approximate
one-way
travel time
Frequency
in minutes
17-22 minutes
Peak 10-15
Nonpeak 15-20
22-27 minutes
Peak 10-15
Nonpeak 15-20
17-22 minutes
Peak 10-15
Nonpeak 15-20
13-18 minutes
Peak 10-15
Nonpeak 15-20
22-27 minutes
Peak 10-15
Nonpeak 15-20
17-22 minutes
Peak 10-15
Nonpeak 15-20
Renaissance Boston Waterfront
Walk
Hotels
Seaport Hotel
Westin Boston Waterfront
24
No Shuttle Service
SMOKING
Boston Convention and Exhibition Center is a
nonsmoking facility.
SPEAKER READY ROOM
Faculty members and abstract presenters must
upload their PowerPoint presentation in advance
of their session in order to have it pre-loaded
onto the ASTRO conference network. To ensure presentations have been properly uploaded, faculty
members and abstract presenters are asked to
check in at the Speaker Ready Room to review the
information and make any last minute edits.
Presentations should be saved on a portable device
and brought to the Speaker Ready Room at least 24
hours in advance of presentation, or upon arrival at
the Boston Convention and Exhibition Center.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 6:00 p.m.
6:30 a.m. - 5:00 p.m.
Thank you to the groups who have so generously
donated to the 2012 Survivor Circle Passport
Program: (List as of September 21, 2012)
Pitts Little Corp
RC Billing
Landauer Medical Physics
TECHNOLOGY HELP DESK
Need help using ASTROmobile, the official app for
the Annual Meeting? Have questions about the
touch screen interactive wayfinder stations that
will help you navigate the convention center? Stop
by the Technology Help Desk located in the North
Lobby at the Boston Convention and Exhibition
Center to get your technology related questions
answered.
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
7:00 a.m. - 5:00 p.m.
6:30 a.m. - 5:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 6:00 p.m.
7:00 a.m. - 3:15 p.m.
SURVIVOR CIRCLE
ASTRO Resource Center - Booth 8043, Exhibit Hall
In 2003, ASTRO created the Survivor Circle as a
way to honor cancer survivors. Each year, ASTRO
partners with two local patient support organizations and features them at the Survivor Circle at the
Annual Meeting. It was our hope that by partnering
with local organizations in the cities that host our
meeting, we would be able to not only give back
to the cities we visit, but also help raise awareness of these important organizations among our
members.
Through generous donations from exhibitors and
attendees, ASTRO raises funds for the two organizations featured in the Survivor Circle. Since its inception, the Survivor Circle has raised nearly $200,000
for our partner organizations.
Stop by the Survivor Circle, located in booth 8043 to
learn more about the recipients of this year’s Survivor Circle Grant — Arms Around Arlington
Center for Cancer Support and Surviving and
Moving Forward: The SAMFund for Young Adult
Survivors of Cancer.
25
TRANSPORTATION
VIRTUAL POSTERS
Boston offers a number of convenient transportation options to help attendees easily get around
the city.
Hall C, Exhibit Hall
Computer terminals and seating are available to
view the virtual poster displays at your leisure. Correspond with presenters or forward a presentation to a colleague or your home office.
Airport
Boston Logan Airport is 12 miles from downtown Boston. Outbound scheduled buses,
shared ride and long distance vans, taxis and hotel
and rental car courtesy vans are located in the
arrival area of each terminal.
Taxi
On average, a one-way taxi ride from the airport
to downtown can range from $20 to $45. All areas
within a 12 mile radius of downtown Boston are
charged by meter. All fares departing Boston Logan
Airport are charged an additional fee of $2.25, plus
a $5.25 fee for harbor tunnel crossings. If you are
going to a hotel outside the 12 mile radius of
downtown Boston, there will be a flat rate charged.
Subway
Boston’s downtown transportation system, better
known as the “T,” connects all of Boston and its
suburbs by subway, standard rail, bus and commuter boat. The “T” connects the airport with the
convention centers and hotels, as well as point-topoint access anywhere in the city. The Silver Line
offers direct public transportation to the Boston
Convention and Exhibition Center from both
Boston Logan Airport and downtown Boston via
the Seaport World Trade Center.
VIRTUAL MEETING
All full-conference attendees receive the Virtual
Meeting with their registration at no additional
cost. With the Virtual Meeting, you can extend your
learning experience with access to the 2012 ASTRO
sessions long after the meeting is over. You will
receive streaming content that has been digitally
recorded live and published as audio synchronized
to the speaker presentations*. Approximately six
weeks after the meeting, full conference attendees
will receive an email with a link providing access to
the Virtual Meeting.
*Presentations are included in the Virtual Meeting as
approved per faculty.
26
Hours of Operation:
Sunday, October 28
Monday, October 29
Tuesday, October 30
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 6:45 p.m.
10:00 a.m. - 5:00 p.m.
WIRELESS INTERNET ACCESS
Complimentary wireless Internet access is provided
in all common areas and session rooms throughout the Boston Convention and Exhibition
Center. Attendees can bring their laptop to check
email, complete the evaluation or surf the Internet.
Laptops must have a Wi-Fi card to connect.

 Restrooms
EXHIBIT LEVEL
052
E Elevator
Escalator




ASTRO Sessions
Exhibitor
Registration


Floor Plans
27
161

160
E Elevator
159


E
E
Escalator


E
158
157
156
E
Skybridge
E


E
153

104
AB
101
Press Office
151
102
 Concessions
103
Room

Faculty/VIP
Office Speaker Ready

Career
Fair
eContouring
Learning Lab
154
105
T Public Transit


EXHIBIT HALL A/B
 Shuttle Bus


Food Court

PAC
Lounge
E
Main Entrance to Exhibit Hall

 Restrooms
107
POSTERS HALL C
108


Skybridge
28
ASTRO Sessions
ASTRO Offices
First Aid
Technology Desk


 Information and


CE Central
Business Center
Coat Check
ASTRO Attendee
Registration
MEETING LEVEL 1
109

Poster Entrance
Floor Plans
CATWALK
M255
FS PANTRY 131
Open to
Exhibit Hall
below
CATWALK
K255

 Restrooms
EMER.
ELEC.
K230
E
E
E Elevator
MEETING LEVEL 2
ST-K4






259
Escalator
260
E
FOOD COURT MECHANICAL SHAFT
212 211


CATWALK
J255
258
FS699.2
Open to
Exhibit Hall
below
CATWALK
G255
210


256
E
E
FB
ASTRO Sessions
257
FOOD COURT MECHANICAL SHAFT
209 208


FB


255
E


FB
254
206
CATWALK
F255
253
FS699.1
Open to
Exhibit Hall
below
CATWALK
D255
205
FS220.1
FS710.2
204 203
Floor Plans
Skybridge to Westin Boston
Waterfront Hotel
ITEM
ITEM
29
30
Open to
Exhibit Hall
below

 Restrooms
E Elevator
BALLROOM LEVEL
ST-M4
ST-K4
Escalator
Open to
Exhibit Hall
below
Open to
Exhibit Hall
below




Grand Ballroom
General Session
AREAWAY
A315
E
E
FB
FB
FB
Floor Plans
INSIDE:
eContouring Learning Lab
Live SAM Sessions
ARRO Program
Meeting Highlights
Nurses’ Program
Schedule of Events by Day
How do we make real progress in CT solutions?
By making real connections.
Designing our CT meant understanding the needs of doctors while also considering the best possible
patient care. The result? The Brilliance CT Big Bore simulation system that puts the patient in the
same position for planning as for treatment. So you can adapt
the simulations to your detailed needs and can customize
to produce more accurate, virtually artifact free 4D images.
To see how, visit us at www.philips.com/bigboreCT.
These sessions are designed to provide crucial clinical education for professionals. Attendees will have an
opportunity to discuss issues such as imaging, target delineation, quality assurance and its frequency and
achievable accuracy.
Schedule
Kenneth Hu, MD, Program Chairman
Sarah Hoffe, MD, Program Co-chairman
Room: 153A-C
Sunday, October 28
8:00 a.m. - 9:30 a.m.
8:00 a.m. - 9:30 a.m.
Esophageal Cancers
Head and Neck Cancers II
Sarah Hoffe, MD, Moffitt Cancer Center
Ken Meredith, MD, Moffitt Cancer Center
Avraham Eisbruch, MD, University of Michigan Health Systems
Suresh Mukherji, MD, University of Michigan Health Systems
10:30 a.m. - 12:00 p.m.
Lymphoma
Stephanie Terezakis, MD, Johns Hopkins University
Steve Cho, PhD, Johns Hopkins University
10:30 a.m. - 12:00 p.m.
Gynecological Cancers
Arno J. Mundt III, MD, University of California
San Diego
Beth A. Erickson, MD, Medical College of Wisconsin
1:00 p.m. - 2:30 p.m.
Lung Cancers
Billy W. Loo, MD, PhD, Stanford University
1:00 p.m. - 2:30 p.m.
Gastrointestinal Cancers
3:30 p.m. - 5:00 p.m.
Head and Neck Cancers I
Christopher Nutting, MD, Royal Marsden Hospital
Karyn Goodman, MD, MS, Memorial Sloan-Kettering Cancer Center
Corinne Winston, MD, Memorial Sloan-Kettering Cancer Center
Ross Abrams, MD, FASTRO, Rush University Medical Center
3:30 p.m. - 5:00 p.m.
Prostate Cancers
Michael J. Zelefsky, MD, Memorial Sloan-Kettering Cancer Center
Ticketed event. Separate registration required.
33
Live Self-Assessment Modules (SAMs)
Back by popular demand, Annual Meeting participants will have an opportunity to earn
Self-Assessment Module (SAM) credit in addition to CME credit. Attendees wishing to
earn SAM credit must preregister for each of the SAMs they wish to participate in.
All Live SAM sessions are open to paid meeting attendees, but only Live SAM ticket
holders can participate in the Live SAM component of these sessions. Preregistration is
required and can be done on-site at the registration desk if seats are available.
ASTRO staff will email you 30-days post-meeting with your individual score and directions on how to print your certificate of completion from the ASTRO website. Your
SAM credits will be uploaded into your My MOC Transcript page on the ASTRO website
and if you choose, you can have your credits automatically transferred to the ABR
through the credit gateway.
Each of these sessions will be submitted to the ABR for Self-Assessment Module (SAM)
qualification.
Live SAM Policy
•
•
•
Live SAM registrants MUST be in the designated Live SAM room 15 minutes
prior to the start of the session. If you are not in the room at this time, your seat
may be given away to another attendee on the wait list.
No refunds, extensions or substitutions will be made for those registrants who,
for any reason, were unable to attend or were tardy for the session.
Registrants must answer all of the required assessment and evaluation
questions in order to receive credit for the Live SAM. Participants who do not
complete the required questions will NOT receive SAM credit and will NOT
receive a refund.
If you have any questions about the Live SAMs, SAM requirements or MOC, please
visit the CE Central in the North Lobby.
Live SAM Session: Ticket and Seperate Registration is required to participate in the Live SAM Component of the session.
34
Live SAM Schedule
Sunday, October 28
Tuesday, October 30
Educational Session 103
4:15 p.m. - 5:45 p.m.
Pancreatic Cancer: Current Treatment
Approaches and Controversies
1:15 p.m. - 2:45 p.m.
Low/High Grade Gliomas – An Update
Room: 107 A-C
Room: 107 A-C
Christopher H. Crane, MD, MD Anderson Cancer Center
Joseph Herman, MD, MS, Johns Hopkins University
Changhu Chen, MD, University of Colorado
Daphne Adele Haas-Kogan, MD, University of
California San Francisco
John Kirkpatrick, MD, PhD, Duke University
Monday, October 29
11:00 a.m. - 12:30 p.m.
Integration of Systemic Treatment with Radiation Therapy for Head and Neck Cancer
Room: 107 A-C
Ezra Cohen, MD, University of Chicago
David Rosenthal, MD, MD Anderson Cancer Center
Roy Tishler, MD, PhD, Dana-Farber Cancer Institute
4:00 p.m. - 5:30 p.m.
Panel 08
Brachytherapy Fundamentals and Evolving
Paradigms
11:00 a.m. - 12:30 p.m.
Advanced Treatment of Non-small Cell Lung
Cancer: Using All the Tools (Imaging, Motion
Correction and IMRT) Promises and Pitfalls –
A Case Based Approach
Room: 107 A-C
Indrin Julian Chetty, PhD, Henry Ford Health System
Craig W. Stevens, MD, PhD, H. Lee Moffitt Cancer Center
James J. Urbanic, MD, Wake Forest Univeristy School of
Room: 107 A-C
Robert Cormack, PhD, Harvard Medical School
Beth Erickson, MD, Medical College of Wisconsin
Christian Kirisits, DSc, Medical University of Vienna
Paul Nguyen, MD, Dana-Farber/Brigham and Women’s Cancer Center
Symbol Key:
A
ARON
Ticketed Event/ Nurses’
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
35
Transforming Care through Innovation
Sunday, October 28
8:00 a.m. - 12:45 p.m.
8:00 a.m. - 8:10 a.m.
|
Room: Grand Ballroom
Welcome Address
8:10 a.m. - 8:20 a.m.
SESSION I: Introduction
8:10 a.m. - 8:20 a.m.
Why Innovation?
8:20 a.m. - 9:50 a.m.
SESSION II: The Promise of Innovation
Phillip Devlin, MD
Massachusetts General Hospital, Harvard Medical School
Michael L. Steinberg, MD, FASTRO President, ASTRO
8:20 a.m. - 8:50 a.m.
Featured Presentation: What is Innovation
in Health Care and Can It Be Taught?
Roberta B. Ness, MD, MPH
The University of Texas School of Public Health
8:50 a.m. - 9:25 a.m.
Featured Presentation:
Transforming Radiation Oncology
Care – The Promise of Innovation
Edward C. Halperin, MD
New York Medical College
9:25 a.m. - 9:50 a.m.
Featured Presentation: Medical Evidence
Reconsidered – Thinking Beyond the
Randomized Clinical Trial
John P. Concato, MD
Yale School of Medicine
10:00 a.m. - 10:15 a.m.
BREAK
10:15 a.m. - 11:15 a.m.
SESSION III: Advancing Innovation in Radiation Oncology –
Redesign, Repurpose, Restructure
10:15 a.m. - 10:35 a.m.
The Future of Technological
Innovation in Radiation Oncology
T. Rockwell Mackie, PhD
University of Wisconsin School of Medicine
10:35 a.m. - 10:55 a.m.
Biological Innovation: Radiobiology Beyond the Radio-sensitization
William H. McBride, DSc, PhD David Geffen School of Medicine at UCLA
10:55 a.m. - 11:15 a.m.
Phase I Trials in Radiation Oncology –
Robert D. Timmerman, MD
An Idea Whose Time has Come?
UT Southwestern Medical Center
36
11:15 a.m. - 12:15 p.m.
SESSION IV: Innovative Designs for Delivery of Radiation Oncology Care
11:15 a.m. - 11:35 a.m. Safety – Out of the Box: Black Box,
Big Brother
Daniel Low, PhD
David Geffen School of
Medicine at UCLA
11:35 a.m. - 11:55 a.m.
Smarter Radiation Oncology
Louis Potters, MD, FASTRO
North Shore-LIJ Health System
Hofstra North Shore-LIJ School
of Medicine
11:55 a.m. - 12:15 p.m.
Accountable Care and Novel Payment
Systems: Will Radiation Oncology Endure?
Najeeb Mohideen, MD
Northwest Community Hospital
12:15 p.m. - 12:35 p.m.
SESSION V: Lessons Learned
12:15 p.m. - 12:35 p.m.
What Did We Learn Today? The Real Time
Learning Health System for Radiation Oncology
12:35 p.m. - 12:45 p.m.
Concluding Remarks
Anthony L. Zietman, MD
FASTRO,
Massachusetts General
Hospital, Harvard Medical
School
Michael L. Steinberg, MD
FASTRO,
President, ASTRO
37
ARRO Program
Monday, October 29
ARRO Career Seminar*
ARRO Poster Walk With a Professor*
10:00 a.m. - 5:30 p.m.
Room: 160 A-C
12:30 p.m. - 1:45 p.m.
(Box Lunch)
Room: Hall C – Poster Lounge
Refer to page 39 for program schedule.
6:30 p.m. - 8:30 p.m.
ARRO Reception*
12:30 p.m. - 1:45 p.m.
Ned Devine’s
1 Faneuil Hall
Marketplace, Quincy Market
Boston, MA 02109
(Box Lunch)
Shuttle Service will not be provided to the ARRO
Reception. However, if departing from the Boston
Convention and Exhibition Center for the
reception, you are welcome to take shuttle bus
route #4 from the convention center to the Boston
Marriott Long Wharf. Ned Devine’s is an
approximate 7-10 minute walk from the Boston
Marriott Long Wharf.
Sunday, October 28
How to Review a Scientific Paper Workshop*
Room: 159
Moderator:
W. Robert Lee, MD, MEd, Duke University
Robert J. Amdur, MD, University of Florida
Soren M, Bentzen, DSc, PhD, University of Wisconsin
Anthony V. D’Amico, MD, PhD, FASTRO, Brigham and Women’s Hospital
Lynn D. Wilson, MD, MPH, FASTRO, Yale University School of Medicine
Anthony L. Zietman, MD, FASTRO, Massachusetts General Hospital
12:45 p.m. - 1:45 p.m.
ARRO Annual Luncheon*
Room: 160 A-C
5:30 p.m. - 6:45 p.m.
Poster Viewing Session and Reception*
Room: Hall C
Guest Speaker: Leonard L. Gunderson, MD, MS, FASTRO, Chairman, ASTRO Board of Directors
6:15 p.m. - 6:45 p.m.
ARRO and Medical Students Meet
and Greet
Room: Hall C - Poster Lounge
*This session is not accredited for continuting medical
education credits.
Wednesday October 31
12:30 p.m. - 1:30 p.m.
ARRO Meet the Professor Luncheon*
Ticketed Event: Seperate registration required.
38
Room: 160 A-C
Saturday, October 27, 2012
10:00 a.m. - 5:30 p.m.
Room: 160 A-C
This year’s program combines a variety of timely topics for residents at all stages of training.
Using the audience interactive system, several presentations identified with the interactive
symbol are intended to facilitate interaction among participants from different communities.
10:00 a.m. - 10:10 a.m.
Opening Remarks – ARRO Executive Committee
10:10 a.m. - 10:30 a.m.
2012 Global Health Scholar Award Presentations
10:10 a.m. - 10:20 a.m.
Tracy Bray, MD, Loyola University Medical Center
10:20 a.m. - 10:30 a.m.
Niraj Mehta, MD, University of California Los Angeles Affiliated Hospitals
10:30 a.m. - 11:00 a.m.
Keynote Address: Mentorship and Career-Life Balance
Nancy P. Mendenhall, MD, University of Florida
William M. Mendenhall, MD, University of Florida
11:00 a.m. - 11:45 a.m.
Aspects of Physics to Consider in Your First Practice
Rebecca M. Howell, PhD, MD Anderson Cancer Center
11:45 a.m. - 12:15 p.m. Incorporating Brachytherapy Into Your Future Practice
Bradley R. Prestidge, MD, MS, President, American Brachytherapy Society
12:15 p.m. - 12:45 p.m.
Break – Box Lunch
12:45 p.m. - 1:45 p.m.
Residents as Teachers: Using Teaching Principles to Enhance Medical Education, Health Care Teamwork and Patient Care
Alisa Nagler, JD, EdD, Duke University
1:45 p.m. - 2:30 p.m.
Applying for Jobs and Entering Practice: A Panel Discussion*
Moderator: Lisa A. Kachnic, MD, Boston Medical Center
Panelists:
Julie A. Bradley, MD, University of Florida
Eileen P. Connolly, MD, PhD, Columbia University Medical Center
Stephen L. Harris, MD, Radiation Oncology Associates of New England
2:30 p.m. - 2:45 p.m.
Afternoon Break
2:45 p.m. - 4:15 p.m.
Negotiations Inside and Outside the Clinic
Melissa Brodrick, MEd, Ombudsman, Harvard Medical School
4:15 p.m. - 4:50 p.m.
Practice Entry Survey Results
Terry J. Wall, MD, JD, FASTRO, St. Luke’s Cancer Institute
4:50 p.m. - 5:00 p.m.
Audience Feedback and Evaluation
5:00 p.m. - 5:25 p.m.
Legal Aspects of Entering Practice
5:25 p.m. - 5:30 p.m
Closing Remarks
Aparna Kesarwala, MD, PhD, Chairman, ARRO Executive Committee
* This Program is not accredited for continuing medical education credits.
39
Meeting Highlights
Sunday, October 28
3:30 p.m. - 4:15 p.m.
Featured Lecture: Improvements and
Innovation at the Center for Devices
and Radiological Health*
Room: 160 A-C
Michael O’Hara, PhD,
Food and Drug Administration
Introduction by
Howard Sandler, MD, MS,
FASTRO, Cedars Sinai Medical Center
* This session is not accredited for continuting medical
education credits.
board of directors of the American College of
Emergency Physicians, Kellermann was subsequently given the College’s highest award for leadership. Elected to the Institute of Medicine (IOM) in
1999, Kellermann co-chaired the IOM Committee
on the Consequences of Uninsurance, which issued
six reports on this topic between 2001 and 2004.
He also served on the IOM’s Committee on the Future of Emergency Care in the U.S. Health System
and the Committee on Effectiveness of National
Biosurveillance Systems: BioWatch and the Public
Health System. As a Robert Wood Johnson Health
Policy Fellow (2006–07), Kellermann worked for
the professional staff of the Committee on
Oversight and Government Reform, U.S. House
of Representatives. A clinician and researcher, he
practiced and taught emergency medicine for
more than 25 years in public teaching hospitals in
Seattle, Memphis and Atlanta.
Monday, October 29
9:45 a.m. - 10:45 a.m.
Keynote Address I
Arthur L. Kellermann, MD, MPH, RAND Health
Introduction by Susan A. McCloskey, MD,
University of California Los Angeles
Arthur Kellermann
is vice president
and director of RAND
Health and holds the
Paul O’Neill Alcoa Chair
in Policy Analysis at the
RAND Corporation.
Before joining RAND,
he was a professor of
emergency medicine and public health and associate dean for health policy at the Emory School of
Medicine in Atlanta. Kellermann founded Emory’s
Department of Emergency Medicine and served as
its first chairman from 1999 - 2007. He established
the Emory Center for Injury Control, and holds
“excellence in science” awards from two organizations: the Society for Academic Emergency
Medicine and the Injury Control and Emergency
Health Services Section of the American Public
Health Association. A two-term member of the
40
Monday, October 29
1:45 p.m. - 2:30 p.m.
Presidential Address:
The Patient Not Treated
Michael L. Steinberg, MD,
FASTRO, President, ASTRO
Introduction by
Paul E. Wallner, DO, FASTRO,
21st Century Oncology
Tuesday, October 30
Keynote Address II: Future Trends in
Cancer Survivorship*
Keynote Address III: Value-based
Health Care Delivery
9:45 a.m. - 10:45 a.m.
9:45 a.m. - 10:45 a.m.
Edward M. Kennedy Jr., President and Co-founder, Marwood Group
Introduction by Jay S. Loeffler, MD, FASTRO,
Massachusetts General Hospital
Michael E. Porter, PhD, MBA, Harvard Business School
Introduction by Bruce G. Haffty, MD, FASTRO,
UMDNJ Robert Wood Johnson Medical School
Mr. Kennedy is the president and co-founder
of Marwood Group and
Co., a health care focused
financial services firm with
offices in New York,
Washington, London and
Kuwait specializing in
proprietary health care
research, asset management and private equity
advisory services. Previously, Mr. Kennedy served as
an associate and later as counsel to the law firm of
Wiggin and Dana located in New Haven, Conn. Mr.
Kennedy’s health law practice focused primarily on
state and federal regulatory and reimbursement
issues affecting hospitals, home care agencies, long-term care providers, physicians and mental
health providers. In addition, Mr. Kennedy served
as director of legal and regulatory affairs at the
Connecticut Hospital Association, counseling acute
care providers and policy-makers on a wide variety
of emerging health care issues. Mr. Kennedy has also
been an active leader in the civil rights movement
for persons with disabilities. In his disability law
practice, he advised companies about how to best
expand opportunities for persons with disabilities
and how to avoid liability under the Americans
with Disabilities Act. He continues to serve on
the corporate and advisory boards of numerous
disability organizations and lectures nationwide
on topics relating to health and disability law. Mr.
Kennedy received an undergraduate degree from
Wesleyan University, a master’s degree from Yale
University’s School of Forestry and Environmental
Studies, and a law degree from the University of
Connecticut School of Law.
* This session is not accredited for medical education
credits.
Michael E. Porter is a
leading authority on
competitive strategy, the
competitiveness and
economic development of
nations, states and regions,
and the application of competitive principles to
social problems such as
health care, the environment and corporate responsibility. Professor Porter is generally recognized as
the father of the modern strategy field, as has been
identified in a variety of rankings and surveys as
the world’s most influential thinker on management and competitiveness. He is the Bishop William
Lawrence University Professor, based at Harvard
Business School. A University professorship is
the highest professional recognition that can be
awarded to a Harvard faculty member. In 2001,
Harvard Business School and Harvard
University jointly created the Institute for Strategy
and Competitiveness, dedicated to furthering
Professor Porter’s work. He is the author of 18
books and more than 125 articles. He received a
BSE with high honors in aerospace and mechanical engineering from Princeton University in 1969,
where he was elected to Phi Beta Kappa and Tau
Beta Pi. He received an MBA with high distinction in
1971 from the Harvard Business School, where he
was a George F. Baker Scholar and a PhD in Business
Economics from Harvard University in 1973.
41
Nurses’ Program A
ARON
A series of sessions have been identified throughout the Annual Meeting Program that are pertinent for radiation oncology nurses. The Nurses’ Reception and Luncheon also give nurses the opportunity to network with their fellow nurses.
Sunday October, 28
Monday, October 29
When a Patient in Radiation Has a Cardiac Device
Role of the Advanced Practice Nurse
(APN) in a Radiation Oncology Setting
11:00 a.m. - 12:30 p.m.
Room: 204 A-B
Mary Ellyn Witt, MS, RN, University of Chicago Medical
Center
12:45 p.m. - 1:45 p.m.
Nurses’ Welcome and Orientation
Luncheon*
Room: 257 A-B
Joanne Moar, RN, OCN, Massachusetts General Hospital
3:30 p.m. - 5:00 p.m.
Bare Facts and Treatments Regarding
Skin Toxicities
Room: 204 A-B
Marilyn Haas, PhD, ANP-BC, Mission Hospital
Barbara Holmes Gobel, RN, MS, AOCN,
Northwestern Memorial Hospital
Pamela Viale, RN, MS, CS, ANP, AOCNP, University of California San Francisco
5:30 p.m. - 6:30 p.m.
Nurses’ Reception*
Room: 257 A-B
Guest Speakers – John Grace and Joan Raducha
John Grace, a cancer survivor and his wife Joan
Raducha will discuss “Surviving and Thriving - With
Cancer a Part of Our Lives 2005-2012”. They will
discuss the experience of being diagnosed and
then treated for head and neck, then lung and most
recently appendix cancers. They will describe facing
the diagnosis, the treatment experience, and the
challenges of decision making regarding treatment
options and continuance. And finally, they will talk
about how they have come to thrive by learning to
live with cancer as a part of their lives.
*Event open to Nurse and Nurse Practitioner attendees only.
42
11:00 a.m. - 12:30 p.m.
Room: 259 A-B
Vanna M. Dest, MSN,APRN, BC, AOCN, Smilow Cancer Hospital Yale New Haven, Saint Raphael Campus
Diane Doyle, MS, APRN, BC, AOCN,
Elene Viscosi, APRN, BC, Massachusetts
General Hospital
Tuesday, October 30
8:00 a.m. - 9:30 a.m.
Improving Outcomes in Geriatric Patients
Through Use of Comprehensive Geriatric Assessment Tools Available to Make It Happen
Room: 153 A-C
Diane Cope, PhD, ARNP, Florida Cancer Specialists
and Research Institute
Lynn Heup, GNP-BC/AOCNP, MS, Emory Healthcare
1:15 p.m. - 2:45 p.m.
Protons, Neutrons and Advanced Technologies in Radiation Therapy
Room: 206 A-B
Jeanne Sixta, RN, BSN, OCN, NIU Institute of Neutron Therapy at Fermilab
Catherine Mannix, RN, MSN, OCN, The Clark Center for Radiation Oncology
Michael Kirk, PhD, Mass General North Shore Center for Outpatient Care
3:00 p.m. - 4:30 p.m.
Adult Cancer Survivors: One Size
Doesn’t Fit All
Room: 153 A-C
Richard Boyajian, RN, MS, NP, Dana-Farber Cancer Institute
Saturday | October 27
8:00 a.m - 9:30 a.m.
1:00 p.m - 4:00 p.m.
Esophageal Cancers
Room: 159
Room: 153 A-C
Sarah E. Hoffe, MD, Moffitt Cancer Center
Ken Meredith, MD, Moffitt Cancer Center
10:30 a.m. - 12:00 p.m.
Lymphoma
Room: 153 A-C
Stephanie Terezakis, MD, Johns Hopkins University
Steve Cho, MD, Johns Hopkins University
10:00 a.m. - 5:30 p.m.
Box Lunch Provided
Room: 160 A-C
Refer to page 39 for full program schedule.
*This session is not accredited for continuing medical
education credits.
1:00 p.m. - 2:30 p.m.
Lung Cancers
Room: 153 A-C
Billy W. Loo, MD, Stanford University
Symbol Key:
A
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
Young Physicians’ Session*
Shilpen A. Patel, MD, Moderator, University of Washington
Reshma Jagsi, MD, University of Michigan
Anthony Zietman, MD, FASTRO, Massachusetts General Hospital
David C. Beyer, MD, FASTRO, Arizona Oncology Services
Kenneth MacDonald , MD, Providence Medical Center
Tim R. Williams, MD, FASTRO, Lynn Cancer Institute
Sameer R. Keole, MD, Radiation Medicine Associates
Theodore L. DeWeese, MD, Johns Hopkins School of Medicine
Louis Potters, MD, FASTRO, North Shore-LIJ Health System
Stephen M. Hahn, MD, University of Pennsylvania School of Medicine
Nancy Mendenhall, MD, University of Florida
William Mendenhall, MD, University of Florida
Paul E. Wallner, DO, FASTRO, 21st Century Oncology
This workshop will address several key issues facing
early career physicians and will provide a forum for
open discussion among peers. Distinguished faculty
will share their experience and insights on several
topics, to include:
• Jumping Ship – How, when, where and why to
change jobs when you are early-career.
• Negotiating a contract when you are established in the field.
• Changing from private practice to academics (or vice versa).
• Maintenance of Certification - How? What? Where? When?
The educational focus is targeted toward young
physicians, less than 10 years in practice.
*This session is not accredited for continuing medical education credits.
43
Saturday | October 27
3:30 p.m. - 5:00 p.m.
Head and Neck Cancers I
Room: 153 A-C
Christopher M. Nutting, MD, Royal Marsden Hospital
ARRO Reception
6:30 p.m. - 8:30 p.m.
Ned Devine’s
1 Faneuil Hall
Marketplace, Quincy Market
Boston, MA 02109
Shuttle service will not be provided to the ARRO
Reception. However, if departing from the Boston
Convention and Exhibition Center for the reception,
you are welcome to take shuttle bus route #4 from
the convention center to the Boston Marriott Long
Wharf. Ned Devine’s is an approximate 7-10 minute
walk from the Boston Marriott Long Wharf.
44
Sunday | October 28
6:30 a.m. - 8:00 a.m.
10:30 a.m. - 12:00 p.m.
International Attendee
Welcome Breakfast
Gynecological Cancers
Room: 205 A-C
Room: 153 A-C
8:00 a.m. - 8:10 a.m.
Welcome Address
Arno Mundt III, MD, University of California San Diego
Beth A. Erickson, MD, Medical College of Wisconsin
Phillip M. Devlin, MD, Massachusetts General Hospital, Harvard Medical School
11:00 a.m. - 12:30 p.m.
8:00 a.m. - 9:30 a.m.
When a Patient in Radiation Has a Cardiac
Device
Nurses’ Session
Room: 204 A-B
A
Head and Neck Cancers II
ARON
Room: 153 A-C
Mary Ellyn Witt, MS, RN, University of Chicago Medical Center
Suresh Mukherji, MD, University of Michigan Health Systems
8:00 a.m. - 12:45 p.m.
Transforming Care Through Innovation
12:45 p.m. - 1:45 p.m.
ARRO Annual Luncheon
Room: 160 A-C
Guest Speaker:
Leonard L. Gunderson, MD, MS, FASTRO, Chairman, ASTRO Board of Directors
See page 36 for full schedule.
12:45 p.m. - 1:45 p.m.
Nurses’ Welcome and Orientation Luncheon
10:00 a.m. - 5:00 p.m.
Exhibit Hall Opens
Room: 257 A-B
Room: Halls A/B
A
ARON
Joanne Moar, RN, OCN, Massachusetts General Hospital
10:00 a.m. - 5:00 p.m.
Poster Viewing
Room: Hall C, Exhibit Hall
Symbol Key:
A
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
45
Sunday | October 28
12:45 p.m. - 1:45 p.m.
Health Policy Socioeconomic Luncheon*
2013 Radiation Oncology Coding and Reimbursement Update - A Discussion on the Challenges Affecting the Specialty in the Current Reimbursement Environment
Room: 107 A-C
Box Lunch Provided
A preview of the 2013 proposed rule changes to
the Medicare Physician Fee Schedule and Hospital
Outpatient Prospective Payment System, as well
as other payment and coding changes for 2013,
will be presented. Speakers will provide details on
Medicare spending trends for radiation oncology
services. The session will conclude with a discussion
of actions taken by the Medicare agency and private
payers to control health care spending and how
ASTRO has actively engaged with them and other
stakeholders to address these concerns.
Co-moderators:
Joel Cherlow, MD, PhD, Long Beach Memorial Medical Center
Thomas Eichler, MD, Thomas Johns Cancer Center
Speakers:
David C. Beyer, MD, FASTRO, Arizona Oncology Services
Najeeb Mohideen, MD, Northwest Community Hospital
education credits.
1:00 p.m. - 2:30 p.m.
Gastrointestinal Cancers
Room: 153 A-C
Karyn A. Goodman, MD, MS, Memorial
Sloan-Kettering Cancer Center
Corinne B. Winston, MD, Memorial Sloan-Kettering Cancer Center
Ross Abrams, MD, FASTRO, Rush University Medical Center
1:45 p.m. – 3:15 p.m.
Scientific Session A
Clinical Trials and Innovation in Care
Room: 210 A-C
Co-moderators: Lynn D. Wilson
Benjamin Movsas
1:45
Stefano Arcangeli
5
Is Stereotactic Body Radiation Therapy (SBRT) an
Attractive Option for Unresectable Liver Metastases?
Early Results From a Phase II Trial
1:52
Tracy S. Bray
6
Prospective Evaluation of Dual-energy Imaging in
Patients Undergoing Image Guided Radiation Therapy
for Lung Cancer: Initial Clinical Results
Resident Clinical/Basic Science Research Award
Winner
1:59
David Jaffray
Discussant
2:04
Howard M. Sandler
Radium-223 Chloride Safety and Use of External
Beam Radiation Therapy (EBRT) in the Phase III
Randomized Trial (ALSYMPCA) in Patients With
Castration-resistant Prostate Cancer (CRPC) and
Bone Metastases
Ticketed Event/Seperate registration required
46
7
Sunday | October 28
2:11
Mary K. Gospodarowicz
8
Final Analysis of Intergroup Randomized Phase III
Study of Androgen Deprivation Therapy (ADT) +
Radiation Therapy (RT) in Locally Advanced Prostate
Cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110;
NCT00002633)
1:45 p.m. - 3:15 p.m.
2:18
9
1:45
Julie Jung Kang
14
Radiation of Potential Local Cancer Stem Cell Niches
Improves Survival of Patients With Glioblastoma
Multiforme
10
1:55
Kyle Cuneo
15
Impact of Concurrent and Adjuvant Bevacizumab on
the Risk of Radiation Necrosis Following Radiosurgery
for Recurrent Glioma
Jason Efstathiou
Discussant
2:23 Arnab Chakravarti
A Revised RTOG Recursive Partitioning Analysis
(RPA) Model for Glioblastoma Based Upon
Multi-platform Biomarker Profiles
2:30
Gregory Cairncross
IDH Status Predicts Benefit From PCV+RT in
Anaplastic Oligodendroglioma (RTOG 9402)
2:37
Kevin Camphausen
Discussant
2:42
Beryl McCormick
11
Low Risk Breast Ductal Carcinoma In Situ (DCIS):
Results From the RTOG Phase III 9804 Trial
2:49
Kavita Dharmarajan
12
Patterns of Relapse From a Phase III Study of
Response-based Therapy for Intermediate-risk
Hodgkin lymphoma (AHOD0031): A Report From the
Children’s Oncology Group
2:56
Jonathan J. Beitler
RTOG 90-03: Final Report
13
3:03
Peter Hoskin
LBA3
FoRT: A Phase III Multi Center Prospective
Randomized Trial of Low Dose Radiotherapy for
Follicular and Marginal Zone Lymphoma
Scientific Session B
CNS I - Primary Brain Tumors
Room: 206 A-B
Moderators: Changhu Chen
Joseph Contessa
2:05
Lawrence Kleinberg
16
An American Brain Tumor Consortium (ABTC) Phase
I Trial of Veliparib (ABT-888), Temozolomide (TMZ),
and Concurrent Radiation Therapy (RT) for Newly
Diagnosed Glioblastoma Multiforme (GBM): Need
for Modification to Approach for Combining These
Therapies
2:15
Meiling Deng
17
A Phase I/II Clinical Trial of Dose Escalation on Biological Target Volume With Intensity Modulated
Radiation Therapy: The Long-term Results
2:25
Linda Chen
Increased Radiation Dose to the SVZ Improves Survival in Patients With GBM
18
2:35
Andrew Trister
19
A Novel Metric of Patient-specific Response to Treatment for Glioblastoma Discriminates Patients
With Pseudo-progression
2:45
Siham Sabri
20
Novel Role of O6-methylguanine Methyltransferase in
the Invasion/proliferation Dichotomy in Glioblastoma
47
Sunday | October 28
2:55
Toshihiko Luchi
21
Hypo-fractionated IMRT With TMZ for GBMs Tailor-made Setting of Treatment Doses Owing to
MGMT-methylation Status
2:35
Marta Scorsett
27
Stereotactic Body Radiation Therapy With Ablative Dose on Liver Metastases: Radiation Induced
Liver Disease (Rild) and Toxicity Assessment
3:05
2:45
Anand Mahadevan
Stereotactic Body Radiotherapy for Unresectable
Intrahepatic and Hilar Cholangiocarcinoma
28
2:55
Michael Chuong
Stereotactic Body Radiation Therapy (SBRT) for Borderline Resectable and Locally Advanced Pancreatic Cancer Is Effective and Well-Tolerated
29
Arnab Chakravarti
Discussant
1:45 p.m. - 3:15 p.m.
Scientific Session C
GI I - Hypofractionated and Stereotactic Radiotherapy for Hepatic/Biliary/Pancreatic
Tumors
Room: 259 A-B
Moderators: Bryan Chang
Charles Thomas
3:05
1:45
Hany Soliman
22
Phase II Trial of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver
Metastases
1:45 p.m. - 3:15 p.m.
1:55
Foster Lasley
23
Phase I-II trial of Stereotactic Body Radiotherapy (SBRT)
in Patients With Hepatocellular Carcinoma, Chil Pugh’s
Class scientific session (CPC) A and B: Interim Analysis
of Treatment Variables Affecting Toxicity and Outcome
2:05
Anthony Brade
24
Phase I Study of Sorafenib and SBRT for Advanced
Hepatocellular Carcinoma
2:15
Alexander Kirichenko
25
Outcomes of Stereotactic Radiotherapy (SRT) for
Primary and Metastatic Liver Tumors with 3-D CT and
Single Photon Emission Computed Tomography (3-D
CT/SPECT) Treatment Planning
2:25
Anthony Brade
Phase I Study of Sorafenib and Whole Liver Radiotherapy (WLRT) or Stereotactic Body Radiotherapy (SBRT) for Liver Metastases
48
26
Karyn Goodman
Discussant
Scientific Session D
GU I - Prostate Cancer: Toxicity/Second Cancers
Room: 258 A-C
Moderators: Ronald Chen
Timothy Showalter
1:45
Phillip Gray
30
Patient-reported Quality of Life in Prostate Cancer Patients Treated With 3-D Conformal, Intensity Modulated or Proton Beam Radiotherapy
1:55
James Yu
31
Proton Radiotherapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated
Radiotherapy
2:05
Daniel Spratt
32
Long-term Survival and Toxicity of Patients Treated
With Ultra-high-dose IMRT for Localized Prostate
Cancer
2:15
Raymond Mak
33
Acute and Late Urinary Toxicity After Radiation
Therapy in Men With and Without an Intact Prostate
Gland: A Secondary Analysis of RTOG 9408 And 9601
Suggesting This Toxicity Is Not Due to Bladder Injury
2:25
Jeff Michalski
34
Dose Volume Analysis of Grade 2+ Late GI Toxicity on
RTOG 0126 After High-dose 3-D CRT or IMRT
Sunday | October 28
2:35
Tiziana Rancati
35
Rectal Toxicity 7 Years After High-dose Radiation for
Prostate Cancer: Clinical and Dosimetric Predictors
2:45
Joanne Jang
36
Long-term Quality of Life After Definitive Treatment
for Prostate Cancer: Patient Reported Outcomes in the
Second Post-treatment Decade
2:55
Hima Musunuru
Second Primary Cancers Occurring After I-125 Brachytherapy As Monotherapy for Early Prostate
Cancer
37
3:05
Jay Ciezki
38
Twenty-year Competing Risk Analysis of Secondary
Malignancies After External Beam Radiation for Post-Operative Treatment of Prostate Cancer Patients
From the SEER Database
2:25
Rania Hashem
43
Defining the Impact of the Use of Oral Contrast in
Pelvic Intensity Modulated Radiation Therapy (IMRT):
An RTOG 0418 Secondary Analysis
2:35
Daniel Simpson
44
CT and MRI-based Image-guided Brachytherapy for
Cervical Cancer: A Multi-institutional Report
2:45
Nina Mayr
45
Low-perfusion Tumor Subvolumes, Assessed by the
Heterogeneity Functional Risk Volume Method, and
Treatment Outcome in Cervical Cancer: Does Hemoglobin Matter?
2:55
Maria Thomas
46
Intratumoral Heterogeneity Assessed by Extraction of
Texture Features From PET Images of Cervical Cancer
Patients
GYN I - Cervical Cancer
3:05
Shankar Siva
47
Routine Follow-up Rarely Detects Disease Recurrence
After a Complete Response on FDG-PET in Patients
With Locally Advanced Cervical Cancer
Moderators: Ann Klopp
Sheida Mani
1:45 p.m. - 3:15 p.m.
1:45 p.m. - 3:15 p.m.
Scientific Session E
Room: 254 A-B
1:45
William Small Jr.
39
RTOG 0417: Efficacy of Bevacizumab in Combination
With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally
Advanced Cervical Carcinoma
1:55
Masaru Wakatsuki
40
Impact of Boost Irradiation on Pelvic Lymph Node
Control in Patients With Cervical Cancer
2:05
Ajeet Gandhi
41
Early Clinical Outcomes of Intensity Modulated vs.
Conventional Pelvic Radiotherapy for Locally Advanced Carcinoma Cervix : A Prospective Randomized Study
2:15
He Zhu
42
Longitudinal Study of Acute Hematologic Function in Cervical Cancer Patients Treated With Chemoradiotherapy
Scientific Session F
Head and Neck I – Target Delineation/Patterns
of Failure
Room: 052 A-B
Moderators: James Bonner
Jimmy Caudell
1:45
Krzysztof Skladowski
48
Continuous Accelerated Irradiation of 7-days-a-week
(CAIR) Has Given the Same Long-term Results Like 7
Fractions in 5-days-a-week. Report on Phase III Clinical
Trial in Head and Neck Cancer Patients
1:55
Mitchell Machtay
49
Long-term Outcome From RTOG 99-03: RT With or
Without Erythropoietin for Anemic Head and Neck
Cancer Patients
2:05
Juliette Thariat
50
Predicting the Response to EGFR Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Cancer, The
Carissa Gortec 2004-02 Study
49
Sunday | October 28
2:15
Quynh-Thu Le
Discussant
2:25
Christopher Spencer
51
Limiting High Level II and Contralateral Retropharyngeal Lymph Node (RPN) Treatment in
Selected Patients With Head and Neck Squamous Cell
Carcinoma (HNSCC)
2:35
Kenneth Hu
52
Five-year Outcomes of Oropharynx (OPX) Targeted
Radiotherapy (RT) for Metastastic Squamous Cell
Carcinoma of Unknown Primary (MUP) in the Head
and Neck
2:45
Abrahim Al-Mamgani
Unilateral Neck Irradiation for Well-lateralized Oropharyngeal Cancer: Excellent Outcome, Low Toxicity Profile and Good Quality of Life Scores
Avraham Eisbruch
1:45 p.m. - 3:15 p.m.
Biologic Prognostic/Predictive Factors
Room: 109 A-B
Moderators: Kevin Kozak
Nicole Simone
2:55
Alan Pollack
62
Prospective Validation of Diagnostic Tumor Tissue
Ki-67 as the Most Significant Predictor of Outcome
in Men Treated for Prostate Cancer on a Randomized
Trial
1:45 p.m. - 3:15 p.m.
1:45
Joshua Anderson
55
Kinomic Profiling Identifies Pathways of Her2 Targeted
Therapy Resistance in Her2 Positive Breast Cancer Cell
Lines
Scientific Session H
Adaptive Radiation Therapy
Room: 205 A-C
Moderators: Lei Dong
Jean Pouliot
56
2:05
Yoko Harima
57
Apolipoprotein C-ii Is a Potential Serum Biomarker As
a Prognostic Factor of Patients With Locally Advanced
Cervical Cancer After Chemoradiotherapy
2:35
Jeff Bruce
60
The Role of microRNAs in Human Nasopharyngeal
Carcinoma
3:05
Terence Williams
63
Caveolin-1 Expression Correlates With Outcomes in
Pancreatic Ductal Carcinoma: A Secondary Analysis of
RTOG 9704.
Scientific Session G
50
2:25
Xiong Wei
59
Vimentin (EMT Marker Protein) Score Predicts Resistance to Erlotinib and Radiotherapy for Patients
With Stage III Non-small Cell Lung Cancer on a Prospective Phase II Trial
2:45
Daniel Oh
61
Radiation Induced Gene Signature Predicts Pathologic
Complete Response to Neoadjuvant Chemotherapy in
Breast Cancer Patients
Discussant
1:55
Philip Wong
A Potential Prognostic micro-RNA Signature for Distant Metastasis in Soft-tissue Sarcomas
58
53
2:55
Annie Chan
54
Intensity Modulated Radiation Therapy and Level IB
Nodal Coverage for Oropharyngeal Carcinoma
3:05
2:15
Kelly MacArthur
A Telomerase-based Assay Tracks Changes in Circulating Tumor Cells in Patients Undergoing Radiation Therapy
1:45
Martha Matuszak
64
The Importance of Dry Run Credentialing for RTOG
1106/ACRIN 6697: A Trial of Individualized Adaptive
Radiotherapy for Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
1:55
Q. Jackie Wu
65
Knowledge-based Organ-at-risk Sparing Models and
Individualized Trade-offs in IMRT Planning
Sunday | October 28
2:05
Camille Noel
66
Risk Analysis for Clinical Implementation of Adaptive
Radiation Therapy
2:15
Xiaojian Chen
Online Adaptive Replanning for Partial Breast Irradiation
67
2:25
Scott Merrick
68
Superiority of a Real-time Planning Technique Over
Image Guided Radiation Therapy for the Treatment of
Primary Prostate Cancers
2:35
Nienke Holtzer 69
Roll and Pitch Correction in Head and Neck Patients
by Rapid Adaptation of Volumetric Modulated Arc
Treatment Plans
2:45
Guillaume Cazoulat
70
How Accurate Is Deformable Image Registration to
Calculate Cumulative Dose From Fraction to Fraction
in Prostate IGRT?
2:55
X. Allen Li
Combined Online and Offline Adaptive Radiation
Therapy
Manpreet Bedi
1002
Increase in Tumor Size on MRI is Associated With
Greater Pathologic Necrosis and Poor Survival in Patients With Soft Tissue Sarcoma of Extremity and
Body Wall Treated With Neoadjuvant Radiotherapy
Martin Vallieres
1003
FDG-PET Features and Outcomes in Patients With Soft
Tissue Sarcomas of the Extremities]
Adam Liss
1004
Predictive Factors for Chronic Lower Extremity Edema
After Multimodality Limb-sparing Therapy of Soft Tissue Sarcoma of the Proximal Lower Extremity
1005
The Safety and Efficacy of Primary Radiation Therapy
Without Upfront Surgery for Merkel Cell Carcinoma
David Roberge
1006
Interobserver Variation in Suspicious Edema Definition
for Pre-operative Radiotherapy in Soft Tissue Sarcoma
of the Extremity
71
3:05
Nadia Octave
72
Automatic Process for Daily Treatment Plan Selection
With a New Online/Offline Adaptive IGRT Technique
Using Daily Cone Beam CT
1:45 p.m. - 3:15 p.m.
Digital Poster Discussion 01
Sarcoma/Skin Cancer
Room: 156 A-C
Discussants: Christopher Barker
Thomas DeLaney
Lara Best
1001
Use of Protoporphyrin Fluorescence to Determine
Clinical Target Volume Margins for Non-melanotic Skin
Cancers Treated With Primary Radiotherapy
Neil Desai
1007
Reduced Toxicity With Intensity Modulated Radiotherapy (IMRT) for Desmoplastic Small Round
Cell Tumor (DSRCT)
Angela Hong
1008
Extracorporeal Radiation Therapy As Part of the Limb
Salvage Management: A Review of 99 Cases
C. Jillian Tsai
1009
Dermatofibrosarcoma Protuberans: Long-term Outcomes of Fifty Three Patients Treated With Conservative Surgery and Radiation Therapy
Joost Nuyttens
1010
Impact of Different Immobilization Devices and Set-up
Correction Protocols on Required CTV-PTV Margins in
Patients With a Sarcoma of the Lower Extremities
Mauricio Cambeiro
1011
Conservative Surgery and Intraoperative Radiotherapy
for Locally Recurrent Soft Tissue Sarcomas of the
Extremities and the Superficial Trunk
51
Sunday | October 28
Afshin Rashtian
1012
Preoperative Stereotactic Body Radiation Therapy
(SBRT) With Cyberknife for Soft Tissue Sarcoma (STS)
1:45 p.m. - 3:15 p.m.
Lung
Room: 157 A-C
Discussants: Clifford G. Robinson
Robert Timmerman
Megan Daly
1013
Patterns of Care for Thoracic Stereotactic Body Radiotherapy Among Practicing Radiation Oncologists
in the United States
John Cuaron
1014
Stereotactic Body Radiation Therapy for Primary Lung
Cancers >3cm
Todd DeWees
1015
Defining Optimal Comorbidity Measures for Patients
With Medically Inoperable Early Stage Non-small Cell
Lung Cancer (NSCLC) Treated With Stereotactic Body
Radiation Therapy (SBRT)
Yung Hsien Liu
1016
Stereotactic Ablative Radiotherapy for Multiple
Primary Lung Cancer
Ditte Eklund Nygaard
1017
Interfractional Variation of Respiratory Lung Tumor
Displacement
Jonathan Abelson
1018
Feasibility of Pulmonary Interstitial Lymphography-guided Targeting in Stereotactic Ablative Radiotherapy of Lung Tumors
Melissa Liriano
1019
Trimodality Therapy for Locally Advanced Non-small
Cell Lung Cancer (NSCLC): Predictors of Surgical Drop
Out
Michael Milano
1020
Definitive Radiation for Stage I Non-small Cell Lung
Cancer: A Population-based Study of Survival
52
Sashendra Senthi
1021
Using Deformable Dose Registration to Improve Planning for High-dose Thoracic Re-Irradiation
Alexandros Papachristofilou
1022
Prospective International Trial of Endobronchial
Implantation of Electromagnetic Fiducials for Localization and Real-time Tracking of Tumors in Lung
Cancer Patients Undergoing Radiotherapy (RT)
Line Claude
1023
Acute Radiation Pneumonitis in Non-small Cell Lung
Cancer: Is Respiratory-gated Control Useful? Results
of a French Prospective Randomized Study
Nathan Becker
1024
Analysis of Serial FDG 4-D PET Images Acquired During
Radiotherapy in Advanced Lung Cancer Patients
Resident Digital Poster Recognition Award Winner –
PHYSICS
1:45 p.m. - 3:15 p.m.
Difficult Cases in Breast Cancer
Room: 253 A-C
Jay R. Harris, MD, FASTRO, Dana-Farber Cancer Institute
Thomas Buchholz, MD, PhD, FASTRO, MD Anderson
Cancer Center
Terry Mamounas, MD, Northeastern Ohio Universities Colleges of Medicine
Julia White, MD, Stephanie Spielman Comprehensive Breast Center Center
Eric Winer, MD, Dana-Farber Cancer Institute
Symbol Key:
A
ARON
Separate
Session
registration
required.
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
Sunday | October 28
1:45 p.m. - 3:15 p.m.
Challenging Cases of Hodgkin’s Lymphoma
and Non-Hodgkin’s Lymphoma
Room: 107 A-C
Peter Mauch, MD, FASTRO, Harvard Medical School
David Hodgson, MD, Princess Margaret Hospital
Bouthaina Dabaja, MD, MD Anderson Cancer Center
Richard Hoppe, MD, FASTRO, Stanford University
Ann LaCasce, MD, Harvard Medical School
1:45 p.m. - 3:15 p.m.
ASTRO’s 2012 Workforce Survey Results
and Discussion*
Moderator:
Robert Miller, MD, MS, Chairman, ASTRO Membership committee, Mayo Clinic College of Medicine
Panelists:
Surjeet Pohar, MD, Chairman, ASTRO Workforce Subcommittee, Lourdes Hospital
Christine Olsen, MD, MS, Vice-chairman, ASTRO Workforce Subcommittee, Dana-Farber Cancer Institute/Brigham and Women’s Hospital
Anna Arnone, Member Relations and
Communications Vice President, ASTRO
Anushree Vichare, MBBS, MPH, Measure
Development Manager, ASTRO
education credits.
Room: 204 A-B
This session will provide an overview of the results
from ASTRO’s 2012 Radiation Oncology Workforce
Survey. The session will summarize the overall results
and the results for each workforce segment including
radiation oncologists, radiation oncology residents,
physician assistants in radiation oncology, nurse
practitioners in radiation oncology, nurses in radiation
oncology, radiation physicists, medical dosimetrists,
radiation therapists/technologists and practice managers/administrators. The presenters will answer
the following research questions:
1. What are the characteristics of the current radiation oncology workforce?
2. What are the needs and concerns of the current
workforce?
3. What are the opportunities for improving quality
and safety in patient care?
4. What can we predict about the characteristics and
needs of the future radiation oncology workforce?
Symbol Key:
A
3:30 p.m. - 4:15 p.m.
Featured Lecture: Improvements and
Innovation at the Center for Devices and
Radiological Health
Room: 160 A-C
Michael O’Hara, PhD, Food and Drug Administration
Introduction by Howard M. Sandler, MD, FASTRO, Cedars-Sinai Medical Center
3:30 p.m. - 5:00 p.m.
Prostate Cancers
Room: 153 A-C
Michael J. Zelefsky, MD, Memorial Sloan-Kettering Cancer Center
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
53
Sunday | October 28
3:30 p.m. - 5:00 p.m.
4:15 p.m. - 5:45 p.m.
Bare Facts and Treatments Regarding Skin
Toxicities
Innovative Approaches to the Management of
Spinal Metastasis
Nurses’ Session
Room: 204 A-B
A
ARON
Marilyn Haas, PhD, ANP-BC, Mission Hospital
Barbara Holmes Gobel, RN, MS, AOCN, Northwestern Memorial Hospital
Pamela Viale, RN, MS, CS, ANP, AOCNP, University of California San Francisco
4:15 p.m. - 5:45 p.m.
Panel 01
The Role of Innovation in Breast
Conservation – Cure, Convenience and Cost
Room: 253 A-C
Moderators:
Benjamin Smith, MD, MD Anderson Cancer Center
Panelists:
Benjamin Smith, MD, MD Anderson Cancer Center
Gary Freedman, MD, University of Pennsylvania
Andre Konski, MD, Wayne State University School of Medicine
54
Panel 02
Room: 052 A-B
Moderators:
Eric Lin Chang, MD, USC Keck School of Medicine
Simon Lo, MD, UH Seidman Cancer Center
Panelists:
Arjun Sahgal, MD, Princess Margaret Hospital
Peter Gerszten, MD, PhD, MPH, University of Pittsburgh Medical Center
Samuel Ryu, MD, Henry Ford Hospital
4:15 p.m. - 5:45 p.m.
Panel 03
Pareto Frontiers: Physician-Driven Treatment
Planning
Room: 210 A-C
Moderators:
Sasa Mutic, PhD, Washington University School of Medicine
Todd Pawlicki, PhD, University of California, San Diego
Panelists:
Kevin Moore, PhD, University of California San Diego
Daniel Low, PhD, University of California Los Angeles
Thomas Bortfeld, PhD, Massachusetts General Hospital
Sunday | October 28
4:15 p.m. - 5:45 p.m.
4:15 p.m. - 5:45 p.m.
Cancer Survivorship: Multidisciplinary Care of
Patients After Treatment Completion
Radiation/Chemoradiation and Biological Targeting
Moderator:
Ronald Chen, MD, University of North Carolina at Chapel Hill
Panelists:
Lawrence B. Marks, MD, FASTRO, University of
North Carolina
Lawrence Berk, MD, PhD, University of South Florida Moffitt Cancer Center
Stephen Edge, MD, Roswell Park Cancer Institute
Janet de Moor, PhD, MPH, National Cancer Institute
George Wilson, PhD, William Beaumont Hospital
Robert Bristow, MD, PhD, Princess Margaret Hospital-University of Toronto
Panel 04
Room: 109 A-B
4:15 p.m. - 5:45 p.m.
Panel 05
Impact of Genetic Factors, Autoimmunity and Comorbidity on Radiotherapy Toxicity
Room: 258 A-C
Moderator:
Bin Teh, MD, The Methodist Hospital
Panelists:
Zhongxing Liao, MD, Cancer Hospital of FuDan University
Arnold Paulino, MD, The Methodist Hospital
David E.Wazer, MD, FASTRO, Tufts Medical Center
Room: 254 A-B
5:30 p.m. - 6:30 p.m.
Nurses’ Reception*
Room: 257 A-B
A
ARON
John Grace, a cancer survivor and his wife Joan Raducha will discuss “Surviving and Thriving - With
Cancer a Part of Our Lives 2005-2012”. They will discuss
the experience of being diagnosed and then treated
for head and neck, then lung and most recently appendix cancers. They will describe facing the diagnosis, the treatment experience, and the
challenges of decision making regarding treatment
options and continuance. And finally, they will talk
about how they have come to thrive by learning to live
with cancer as a part of their lives.
*Event open to Nurse and Nurse practitioner attendees only.
4:15 p.m. - 5:45 p.m.
Pancreatic Cancer: Current Treatment Approaches and Controversies
Room: 107 A-C
Christopher Crane, MD, MD Anderson Cancer Center
Joseph Herman, MD, MS, Johns Hopkins University
Symbol Key:
A
ARON
Separate
Session
registration
required.
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
55
Monday | October 29
8:00 a.m. - 9:30 a.m.
8:00 a.m. - 9:30 a.m.
Optimal Sequencing of Radiotherapy and
Types of Reconstruction Post-mastectomy
Management of Oropharynx Cancer and Associated Toxicities
Lori J. Pierce, MD, FASTRO, University of Michigan
Kelly Hunt, MD, MD Anderson Cancer Center
Bernard Lee, MD, MBA, Beth Israel Deaconess Medical Center
Karen Hoffman, MD, MD Anderson Cancer Center
Alice Ho, MD, Memorial Sloan-Kettering Cancer Center
Adam Garden, MD, MD Anderson Cancer Center
Room: 205 A-C
8:00 a.m. - 9:30 a.m.
Role of Biologic Imaging in CNS Tumors
Room: 153 A-C
Michael Chan, MD, Wake Forest University Medical Center
John Fiveash, MD, University of Alabama at
Birmingham
8:00 a.m. - 9:30 a.m.
Challenging Cases in GI Malignancy
Room: 107 A-C
Theodore Hong, MD, Massachusetts General Hospital
Prajnan Das, MD, MS, MD Anderson Cancer Center
Sam Yoon, MD, Massachusetts General Hospital
Caio Rocha-Lima, MD, University of Miami
Room: 210 A-C
8:00 a.m. - 9:30 a.m.
Historical Perspective of Pediatric Radiation
Oncology, Particle Radiation Therapy and
Combined Modality for GI Malignancies
Room: 206 A-B
Gustavo S. Montana, MD, FASTRO, Duke University Medical Center
Edward Halperin, MD, New York Medical College
Herman D. Suit, MD, FASTRO, Massachusetts General Hospital
Christopher G. Willett, MD, FASTRO, Duke University Medical Center
8:00 a.m. - 9:30 a.m.
Updated Roles and Rules for Radiation Therapy of Indolent and Aggressive Lymphomas
Room: 109 A-B
Andrea Ng, MD, Brigham and Women’s Hospital
Joachim Yahalom, Memorial Sloan-Kettering Cancer
Center
8:00 a.m. - 9:30 a.m.
Management of High-risk Prostate Cancer
(Including Post-operative XRT)
Room: 258 A-C
Alan Pollack, MD, PhD, University of Miami Miller School of Medicine
Richard Valicenti, MD, UC Davis Medical Center
Yoshiya Yamada, MD, Memorial Sloan-Kettering Cancer Center
8:00 a.m. - 9:30 a.m.
Cancer Emergencies
Room: 160 A-C
Charles Thomas, MD, Oregon Health and Science University
James Yu, MD, Yale University School of Medicine
Symbol Key:
A
ARON
Separate
Session
registration
required
56
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
Monday | October 29
11:00 a.m. - 12:30 p.m.
8:00 a.m. - 9:30 a.m.
Radiobiology of Hypofractionation and IMRT
Room: 052 A-B
Michael Joiner, PhD, Wayne State University
Robert Timmerman, MD, University of Texas Southwestern Medical Center
Scientific Session I
Best of Physics
Room: 210 A-C
Moderators: David Jaffray
Paul Keall
11:00
Paige Summers
Comparison of Clinical Parameters for Proton
Therapy in the United States
8:00 a.m. - 9:30 a.m.
Image Guidance in the Treatment Room: Technology and Strategies
73
Room: 253 A-C
11:10
Shyam Rao
74
A Novel Voxel-Based Analysis of the Development
of Trismus Following Chemoradiation for Oropharyngeal (OPC) Cancer
Sasa Mutic, PhD, Washington University School of Medicine
Jean-Pierre Bissonnette, PhD, Princess Margaret Hospital
Patrick Kapelian, MD, University of California Los Angeles
11:20
Xiaofeng Yang
75
Ultrasound Nakagami Imaging to Evaluate Neck
Fibrosis Following Head and Neck Radiotherapy: A Feasibility and Reproducibility Study
11:30
John Bayouth
Establishing a Relationship Between Radiosensitivity of Lung Tissue and Ventilation
9:45 a.m. - 10:45 a.m.
Keynote Address I
Arthur L. Kellermann, MD, MPH,
RAND Health
Introduction by
Susan A. McCloskey, MD, University of California Los Angeles
76
11:40
Joseph Deasy
77
Independent Test of a Model to Predict Radiation
Pneumonitis After Definitive Radiotherapy for Locally Advanced NSCLC: Heart Irradiation Is (Again)
a Statistically Significant Risk Factor
11:50
Francisco Salguero
78
Significance of Microscopic Disease Extension in
Regional Control of Lung Cancer
10:00 a.m. - 5:00 p.m.
Exhibit Hall
Room: Halls A/B, Exhibit Hall
12:00
Kristin Karlsson
79
A Retrospective Study of Bronchial Doses and
Radiation Induced Atelectasis After SBRT of Lung
Tumours Located Close to the Bronchial Tree
10:00 a.m. - 6:45 p.m.
Poster Viewing
Symbol Key:
A
12:10
Ngoc Pham
Pre-treatment PET Predicts Clinical Radiation Pneumonitis in Esophageal Cancer Patients
80
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
57
Monday | October 29
12:20
Carmen Ares
81
Chordomas and Chondrosarcomas of the Skull Base:
Clinical Outcomes of the Paul Scherrer Institute
Experience Using Spot Scanning Proton Radiation
Therapy
12:10
Mina Shenouda
89
Prognostic Outcome of Local-regional Recurrence
in Breast Cancer Patients Treated by Breast Conservation Treatment
12:20
Meena Moran
Discussant
11:00 a.m. - 12:30 p.m.
Scientific Session J
11:00 a.m. - 12:30 p.m.
Scientific Session K
Breast I - Early-stage Local Therapy
Room: 205 A-C
CNS II - Low Grade, Benign and Spine
Room: 206 A-B
Moderators: Jennifer De Los Santos
Eleanor Walker
11:00
Randi Cohen
Improved Survival With Adjuvant Radiation in
Elderly Women With Early-stage Breast Cancer
Moderators: Helen Shih
Stephanie Weiss
82
11:10
Kenneth Roberts
83
Temporal Trends in Radiation Modalities Among
Older Women With Favorable Risk Breast Cancer
11:20
Mariam Korah
84
Implications of Omitting Radiation After Breast
Conserving Surgery in Elderly Women With Low-risk
Invasive Breast Cancer
11:30
Weisi Yan
85
Age, Hormonal Receptor Status, Ethnicity and Adjuvant Radiation Therapy As Predictive Factors
for Cancer - Related Death in Elderly Patients Aged
70 Years and Older With Early-stage pT1a,b N0
Breast Cancer: A NCI-SEER Database Analysis
11:00
Ryan Youland
90
Five Decades of Adult Low-grade Gliomas: Patterns
of Care Over Time
11:10
Helen Shih
Proton Therapy for Low Grade Gliomas: A Pilot
Study
91
11:20
John Lucas
92
Predictors of Durability of Response for Gamma
Knife Stereotactic Radiosurgery in the Treatment of
Trigeminal Neuralgia
11:30
Jona Hattangadi
Single Fraction Proton Beam Stereotactic Radiosurgery (PSRS) for Inoperable Cerebral Arteriovenous Malformations (AVMs)
93
11:40
Sounok Sen
86
Understanding Costs and Value of Newer Radiation
Modalities Among Older Women With Breast Cancer
11:40
Anoop Haridass
94
Technique for Using Dynamic CT Angiography
(dCTA) for FrameleScientific Session Stereotactic
Radiosurgical (SRS) Planning of Intracranial Arterio
Venous Malformations (AVM)
11:50
Charles Simone
87
Cardiac Toxicity is Not Increased 25 Years After
Treatment of Early-stage Breast Carcinoma With
Mastectomy or Breast Conservation Therapy From
the National Cancer Institute Randomized Trial
11:50
Colin Champ
95
Long term Outcomes of Low Dose Fractionated
Stereotactic Radiotherapy of 46.8 Gy for Acoustic
Schwannomas: The Thomas Jefferson University
Experience
12:00
Irene Karam
88
Treatment Patterns and Locoregional Recurrence
Outcomes in Patients With pN0(i+) Breast Cancer
12:00
Emily Tanzler
The Role of Proton Radiotherapy for Multiple Meningiomas
58
96
Monday | October 29
12:10
Yoshiya Yamada
97
Dynamic Contrast Enhanced MRI Based Assessment
of Tumor Response to High Dose Spine Stereotactic
Radiosurgery
12:20
Ameen Al-Omair
98
The risk of Vertebral Compression Fracture (VCF)
Post-spine Stereotactic Body Radiotherapy (SBRT)
and Evaluation of the Spinal Instability Neoplastic Score (SINS)
11:00 a.m. - 12:30 p.m.
11:50
Ravi Shridhar
105
Preoperative Dose Painting IMRT Chemoradiation
to 56 Gy In Esophageal Cancer Doubles Pathologic
Complete Response Rate Without Increasing Toxicity
12:00
Brian Czito
106
A Phase I/II Study of Capecitabine (Cape), Oxaliplatin (Ox), Panitumumab (Pmab) and External
Beam Radiation Therapy (RT) for Patients With
Esophagogastric Carcinoma (EC)
12:10
Scientific Session L
Theodore Hong
Discussant
GI II - Esophageal and Gastric: Understanding
Toxicity-improving Outcomes
11:00 a.m. - 12:30 p.m.
Moderators: William Jones
Rebecca Wong
Health Services Research I – Clinical Trials and
Guidelines
Room: 160 A-C
11:00
Masamitsu Hatakenaka
99
Acute Cardiac Impairment Associated With Concurrent Chemoradiotherapy for Esophageal
Cancer
11:10
Jingya Wang
100
Radiation Modality Is a Strong Predictor for Postoperative Pulmonary and GI Complications
after Trimodality Therapy for Esophageal Cancer
11:20
Matthew McCurdy
101
Predicting Symptomatic Radiation Pneumonitis Using Exhaled Nitric Oxide and [18F]
Fluorodeoxyglucose Positron Emission Tomography
11:30
Xueying Qiao
102
A Prospectively Randomized Study of Clinical Target
Volume Margins for Three-dimensional Conformal
Radiotherapy in Patients With Squamous Cell Carcinoma of Thoracic Esophagus
11:40
Heath Skinner
Metformin Use is Associated With Improved Response to Neoadjuvant Chemoradiation in Esophageal Adenocarcinoma
103
104
Withdrawn Scientific Session M
Room: 153 A-C
Moderators: Karen Hoffman
Robert Prosnitz
11:00
Stephen Edge
107
Impact of Guideline Changes in the Elderly With
Early Breast Cancer (BC): Practice Patterns at NCCN
Institutions
11:10
Daniela Buscariollo
108
Comparison of the Level of Evidence Supporting
Practice Guidelines in Cancer Care Between Therapeutic Modalities
11:20
Cary Gross
109
An Assessment of the Collective Efforts of Clinical
Trials to Provide Evidence-based Practice Guidelines
in Cancer Care
11:30
Bruce Minsky Discussant
11:40
Alysa Fairchild
110
Does Quality of the EORTC Dummy Run Predict
Outcomes of Multi-center Clinical Trials?
11:50
Sanjay Aneja
111
The Funding of Phase 3 Clinical Trials Examining
Radiation Compared With That of Other Modalities
59
Monday | October 29
12:00
Kaveh Zakeri
112
Improving the Efficiency of Clinical Trials Through
Selection Models
12:10
Kosj Yamoah
113
Radiation Intensification in the Context of Concurrent Chemotherapy: Fruitful or Futile? A 20-year Meta-analysis of Phase III Randomized Controlled Trials Across Session Different Disease
Sites
12:20
Sabine Mueller
114
Retrospective Cohort Analysis of Risk of First and
Recurrent Stroke in Childhood Cancer Survivors
Treated With Cranial Radiation Therapy
11:00 a.m. - 12:30 p.m.
Scientific Session N
Lung I - SBRT: Efficacy/Response Assessment/
Toxicity
Room: 052 A-B
Moderators: Steven Feigenberg
Ramesh Rengan
11:00
Yasushi Nagata
115
Stereotactic Body Radiation Therapy for T1N0M0
Non-small Cell Lung Cancer: First Report for Inoperable Population of a Phase II Trial by Japan
Clinical Oncology Group (JCOG 0403)
11:10
Christopher Platta
116
Sublobar Resection With Intraoperative 125I Brachytherapy vs. Stereotactic Body Radiation
Therapy for Treatment of Clinical Early Stage q
Non-small Cell Lung Cancer in Patients Not Eligible
for Lobectomy
11:20
Suresh Senan
117
Patterns of Disease Recurrence Following Either Stereotactic Ablative Radiotherapy (SABR) or Lobectomy By Video-assisted Thoracoscopic Surgery (VATS) In Stage I-II Non-small Cell Lung
Cancer: Outcomes of a Propensity Score-matched
Analysis
60
11:30
Patrick Cheung
118
A Phase II Study of Accelerated Hypofractionated
3-Dimensional Conformal Radiotherapy for
Inoperable T1-3 N0 M0 Non-small Cell Lung Cancer:
NCIC CTG BR.25
11:40
Brian Kavanagh
Discussant
11:50
Sinisa Stanic
119
No Clinically Significant Changes in Pulmonary
Function Following Stereotactic Body Radiation
Therapy (SBRT) Among Medically Inoperable
Patients With Early Stage Peripheral Non-small Cell
Lung Cancer: An Analysis of RTOG 0236
12:00
Lane Rosen
120
Monitoring the Response of Stereotactic Body Radiotherapy (SBRT) in Patients With Early-stage
Lung Cancer Using Serial Positron Emission Tomography (PET)
12:10
Rainer Klement
121
Is There a Dose Response Relationship for Pulmonary Function Changes After Stereotactic
Body Radiotherapy for Early Stage NSCLC?
12:20
Hiroshi Onishi
122
Stereotactic Body Radiotherapy in 95 Patients With
Lung Tumors Composed of Ground-glass Opacity
(GGO): Results of a Retrospective Multi-center study
11:00 a.m. - 12:30 p.m.
Scientific Session O
Palliative Care/Quality of Life
Room: 109 A-B
Moderators: Stephen Thomas Lutz
Anand Mahadevan
11:00
Clayton Hess
123
Prospective Psychosocial Distress Screening in
Radiation Oncology Patients at a Tertiary Academic
Medical Center: What Does Implementation of
Current NCCN Distress Management Guidelines
Actually Accomplish?
Monday | October 29
11:10
Michael Buckstein
124
Genome Wide Association Study to Identify Genetic
Variants Associated With the Development of
Erectile Dysfunction Following Radiotherapy for
Prostate Cancer
11:20
Luluel Khan
125
Predictive Factors for Overall Quality of Life in Advanced Cancer Patients From Eortc Qlq-pal-15
11:30
Nora Janjan
Discussant
11:40
James Murphy
Inequality In Palliative Radiotherapy: A Population-based Analysis
11:10
Brian Winey
132
In Vivo Treatment Verification Using In-room PET
in Proton Radiation Therapy: First Clinical Trials and
Evaluation of Short-length Scan
11:20
Julia-Maria Osinga 133
Proton and Ion Beam Radiotherapy: A Microscopic
Dosimetry System for Radiobiology and Treatment
11:30
Byung Jun Min
134
Applications of Proton Digital Tomosynthesis in
Proton Beam Therapy
126
11:50
Chris Fosker
127
Tailoring Palliative Radiotherapy (RT) Towards the
End of Life – The Importance of ECOG Performance
Status
12:00
Sophia Lane
128
Radiotherapy for Intubated Patients With Malignant
Airway Obstruction: Futile or Facilitating Extubation?
12:10
Monica Krishnan 129
Factors Predicting Life Expectancy in Patients With
Metastatic Cancer Receiving Palliative Radiotherapy
12:20
Christina Son
130
Dosimetric Predictors of Radiation-induced Vaginal
Stenosis in Rectal and Anal Cancer Patients
11:00 a.m. - 12:30 p.m.
Scientific Session P
Particle Therapy
Room: 258 A-C
Moderators: Jatinder Palta
Alexei Trofimov
11:40
Tsunashima Yoshikazu
135
Experimental Evaluation of the Interplay Effect
and Motion Management by Respiratory Gating
in Synchrotron Based Spot Scanning Proton Beam
Delivery
11:50
Satoshi Nakamura
136
Development of Fast And High-spatial-resolution
Three-dimensional Dosimetry Equipment for Both
the Narrow Beam and the Broad Beam in Proton
Therapy
12:00
Harald Paganetti
137
Advanced Dose Calculation to Reduce Uncertainties in Treatment Planning and Delivery
for Proton Therapy Patients
12:10
Vadim Moskvin
138
Skin Reaction for Spine and Brain Patients at a
Health Proton Therapy Center: A Retrospective
Study and Physics Consideration
12:20
Brian Yeh
139
Adaptive Replanning Is Required During Intensity Modulated Proton Therapy for Head And
Neck Cancers
11:00
Maria Francesca Spadea
131
Contrast Enhanced Proton Radiography for In-room
Soft-tissue Based Setup
61
Monday | October 29
11:00 a.m. - 12:30 p.m.
Biology
Room: 156 A-C
Discussants: Robert Den
Gayle Woloschak
Felix Feng
1025
A Tissue-specific Long Non-coding RNA Controls
Homologous Recombination in Prostate Cancer
Basic Science Abstract Award Winner -BIOLOGY
Somaira Nowsheen
1026
Synthetic Lethal Interactions Between EGFR and
PARP Inhibition in Triple Negative Breast Cancer
Richard Bakst
1033
Low Dose Radiation to the Nerve Alone Impairs Perineural Invasion Independent of Cancer Cell
Death
Resident Clinical/Basic Science Research Award
Winner – BIOLOGY
Mohamed Abazeed
1034
Nrf2 Pathway Activation Regulates Radiation Resistance in Lung Squamous Cell Carcinoma
Resident Digital Poster Recognition Award
Winner - BIOLOGY
Serah Choi
1027
Quantitative Proteomics Reveal ATM Kinase-dependent Exchange in DNA Damage
Response Complexes
Brian Baumann
1035
An Integrated Method for Reproducible, Accurate
Image-guided Stereotaxic Cranial Irradiation of
Brain Tumors Using the Small Animal Radiation
Research Platform (SARRP)
Susan McGovern
1028
Extracellular Domain Mutations in EGFR Occur
Uniquely in Glioblastoma and Favor Ligand Independent Formation of the Active State
Dwight Heron
1036
Apoptosis Imaging With 18F-ML-10 Is an Early Predictor of Response of Brain Metastases Treated
With Stereotactic Radiosurgery
Nishant Gandhi
1029
Novel Hsp90 Inhibitor NVP-AUY922 Radiosensitizes
Prostate Cancer Cells
11:00 a.m. - 12:30 p.m.
Genitourinary
Joshua Silverman
1030
Pilot Trial of Radiotherapy and GM-CSF in Metastatic
Cancer: Abscopal Responses
Christopher Willey
1031
Kinomic Proband Model of Radiation Response
From Patient-derived Gbm Xenolines
Samayita Das
1032
Carbon Irradiation Exerts Potent Antiangiogenic
Effects Via Downregulation of Vascular Endothelial
Growth Factor in Lung and Prostate Cancer Models
62
Room: 157 A-C
Discussants: Ronald Ennis
Andrew K. Lee
Shinichi Shimizu
1037
Decreasing Acute and Late Toxicity Using Urethral
Dose Reduction and Smaller Safety Margin Around
CTV for Prostate Cancer Intensity-Modulated Radiation Therapy (IMRT) With a Real-Time Tumor-Tracking (RTRT) System
George Rodrigues
1038
The Prostate Cancer Risk Stratification (ProCaRS)
Project: Recursive Partitioning Risk Stratification
Analysis
Monday | October 29
Ayal Aizer
1039
Physician Bias, Referral to a Medical Oncologist and
Active Surveillance in Low-risk Prostate Cancer
11:00 a.m. - 12:30 p.m.
Kris Huang
1040
Primary Prostate Radiotherapy: Where Are We Failing?
Room: 253 A-C
Michael Yassa
1041
Late Consequential Effects of Hypofractionated
Radiotherapy in Prostate Cancer: Impact of Acute
Toxicity on Toxicity at 4 Years and 8 Years
Natasha Townsend
1042
Recursive Partitioning Analysis of Intermediate-risk
Prostate Cancer Patients Identifies Subgroup Risk
Categories
Zvi Symon
1043
Volumetric Modulated Arc Therapy With a Gentle
Hypofractionated Concomitant Integrated Prostate
Boost: Toxicity and Quality of Life Outcomes
Amar Challapalli
1044
Establishing the Use of [11C]Choline PET-CT As
an Image-based Biomarker in Prostate Cancer:
Evaluation of [11 C]Choline Parameters Following
Neoadjuvant Androgen Deprivation and Radical
Radiotherapy
David Beyer
1045
Brachytherapy Alone May Be Sufficient for Most
Early Prostate Cancer Patients
Drew Moghanaki
1046
Elective Pelvic Lymph Node Irradiation, Without
Androgen Deprivation Therapy, During Post-prostatectomy Salvage Radiotherapy
Jesse Alexander
1047
Pre-plan Dosimetry As a Predictor of Clinical Outcome for 125I Permanent Prostate Implants (PPI)
Jeffrey Martin
1048
Do Testosterone Kinetics After Radiation Therapy
(RT) Predict Biochemical Failure (BCF) for Low- and
Intermediate-risk Prostate Cancer (CaP)?
Difficult Cases in Endometrial and Vaginal
Cancer
Arno Mundt, MD, UC San Diego Radiation Oncology
Kaled Alektiar, MD, Memorial Sloan-Kettering Cancer Center
Ann Klopp, MD, MD Anderson Cancer Center
Ellen Jones, MD, PhD, UNC Radiation Oncology
11:00 a.m. - 12:30 p.m.
Integration of Systemic Treatment with Radiation Therapy for Head and Neck Cancer
Room: 107 A-C
Roy Tishler, MD, PhD, Dana-Farber Cancer Institute
Ezra Cohen, MD, University of Chicago
David Rosenthal, MD, MD Anderson Cancer Center
11:00 a.m. - 12:30 p.m.
Nurses’ Session
Role of the Advanced Practice Nurse (APN) in a
Radiation Oncology Setting
Room: 259 A-B
A
ARON
Vanna M. Dest, MSN, APRN, BC, AOCN, Smilow Cancer Hospital Yale New Haven, Saint Raphael Campus
Diane Doyle, MS, APRN, BC, AOCN, Massachusetts General Hospital
Elene Viscosi, APRN, BC, Massachusetts General
Hospital
Symbol Key:
A
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
63
Monday | October 29
11:00 a.m. - 12:00 p.m.
Foreign Language Poster Walks*
Room: Hall C, Poster Check-in Desk
International Poster Walks will be offered in Chinese and Spanish, and will review selected
abstracts based on disease site. Please note that this
event is open to International attendees only. Please
refer to the details below for further information.
CHINESE POSTER WALK
Faculty: W. Ken Zhen, MD
Disease Site: Head and Neck
Moderator:
Nina A. Mayr, MD, FASTRO, The Ohio State University
Panelists:
Colleen F. Lawton, MD, FASTRO
ASTRO President-elect, Medical College of Wisconsin
Barit L. Madsen, MD, Peninsula Cancer Center
Mary K. Martel, PhD, FASTRO, MD Anderson Cancer Center
Nancy S. Tarbell, MD, FASTRO, Harvard Medical School
SPANISH POSTER WALK
Faculty: Adela Poitevin, MD
Disease Site: Breast, CNS and Prostate
12:30 p.m. - 1:45 p.m.
education credits.
Box Lunch Provided
How to Review a Scientific Paper Workshop*
Room: 159
12:30 p.m. - 1:45 p.m.
AAWR/ASTRO Luncheon* A Mentorship Panel for Women in Radiation
Oncology
Room: 257 A-B
Join us for the annual AAWR/ASTRO Luncheon
Panel. This diverse panel of accomplished women
radiation oncologists will discuss and answer questions on professional advancement in academic and community practice, opportunities
and challenges and involvement in health care
politics, for women in Radiation Oncology.
Moderator :
W. Robert Lee, MD, MEd, Duke University
Workshop Faculty:
Robert J. Amdur, MD, University of Florida
Soren M. Bentzen, DSc, PhD, University of Wisconsin
Anthony V. D’Amico, MD, PhD, FASTRO,
Brigham and Women’s Hospital
Lynn D. Wilson, MD, MPH, FASTRO, Yale University School of Medicine
Anthony L. Zietman, MD, FASTRO, Massachusetts General Hospital
12:30 p.m. - 1:45 p.m.
ARRO Poster Walks With a Professor Box Lunch Provided
Room: Hall C, Poster Lounge
Symbol Key:
A
ARON
Separate
Session
registration
required
64
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
Monday | October 29
1:45 p.m. - 2:30 p.m.
Presidential Address: The Patient Not Treated
Michael L. Steinberg, MD, FASTRO, President, ASTRO
Introduction by: Paul E. Wallner, DO, FASTRO, 21st Century Oncology
2:30 p.m. – 3:45 p.m.
Plenary Session
Co-moderators: Lynn D. Wilson
Benjamin Movsas
2:30 p.m.
Robert C. Miller
LBA1
N09C6 (Alliance) - A Phase III, Randomized
Double-blind Study of Doxepin Rinse vs. Placebo in
the Treatment of Acute Oral Mucositis Pain in Patients
Receiving Head and Neck Radiotherapy With or Without Chemotherapy
3:06 p.m.
Michael J. Zelefsky
3
Results of a Prospective Randomized Double-blind
Placebo-controlled Trial Evaluating the Use
Prophylactic Sildenafil Citrate During Radiation
Therapy in the Treatment of Prostate Cancer
3:13 p.m.
2:37 p.m.
Paul Harari
2:42 p.m.
Nadia Laack
Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiation Therapy (WBRT): First Report of RTOG
0614, a Placebo-controlled, Double-blind, Randomized Trial
2:49 p.m.
Vinai Gondi
1
Discussant
2:54 p.m.
Nitin Ohri
2
Radiation Therapy Protocol Deviations are Associated With Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials
Resident Clinical/Basic Science Award
Winner – CLINICAL
3:01 p.m.
Ross Abrams
Thomas Pisansky
Discussant
Discussant
3:18 p.m.
Timothy J. Whelan
LBA2
Interim Toxicity Results From RAPID: A Randomized
Trial of Accelerated Partial Breast Irradiation (APBI) Using 3-D Conformal External Beam Radiation
Therapy (3-D CRT)
3:25 p.m.
Bruce Haffty
Discussant
3:30 p.m.
Aileen B Chen
4
Patient Beliefs About Palliative Radiation Therapy
(RT) in Incurable Lung Cancer
3:37 p.m.
Thomas Lynch Discussant
Discussant
65
Monday | October 29
4:00 p.m. - 5:30 p.m.
4:00 p.m. - 5:30 p.m.
Post Mastectomy Radiotherapy After Neo- adjuvant Chemotherapy: Update on Indications for Treatment
Brachytherapy Fundamentals and Evolving
Paradigms
Panel 06
Panel 08
Room: 210 A-C
Moderator:
Catherine Park, MD, University of California,
San Francisco
Panelists:
Yunn-Yi Chen, MD, PhD, University of California,
San Francisco
Barbara L. Fowble, MD, FASTRO, University of California, San Francisco
Terry Mamounas, MD, Northeastern Ohio Universities Colleges of Medicine
Thomas Buchholz, MD, PhD, FASTRO, MD Anderson Cancer Center
Room: 107 A-C
Moderator:
Panelists:
Christian Kirisits, DSc, Medical University of Vienna
Paul Nguyen, MD, Dana-Farber/Brigham and Women’s Cancer Center
4:00 p.m. - 5:30 p.m.
Panel 09
The Role of Innovation in Palliation – Is the
Benefit Worth the Cost?
4:00 p.m. - 5:30 p.m.
Panel 07
Room: 160 A-C
Innovations in Stereotactic Body Radiation
Therapy for Lung Cancer
Room: 205 A-C
Moderators:
Andrea Bezjak, MD, Princess Margaret Hospital
Joe Chang, MD, PhD, MS, MD Anderson Cancer Center
Panelists:
Billy Loo, MD, PhD, Stanford University
Ben Slotman, MD, PhD, VU University Medical Center
Moderators:
Carol Hahn, MD, Duke University Medical Center
Stephen Thomas Lutz, MD, Blanchard Valley Regional Health Center
Panelists:
Carol Hahn, MD, Duke University Medical Center
Stephen Thomas Lutz, MD, Blanchard Valley Regional Health Center
4:00 p.m. - 5:30 p.m.
Panel 10
Cancer Genesis, Treatment and Late Effects
Across the Age Spectrum
Room: 153 A-C
Symbol Key:
A
ARON
Separate
Session
registration
required.
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
66
Moderators:
Louis S. Constine, MD, FASTRO, University
Rochester Medical Center
Panelists:
Jacqueline Williams, PhD, FASTRO, University of
Lawrence Marks, MD, FASTRO, University of North Carolina
Monday | October 29
Louis S. Constine, MD, FASTRO, University
Lois Travis, ScD, MD, University of Rochester Medical Center
4:00 p.m. - 5:30 p.m.
5:30 p.m. - 6:30 p.m.
2012 NCI/ASTRO Diversity Session and
Reception*
Improving Cancer Care Globally: A Call to
Service in Radiation Oncology
Room: 159
Cancer of the Colon, Rectum and Anus
Room: 258 A-C
Karyn Goodman, MD, MS, Memorial Sloan-Kettering Cancer Center
Brian Czito, MD, Duke University Medical Center
4:00 p.m. - 5:30 p.m.
Volumetric Modulated Arc Therapy: Planning
and Quality Assurance
Room: 253 A-C
Charles Mayo, PhD, Mayo Clinic
Todd Pawlicki, PhD, University of California, San Diego
Jean Moran, PhD, University of Michigan
5:30 p.m. - 6:45 p.m.
Poster Viewing Session and
Reception*
Room: Hall C
During this session, all poster presenters are asked
to stand by their poster to answer questions about
their research. New this year will be a presentation
area where the poster viewing award winners will
provide highlights of their research and be
available for questions. The presentation schedule
will be on-site.
*This session is not accredited for continuing Medical
Education Credits.
Members of the National Cancer Institute and Cancer Disparities Research Partnership (CDRP) project invite you to join them for an in-depth
look at the disconcerning disparities in cancer
care around the globe. Expert speakers who have
completed groundbreaking work to improve the
delivery of radiation oncology services in developing nations will share their stories and
insights.
Moderator:
Patrick Maguire, MD, Coastal Carolina Radiation Oncology
Desperate and Disparate in a Time of Many
Transitions: Improving All Research and Practice in Radiation Oncology
Introduction: Bhadrasain Vikram, MD, National Cancer Institute
Speaker: Glenn Jones, MD, Peel Regional Cancer Center
Cambodian Radiation Therapy Project
Introduction: Luqman Dad, MD, Annapolis Radiology Associates
Speaker: Tracy Bray, MD, Loyola University Medical Center
Possible Business Models for Radiation
Therapy Facilities in Bangladesh
Introduction: Bhadrasain Vikram, MD, National Cancer Institute
Speaker: Richard Love, MD, Ohio State University
education credits.
67
Tuesday | October 30
8:00 a.m. - 9:30 a.m.
8:00 a.m. - 9:30 a.m.
Breast Cancer Management: Early Stage
Disease
Improving Outcomes in Geriatric Patients
Through Use of Comprehensive Geriatric Assessment, Tools Available to Make It Happen
Room: 258 A-C
Meena Moran, MD, Yale University School of Medicine
Julia Wong, MD, Brigham and Women’s Hospital
Room: 153 A-C
A
ARON
8:00 a.m. - 9:30 a.m.
Esophagus and Gastric Cancer: Contemporary
Treatment Approaches
Room: 253 A-C
Diane Cope, PhD, ARNP, Florida Cancer Specialists and Research Institute
Lynn Heup, GNP-BC/AOCNP, MS, Emory Healthcare
8:00 a.m. - 9:30 a.m.
Gary Yang, MD, Loma Linda University
Harvey Mamon, MD, PhD, Brigham and Women’s Hospital
External Beam Radiotherapy for Prostate
Cancer: Dose, Volume, Fractionation
Room: 205 A-C
8:00 a.m. - 9:30 a.m.
Jason Efstathiou, MD, PhD, Massachusetts General Hospital
Eric Horwitz, MD, Fox Chase Cancer Center
Controversies in the Management of Interactive Endometrial Cancer
8:00 a.m. - 9:30 a.m.
Room: 107 A-C
William Small Jr., MD, FASTRO, The Robert H. Lurie Comprehensive Cancer Center of
Northwestern University
Julian Schink, MD, Northwestern Univsersity Feinberg School of Medicine
Radiation Oncology in the Developing World –
How to Bridge the Gap
Room: 052 A-B
Bernard J. Cummings, MB, ChB, FASTRO, Princess Margaret Hospital
Jatinder Palta, PhD, University of Florida
Mario Baeza, OCN, Instituto de Radiomedicina
Tim R. Williams, MD, FASTRO, Lynn Cancer Institute
8:00 a.m. - 9:30 a.m.
Symbol Key:
A
Room: 206 A-B
ARON
Separate
Session
registration
required
68
Pediatric Tumors: Update on Pediatric Sarcomas and Hodgkin’s Lymphoma
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
Stephanie Terezakis, MD, Johns Hopkins School of Medicine
Suzanne Wolden, MD, Memorial Sloan-Kettering Cancer Center
8:00 a.m. - 9:30 a.m.
Soft Tissue and Bone Sarcoma – Management
of Difficult Cases
Room: 204 A-B
9:45 a.m. - 10:45 a.m.
Keynote Address II:
Future Trends in Cancer
Survivorship*
Elizabeth Baldini, MD, Brigham and Women’s Hospital
Thomas DeLaney, MD, Massachusetts General Hospital
Chandrajit Raut, MD, Brigham and Women’s Hospital
R. Lor Randall, MD, University of Utah
Robert Maki, MD, PhD, Mount Sinai School of Medicine
Edward M. Kennedy Jr., President and
Co-founder, Marwood Group
Introduction by: Jay S. Loeffler, MD, FASTRO,
*This sesson is not accredited for continuing Medical
Education Credits.
8:00 a.m. - 9:30 a.m.
10:00 a.m. - 5:00 p.m.
Cell Death Processes and Bystander Effects:
Relevant to Clinical Radiotherapy
Room: Halls A/B
Theodore DeWeese, MD, Johns Hopkins School of Medicine
Frank Pajonk, MD, PhD, UCLA Health systems
Kevin Prise, MD, Queen’s University Belfast
10:00 a.m. - 5:00 p.m.
Room: 109 A-B
8:00 a.m. - 9:30 a.m.
Practical Use of Image Registration and Data
Fusion for Planning, Delivery and Adaptation
of Radiotherapy
Room: 160 A-C
Kristy Brock, PhD, Princess Margaret Hospital
Marc Kessler, PhD, University of Michigan
Patrick Kupelian, MD, University of California , Los Angeles
Exhibit Hall
Poster Viewing
10:45 a.m. - 12:00 p.m.
Awards Ceremony
Gold Medal, Honorary Member, Fellows and
Survivor Circle
The Awards Ceremony is held in honor of ASTRO’s
2012 award recipients and Fellows. Show your appreciation for these premier leaders by joining in
the celebration of their accomplishments.
69
12:00 p.m. - 1:15 p.m.
Business Meeting
Room: 210 A-C
ASTRO voting members (Active, Affiliate, Allied or
International members) are invited to attend the
Business Meeting. Leaders of the Society will discuss
and make presentations on important topics of
interest to ASTRO members. You should not miss
this important meeting. Lunch will be served.
Scientific Session Q
GU II - Prostate Cancer: Prognostic Factors
Room: 258 A-C
2:35
Moderators: Alan Pollack
Andrew Wang
1:15
Arie Dosoretz
140
A Decision Analysis to Assess the Value of Prostate
Cancer Screening: A Shift in Focus From Prostate
Cancer Specific Mortality to Distant Metastasis Free
Survival
1:25
George Rodrigues
141
The Prostate Cancer Risk Stratification (ProCaRS)
Project: Database Construction and Outcome
Analysis
1:35
Jonathan Schoenfeld
142
Single Nucleotide Polymorphism in Inflammatory
Gene RNASEL Predicts Outcome After Radiotherapy
for Localized Prostate Cancer
1:45
Danielle Margalit
143
Genetic Variation in the Antioxidant Gene Superoxide Dismutase 2 (SOD2) and Response to
Radiation Therapy (RT) for Prostate Cancer (PCa)
70
2:15
Neelam Tyagi
146
Quantifying Tumor Agressiveness Using Diffusion
Weighted MRI for Prostate Cancer
2:25
Radka Stoyanova
147
Determinants of Prostate Biopsy Positivity Two Years
After Radiotherapy for Men With Prostate Cancer
Treated on a Randomized Trial
1:15 p.m. - 2:45 p.m.
1:55
Felix Feng Validation of a Genomic-clinical Classifier for Predicting Clinical Progression in Post-prostatectomy High-risk Prostate Cancer.
2:05
Daniel Krauss
145
Neuroendocrine Differentiation in Gleason Score
7-10 Prostate Adenocarcinoma Treated With Primary
Radiotherapy: A New Prognostic Variable to be
Considered
144
Theodore DeWeese
Discussant
1:15 p.m. - 2:45 p.m.
Scientific Session R
Head and Neck II - Treatment Toxicity
Room: 052 A-B
Moderators: Beth Beadle
Roy Tishler
1:15
Sophie Otter
148
Atlas Based Dose Volume Modeling of Individual
Patient Dose-distribution (Oral and Pharyngeal
Mucosa) to Predict the Risk of Acute Grade 3 Oral
and Pharyngeal Mucositis
1:25
Marianne Feen Roenjom
149
Hypothyroidism After Primary Radiotherapy in
Squamous Cell Carcinoma of the Head and Neck
(HNSCC)
1:35
Samuel Swisher-McClure
150
Risk of Fatal Cerebrovascular Accidents (CVA) in
Patients Treated With Radiotherapy (RT) or Surgery
for Early Stage Glottic Larynx Cancer
Withdrawn
151
1:45
John Lukens
152
Late Consequential Surgical Bed Soft Tissue Necrosis in Advanced Oropharyngeal Squamous
Cell Carcinomas (OP-SCC) Treated With Transoral
Robotic Surgery (TORS) and Postoperative Radiation
(PORT)
1:55
Aashish Bhatt
153
Impact of Transcutaneous Neuromuscular Electrical
Stimulation for Dysphagia in Head and Neck Cancer
Patients Treated With Definitive Chemoradiation
2:05
Tessa Goldsmith
154
Swallowing Function After Proton Beam Therapy for
Nasopharyngeal Cancer: A Prospective Study
2:15
Katherine Hutcheson
155
Swallowing Outcomes After Adaptive Radiotherapy
for Oropharyngeal Cancer: Results of a Prospective
Trial
2:25
Bharat Mittal
156
Effect of Recombinant Human Deoxyribonuclease
(rhDNase) on Oropharyngeal Secretions in Patients
With Head and Neck Cancers Treated With Radio-chemotherapy
1:15 p.m. - 2:45 p.m.
Scientific Session S
Pediatrics I - CNS
Room: 154
Moderators: Arthur Liu
Torunn Yock
1:35
Jonathan Verma
159
Reproducibility of Patient Positioning in Supine and
Prone Craniospinal Irradiation in the Treatment of
Medulloblastoma
1:45
Raymond Mailhot
160
A Consensus Atlas for Whole Ventricular Irradiation
for Pediatric Germ Cell Tumors: Survey Results and
Guidelines
1:55
Rachel Jimenez
Proton Radiotherapy for High-risk Pediatric Medulloblastoma: Outcomes for Very Young Children Treated With Upfront Chemotherapy
161
2:05
Harold Agbahiwe
162
A Prospective Study of Cerebral, Frontal Lobe and
Temporal Lobe Volume, and Neuropsychologic
Performance in Children With Primary Brain Tumors
Treated With Cranial Radiation
2:15
Arnold Paulino
163
Impact of Target Volume on Local Control After
Intensity Modulated Radiation Therapy (IMRT) for
Pediatric Low Grade Glioma
2:25
Kristin Redmond
164
Motor Dysfunction Following Cranial Irradiation for
Pediatric Brain Tumors: A Prospective Study
2:35
Tamara Vern-Gross
165
Prospective Evaluation of Local Control and Late
Effects of Image Guided Radiotherapy in Childhood
High Grade Glioma
1:15
Jihyeon Joo
157
Treatment Outcome of Radiation Therapy for Intracranial Germinoma: Suggestion of Radiation
Field When Combined to Upfront Chemotherapy
1:25
Patrik Brodin
158
Reducing the Risk of Neurocognitive Impairment by
Protecting the Neurogenic Niches During Radiation
Therapy for Pediatric Medulloblastoma
Symbol Key:
A
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
71
1:15 p.m. - 2:45 p.m.
1:15 p.m. - 2:45 p.m.
Lung II - Biologics and Chemo/Radiation
Therapy
Lymphoma - Outcomes (Efficacy, Toxicity) and
Innovations
Moderators: Shilpen Patel
Gregory Videtic
Moderators: Louis S. Constine
Kenneth Roberts
1:15
Gregory Gan
166
Ablative Local Therapy Extends the Clinical Benefit
of Crizotinib in Alk-positive Lung Cancer
1:25
Hans Theodor Eich
173
Involved Field (IF) vs. Extended Field (EF) Radiotherapy (RT) for Patients in Early Unfavorable
Stages of Hodgkin Lymphoma: 10-year Update of
the HD8 Trial of the German Hodgkin Study Group
(GHSG)
Scientific Session T
Scientific Session U
Room: 160 A-C
1:25
Yasumasa Nishimura
167
Phase II Study of Nimotuzumab in Combination
With Concurrent Chemoradiotherapy (CRT) in
Patients With Locally Advanced Non-small Cell Lung
Cancer (NSCLC)
1:35
Marcos Santos
168
Meta Analysis of Toxicities in Phase I or II Trials
Studying the Use of Target Therapy (TT) Combined
to Radiotherapy in Patients With Locally Advanced
Non-small Cell Lung Cancer (NSCLC)
1:45
Ritsuko Komaki
169
The Phase II Trial of Erotinib and Radiotherapy Following Chemoradiotherapy for Patients With
Stage III Non-small Cell Lung Cancer Has Shown a
Favorable Response Profile
1:55
Hak Choy
Discussant
2:05
Weili Wang
170
Single Nucleotide Polymorphisms in DNA Repair
Genes May Be Associated With Survival in Patients
With Non-small Cell Lung Cancer Treated With
Definitive Radiotherapy
2:15
Mohamad Fakhreddine
171
Poor Glycemic Control During Radiochemotherapy
Contributes to Reduced Local Control and Overall
Survival in Patients With Non-small Cell Lung Cancer
2:25
James Welsh
172
Implications of KRAS Mutations on Outcomes in
Non-small Cell Lung Cancer Treated With Radiation
Therapy
72
Room: 153 A-C
1:35
Berthe Aleman
Second Cancer Risk 40 Years After Hodgkin Lymphoma Treatment
174
1:45
Maja Vestmoe Maraldo
Involved Node Radiotherapy for Hodgkin
Lymphoma: Treatment Outcome in a Single-institution Cohort
175
1:55
Andrea Ng
Discussant
2:05
Marianne Aznar
176
Deep-inspiration Breath Hold vs. IMRT in Minimizing
Late Side Effects in Hodgkin Lymphoma
2:15
Gabriele Reinartz
177
Stage-adapted Radiotherapy for Treatment of
Localized Gastric Marginal Zone Lymphoma in 326
Patients: Results of the German Study Group on
Gastrointestinal Lymphoma (DSGL)
2:25
Andrea Russo
178
Low-dose Involved Field Radiation in the Palliation
of Non-Hodgkin Lymphoma: Predictors of Response
and Treatment Failure
2:35
Bouthaina Dabaja
179
Mid-Therapy PET Scan Significantly Predict
Outcome in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Chemotherapy
Alone But Not When Consolidation Radiation Is
Added
2:45
Run-Ye Wu
180
Patterns of Local Extension and Regional Spread
in Early Stage Nasal NK/T-cell Lymphoma Based on
Magnetic Resonance Imaging
1:15 p.m. - 2:45 p.m.
Scientific Session V
Translational Radiobiology
2:15
Qifeng Wang
187
ATM Polymorphisms Are Associated With Radiosensitivity for Patients With Esophageal
Squamous Cell Carcinoma Underwent Preoperative
Radiotherapy
2:25
Ruth White
188
Cancer Stem Cell Specific MicroRNA Aberrations in
a Model of Recurrent Squamous Cell Carcinoma:
Implications for Targeted Radiosensitization
2:35
Caroline Chung
Phase I Dose Escalation Study of Sunitinib and
Radiosurgery for Brain Metastases
Room: 109 A-B
Moderators: Fei-Fei Liu
Phouc Tran
1:15
Eddy Yang
181
Human HER2+ Breast Cancer Susceptibility to
Poly(ADP-Ribose) Polymerase Inhibitors Independent of a Homologous Recombination
Repair Defect
Basic Science Abstract Award Winner – BIOLOGY
1:25
Kamila Nowak
182
PF02340166 Inhibits ALK Downstream Effectors and
Increases Sensitivity to Radiation in Cells Harboring
the EML4-ALK Fusion
1:35
Yuta Shibamoto
183
IMAX (Immunity-maximized) Cancer Therapy:
Combination of Dendritic Cell-based Vaccine and
Intensity Modulated Radiation
1:45
In Ah Kim
MicroRNA-200c Increases Radiosensitivity of Human Cancer Cells With Activated EGFR or HER2-Associated Signaling
2:05
Ji-Hong Hong
186
Combination of Vessel-targeting Agents With Fractionated Radiotherapy: The Role of SDF-1/
CXCR4 Pathway
184
1:55
Harriet Eldredge
185
Whole Brain Radiotherapy and Chloroquine in
Patients With Brain Metastases: Outcomes and
Response Related to IDO2 Gene Single-Nucleotide
Polymorphisms
189
1:15 p.m. - 2:45 p.m.
Scientific Session W
Radiobiological Modeling
Room: 204 A-B
Moderators: Joseph Deasy
Mary Martel
1:15
Almut Troeller
190
Comparison of Normal Tissue Complication Probability (NTCP) Model Outcomes for Conformal
Radiotherapy (CRT) vs. Intensity Modulated Radiotherapy (IMRT) of Prostate Cancer
1:25
Timothy Schultheiss
191
A Cross-species Model for Radiation Myelopathy
1:35
Chul Hee Min
192
Dose Response Relationship for Permanent Alopecia
in Pediatric Medulloblastoma Patients Treated With
Proton Radiotherapy
Symbol Key:
A
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
73
1:45
Quentin Diot
193
Modeling of Radiographic Changes in Normal Lung
Tissue in Patients Treated With Conventional and
Hypofractionated Radiation Therapy
1:55
Sangkyu Lee
A Bayesian Network Approach for Multivariate
Radiation Pneumonitis Modeling
194
2:05
Ellen X.Huang
Independent Test of a Model to Predict Severe
Acute Esophagitis
195
2:15
Lindsey Appenzoller 196
Predicting Dose-Volume Histograms for Organs at
Risk in IMRT Planning
2:25
Mariana Guerrero
197
Radiobiological Modeling Based on FDG PET Data
for Esophageal Cancer
2:35
Di Yan
198
Radio-inducible Adaptive Response Effect on Hypo-fractionation of Lung Cancer Radiotherapy
1:15 p.m. - 2:45 p.m.
Scientific Session X
IGRT Process and Technologies
1:45
Sarah Geneser
202
The Impact of Errors in Non-rigid Medical Image
Registration Methods on Dose Warping Accuracy
1:55
Bowen Meng
203
Single Scan Scatter Correction in Cone Beam CT Using a Stationary Boundary Blocker and Compressed Sensing Based Scatter Estimation
2:05
Paul Keall
204
Real-time Tumor Deformation Tracking Using Dynamic Multi leaf Collimator (DMLC)
Basic Science Abstract Award Winner – PHYSICS
2:15
Su-Min Zhou
205
Using Respiratory Invariant Points Obtained From
4-D Simulation Study to Provide Accurate Body
Setup Correction for Gated Radiotherapy Patients
2:25
Hao Li
206
Generation of Virtual Monochromatic (VM) CBCT
From Dual kV/MV Beam Projections
2:35
John DeMarco
207
Patient-specific Quantification of the Dosimetric
Impact of Motion During Radiotherapy: A Clinically
Usable Tool
Room: 205 A-C
Moderators: Stanley Benedict
Katja Langen
1:15
Sukhjeet Batth
199
Differences in Clinical Outcome Among Patients
Treated by Intensity Modulated Radiotherapy With
and Without Image-Guidance for Head and Neck
Cancer
1:25
Karen Vineberg
200
The Influence of Rotation on Delivered Dose in
Oropharyngeal Cancer
1:35
Michael Howard
201
Using Mathematical Modeling to Specify Treatment
Margins for Prostate Cancer May Reduce Radiation
Dose to Bladder and Rectum
74
1:15 p.m. - 2:45 p.m.
Breast
Room: 156 A-C
Discussants: Lena Specht
Jean Wright
Maha Jawad
1049
Seven-year Clinical Outcomes Following Accelerated Partial Breast Irradiation Stratified by
ASTRO Consensus Groupings
Resident Digital Poster Recognition Award
Winner – CLINICAL
Robert Hong
1050
Results of the SAVI Research Collaborative Group
Registry: Correlating Clinical Toxicity With Dosimetric Parameters in Patients Treated With APBI
Using Strut-Based Brachytherapy
Mylin Torres
1058
Prospective Longitudinal Study of Radiation-induced Cutaneous Toxicity in Breast Cancer Patients Undergoing Breast Conserving
Therapy
Betro Sadek
1051
Does Lobular Carcinoma In-Situ (LCIS) at the Surgical
Margins Increase the Risk of Local Failure in Patients
With Invasive Breast Cancer Receiving Conservative
Treatment?
Gonzalo Vazquez
1059
Long-term Changes in Pulmonary Function After
Incidental Lung Irradiation for Breast Cancer: A
Prospective Study With 7-year Follow-up
Tiffany Tam
1052
Multifocal/Multicentric Breast Cancer Is Associated
With Increased Local Recurrence
Erin Kane
1053
Compliance of Previously Treated Left Breast Cancer
Patients With RTOG 1005 Guidelines
David Weksberg
Outcomes and Predictive Factors for Salvage
Therapy After Locoregional Recurrence Following Breast Conserving Therapy With
Neoadjuvant Chemotherapy
1054
Nils Arvold
1055
Brain Metastases After Breast-Conserving Therapy
for Early-stage Breast Cancer: Incidence and
Characteristics by Subtype
Zachary Zumsteg
1056
Breast-Conserving Therapy Achieves Equivalent Locoregional Outcomes Compared to Mastectomy
in Women With T1-2N0 Triple Negative Breast Cancer
Manjeet Chadha
1057
Does Post Mastectomy Radiation Therapy (PMRT)
After Deep Inferior Epigastric Perforator Flap (DIEP)
Reconstruction Increase Complications?
Emma Fields
1060
Male Breast Cancer in the United States: A Surveillance, Epidemiology and End Results Analysis
1:15 p.m. - 2:45 p.m.
Gastrointestinal
Room: 157 A-C
Discussants: A. Bapsi Chakravarthy
Salma K. Jabbour
Aryavarta Kumar
1061
Outcomes of Liver Resection for Hepatocellular
Carcinoma Patients: A Cleveland Clinic Experience
Claudia Menichelli
1062
SBRT for Liver Metastases: Results on 173 Treated
Lesions
Jeffrey Meyer
1063
Single-fraction Stereotactic Irradiation of Liver Metastases: Preliminary Results of a Phase I Trial
Iris Ernst
1064
Individualized High Precision Radiotherapy for Liver
Tumors Based on 4-D List Mode PET/CT
Jie Ding
1065
Radiosensitivity Enhancement of Human Hepatocellular Carcinoma Cell Line SMMC-7721 by
Sorafenib Through the MEK/ERK Signal Pathway
75
John Mikell
1066
Tumor Size on Abdominal MRI vs. Pathologic
Specimen in Resected Pancreatic Adenocarcinoma:
Implications for Radiotherapy Planning
David Horowitz
1067
Management of Borderline Resectable Pancreatic
Adenocarcinoma With Neoadjuvant GTX Chemotherapy Followed by Combined Chemoradiation
Andrzej Wojcieszynski
1068
The Impact of Radiation Therapy Sequence on
Survival and Cardiopulmonary Mortality in the Combined Modality Treatment of Esophageal Cancer: A SEER Analysis
Youling Gong
1069
Salvage Concurrent Radio-chemotherapy for Post-operative Local Recurrence of Squamous
Cell Esophageal Cancer
Marcel Verheij
1070
Performance of a Nomogram Predicting Disease-specific Survival After an R0 Resection for
Gastric Cancer in Patients Receiving Postoperative
Chemoradiotherapy
Terence Sio
1071
Outcome of Transplant-Fallout Patients With Unresectable Cholangiocarcinoma
Gang Cai
1072
Phase II Study of Irinotecan and Capacitabine Concurrent With Intensity-Modulated Radiation
Therapy in the Treatment of Recurrent Rectal Rancer
Symbol Key:
A
ARON
Separate
Session
registration
required.
76
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
Registration
required
1:15 p.m. - 2:45 p.m.
Advances in Treatment Planning for Prostate
Cancer
Room: 253 A-C
Cynthia Menard, MD, Princess Margaret Hospital
Mark Buyyounouski, MD, MS, Fox Chase Cancer Center
1:15 p.m. - 2:45 p.m.
Low/High Grade Gliomas – An Update
Room: 107 A-C
Changhu Chen, MD, University of Colorado
Daphne Adele Haas-Kogan, MD, University of
California San Francisco
John Kirkpatrick, MD, PhD, Duke University
1:15 p.m. - 2:45 p.m.
Nurses’ Session
Protons, Neutrons and Advanced Technologies in Radiation Therapy
Room: 206 A-B
A
ARON
Jeanne Sixta, RN, BSN, OCN, NIU Institute of
Neutron Therapy at Fermilab
Catherine Mannix, RN, MSN, OCN, The Clark Center for Radiation Oncology
Michael Kirk, PhD, Mass General North Shore
Center for Outpatient Care
3:00 p.m. - 4:30 p.m.
Scientific Session Y
Breast II - Treatment Techniques
Room: 205 A-C
Moderators: Sanjeev Aggarwal
Alice Ho
4:10
N. Rodriguez de Dios
215
Interim Cosmetic Results and Toxicity Using 3-D
Conformal External Beam Radiotherapy to Deliver
Accelerated Partial Breast Irradiation in Patients
With Early-stage Breast Cancer
4:20
3:00
Etin-Osa Osa
208
Prospective Randomized Trial of Prone Accelerated
Whole Breast Radiotherapy With a Concurrent Daily
vs. Weekly Boost to the Tumor Bed: Acute Toxicity
3:10
Ran Peng
209
Intensity Modulated Radiotherapy With Integrated
Boost After Breast Conservative Surgery in Breast
Cancer Patients: A Prospective Study
3:20
Florian Wuerschmidt
210
Dose to LAD Might Be Critical in Prone Whole Breast
Irradiation: A Dosimetric Comparison of Coronary
Arteries and Heart in Prone vs. Supine Whole Breast
Irradiation
3:30
Chirag Shah
211
Should Ductal Carcinoma In Situ Be Removed From
the ASTRO Cautionary Group for Off-Protocol Use
of Accelerated Partial Breast Irradiation (APBI)? A
Pooled Analysis of Outcomes for 300 Patients With
DCIS Treated With APBI
3:40
Peter Chen
212
Clinical Efficacy of Two vs. 5-day Accelerated Partial
Breast Irradiation Delivered Via Balloon-based
Brachytherapy: Results of A Matched Pair Analysis
3:50
Alphonse Taghian
213
Three-dimensional Conformal External-Beam Accelerated Partial Breast Irradiation (3-D APBI):
Results of a Phase I Dose Escalation Study
Julia White
Discussant
3:00 p.m. - 4:30 p.m.
Scientific Session Z
GI III - Pancreatic Cancer
Room: 206 A-B
Moderators: Michael Haddock
Sarah Hoffe
3:00
Natalie Ausborn
BRCA Expression: A Biomarker in Resectable Pancreatic Cancer?
216
3:10
David Yu
217
A Synthetic Lethal Screen Identifies Genes That Mediate Gemcitabine Resistance in Pancreatic Cancer
3:20
Sunpreet Rakhra 218
A Multi-institute Retrospective Review of Concurrent Full-dose Gemcitabine With Radiation
vs. Concurrent Fluorouracil With Radiation for Locally Advanced Pancreatic Cancer
3:30
Jordan Kharofa
219
Neoadjuvant Chemoradiation With IMRT in Resectable and Borderline Resectable Pancreatic
Cancer (PCa)
3:40
Shane Lloyd
220
A Comparison of Three Treatment Strategies for
Locally Advanced and Borderline Resectable Pancreatic Cancer
4:00
Robert Kuske
214
Accelerated Partial Breast Irradiation for Select
Breast Cancers in the Presence of Augmentation
77
3:50
Francoise Mornex
221
Revisiting the Multimodal Adjuvant Treatment of
Pancreatic Carcinoma Through Optimized Regimen
Combining Gemcitabine Plus Oxaliplatin Chemotherapy Followed by Concurrent Gemcitabine and Modern Radiation Therapy:
Long-term Survival Favorable Results
4:00
William Hall
222
Influence of Adjuvant Radiation Therapy Dose
and Fraction on Overall Survival for Pancreatic Adenocarcinoma
4:10
Thomas Brunner
223
Results of a Multi-center Randomised Phase II Trial
Of Resection +/- Neoadjuvant Chemoradiotherapy
in Pancreatic Cancer
4:20
Edgar Ben-Josef
Discussant
3:00 p.m. - 4:30 p.m.
Scientific Session AA
GU III - Prostate Cancer: High risk/Androgen
Deprivation/Metastatic PCA
Room: 258 A-C
Moderators: Mark Buyyounouski
Paul Nguyen
3:00
Zachary Zumsteg
224
Short-term Androgen Deprivation Decreases
Distant Metastasis and Prostate Cancer Specific
Mortality in Intermediate-risk Prostate Cancer
Patients Undergoing Dose Escalated External Beam
Radiotherapy
3:10
Daniel Hamstra
225
Gleason Pattern 5 Is Associated With an Increased
Risk for Metastasis Following Androgen Deprivation
Therapy (ADT) and Radiation: An Analysis of RTOG
9202 and 9902
78
3:20
Nancy Mendenhall
226
Early Patterns of Failure in a Prospective Trial of
Concomitant Docetaxel and Proton Therapy for
High-risk Prostate Cancer
3:30
Nicholas Sanfilippo
227
Long-term Follow-up of a Prospective Phase I-II
Study of Concurrent Paclitaxel and Radiation Therapy With Hormonal Ablation in Locally Advanced Prostate Cancer
3:40
Chi Zhang
228
Metformin Improves Prostate Cancer Specific
Survival and Inhibits the Development of Castrate
Resistant Metastasis
3:50
Arti Parekh
229
Identification of Comorbidities That Place Men at
Highest Risk of Harm from Androgen Deprivation
Therapy for Prostate Cancer
4:00
Scott Morgan
230
Who Dies from Prostate Cancer? An Analysis of the
SEER Database
4:10
Kimberley Mak
231
Diabetes and Cardiovascular Mortality in Men With
Locally Advanced Prostate Cancer: Updated Analysis
from RTOG 92-02
4:20
Rahul Tendulkar
232
Mortality in Men Treated With Radiotherapy and
Androgen Deprivation for High-risk Prostate Cancer
in the Modern Era is Driven by Non-Prostate Cancer
Deaths
3:00 p.m. - 4:30 p.m.
Scientific Session BB
GYN II - Endometrial, Vulvar, Vagina, Ovarian
Cancer
Room: 109 A-B
Moderators: Lilie Lin
William Small
3:00
Hannah Yoon
233
Contouring Guidelines of the Inguinal Lymph
Nodes Using Lymphangiograms for the Delivery of
Radiotherapy in Gastrointestinal, Gynecological and
Genitourinary Cancers
3:10
Mei Ling Yap
234
The Prognostic Significance of Human Papilloma
Virus and P16 In Patients With Vulvar Squamous Cell
Carcinoma Treated With Radiotherapy
3:20
Aaron Brown
235
Involved-field Radiation Therapy for Locoregionally
Confined Ovarian Cancer
3:30
Larissa Lee
236
Non-serous Histology and Platinum Sensitivity Are
Prognostic in Localized Recurrent Ovarian Cancer
Treated With Radiation Therapy (RT)
3:40
Ji Hyun Kim
237
Stage I and II Endometrial Adenocarcinoma: Analysis
of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy
3:50
Richard Cattaneo II
238
Interval Between Hysterectomy and Start of
Radiation Treatment is Predictive of Recurrence
in Patients With Endometrial Carcinoma. A single
Institution Experience
4:00
Emily Dunn
239
Predictive Factors for Recurrence Following
Post-operative Vaginal Cuff Brachytherapy Alone for
Stage I Endometrial Cancer
4:10
Dane Cohen
240
A Cost Analysis of Two Different Planning Strategies
for the Delivery of Vaginal Vault Brachytherapy
4:20
Jared Robbins
241
The Impact of Age-adjusted Charlson Comorbidity
Index on Survival in Patients With Early-stage Uterine Carcinoma. A Single Institution Study
3:00 p.m. - 4:30 p.m.
Scientific Session CC
Health Services Research II - Quality of Care
Room: 204 A-B
Moderators: Prajnan Das
Timothy Showalter
3:00
Anand Shah
242
Physician Evaluation of Web-based Consumer
Health Information on Proton Therapy for Prostate
Cancer
3:10
Patricia Hardenbergh
243
Linking Community Cancer Center Physicians to
Disease Site-specific Experts
3:20
Nabeel Arastu
The Incidence and Factors Associated With Unplanned Hospital Admissions in Patients Receiving Radiation Therapy
244
3:30
Susan McCloskey
245
Adapting the PRO-CTCAE for Patient Reporting of
Toxicity in Radiation Oncology
3:40
Louis Potters
246
How Treatment Pathways Can Be Used to Measure
the Value of Cancer Care in the Era of the Accountable Care Act
3:50
Robin Famiglietti
247
Determinants of Patient Satisfaction for Patients
Receiving Radiation Therapy
79
4:00
Amit Maity
Improving Safety Culture Through Incident Reporting
248
4:10
Aaron Kusano
249
Burnout in Academic Chairs of Radiation Oncology
in the United States: The SCAROP Survey
3:40
Maria Werner-Wasik
Discussant
3:50
Ben Wilkinson
255
Volumetric Analysis of FDG-PET Uptake After Local Recurrence Following Stereotactic Body Radiotherapy for Early-stage Non-small Cell Lung
Cancer
4:20
Hodaka Numasaki
250
Japanese Structure Survey of Radiation Oncology in
2009 Based on Institutional Stratification of Patterns
of Care Study
4:00
Victor Mangona
256
SUV Kinetics of Weekly 18F FDG-PET During Radiotherapy Predict Eventual Outcome in
Locally-advanced Non-small Cell Lung Cancer
(NSCLC)
3:00 p.m. - 4:30 p.m.
4:10
Nadya Shusharina
Correlation of FDG Avid Volumes of Initial and
Recurrent Lung Cancers After Radiotherapy or
Chemoradiotherapy
Scientific Session DD
Lung III - Toxicity and Brain/PET
Room: 160 A-C
Moderators: Jeffrey Bogart
Roy Decker
3:00
Hidenari Hirata
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiotherapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma
251
257
4:20
Daniel Tandberg
258
Prognosis and Patterns of Failure of Patients With
NSCLC Having Hypermetabolic Mediastinal Lymph
Nodes on Preoperative PET but N0-N1 Disease on
Pathological Analysis
3:00 p.m. - 4:30 p.m.
3:10
Hong Qing Zhuang
252
Phase II Study of WBRT With or Without Concurrent
Erlotinib for Patients With Brain Metastases From
Lung Adenocarcinoma
3:20
Brian Alexander
253
Aggressive Therapy to the Thoracic Primary is Associated With Improved Survival in Patients With
Non-small Cell Lung Carcinoma Presenting With
Synchronous Metastases Limited to the Brain
3:30
Elizabeth Gore
254
Phase III Comparison of Prophylactic Cranial Irradiation vs. Observation in Patients With Locally
Advanced Non-small Cell Lung Cancer: Updated
Analysis of RTOG 0214
80
Scientific Session EE
Biodosimetry and Normal Tissue Radiobiology
Room: 254 A-B
Moderators: Deborah Citrin
Brian Marples
3:00
Naduparambil Jacob
259
Circulating MicroRNA-21 As a Sensitive Marker for
Radiation Biodosimetry
3:10
Deborah Citrin
260
Bone Marrow Mesenchymal Stromal Cell Infusion
Improves Radiation-induced Cutaneous Fibrosis in a
Murine Model
3:20
Junqiang Tian
Darinaparsin: Tumor Radiosensitizer That Radioprotects Intestinal Epithelium
261
3:30
Melvin Chua
262
DNA Double-strand Break Repair and Induction
of Apoptosis In Relation to Late Normal Tissue
Responses Following Radiotherapy for Early Breast
Cancer
3:40
Cullen Taniguchi
263
Prolyl Hydroxylase Inhibition Protects Against and
Mitigates Radiation-Induced Gastrointestinal Toxicity Through Improved Integrity and Function
of the GI Epithelium
3:50
Saikat Das
264
Probability of Radiographic Radiation Pneumonitis
(RP) and Fibrosis (RF) After Stereotactic Ablative
Radiotherapy (SABR) for Lung Cancer using NTCP
model
4:00
Brian Marples
265
A New Use for an Old Treatment: Radiation Therapy
and Alzheimer’s Disease
4:10
Mackenzie McGee
266
Ionizing Radiation May Lead to Downregulation
of Amyloid Precursor Proteins Causing Significant
Reductions in β-Amyloid Plaque Burden in a Murine
Model for Alzheimer’s Disease
4:20
Alexander Stessin
267
Fty720, Sphingosine 1-phosphate Receptor Modulator, Selectively Radioprotects Hippocampal
Neural Stem Cells
3:00 p.m. - 4:30 p.m.
Scientific Session FF
Tumor Imaging and Delineation
Room: 052 A-B
Moderators: Indrin Chetty
Jan-Jakob Sonke
3:00
Catherine Coolens
268
Feasibility of a Novel 4-D Perfusion CT Method for
Response Assessment in Hepatocelullar Carcinoma
Patients Treated With Radiation And Sorafenib
3:10
Jiajia Ge
269
Planning Four-dimensional Computational Tomography (4-D CT) Cannot Adequately Represent
Daily Intrafractional Motion of Abdominal Tumors
3:20
Gregory Perkins
270
Prospective Study of Three-dimensional Isotropic MRI-SIM Imaging of the Head and Neck At
1.5T: Comparison With Two-dimensional Imaging
Sequences
3:30
Nataliya Kovalchuk
271
Repeat CT Simulation During Whole Breast Irradiation Can Influence the Selection of Treatment
Modality for Breast Cancer Tumor Bed Boost
3:40
Ion Moraru
272
Multimodality Image-based Target and Normal
Structure Delineation for Dose Painting of Pancreatic Cancer
3:50
Xin Ming
A Novel Auto-segmentation Method for Lung
Tumor on 18F-FDG PET images
273
4:00
Cungeng Yang
274
Deformable Breast MRI and CT Registration for
Radiation Treatment Planning Using B-Spline With
Rigidity and Feature Point Distance Regularization
81
4:10
Christian Hollensen
275
Does the Progress in Radiotherapy Make Higher
Demand to Inter-observer Variability Correction? A
Case Study of IMRT and Volumetric Arc Therapy
4:20
Eman Al Sulaimani
276
Evaluation of an Internal Surrogate for Mediastinal
Lymph Node Localization
Central Nervous System
Room: 156 A-C
Discussants: Laurie Gaspar
Samuel Ryu
Rebecca Wong
1073
Radiological Diagnosis of Malignant Spinal Cord
Compression – A More Favorable Entity?
Scott Soltys
1074
Stereotactic Radiosurgery for the Treatment of
Spinal Metastases: Analysis of Tumor Control and
Patterns of Failure
1075
D. Michael Lovelock
1076
Correlation of Local Failure With Measures of Dose
Insufficiency in the High-dose Single-fraction Treatment of Bony Metastases
Shahed Badiyan
1077
I-125 Episcleral Plaque Brachytherapy for Uveal
Melanoma: A 15 Year Single Institution Experience
Symbol Key:
A
ARON
Separate
Session
registration
required
82
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
Bradford Perez
1079
Evaluating the Relationship Between Prescription
Dose and Overall Survival Among Patients Treated
With I-125 Brachytherapy for Posterior Uveal Melanoma
Kavita Mishra
1080
Long Term Update on UCSF-LBNL Prospective,
Randomized Trial: Charged Particles vs. Iodine-125
Plaque Therapy in the Management of Uveal Melanoma
3:00 p.m. - 4:30 p.m.
Matthias Guckenberger
Variability in Spine Radiosurgery Treatment Planning – Results of an International
Multi-institutional Study
Leonel Kahn
1078
I-125 Plaque Brachytherapy for Choroidal Melanoma: Mature Single-institution Outcomes
Yuta Shibamoto
1081
Primary Central Nervous System Lymphoma (PCNSL)
Treated by Radiotherapy: A Nationwide Survey of
2005-2009 Patients and Comparison With 1985-2004
Data
Alexander Stessin
1082
The Role of Postoperative Radiotherapy in the
Treatment of Meningeal Hemangiopericytoma: A
Surveillance, Epidemiology and End Results (SEER)-based Analysis
Carolyn Barnes
1083
Fractionated Proton Beam Therapy of Acoustic
Neuromas and Hearing Preservation
Stephanie E. Combs
1084
Long Term Results and Patient Self-reported
Outcome in Patients Treated With Fractionated
Stereotactic Radiotherapy (FSRT) or Stereotactic
Radiosurgery (SRS) for Acoustic Neuroma
3:00 p.m. - 4:30 p.m.
Aaron Wild
1094
Utility of Fiducials in Image-guided SBRT for Patients
With Locally Advanced Pancreatic Cancer: Analysis
of Visibility and Migration
SBRT Techniques
Room: 157 A-C
Discussants: Daniel Low
Gikas Mageras
Benjamin Fahimian
1085
Prospectively Gated CBCT for Volumetric Image
Guidance in SBRT
Joerg Rottmann
1086
Real-time Tracking of Markerless Lung Tumors During SBRT With Continuous MV Imaging
Robert Taylor
1087
Intrafraction Fiducial Tracking With Real-time Treatment Intervention in Lung SBRT
Gitte Persson
1088
Feasibility and Stability of Trans-thoracic Implanted
Markers in Peripheral Lung Tumors for Stereotactic
Body Radiotherapy
Joanne Zhung
1089
Evaluation of RTOG Guidelines for Monte Carlo
Based Lung SBRT Planning
Michael Velec
1090
Impact of Dose-probability PTV Margins and Mean
Respiratory Position on Liver SBRT Dose
James Christensen
1091
Treatment Dose Verification in Liver SBRT Using a
Deformable Respiratory Motion Model and Treatment Beam’s-eye-view Fluoroscopy With
Tumor Tracking
Peng Dong
4pi Radiotherapy for Liver SBRT
1092
Wensha Yang
1093
Is Cone Beam CT Alone Sufficient for Localization of
Pancreas/Liver Tumor During Free-breathing SBRT?
Claudio Sole
1095
Stereotactic Ablative Radiotherapy Delivered by Image Guided Helical Tomotherapy for Extracraneal
Oligometastasis
Wilko Verbakel
1096
Digital Tomosynthesis Performance for Spine
Tracking
3:00 p.m. - 4:30 p.m.
Head and Neck Case Presentations
Room: 253 A-C
Louis B. Harrison, MD, FASTRO, Beth Israel Medical Center
Robert Amdur, MD, University of Florida
Robert Haddad, MD, Dana-Farber Cancer Institute, Havard Medical School
Adam Jacobson, MD, Beth Israel Medical Center
3:00 p.m. - 4:30 p.m.
Radiation Oncology in the Era of Delivery
System and Payment Reform
Room: 107 A-C
C. Leland Rogers, MD, Gamma West Cancer
Services
Miranda Kim, MD, MBA, University of Pennsylvania Health Systems
Lee Newcomer, MD, United Healthcare
Justin Bekelman, MD, University of Pennsylvania
Najeeb Mohideen, MD, Northwest Community Hospital
Dean Rosen, Mehlman Vogel Castagnetti
83
3:00 p.m. - 4:30 p.m.
4:45 p.m. - 6:15 p.m.
Adult Cancer Survivors: One Size
Doesn’t Fit All
Innovative Clinical Trial Designs
Nurses’ Session
Panel 12
Room: 153 A-C
A
ARON
Richard Boyajian, RN, MS, NP, Dana-Farber Cancer Institute
4:45 p.m. - 6:15 p.m.
Panel 11
Quality Control of Lung SBRT: From 4-D Simulation to 4-D Verification
Room: 210 A-C
Moderators:
Stanley Benedict, PhD, University of Virginia Health System
Fang-Fang Yin, PhD, Duke University Medical Center
Panelists:
Jeffrey Bradley, MD, Washington University School of Medicine
Jing Cai, PhD, Duke University Medical Center
Krishni Wijesooriya, PhD, University of Virginia
Room: 253 A-C
Moderators:
Brian Alexander, MD, Dana-Farber/Brigham and
Women’s Cancer Center
Giovanni Parmigiani, PhD, Dana-Farber/Brigham and
Women’s Cancer Center
Panelists:
Donald Berry, PhD, MD Anderson Cancer Center
Kathleen Blake, MD, MPH, Center for Medical Technology Policy
Michael Krams, MD, Janssen Pharmaceuticals
Daniel Normolle, PhD, University of Pittsburgh
Lorenzo Trippa, PhD, Dana-Farber/Brigham and Women’s Cancer Center
4:45 p.m. - 6:15 p.m.
Panel 13
Patient Reported Outcomes: “Hearing the
Patient’s Voice” in a User-friendly and
Meaningful Way
Room: 109 A-B
Moderator:
Benjamin Movsas, MD, Henry Ford Health System
Panelists:
Debroah Watkins-Bruner, PhD, RN, Emory
University
Jeff Sloan, MD, Mayo Clinic
Symbol Key:
A
ARON
Separate
Session
registration
required
84
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
4:45 p.m. - 6:15 p.m.
4:45 p.m. - 6:15 p.m.
Primer on Cost-effectiveness Analysis in Radiation Oncology
Hypofractionation in the Management of
CNS Tumors
Panel 14
Room: 107 A-C
Moderators:
Justin Bekelman, MD, University of Pennsylvania
David Sher, MD, MPH, Rush University Medical Center
Panelists:
G. Scott Gazelle, MD, PhD, Massachusetts General Hospital
James Chambers, PhD, MPharm, Tufts Medical Center
Eve Wittenberg, MPP, PhD, Harvard School of Public Health
Andre Konski, MD, MBA, Wayne State University School of Medicine
Room: 153 A-C
Michael Milano, MD, PhD, University of Rochester
Timothy Solberg, PhD, UT Southwestern Medical Center
4:45 p.m. - 6:15 p.m.
An Overview of Projection Imaging and
Digital Concepts for Radiation Oncology
Room: 258 A-C
Peter Balter, PhD, MD Anderson Cancer Center
Mary Kara Bucci, MD, Anchorage Radiation Therapy Center
4:45 p.m. - 6:15 p.m.
Panel 15
Tumor Metabolism and Radiation Response
Room: 160 A-C
Moderators:
Mark W. Dewhirst, DVM, PhD, FASTRO, Duke University Medical Center
Bradly Wouters, PhD, Ontario Cancer Institute
Panelists:
Matthew Vander Heiden, MD, FASTRO, Massachusetts Institute of Technology
Ruth Muschel, MD, PhD, University of Oxford, Gray Institute
Thomas Brunner, MD, University of Oxford
Jann- Nagina Sarkaria, MD, Mayo Clinic
85
Wednesday | October 31
8:00 a.m. - 9:30 a.m.
8:00 a.m. - 9:30 a.m.
Challenging Cases in the Management of
Newly Diagnosed and Recurrent Prostate
Cancer
Challenging Lung Cancer Cases
Room: 258 A-C
Anthony V. D’ Amico, MD, PhD, FASTRO, Brigham and Women’s Hospital
Juanita Crook, MD, University of British Columbia
Adam Kibel, MD, Washington University School of Medicine
W. Robert Lee, MD, MS, MEd, Duke University
Malcolm Mason, MD, Cardiff University
Room: 253 A-C
Branislav Jeremic, MD, PhD, University of Kragujevac
Zane Hammoud, MD, Henry Ford Hospital
Corey Langer, MD, University of Pennsylvania
8:00 a.m. - 9:30 a.m.
8:00 a.m. - 9:30 a.m.
Management of Less Common Head and
Neck Cancer Including Unknown Primary,
Sinonasal Cancer and Salivary Gland Cancer
Room: 205 A-C
Min Yao, MD, PhD, University Hospitals Case Medical Center
Nancy Lee, MD, Memorial Sloan-Kettering Cancer Center
Quynh-Thu Le, MD, Stanford University
Controversies on the Role of Radiation
Therapy in the Management of Hodgkin
Lymphoma (HL)
Room: 153 A-C
Peter M. Mauch, MD, FASTRO, Harvard Medical School
Lena Specht, MD, PhD, Rigshospitalet, University of Copenhagen
8:00 a.m. - 9:30 a.m.
Integration of Safety in Quality Assurance
Programs
8:00 a.m. - 9:30 a.m.
Difficult Cases in Cervical and Vulvar Cancer
Management
Room: 107 A-C
Patricia J. Eifel, MD, FASTRO, MD Anderson Cancer Center
Anthony Russell, MD, Massachusetts General Hospital
Lilie Lin, MD, University of Pennsylvania
Akila Viswanathan, MD, Brigham and Women’s Hospital
Catheryn Yashar, MD, University of California San Diego
86
Room: 109 A-B
Benedick A. Fraass, PhD, FASTRO, Cedars-Sinai Medical Center
Ramon Alfredo Siochi, PhD, University of Iowa Hospital and Clinic
8:00 a.m. - 9:30 a.m.
ASTRO/PROS Session: Challenging Cases in
Childhood Brain Tumors
Room: 206 A-B
Nadia Laack, MD, MS, Mayo Clinic
Anita Mahajan, MD, MD Anderson Cancer Center
Daniel Hamstra, MD, PhD, The University of Michigan
9:45 a.m. - 10:45 a.m.
Keynote Address III:
Value-based
Health Care Delivery
Professor Michael E. Porter,
PhD, Harvard Business School
Introduction by: Bruce G Haffty, MD, FASTRO, UMDNJ Robert Wood Johnson Medical Center
8:00 a.m. - 9:30 a.m.
Alpha Particle Therapy is Here: Incorporating Novel Radiopharmaceuticals
into Your Practice
Room: 204 A-B
Michael Tomblyn, MD, MS, H. Lee Moffitt Cancer Center
James Welsh, MD, MS, Fermi National Accelerator Laboratory
8:00 a.m. - 9:30 a.m.
Molecular Radiobiology - Concepts and Clinical Applications
Room: 254 A-B
Brian Marples, PhD, William Beaumont Hospital
Anthony Chalmers, MD, Beatson West of Scotland Cancer Centrer
8:00 a.m. - 9:30 a.m.
Advanced Treatment Technologies: Design,
Control Systems and Commissioning
11:00 a.m. - 12:30 p.m.
Scientific Session GG
Breast III - Locally Advanced/New Modalities
Room: 205 A-C
Moderators: Shannon MacDonald
Rachel Rabinovitch
11:00
Jee Suk Chang
277
Long-term Survival Outcomes Following Internal
Mammary Node Irradiation in Stage II-III Breast
Cancer: Results of a Large Retrospective Study With
13-Year Follow-up
11:10
Dayssy Diaz
278
Locoregional Outcomes in Clinical Stage IIB Breast
Cancer After Neoadjuvant Therapy and Mastectomy
With or Without Chest Wall and Supraclavicular
Radiation
11:20
Alexander Louie
279
Prospective Evaluation of Radiation Pneumonitis in
Neoadjuvant Concurrent Docetaxel and Radiation
Therapy for Locally Advanced Breast Cancer
Room: 210 A-C
Lei Xing, PhD, Stanford University
Timothy Solberg, PhD, UT Southwestern Medical Center
James Balter, PhD, University of Michigan
11:30
Yasuhiro Ogawa
280
Non-surgical Breast-conservation Treatment
(KORTUC-BCT) Using a New Image-guided,
Enzyme-targeted and Breast Cancer Stem Cell-Targeted Radiosensitization Treatment (KORTUC II) for Patients With Stage I or II Breast
Cancer
87
11:40
Shannon MacDonald
281
Prospective Pilot Study of Proton Radiation Therapy
for Invasive Carcinoma of the Breast Following
Mastectomy in Patients With Unfavorable Anatomy;
First Reported Clinical Experience
11:00 a.m. - 12:30 p.m.
11:50
Rajni Sethi
282
Phase I/II Study of Prone Accelerated IMRT to Treat
the Breast, Level III Axilla and Supraclavicular Nodes
11: 00
Kimberly Johung
286
The Radiosensitivity of Tyrosine Kinase Driven Non-small Cell Lung Cancer
Scientific Session HH
CNS III – Metastasis
Room: 109 A-B
Moderators: Michele Alanso-Basanta
Martin Fuss
12:00
Charlotte Dai Kubicky
283
Prognostic Significance of Number of Positive
Lymph Nodes (+ LNs) in Women With T1-2N1 Breast
Cancer Treated With Mastectomy: Should Patients
With 1, 2 and 3 + LNs Be Grouped Together?
11:10
Ana Kiess
287
Ipilimumab and Stereotactic Radiosurgery for Melanoma Brain Metastases
12:10
Aparna Kesarwala
284
Symptoms, Physical Impairments and Function in
Breast Cancer Patients With 1-3 Positive Axillary
Lymph Nodes
11:20
A. Gabriella Wernicke
288
Phase I/II Study of Neurosurgical Resection and
Intra-operative Cesium-131 Radio-isotope Brachytherapy in Patients With Newly Diagnosed
Brain Metastases
12:20
Melissa Skolny
285
A Nomogram for Estimating the Risk of Lymphedema Following Treatment for Breast Cancer
11:30
Leslie Modlin
289
Risk of Leptomeningeal Disease in Patients Treated
With Stereotactic Radiosurgery Targeting the Post-operative Resection Cavity for Brain Metastases
11:40
Zachary Kohutek
290
Clinical Factors Associated With Radiation Necrosis
After Stereotactic Radiosurgery for Brain Metastases
11:50
Kapila Kalakota
291
Validation of the Breast Cancer Specific Graded
Prognostic Assessment (GPA) for Patients With
Breast Cancer With Brain Metastases
12:00
Brett Cox
292
Spinal Cord Toxicity With Highdose, Single Fraction
Spinal Stereotactic Radiosurgery
12:10
Penny Sneed
293
Risk Factors for Radiation Necrosis After Gamma
Knife Radiosurgery for Brain Metastases
12:20
88
Glenn Stuart Bauman
Discussant
11:00 a.m. - 12:30 p.m.
Scientific Session II
GU IV- Bladder Cancer/Kidney Cancer/
Seminoma
Room: 204 A-B
Moderators: Anne Kiltie
Stanley Liauw
11:00
Rodney Ellis
294
Stereotactic Radiosurgery for Renal Cancer: Phase I
Safety and Toxicity
11:10
Stacey Fedewa
295
Utilization of Potentially Curative Therapies for
Muscle Invasive Bladder Cancer: Results From the
National Cancer Data Base
11:20
Robert Huddart
296
Results of the SPARE Feasibility Study – Selective
Bladder Preservation Against Radical Excision in
Muscle Invasive T2/T3 Transitional Cell Carcinoma of
the Bladder (CRUK/07/011)
11:30
Jason Efstathiou
297
Factors Associated With Clinical-Pathologic Stage
Discrepancy in Bladder Cancer Patients Treated
With Radical Cystectomy: Implications for Treatment
Selection and Comparative Studies
11:40
Justin Bekelman
298
Radical Cystectomy (RC) vs. Bladder Preservation
Therapy (BPT) for Muscle-Invasive Bladder Cancer
12:10
Christopher Hallemeier
301
Long-term Outcomes of Radiotherapy for Stage II
Testicular Seminoma
12:20
Nicholas James
Discussant
11:00 a.m. - 12:30 p.m.
Scientific Session JJ
Health Services Research III – Large
Population-based and Decision Analysis
Room: 153 A-C
Moderators: B. Ashleigh Guadagnolo
Rinaa Punglia
11:00
Trevor Royce
302
Does Patient Life Expectancy (LE) Affect Receipt of
Routine Cancer Screening in the United States? A
Population-Based Study
11:10
B. Ashleigh Guadagnolo
303
A Population-based Study to Assess Utilization of
Radiation Therapy at the End of Life Among U.S.
Medicare Beneficiaries
11:20 Cary Gross Discussant
11:30
Gary Walker
304
Evaluating the Accuracy of Receipt of Breast Radiation Therapy in the Surveillance, Epidemiology
and End Results Database
Withdrawn
305
11:50
William Shipley
299
Long-term Outcomes After Bladder Preserving
Combined Modality Therapy for Muscle-Invasive
Bladder Cancer: A Pooled Analysis of RTOG 8802,
8903, 9506, 9706, 9906 and 0233
11:40
Carl Nelson
306
Certificate of Need (CON) Status and Its Impact on
Overtreatment of Low-risk Prostate Cancer in the
Elderly
12:00
Benjamin Goldsmith
300
Common Iliac Nodal Involvement in Clinical T2 Bladder Cancer: Implications for Definitive Radiation
11:50
Pavan Jhaveri
Emergence of Integrated Urology-Radiation Oncology Practices in the State of Texas
307
89
12:00
Nataniel Lester-Coll
308
Balancing Competing risks of Recurrence and Death
From High-risk Prostate Cancer vs. Cardiovascular
Mortality in Men Treated With Hormonal Therapy:
A Decision Analysis
12:10
Ravi Parikh
309
Primary Radiotherapy vs. Radical Prostatectomy for
High-risk Prostate Cancer: A Decision Analysis
11:00 a.m. - 12:30 p.m.
Scientific Session KK
Biologic Radiosensitizers I
Room: 206 A-B
Moderators: Christopher Barker
Amit Maity
11:00
Tina Dasgupta
310
Survival Advantage With Radiation Combined With
A Selective BRAFV600E Inhibitor In An Orthotopic,
Intracranial Model Of BRAFV600E-mutated High-grade Gliomas
11:10
David Viertl
311
Tumor Radiosensitization Induced by a-RasGAP
Derived Peptide and Its Pharmacokinetic in Mice
11:20
Yong Cha
312
Aging-related Tumor Suppressor SIRT2 Modulates
Cancer Metabolism Through Regulation of Pyruvate
Kinase M2 (PKM2)
11:30
Kazi Ahmed
313
NF-kB-Mediated β1-integrin Overexpression in
Radioresistance of Malignant Breast Cells in Three-dimensional Culture
314
11:50
Amit Maity
315
Inhibition of Autophagy As a Strategy to Augment
Radiosensitization by the Dual PI3K/mTOR Inhibitor
NVP-BEZ235
12:00
Manuel Roehrich
316
Triple Therapy of Radiation and Combined Integrin
and EGFR Blockade in an Orthotopic Glioblastoma
Model
12:10
Vasu Tumati
317
AZD5438, an Inhibitor of CDK 1, 2 and 9, Enhances
the Radiosensitivity of Non-small Cell Lung Carcinoma Cells
12:20
Heping Yan
318
Targeting of Radiation Inducible Antigen on Human
Lung Cancer Cells
11:00 a.m. - 12:30 p.m.
Scientific Session LL
Patient Safety and Quality Assurance
Room: 253 A-C
Moderators: Benedick Fraass
Todd Pawlicki
11:00
Stephen Kry
319
Algorithms Used in Heterogeneous Dose Calculations Show Systematic Error As Measured With the Radiological Physics Center’s Anthropomorphic Thorax Phantom Used for RTOG
Credentialing
11:10
Dan Ruan
320
Plan Quality Inference and Cross Validation for Standardization and Consistency Evaluation
11:20
Tarun Podder
321
AAPM-ESTRO Guidelines for Image-Guided Robotic
Brachytherapy: Report from Task Group 192
90
11:40
Henning Willers
Recombinational DNA Repair Defects in Lung
Cancer and PARP Inhibitor Sensitivity
11:30
Heming Zhen
322
The Impact of TPS and Machine Delivery Errors
on Clinical Outcomes As Estimated by Biological
Models
11:40
Olivier De Hertogh
323
The Weakest Link – Medical Physicists Need Dedicated Software and Further Training to Improve
the Quality of Rotational IMRT
11:50
Samantha Price
324
A Real-time Scintillating Fiber Detector to Improve
Patient Safety in External Beam Radiotherapy
11:10
Parag Parikh
329
Comparison of Onboard Low-field MRI vs. CBCT/
MVCT For Anatomy Identification in Radiotherapy
11:20
Matthew Abramowitz
330
Noninvasive Real-time Prostate Tracking Using a
Transperineal Ultrasound Approach
11:30
Christoph Tremmel
331
Dual Energy CT: Treatment Planning for Proton
and Ion Radiotherapy Beyond Standard Tissue Composition
12:00
Maria Anna Czerminska
325
Data Integrity Verification System to Improve Safety
of Radiation Therapy Treatments
11:40
Wilfred Ngwa
In Vitro Dose Enhancement From Gold Nanoparticles During Low-dose-rate Gamma Irradiation With I-125 Brachytherapy Seeds
12:10
Daniel Letourneau
326
Multi-center Collaborative Quality Assurance
Program for the Province of Ontario, Canada: First
Year Results
11:50
Yusung Kim
333
Local Targeted Delivery of Micro-size Radiotherapy-source Using Temperature-sensitive
Hydrogel (RT-GEL)
12:20
Andrea Lo
327
A Province-wide Quality Assurance (QA) Review of
Stereotactic Body Radiotherapy (SBRT) Treatment
Planning for Lung Cancer
12:00
Lanade Souza-Lawrence 334
Novel Applications of an Injectable Radio-opaque
Hydrogel Tissue Marker for Management of Thoracic
Malignancies
11:00 a.m. - 12:30 p.m.
12:10
Manish Sethi
335
Tunable Drug Release of Polymeric Nanoparticles
for the Delivery of DNA Double-strand Break Repair
Inhibitors
Scientific Session MM
Emerging Technologies and Concepts
Room: 210 A-C
Moderators: James Balter
Fang-Fang Yin
11:00
Yu Kuang
328
Development of XFCT Imaging Strategy for Monitoring the Spatial Distribution of Platinum
Drugs: Instrumentation and Phantom Validation
332
12:20
Xiaoming Chen
336
In Vivo Evaluation of the Therapeutic Effects of
Non-thermal Focused Ultrasound, Radiation and
Their Combination for Prostate Cancer Therapy
91
11:00 a.m. - 12:30 p.m.
11:00 a.m. - 12:30 p.m.
Sarcoma and Cutaneous Tumors
Head and Neck
Moderators: Jonathan Ashman
Elizabeth Baldini
Discussants: Annie Chan
Loren Mell
Scientific Session NN
Room: 254 A-B
11:00
Michael Macmanus
FDG-PET Scanning Has a High Impact on the Management of Patients With Merkel Cell Carcinoma
Room: 156 A-C
337
11:10
Matthew Johnson
338
Absolute Lymphocyte Count As a Prognostic Factor
for Merkel Cell Carcinoma
11:20
Naamit Gerber
339
Survival of Adult Rhabdomyosarcoma Patients
Treated on Multimodality Protocols
11:30
Ajay Bhatnagar
340
Non-melanoma Skin Cancer Treated With Electronic
Brachytherapy: Results At Two Years
11:40
Yen-Lin Evelyn Chen
341
Prognosis of Radiation Associated Bone and Soft
Tissue Sarcomas
11:50
Terence Sio
342
Intensity Modulated (IMRT) and Intraoperative Electron (IOERT) Radiation Therapy for Retroperitoneal and Intrapelvic Sarcoma
12:00
Sean McBride
Retroperitoneal Sarcoma (RPS): Evaluation of Loco-regional Recurrences (LRR) After Pre-
operative Radiation Therapy (RT) and Potential Benefit of Dose Escalation Using
Dose Painting
343
12:10
Katsuya Maruyama
344
Carbon Ion Radiotherapy for Chondrosarcoma
12:20
Charles Catton
Interfractional Changes of Retroperitoneal Sarcomas During Pre-operative Radiotherapy
92
345
Robert Olson
1097
25 Year Survival Outcomes for Squamous Cell Carcinomas of the Head and Neck: Population-based Outcomes from a Canadian Province
Nikhil Rao
1098
Factors Predicting for Local Control in Patients With
Desmoplastic Melanoma
Dennis Sopka
1099
Dysplasia at the Margin? Investigating the Case for
Subsequent Therapy in Squamous Cell Carcinoma of
the Oral Tongue
Shao Hui Huang
1100
Temporal Regression of Cervical Lymph Node in
N2-N3 Head and Neck Cancer Treated With Primary
Radiotherapy ± Chemotherapy: Stratified by HPV
Status
Klaudia Hunter
1101
The Effect of Differences in Planned and Delivered
Parotid Doses on Salivary Output
John Waldron
1102
Neck-specific Outcome of N2-N3 Head and Neck
Cancer Treated With Radiation +/- Chemotherapy
Rachit Kumar
1103
Radiation Dose to the Floor of Mouth Muscles Predicts Swallowing Complications After Chemoradiation in Oropharyngeal Squamous Cell
Cancer
Jiade Lu
1104
Multi-national Survey on Delivery of Radiation
Therapy for Nasopharyngeal Carcinoma
Yahua Zhong
1105
Phase II Trial of Docetaxel and Cisplatin Neoadjuvant
Chemotherapy Followed by Intensity Modulated
Radiotherapy With Concurrent Cisplatin in
Advanced Nasopharyngeal Carcinoma
Jiayi Huang
1106
A Matched Pair Comparison of Intensity Modulated
Radiation Therapy With Cetuximab vs. Intensity
Modulated Radiation Therapy with Platinum-based
Chemotherapy for Locally Advanced Head Neck
Cancer
Harry Quon
Phase II Study of Radiotherapy Dose
De-intensification for HPV-Associated
Oropharyngeal Carcinoma
1107
Jia-Shing Wu
1108
Long-term Outcome of a Risk-adapted Protocol for
Nasopharyngeal Carcin
11:00 a.m. - 12:30 p.m.
Bridget Koontz
1112
Significant Variation in Provider Discussion of Sexual
Side Effects With Radiotherapy Patients
William Wong
1113
Symptoms and Quality of Life in Men Before and
After Radiation Therapy for Prostate Cancer
Jai Prakash Agarwal
1114
Improved Quality of Life (QOL) Outcomes in Patients
With Head and Neck Squamous Cell Carcinoma (HNSCC) Treated With Intensity Modulated Radiation Therapy (IMRT) Compared to Three
Dimensional Conformal Radiotherapy (3-D CRT):
Evidence From a Prospective Randomized Study
Clayton Hess
1115
The Hess Radiotherapy Coping Index (HRCI or
“Hershey”), A Feasibility Study: A Practical Psychosocial Assessment for the Busy Radiation
Oncology Practice
Christine Hill-Kayser
1116
Positive Impact of Internet-based Survivorship Care
Plans on Health Care and Lifestyle Behaviors
Palliative - Quality of Life
Room: 157 A-C
Discussants: Thomas Dilling
Mark Henderson
Samuel Chao
Spine Stereotactic Body Radiation Therapy Outcomes Correlated to Dosimetric Factors
Mark Hurwitz
1109
Magnetic Resonance Guided Focused Ultrasound
Surgery for Painful Bone Metastases Is a Safe and
Effective Treatment in Patients for Whom Radiation
Therapy Is Contraindicated: Results of a Multi-center
Phase III Trial
Ying Hou
1118
Correlation Between Dose-volume Parameters and
Patient-Reported Quality of Life (QOL) During Image
Guided Intensity Modulated Radiation Therapy
(IGRT) for Prostate Cancer
Zachary Epstein-Peterson
1110
Postoperative Radiation Therapy For Bone Metastases: The Role of Coverage of the Surgical Hardware and Dose Intensity in Treatment Outcomes
1117
Bradford Hoppe
1119
Patient-reported Quality of Life Following Treatment of Prostate Cancer With Proton Therapy
Andrew Chiang
1111
Incidence of Pain Flare Following Stereotactic Body
Radiotherapy for Bone Metastases
93
11:00 a.m. - 12:30 p.m.
1:30 p.m. - 3:00 p.m.
Scientific Session OO
Advanced Treatment of Non-small Cell Lung
Cancer: Using All the Tools (Imaging, Motion
Correction and IMRT) Promises and Pitfalls –
A Case Based Approach
Room: 107 A-C
Craig Stevens, MD, PhD, H. Lee Moffitt Cancer Center
James Urbanic, MD, Wake Forest Univeristy School of Medicine
11:00 a.m. - 12:30 p.m.
Interstitial Brachytherapy for Prostate Cancer:
LDR and HDR, Alone and With External Beam Radiotherapy
Room: 258 A-C
Michael Ghilezan, PhD, OCN, Michigan Health Professionals/21 century Oncology
Mira Keyes, MD, British Columbia Cancer Agency
Al Taira, MD, Western Radiation Oncology
I-Chow Hsu, MD, University of California, San Francisco
12:30 p.m. - 1:30 p.m.
ARRO Meet the Professor Luncheon
Room: 160 A-C
Breast IV - Prognostic Factors
Room: 258 A-C
Moderators: Steven Chmura
Gary Freedman
1:30
Gaorav Gupta
346
Intact RB1 Pathway is Associated With Favorable
Distant Metastasis-free Survival in Triple Negative
Breast Cancer
1:40
Pauline Truong
347
Is Triple Negative Subtype Associated With Higher
Locoregional Recurrence Risk in Women With pT1-2N0 Breast Cancer Treated With Mastectomy?
1:50
Robert Prosnitz
348
Molecular Subtype Predicts Outcome in Nearly All
Subsets of Women With Early-stage Invasive Breast
Cancer Defined by Traditional Clinical and Pathological Prognostic Factors.
2:00
Meena Moran
349
Association Between Tumor Molecular Subtype and
Disease Presentation in Patients With Early-stage
Breast Cancer
2:10
Atif Khan
350
Basal Subtype, As Approximated by Triple-negative
Phenotype, is Associated With Locoregional Recurrence in a Case-control Study of Women With
0-3 Positive Lymph Nodes After Mastectomy
2:20
Audrey Zaccariotto
351
Triple Negative Breast Cancer: Which Factors Predict
for Local Recurrence? A Study of the CORS Group
Symbol Key:
A
ARON
Separate
Session
registration
required
94
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
2:30
Paul Sperduto
352
The Effect of Tumor Subtype on the Time From Primary Diagnosis to Development of Brain Metastases and Survival in Women With Breast
Cancer
2:40
Tony Fyles
353
Post-Menopausal Women With Luminal a Subtype
May Not Require Breast Radiotherapy – Results
From a Randomized Clinical Trial of Tamoxifen +
Radiation
2:50
Jin-Min Nam
Targeting Beta1 Integrin Suppresses Invasive Recurrence in a Three-dimensional Model of Radiation Treated Ductal Carcinoma In Situ
Withdrawn
359
2:10
Woong Sub Koom
360
Patterns of Regional Recurrence After Curative D2
Resection for Stage III (N3) Gastric Cancer:
Implications for Postoperative Radiotherapy
354
1:30 p.m. - 3:00 p.m.
Scientific Session PP
GI IV - GI Cancer: An Antiperistaltic Look
Room: 153 A-C
Moderators: Vivek Mehta
May Abdel-Wahab
1:30
Samuel Ngan
355
Long-term Quality of Life in Patients Treated In
TROG 01.04: A Randomised Trial Comparing Short
Course and Long Course Preoperative Radiotherapy
for Rectal Cancer
1:40
Reena Engineer
356
Escalated Radiation Dose Without Chemotherapy
Does Not Improve Resectability for Locally Advanced Unresectable Rectal Cancer Over Standard Chemo-radiation: Results of a Phase II
Randomized Study.
1:50
Jerome Landry
357
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin
(FOLFOX) and Bevacizumab in Patients With Locally
Advanced Rectal Cancer: ECOG 3204
2:00
Corinne Doll
358
The Significance of Co-expression of Epidermal
Growth Factor Receptor (EGFR) and Ki67 on Clinical
Outcome in Patients With Anal Cancer Treated With
Chemoradiotherapy: An Analysis of RTOG 98-11
2:20
Jessica Freilich
361
Comparative Outcomes for 3-D Conformal vs. Intensity Modulated Radiation Therapy for Esophageal Cancer
2:30
Jeffrey Vainshtein
362
Prognostic Value of CA 19-9 in a Phase I/II Trial of
Dose Escalated Intensity Modulated Radiation Therapy (IMRT) With Concurrent Full-dose
Gemcitabine (G) in Unresectable Pancreatic Cancer
2:40
Joseph Herman
Discussant
1:30 p.m. - 3:00 p.m.
Scientific Session QQ
GU V - Prostate Cancer: Hypofractionation/
Brachytherapy
Room: 254 A-B
Moderators: Jay Ciezki
Drew Moghanaki
1:30
Karen Hoffman 363
Toxcity and Dosimetic Parameters Related to
Conventional vs. Dose-escalated, Hypofractionated
Radiation in Prostate Cancer.
1:40
Giorgio Arcangeli
364
Updated Results and Pattern of Failure in a Randomized Hypofractionation Trial for High-risk
Prostate Cancer
1:50
Alan Katz
365
Five-year Biochemical Control Rates for Stereotactic
Body Radiotherapy for Organ Confined Prostate
Cancer: A Multi-institutional Pooled Analysis
95
2:00
Robert Meier
366
Stereotactic Body Radiotherapy for Intermediate-risk Organ-confined Prostate Cancer:
Interim Toxicity and Quality of Life Outcomes from a
Multi-Institutional Study
2:10
Harvey Quon
367
Dose Escalation of Five-Fraction Radiotherapy for
Prostate Cancer: Quality of Life Comparison of Two
Prospective Trials
2:20
Donald Fuller
368
Prospective Evaluation of SBRT for Low- and
Intermediate-Risk Prostate Cancer: Emulating HDR
Brachytherapy Dose Distribution
1:50
Randa Tao
373
Real-time Peer Review Quality Assurance Conferences Incorporating Physical Examination
for Head and Neck Cancer Radiation Therapy Result
in Clinically Meaningful Target Volume Alteration:
Results of a Prospective Volumetric Analysis
2:00
Ajay Kapur
Streamlining the Head and Neck Treatment Process in Radiation Medicine Using a Kaizen
Approach
374
2:10
Annie Chan
375
A Phase II Trial of Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
2:30
Mark Shilkrut
369
The Addition of Low-does-rate Brachytherapy and
Androgen Deprivation Therapy Decreases Prostate
Cancer Death Compared to Dose-escalated External
Beam Radiation Therapy for High-risk Prostate
Cancer
2:20
Tony Wang
376
Patterns of Failure (POF) After Salvage Re-irradiation
(re-RT) for Recurrent Head and Neck Cancer (HNC):
Implications for Field Design and Consolidation
Therapy
2:40
Atsunori Yorozu
370
A Dose-response Analysis of Biochemical Control
and Toxicity for I-125 Prostate Brachytherapy
2:30
Man Hu
377
The Prognostic Value of Hypoxia-Reoxygenation
During Chemoradiotherapy in Locoregionally Advanced Head and Neck Cancer
2:50
Patrick Kupelian
Discussant
1:30 p.m. - 3:00 p.m.
Scientific Session RR
Head and Neck III - Reirradiation/Quality Assurance
2:40
Maria Grazia Ghi
378
Cetuximab/Radiotherapy (CET+RT) vs. Concomitant
Chemoradiotherapy (cCHT+RT) With or Wothout
Induction Docetaxel/Cisplatin/5Fluorouracil (TPF)
in Locally-advanced Head and Neck Squamous Cell
Carcinoma (LASCCHN). Preliminary Results on Toxicity of a Randomiz
Room: 205 A-C
Moderators: Alexander Lin
Farzan Siddiqui
1:30
L. Matthew Scala
371
High-dose-rate (HDR) Intraoperative Brachytherapy
and Radical Surgical Resection in the Management
of Recurrent Head and Neck Cancer
1:40
Julian Hong
372
Predictive Factors for Locoregional Control After
Salvage Reirradiation of Recurrent Head and Neck
Cancer
96
2:50
Sharon Spencer
Discussant
1:30 p.m. - 3:00 p.m.
2:40
Jayaji Moré
385
Acute Changes in Composition of Exhaled Breath
Predict Radiation Pneumonitis Following Stereotactic Ablative Radiotherapy
Scientific Session SS
Lung IV - Fractionation and Toxicity
Room: 210 A-C
Moderators: Andrea Bezjak
Joe Y. Chang
1:30
Elisabetta Parisi
379
Accelerated Hypofractionated Radiotherapy Using
Tomotherapy Plus Chemotherapy for Inoperable
Locally Advanced Lung Cancer: Preliminary Results
From a Prospective Phase II Trial
1:40
Jeffrey Kuremsky
380
Hypofractionated Radiotherapy for Stage I and II
Non-small Cell Lung Cancer
1:50
Christoph Poettgen
381
Accelerated Hyperfractionated Radiotherapy Within
Trimodality Therapy Concepts for Stage IIIa/b Non-small Cell Lung Cancer: Markedly Higher Rate
of Pathologic Complete Remissions Than With Conventionally Fractionated Radiochemotherapy
2:00
Ken Rosenzweig
Discussant
2:10
Alerson Molotievschi
382
Late Esophageal Stricture Correlates With Decreased Overall Survival For Locally Advanced Non-small Cell Lung Cancer Treated With
Radiotherapy: A Potential Confounder of Dose
Escalation?
2:20
Marco Trovo
383
High-dose Radiation Therapy Delivered With Tomotherapy to the Intact Lung for Malignant Pleural Mesothelioma
2:30
Yevgeniy Vinogradskiy
384
Using Genetically Based Normal Tissue Toxicity
Models to Personalize Prescription Dose: A Proof of
Principle Virtual Study
2:50 David Raben
386
Initial Cooperative Group Experience of Bevacizumab (Bev) Plus Concomitant Chemoradiotherapy (CRT) in Patients With Inoperable Locally-advanced Stage III Non-small
Cell Lung Cancer (LA-NSCLC): Preliminary Results of
S0533
1:30 p.m. - 3:00 p.m.
Scientific Session TT
Informatics/Bioinformatics
Room: 109 A-B
Moderators: David Gius
Andrew Vassil
1:30 Leah Schubert
Analysis of an International Error Reporting Database to Enhance Patient Safety
387
1:40
Kevin Moore
388
Inter-institutional Quality Control of IMRT Treatment
Planning
1:50
Patrick Kupelian
389
Collection of Treatment Plan Parameters and Related Quality Indices Into Radiotherapy Registries
2:00
Olivier Gayou
390
Reducing the Potential for Catastrophic Radiation
Error by Using Historical Treatment Data
2:10
Benjamin King
391
Implementation of Tablet Computers (iPad) in a
Radiation Oncology Clinic
2:20
Peter Gabriel
392
A Semi-Automated Electronic System for Managing
Physician Peer Review of Treatment Plans
97
2:30
Wade Smith
393
Protons Versus X-rays for CNS Tumors: A Decision
Model
2:40
Senthil Gandhidasan
394
Contrasting Oncology Information System Implementations and Their Impact on the Health
Care Delivery in Radiation Oncology
2:50
Timothy Meier
395
Continuous Quality Improvement in Radiation
Oncology is Feasible at a Major Tertiary Teaching
Institution
2:20
Kavita Dharmarajan
401
Radiotherapy Quality Assurance on AHOD0031: A
Report From the Quality Assurance Review Center
(QARC) and the Children’s Oncology Group
2:30
Torun Yock
402
Health-related Quality of Life (HrQOL) in Children
Treated With Proton Radiotherapy for Extra-cranial
Tumors: A Prospective Study
2:40
Joanna Yang
Long-term Results of Radiation Therapy for Rhabdomyosarcoma in Very Young Children
403
2:50
Benjamin Laser
404
Evaluation of the Use of Carbon-11 Methionine PET
Scans in Pediatric Patients With Craniopharyngioma
1:30 p.m. - 3:00 p.m.
Scientific Session UU
Pediatrics II - Non-CNS Tumors
Room: 206 A-B
Moderators: Nadia Laack
Arnold Paulino
1:30 p.m. - 3:00 p.m.
Scientific Session VV
1:30
Safia Ahmed
396
Clinical Outcomes In Adult and Pediatric Ewing
Sarcoma: A Single Institution Comparative Study
1:40
Joanna Yang
397
Local, Regional and Central Nervous System Control
Using IMRT in Parameningeal Rhabdomyosarcoma
Patients
1:50
Daya Nand Sharma
398
Role of Extracorporeal Irradiation in Malignant Bone
Tumors
2:00
Suzanne Wolden
Total Body Irradiation in Very Young Children
399
2:10
Chi Zhang
Epidemiology and Patterns of Care in Craniopharyngioma
400
Biologic Radiosensitizers II
Room: 204 A-B
Moderators: James Bonner
Felix Feng
1:30
James Hansen
405
A Rare Cell-penetrating Anti-DNA Antibody Inhibits
DNA Repair, Sensitizes Tumors to DNA-Damaging
Therapy and Is Synthetically Lethal to BRCA2-
Deficient Cancer Cells
1:40
Philipp Seidel
406
Does Initial or Persistent DNA damage Correlate
With the Enhanced RBE of Carbon vs. Photon Radiotherapy?
1:50
Mohammad Hedayati
407
Exploiting Androgen-induced DNA Double Strand
Breaks: Optimally Sequencing Androgen Suppression and Radiation for the Treatment of
Prostate Cancer
2:00
Peter Paximadis
408
PTEN Modulation of Androgen Receptor Response
to External Beam Radiation in Murine Prostate
Cancer Cell Lines
98
2:10
James Bonner
409
The Role of STAT-3 in Cetuximab-Induced Radiosensitization in Head and Neck Cancer Cells
Alec Block
1123
Analysis and Reduction of Daily kV Planar Imaging
Dose in IGRT Patients
2:20
Kathryn Huber
410
Sequence Dependent Radiosensitization of EGFR
Mutant NSCLC by Gefitinib is Mediated by Senescence
Elisabeth Weiss
1124
Do Surrogates Reliably Represent Lung Tumor Motion? Assessment of Intrafraction Motion Variability of Lung Tumors, Implanted Markers and
Carina
2:30
Alexander Whitley
411
Erlotinib Induces Synthetic Lethality With the Poly
(ADP-Ribose) Polymerase (PARP) Inhibitor ABT-888
in Esophageal Cancer
2:40
Michael Spiotto
412
A High Throughput Cell Based Screen Identifies
Compounds That Inhibit the Viral Oncoprotein E6 in
Human Papillomavirus-positive Cancers
2:50
Michael Baine
413
Unbiased Analysis of Pancreatic Cancer Radiation
Resistance Reveals Cholesterol Biosynthesis As a
Potent Novel Target for Radiosensitization
1:30 p.m. - 3:00 p.m.
IGRT Technologies and Processes
Room: 156 A-C
Discussants: Kristy Brock
Radhe Mohan
Mauro Iori
1120
Voxel-based Dose-painting With a Commercial
Treatment Planning System by Using Two Different
Planning Methods
Carsten Brink
1121
Using Mid-ventilation Phase for Calculation of Treatment Plan for Lung Cancer Patients Might Not
Be Optimal
Dimitri Hristorv
1122
Prone Partial Breast Coronal Arc Irradiation: Combining Intensity Modulated Delivery With
Dynamic Motion of the Couch
John van Sornsen de Koste
1125
Evaluating Digital Tomosynthesis (DTS) for Image-guided Stereotactic Lung Radiotherapy
Yi Rong
1126
Respiratory-gated Deep-inspiration Breath Hold
Left Breast Irradiation Incorporating Real-time 3-D
Surface Optical Tracking and Integrated MV Cine
Acquisition
Adam Riegel
1127
Ultrasound-compatible Thermoplastic Masks for
Patient Immobilization During Intensity Modulated
Radiation Therapy of Head and Neck Cancer
Taeho Kim
1128
Audiovisual Biofeedback Improves Anatomical Position Management in Breath-hold
Andrew Godley
1129
Segmentation Guided Deformable Registration of
Large Organ Variation in the Prostate Region
PengPeng Zhang
1130
Short Arc Digital Tomosynthesis As an Image Enhancement Step for Detection And Localization
of Implanted Markers
Margie Hunt
1131
MV-kV Intra-fractional Imaging During Volume
Modulated Arc Therapy (VMAT): Initial Clinical
Results
99
1:30 p.m. - 3:00 p.m.
3:15 p.m. - 4:45 p.m.
Stereotactic Body RT: Clinical, Biological and
Physics/QA Update
Linac-based Image Guidance for Spatial and
Dosimetric Treatment Verification
Room: 253 A-C
Teamor Nurushev, PhD, Henry Ford Health System
Roy Decker, MD, PhD, Yale University
Jan-Jakob Sonke, PhD, The Netherlands Cancer Institute (NKI-AVL)
1:30 p.m. - 3:00 p.m.
Cervical Cancer Management: Novel Approaches to Image-Guidance
Room: 107 A-C
Akila Viswanathan, MD, Brigham and Women’s Hospital
Panel 17
Room: 253 A-C
Moderators:
Radhe Mohan, PhD, FASTRO, MD Anderson Cancer Center
Mihaela Rosu, PhD, Virginia Commonwealth University
Panelists:
David Jaffray, PhD, Princess Margaret Hospital
Marc Kessler, PhD, University of Michigan
Jan-Jakob Sonke, PhD, The Netherlands Cancer Institute (NKI-AVL)
3:15 p.m. - 4:45 p.m.
3:15 p.m. - 4:45 p.m.
Panel 16
Hypofractionation Dose-response Models for
SRS, SBRT, FSRT: Biology, Physics and Clinic
Room: 210 A-C
Moderators:
J. Martin Brown, PhD, FASTRO, Stanford University
X. Allen Li, PhD, Medical College of Wisconsin
Panelists:
Zhibin Huang, PhD, East Carolina University
Brian Kavanagh, MD, University of Colorado Denver
Nina A. Mayr, MD, FASTRO, Ohio State University
Marc S Mendonca, PhD, Indiana University School of Medicine
100
Panel 18
Evidence-based Management of Testicular
Seminoma, Stage I and II
Room: 254 A-B
Moderators:
Clair Beard, MD, Dana-Farber/Brigham and Women’s Cancer Center
Panelists:
Peter Chung, MD, Princess Margaret Hospital
Jason Efstathiou, MD, PhD, Massachusetts General Hospital
Karen Hoffman, MD, MD Anderson Cancer Center
3:15 p.m. - 4:45 p.m.
3:15 p.m. - 4:45 p.m.
Multi-modality Approach to the Management
of Liver Malignancy and Metastasis
ASTRO Highlights in Spanish
Panel 19
Room: 107 A-C
Moderators:
Huan Giap, MD, PhD, Scripps Proton Therapy Center
Riad Salem, MD, MBA, Northwestern University
Panelists:
Ricky Sharma, MD, PhD, University of Oxford
Riad Salem, MD, MBA, Northwestern University
Andrew Kennedy, MD, Wake Radiology Oncology
Huan Giap, MD, PhD, Scripps Proton Therapy Center
Room: 204 A-B
Beatriz E. Amendola, MD, FASTRO, Innovative Cancer
Institute
Pablo Castro Pena, MD, Instituto de Radioterapia-
Fundacion Marie Curie
Silvia Zunino, MD, PhD, Instituto Privado de Radioterapia
Higinia Cardenes, MD, Indiana University
Roberto Diaz, MD, PhD, Emory University
Marcela de la Torre, MD, University of Buenos Aires
3:15 p.m. - 4:45 p.m.
Treatment Option for Patients with Early-stage
3:15 p.m. - 4:45 p.m.
Panel 20
Biological Controversies and How They Impact
Conventional Radiotherapy
Room: 153 A-C
Room: 258 A-C
Jeffrey Bogart, MD, State University of New York
Frank Detterbeck, MD, Yale Thoracic Surgery
Moderators:
Brian Marples, PhD, William Beaumont Hospital
George Wilson, PhD, William Beaumont Hospital
Panelists:
Søren Bentzen, DSc, PhD, University of Wisconsin School of Medicine and Public Health
Kevin Camphausen, MD, National Cancer Institute
Daniel Zips, MD, University of Tubingen, Germany
Symbol Key:
A
ARON
Separate
Session
registration
required
Award
Recipient
Live
Interactive
SAMs/
Session
Separate
registration
required
101
NOTES
102
A S T R O
55 T H
A N N UA L
M E E T I N G
Meeting Dates: September 22-25, 2013 • Exhibit Dates: September 22-24, 2013 • Georgia World Congress Center • Atlanta
PATIENTS
Hope • Guide • Heal
FIRST
MARK YOUR CALENDAR WITH
THESE IMPORTANT
2013 ANNUAL MEETING DATES
CALL FOR ABSTRACTS SITE OPENS:
December 2012
CALL FOR ABSTRACTS DEADLINE:
February 15, 2013
Please note the early deadline for 2013 abstracts!
ANNUAL MEE TING
www.astro.org/annualmeeting
Join us
next
year in
Atlanta!
NOTES
104
INSIDE:
Poster Presentations
Poster Viewing Hours
The Poster Viewing area is located in Hall C.
Sunday, October 28:
Monday, October 29:
10:00 a.m. - 5:00 p.m.
10:00 a.m. - 5:00 p.m.
Poster Viewing Session and Reception 5:30 p.m. - 6:45 p.m.
Tuesday, October 30:
10:00 a.m. - 5:00 p.m.
NOTE EARLY
DEADLINE FOR
2013 ABSTRACTS!
CALL FOR ABSTRACTS
SITE OPENS:
December 5, 2012
CALL FOR ABSTRACTS
DEADLINE:
February 15, 2013
2012 AMBASSADOR Recognition
ASTRO proudly recognizes our 2012 Corporate Ambassadors
for their outstanding year-round leadership and
support of radiation oncology.
Poster Presentations by Track
BREAST CANCER
2001
Louis Keiler
Community Hospital Experience With
Accelerated Partial Breast Brachytherapy
2002
Vangipuram Shankar
Daily Cone Beam CT Image Guidance
for Oncoplastic BCT IMRT
Treatments - Should It Be a Routine!
2003
Naoki Nakamura
Effects of Geometrical Uncertainties on Whole Breast Radiotherapy: Comparison Between
Four Different Techniques
2004
Lana de Souza-Lawrence
Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens:
Assessment of Skin Toxicity, Cosmetic
Outcomes and Disease Recurrence
2005
Lana de Souza-Lawrence
Addition Of FDG-PET Decreases Inter-observer Variability in Delineation of the Lumpectomy Cavity
for Patients Who Have Poor Cavity
Visualization by CT Alone
2010
Jinli Ma
Irradiation of the Chest Wall and
Regional Nodes As Integrated Volume
With IMRT for Breast Cancer: the
Dosimetry and Acute Side Effects
2011
Jean Wright
Rate of Moist Desquamation in
Patients Receiving Radiation for Breast
Cancer After Mastectomy vs. Breast
Conserving Surgery
2012
Youlia Kirova
Second Malignancies After Breast
Cancer Treatment: Long-term Results
2013
Ben Taylor
Survival for Patients With Inflammatory
Breast Cancer Receiving Mastectomy
is Associated With Radiation Sequence
and Race
2014
Sarahatul Bahiah Yusoff
Bilateral Breast and Regional Nodal Irradiation in Early-stage Breast Cancer
- A Dosimetric Comparison of IMRT
and 3-D Conformal Radiation Therapy
2015
Wee Yao Koh
Hypofractionated Breast Radiotherapy:
Acute Toxicity in Asian Skin Types
2006
Hiroshi Sekine
Virtual Computer Simulation of Skin
Erythema During and After Breast
Conserving Therapy Using Generalized
LQ Model
2016
Elise Furet
How to Boost the Breast Tumor Bed
After Oncoplastic Surgical Procedure Using Surgical Clips and
Image Registration?
2007
Himanshu Nagar
Is There a Tradeoff in Using Modified
High Tangent Field Radiation for
Treating an Undissected Node Positive
Axilla?
2017
Thomas Churilla
Does Regional Micrometastatic
Disease Influence Local Management
in Breast Cancer? A SEER Database
Analysis
2008
Ewa Szumacher
Development of a Patient Decision Aid
for Older Women With Stage 1 Breast
Cancer Considering Adjuvant Treatment Post-lumpectomy
2018
Thomas Churilla
Predictors of Metastatic Disease in
Clinical T1 Node Negative Breast Cancer: A SEER Database Analysis
2009
Florian Wuerschmidt
Intraoperative Radiotherapy With Low
Energy Photons (INTRABEAM) As Boost
Irradiation: Results in 546 Pts. Treated
at Two Community Breast Cancer
Centers
2019
Olga Vujovic
The Significance of Time Interval From
Clinical Presentation to Definitive
Breast Surgery in Node Negative
Breast Carcinoma With Long-term
Follow-up: Clinical Implications
2020
Neeta Kannan
Is There an Advantage to Delivering
Breast Boost in the Lateral Decubitus
Position?
2021
Patrick Maguire
Oncoplastic Surgery and Radiation
Therapy for Breast Conservation:
Patient and Physician Reported
Outcomes
2022
Sabina Venarini
Visualization of the Left Anterior
Descending Coronary Artery on
Computed Tomographic Images Used
for the Planification of Breast Radiation
Treatments
2023
Kara Leonard
Breast Boost Using Noninvasive Image
Guided Breast Brachytherapy vs. En
Face Electrons: A Matched Pair Analysis
2024
Chirag Shah
Outcomes and Toxicities of Three-dimensional Conformal Accelerated Partial Breast Irradiation
2025
Matthew Hardee
Impact of Histological Subtype on the
Outcome of Breast Cancer Brain Metastases Patients Treated With
Gamma Knife Radiosurgery
2026
Rumiko Kinoshita
Co-overexpression of GEP100 With
EGFR Correlates With Early Recurrence
After Breast Conservation Therapy
(BCT)
2027 Patrick Joseph Bonavitacola
Incidental Axillary Coverage Comparison Between 3-D CRT and Hybrid IMRT for Whole Breast Irradiation
2028
Sudha Mahalingam
Accelerated Partial Breast Irradiation
Using Single Lumen Balloon Catheter
for Early Breast Cancer: A Community
Hospital Experience
2029
Michelle Kim
Pathologic Complete Response to
Neoadjuvant Chemotherapy Plus
Trastuzumab Predicts for Improved
Survival in Women With HER2-Positive
Breast Cancer
Poster # correlates with the abstract number listed in the Annual Meeting Proceedings
ASTRO 2012 54TH ANNUAL MEE TING
107
BREAST CANCER/continued
2039Withdrawn
2030
Stefan Claes
A Clinical Study Comparing a Hydroactive Colloid Gel to a Dexpanthenol Cream for the Treatment of Skin Reactions in Breast
Irradiation
2040
Min Xu
The Influence of Delineator and Delineating Criterion on the Delineation of the Tumor Bed Target
and Whole Breast Target After Breast-conserving Surgery
2031
David Marcus
Breast Conservation Rates and Outcomes in Post-Menopausal Women
With Estrogen Receptor-positive Breast
Cancer Treated With Neoadjuvant
Hormonal Therapy or Chemotherapy
2041
Jun Deng
Kilo-Voltage Imaging Doses to
Organs-at-Risk in CBCT-guided Breast
Radiotherapy
2032
Adam Currey
Impact of Sociodemographic Factors
on Management of Breast Cancer:
Results of QRRO Survey
2033
Jessica Wobb
Impact of the Number of Cautionary/
Unsuitable Risk Factors on Outcomes
Following Accelerated Partial Breast
Irradiation
2034
Kristin Kowalchik
Classification System for Identifying
Women at Risk for Altered Partial
Breast Irradiation (PBI) Recommendations Following Breast
Magnetic Resonance Imaging (MRI)
2035
Ana Maria Mena
Acute Toxicity and Cosmetic Outcome
Evaluation in 294 Breast Cancer
Patients (pts) Treated With Hypofractionated Radiotherapy
(HPRT) After Conservative Surgery
2036
Nidhi Patni
A Comparison of Acute and Chronic
Toxicity Profile Between Conventional
and Hypofractionated Whole Breast
Irradiation in Patients Undergoing
Breast Conserving Surgery
2037
Suzhen Wang
Comparisons of Clinical Target Volumes Based on Three-dimensional
CT and Four-dimensional CT Stimulation Images of Breast Irradiation After Breast-conserving
Surgery
2038
Sara Pentimalli
Phase I-II Study of Hypofractionated
Simultaneous Integrated Boost (SIB)
for Adjuvant Radiation Therapy in Early
Breast Cancer Patients: A Report of
Feasibility and Acute Toxicity Results in
the First 50 Treatments
108
2042
Timothy Harris
Matched-Pair Analysis of Women
Treated With DIEP Reconstruction With
or Without Radiation
2043
Jinyu Xue
Dosimetric Comparison of Post Mastectomy Scar Boost Using HDR
Skin Flap vs. Electron Field
2044
Lisa Klepczyk
The Influence of Race and Hormone
Receptor Status on Recurrence in
Patients With Ductal Carcinoma in Situ
(DCIS)
2045
Brandon Stone
Clinical Target Volumes for Accelerated
Partial Breast Irradiation: Are They
Equivalent? A Volumetric Analysis
2046
Bartosz Urbanski
Preliminary Evaluation of Breast
Cancer Patient’s Treatment After Breast
Conserving Therapy (BCT), IORT and
EBRT
2047
Thomas Lanni
Comparison of Reimbursement and
Cost Efficacy Between Accelerated
Partial Breast Irradiation Modalities
2048
Eric Mellon
Toxicity Analysis of Accelerated Partial
Breast Irradiation in Patients Treated
With Daily Image Guidance and
Reduced Treatment Margins
2049
Phillip Prior
CT-based Planning for Node Positive
Breast Cancer Does Not Result in
Excess Lung and Heart Doses
2050
Charu Sharma
Physician Preferences for Post-mastectomy Radiation Techniques in Breast Cancer Patients
With Unreconstructed Chest Walls
2051
Tamara Linne
Secondary Angiosarcoma After Breast-Conserving Therapy Treated
With Hyperfractionated Radiotherapy
With a Median Follow-up of 6.7 Years
2052
Carolina Fasola
Local Regional Recurrence Among
Patients With Pleomorphic Lobular
Carcinoma in Situ: Is There a Role for
Radiotherapy?
2053
Marco Krengli
Prone vs. Supine Position for Adjuvant
Breast Radiotherapy: A Comparative
Planning Study
2054
Wei Wang
4-D CT-based Target Motion and
Treatment Planning Variance for Whole
Breast Radiotherapy Account for
Breathing Motion
2055
Wei Wang
Dose Distribution Analysis in Whole
Breast Intensity Modulated Radiotherapy Based on 4-D CT And
3-D CT
2056
Josef Hammer
Nodal Status and Tumor Location – An Unorthodox Relationship in Breast
Cancer Patients
2057
Steven Feigenberg
Near 25 percent Complete Pathologic
Response Following Preoperative Accelerated Partial Breast Radiotherapy (APBI) Using Three-dimensional Conformal Radiotherapy (3-D CRT)
2058
Zhaozhi Yang
Simultaneous Integrated Boost in
Breast Conserving Radiotherapy: Is
Replanning Necessary for Seroma
Shrinkage?
2059
Michelle Wallace
Clinical Outcomes Following Accelerated Partial Breast Irradiation
Stratified by Estrogen Receptor Status
2060
Erminia Infusino
A Comparative Study of Breast Radiotherapy in Prone Position vs.
Supine Position in Moderate Deep
Inspiration Breath-hold (mDIBH) Technique Using Active Breathing
Control
2061
Adam Currey
The Importance of Three-dimensional
CT Treatment Planning to Optimize
Outcomes From Accelerated Partial
Breast Irradiation (APBI) With Brachytherapy in Early-stage Breast
Cancer
2062
Steven Plimpton
Rethinking the Supraclavicular Field:
Anterior Wedged Pair 3-D Conformal
Radiotherapy vs. Single Anterior
Oblique Field as Treatment of the Axillary Apex and Supraclavicular
Fossa in Node Positive Breast Cancer
2063
Shana Coplowitz
Association of Pain and Pre-treatment
Transforming Growth Factor Beta-1
(TGF-β1) Levels As an Early Predictive
Biomarker in Patients Treated With
Intracavitary Accelerated Partial
Breast Irradiation (IAPBI): Results of a
Prospective Study
2064
Eric Christenson
Preoperative Accelerated Partial
Breast Radiation Is Associated With
Decreased Cd8+ Cells in Patients With
Early Breast Cancer
2065
Sua Yoo
Partial Breast Extra-cranial Radiosurgery: A Dosimetric Evaluation
of Treatment Delivery Accuracy
2066
Naoko Sanuki
Outcomes of Clinically Node Negative
Breast Cancer Without Axillary Dissection: Can the Preserved Axilla Be
Safely Treated With Radiation After a
Positive Sentinel Node Biopsy?
2070
Kujtim Latifi
Comparing Heart and Lung Dose-Volumes Between RTOG 0413
and RTOG 1005 Standards for Patients
Treated With Whole Breast Irradiation
2071
Matthew Abrams
Investigation on the Benefit of PMRT
in Women With High Risk N0 Breast
Cancer
2072
Aparna Surapaneni
Effect of Radiation on Breast Cancer
Specific Survival for Elderly Women
With Early Stage (T1N0 ER+) Breast
Cancer: Review of the SEER Database
2073
Maha Jawad
Impact of Lymphovascular Space Invasion, Extensive Intraductal Component and Multi-focality on Outcomes Following Accelerated
Partial Breast Irradiation
2081
Peng Dong
4pi Therapy for Partial Breast Irradiation
2082
Anton Khouri
Partial Breast Re-Irradiation for
Patients With Ipsilateral Breast Tumor
Recurrence
2083
David Grew
Objective Definition of the Phenotype
of Radiation-induced Breast Fibrosis by
the Moisture Meter D
2084
Orlan Macdonald
Radiotherapy and Male Breast Cancer:
A Population-Based Registry Analysis
2074
Amy Woolley
An Audit to Assess Electronic Portal
Imaging (EPI) and Cone Beam CT
(CBCT) Image Verifcation Methods in
16 Breast Patients
2075
Melanie Letourneau
Outcomes in Post-mastectomy
Patients Treated by Adjuvant Radiotherapy Without Application of
Bolus
2076
Daniela Bejarano
Comparative Analysis of Acute
Radiation Dermatitis in Breast Cancer
Treatment: Concomitant vs. Sequential
Paclitaxel and Radiotherapy
2067
Musaddiq Awan
Can Breast MRI Select Patients For
Treatment With Pre-operative APBI?
2077
Susu Yan
Functional and Molecular Imaging of
the Axilla As the Patient Is in Position
for Radiation Therapy Using a Robotic
Multi-pinhole SPECT System
2068
Frederick Cope
Exploitation Targeting of the CD206
Receptor in Lymph Node-Resident
Reticuloendothelial Cells With a Novel
Synthetic 99mTc-ligand (Tilmanocept)
Significantly Enhances Localization
in Contrast to 99mTc-Colloid: A New
Meta-analysis
2078
Steven Finkelstein
Dosimetric Variables Correlating With
Excellent and Good Cosmetic Outcomes in a Large, Retrospective
Study of APBI With a Strut-based
Breast Brachytherapy Applicator
2069
Mazen Mislmani
Comparison of Different Radiation
Techniques to Achieve Normal Tissue
Sparing and Target Volume Coverage
in the Treatment of Left Sided Early-stage Breast Cancer
2080
Lindsay Weinshank
Once Daily Radiation Therapy for
Inflammatory Breast Cancer: The Mayo
Clinic Experience
2085
Ralph Vatner
Minimal Acute Toxicity Associated With
Concurrent Adjuvant Carboplatin and
Accelerated Radiotherapy for Triple
Negative Breast Cancer
2086
Lynn Chang
Identifying Risk Factors for Locoregional Recurrence Following
Post-mastectomy Radiotherapy
2087
Paris-Ann Ingledew
A Comprehensive Evaluation of the
Quality of Online Resources for Breast
Cancer Patients
2088
Sonia Nguyen
A Tangled Web: An Evaluation of the
Usage of Web-based Information by
Breast Cancer Patients
2089
Philippe Coucke
Variability of Whole Breast Target Volume Delineation Between Prone
and Supine Position: A Multicentric
Study
2090
Mark Hallman
Impact of Regional Nodal Irradiation
on Outcomes of Breast Cancer Patients
With 1-3 Positive Axillary Nodes
2079
Joseph Panoff
The Role of Hormone Therapy for
Node Negative Breast Cancer Patients
With ER + Tumors 1cm or Less
109
BREAST CANCER/continued
2091
Akkamma Ravi
Long-term results of Accelerated
Partial Breast Irradiation (APBI) for
Early-stage Node Negative Breast
Cancer Treated by MammoSite: Evaluation of Loco-regional
Recurrence and Cosmesis With Respect to Body Mass Index (BMI)
2100
Ahmed Salem
Comparison Between Combined
Photon-electron, Photon-only and
Electron-only Beams in Supraclavicular
Irradiation: A Dosimetric Study
2101
Afshin Rashtian
Intra-operative Radiotherarpy (IORT)
for Ductal Carcinoma in Situ (DCIS): A
Single Institution Study
2092
Mieke Govers
Late Toxicity and Cosmetic Outcome
in Patients With Breast Cancer Treated
With Intra-operative Radiotherapy As
an Electron Boost
2102
Angela Lin
Cardiac Sparing With Breath Hold
Technique: A Dosimetric Evaluation of
Benefits in Different Patient Populations
2093
Noah Taylor
Set-up Error Due to Divergence in AccuBoost Image Guided Brachytherapy: Important Clinical
Implications
2103
Margriet Sattler
CTV Boost Margin for Adjuvant Breast
Radiotherapy - Results of a Study
Comparing US vs.CT Imaging
2094
Carmen Popescu
Simultaneous Couch and Gantry
Dynamic Arc Rotation (C-G Darc) in
the Treatment of Breast Cancer With
Accelerated Partial Breast Radiation
Therapy (APBRT)
2095
Valentina Ovalle
Results of a National Breast Cancer
Program in Chile: 318 Women Treated
Under Standardized Clinical Guidelines
2096
Edwin Crandley
Efficiency and Accuracy of Goggle-based Visual Feedback for
Voluntary Deep Inspiration Breath
Hold (DIBH) Radiation Therapy of the
Left Breast
2097
Alan Slomowitz
An Imaging Comparison of Implantable Markers for Delineating
Target Volumes for Soft Tissue
2104
Lisa Goggin
Estimation of Skin Dose for Post-implant Breast Cancer Patients
Using Monte Carlo Simulation
2105
Vincent Vinh-Hung
Topographic Changes of Surgical Clips
for Breast Tumor Bed Localization
Between Prone and Supine Setup
2106
Bevan Ly
Comparison of Clinical Outcomes
in Early-stage Triple Negative Breast
Cancer Treated With Mastectomy vs.
Breast Conserving Therapy
2111
Sarah Quirk
Partial Breast ITV Margin From Population Respiratory PDF
2112
Michael Wong
A Single-Institutional Experience Using
the Strut-Adjusted Volume Implant for
Accelerate Partial Breast Irradiation
2113
Heather Leggett
Dosimetric Comparison of Sequential
Electron vs. Simultaneous Integrated
Boost (SIB) Techniques for Adjuvant
Breast Radiotherapy
2114
Afshin Rashtian
Intra-operative Radiotherapy (IORT)
for Invasive Breast Cancer. A Single
Institution Study
2115
Cristiane Takita
Assessment of Prognostic Features in
Treatment Decision for Ductal Carcinoma in Situ of the Breast
2116
Lisa Goggin
Dosimetric Comparison Between 3-D
Conformal and CyberKnife Plans for
Accelerated Partial Breast Irradiation
2117
Jiho Nam
Improving Dose Homogeneity and
Target Coverage in the Axillary Region
With Minimizing Apical Lung Dose Using Simple Forward-planned
Intensity Modulated Radiation Therapy
in Breast Cancer Patients
2107
Grace Lee
Impact of Local Regional Nodal
Radiotherapy Field Design on Patterns
of Recurrence in Women With Locally
Advanced Breast Cancer
2118
Shih fan Lai
Treatment Outcome, Relapse Patterns
and Prognostic Factors of Adult Medulloblastoma Patients
2108
Jennifer Zook
An Optimum Treatment Technique for
Chestwall Irradiation in Breast Cancer
CENTRAL NERVOUS SYSTEM
2098
Abigail Milby
Incidence and Patterns of Distant Metastases For Patients With Early-stage Breast Cancer After Breast
Conservation Treatment: Competing
Risks Analysis
2109
Jayoung Lee
Improved Local Control Rate in Three-dimensional Radiation Therapy
Era in Early Breast Cancer After Breast-conserving Surgery
2099
Manisha Palta
Use of Adjuvant Radiotherapy in
Elderly Patients With Early-stage Breast
Cancer: Changes in Practice Patterns
After Publication of Cancer and Leukemia Group B (CALGB) 9343
2110
Rebekah Young
A Retrospective Study Evaluating Toxicity in Women With DCIS Undergoing Hypofractionated Adjuvant Radiation Therapy After
Breast Conserving Surgery
2119
Salvador Villa
Comparison of Two Consecutive
Prospective Series of Unresectable
High-grade Glioma Patients Treated
With or Without Neoadjuvant (na)
Chemotherapy Before Standard
Radiochemotherapy and Adjuvant
Temozolamide
2120
Kazuhiro Miwa
Re-irradiation of Recurrent Glioblastoma Multiforme Using Amino
Acid PET/CT/MRI Image Fusion for
Helical Tomotherapy-based Image
Guided Intensity Modulated Radiation
Therapy
110
2121
Yurie Tsutsumi
Efficacy of Reirradiation for Patients
With Recurrent High-grade Glioma
2122
Hyeon Kang Koh
Fractionated Stereotactic Radiotherapy With Intensity Modulation As an Optic Nerve and
Chiasm Sparing Technique in High
Grade Gliomas
2123
Kengo Ogura
Recurrence Patterns of Glioblastoma in
the Era of Temozolomide
2124
Sanjay Aneja
The Influence of Regional Health
System Resources on Receipt of
Post-operative Radiation Therapy for
Glioblastoma Multiforme
2125
Sonal Mayekar
Evaluating Changes in Radiation Treatment Volumes and Outcomes
from Post-operative to Same-day
Planning MRI in High Grade Gliomas:
A Prospective Study
2126
Andrew Bishop
Valproic Acid Use during Radiotherapy
for Glioblastoma is Associated With
Improved Survival
2127
Stephen Lewis
Patterns of Failure As a Function of
Clinical Target Volumes in Patients
With GBM Treated With Radiotherapy
(RT), Temozolamide and Bevacizumab
2128
Kuldeep Sharma
Target Volume Delineation in Post-operative Glioblastoma. Comparison of Flouro-Deoxy Glucose-Positron Emission Tomography (FDG-PET) vs. Magnetic
Resonance Imaging (MRI)
2129
Krishna Veeravalli
Invasiveness of Human Glioma Stem
Cells Controlled by Cord Blood Stem
Cells Via Regulation of Integrin α6,
N-cadherin and Erk Interactions
2130
Andrew Bishop
Anti-epileptic Drug Associated Rash Is
Not More Prevalent During Radiation
Therapy
2131
Clement Ho
Incidence and Outcome of Symptomatic Venous Thromboembolism in Patients With
Glioblastoma Multiforme in Southern
Alberta
2132
Krishna Reddy
Hypofractionated Intensity Modulated
Radiotherapy Altered Patterns of
Failure in Patients With Glioblastoma
Multiforme Treated on a Phase II Trial
2133
Krishna Reddy
Prospective Evaluation of Health-related Quality of Life and Neurocognitive
Status in Patients With Glioblastoma
Multiforme Treated on a Phase II Trial
of Hypofractionated Radiotherapy
With Temozolomide
2134
Soleakhena Ken
Dynamic Susceptibility-weighted
Contrast-enhanced Magnetic Resonance Imaging in Glioblastoma
for a Longitudinal Assessment of
Tumor Perfusion Wth Cerebral Blood
Volume
2135
Minesh Mehta
Phase I Safety and Pharmacokinetic
(PK) Study of Veliparib in Combination
With Whole Brain Radiation Therapy
(WBRT) in Patients (pts) With Brain
Metastases
2136
Menachem Yondorf
Impact of the Extent of Resection
(EOR) on the Volume of Brain Tissue
Exposed to Radiation in Patients
With Newly Diagnosed Glioblastoma
Multiforme (GBM)
2137
Robert Kosztyla
Comparison of High-grade Glioma
Relapses With Radiotherapy Target
Volumes Obtained From MRI and 18F-FDOPA PET
2138
Michael Christensen
Tumor Volume for Glioblastoma As
Defined by Tryptophan PET Offers
Superior Coverage of Recurrence Site
Than Standard MRI-based GTV
2139
Hyejung Cha
Favorable Outcomes of Adjuvant
Radiotherapy for Intracranial Ependymoma: A Single Institution
Experience
2140
Alexandra Deviers
Evaluation of Lactate As a Predictive
Marker of Survival and Local Response
to Radiotherapy in Patients With GBM
2141
Stephan Bodis
Preliminary Experience of Pre-operative RT for Patients With
Glioblastoma Multiforme
2142
Menachem Yondorf
NTCP Modeling of Dose-escalation
Hypofractionated Stereotactic Radiation Therapy (HFSRT) for Patients
With Subtotally Resected (STR) Newly
Diagnosed Glioblastoma Multiforme
(GBM)
2143
Barbara Diletto
Is There a Role for Concomitant
Low-dose Fractionated Radiotherapy
and Chemotherapy in Recurrent or
Progressive Glioblastoma?
2144
Maria E. Rodriguez-Ruiz
Patterns of Failure In Patients With
Glioblastoma Treated With Surgery
and Intensity Modulated Radiation
Therapy and Temozolamide
2145
Reshma Munbodh
Quantification of Tumor Growth Kinetics in Patients Showing Progression From Low-grade to High-grade Gliomas
2146
Anna Paulsson
Comparison of Clinical Outcomes for
Single Focus and Multifocal Glioblastoma
2147
Jessica Guarnaschelli
Prospective Trial Evaluating Difference
in Radiation Target Volume on 3t vs.
1.5 T MR for Patients With Malignant
Gliomas
2148
Ann Morris
Smaller Margins in the Treatment of
Glioblastoma Multiforme: The University of Iowa Experience
2149
Ryan Abel
Distinguishing Pseudoprogression
From True Progression by FLAIR
Volumetric Characteristics Compared
to 45 Gy Isodose Volumes in Treated
Glioblastoma Patients
111
CENTRAL NERVOUS SYSTEM/
continued
2150
Rahul Bhandari
Five Fraction Image Guided Radiosurgery for Benign Meningiomas
2151
Yoshimasa Mori
Gamma Knife Stereotactic Radiosurgery for Non-benign Meningioma
2152
Inga Grills
Mean Cochlear Dose Predicts Hearing
Preservation in Acoustic Neuroma
Patients Treated With Gamma Knife
Stereotactic Radiosurgery
2153
Alex Johnson
Short Course Radiotherapy for Acoustic Neuromas
2154
Nicholas Zaorsky
Fractionated Stereotactic Radiotherapy and Stereotactic Radiosurgery for the Treatment of
Olfactory Groove Meningiomas:
Observations of 13 Patients With or
Without Prior Surgery
2155
Sang Min Yoon
Treatment Outcomes of World Health
Organization Grade II (Atypical) Meningiomas After Surgery With or
Without Postoperative Upfront Radiotherapy
2160
Laura Ochoa
Long-term Outcomes After Fractionated External Bream Radiation (EBRT) for Pituitary
Adenoma: A 25 Year Update of the
Mallinckrodt Institute of Radiology
Experience
2161
Chia-Lin Tseng
Spinal Cord Motion Considerations for
Spine Stereotactic Body Radiotherapy
(SBRT): Does the Cord Move?
2162
Zhibin Huang
Re-irradiation With Stereotactic Body
Radiotherapy (SBRT): Analysis of Human Spinal Cord Tolerance Using
the Generalized Linear-quadratic
Model
2163
Robert Ebeling, III
Dosimetric Accuracy of Ray-Tracing
Algorithm for Treatment of Thoracic
Spine Lesions Using Robotic Radiosurgery
2164
Huifang Anna Zhai
Analysis of Robustness of a Combined
Cranial Photon and MLC-based Spinal
Proton Field Matching Technique for
Delivery of Craniospinal Irradiation
2165
Raphael Pfeffer
Craniospinal Irradiation (CSI) Wth
VMAT: Implementation and Individual
Quality Assurance
2156
Matthew Hardee
Radiologic and Clinical Outcomes
for Acoustic Neuromas Treated With
Gamma Knife Radiosurgery in the
Lower Dose Ranges
2166
Mark Edson
Treatment Trends and Outcomes by
Age in Myxopapillary Ependymoma of
the Spine
2157
Rajni Sethi
Marginal Misses in Gamma Knife Radiosurgery for Meningiomas: Are
Treatment Volume and Dose Adequate?
2167
Yucai Wang
Outcomes After Surgery and Radiotherapy for Spinal Myxopapillary Ependymoma: Update
of the MD Anderson Cancer Center
Experience
2158
Igor Barani
Adaptive Hybrid Surgery: Feasibility of
Planned Subtotal Resection of Benign
Skull Base Tumors Followed bBy Radiosurgery to Minimize Morbidity
Without Compromising Tumor Control
2168
Hadley Sharp
Feasibility of Radiosurgical Decompression of Metastatic Epidural
Spinal Cord Compression (MESCC) in
Nonoperable Patients
2159
Paul Menzel
Low-dose Conformal Radiotherapy for
Ipilimumab-induced Hypophysitis
2169
Shingo Toyama
Long-term Result of Carbon-ion
Radiotherapy for Locally Advanced or
Unfavorably Located Choroidal Melanoma: CT Based Two-port
Orthogonal Therapy Can Reduce the
Incidence of Neovascular Glaucoma
2170
Nobutaka Mizoguchi
Carbon-ion Radiotherapy for Locally
Advanced Primary or Post-operative
Recurrent Epithelial Carcinoma of
Lacrimal Gland: A Phase I/II Dose-escalation Study
2171
Sewit Teckie
Primary Intraocular Lymphoma: Excellent Outcomes With Ocular Radiation Therapy Alone
2172
Shravan Kandula
Association of Complete Clinical
Response and Long-Term Outcome
Among Patients With Biopsy-proven
Orbital Pseudotumor Receiving Modern Radiotherapy
2173
Savita Dandapani
The USC Experience in Treating Medium Sized Choroidal Melanomas
With Eye Physics Eye Plaque Brachytherapy (125-I)
2174
Dan Kunaprayoon
Stereotactic Radiosurgery in the Treatment of Ocular Melanoma
2175
Nisha Patel
Predictors of Tumor Recurrence and
Enucleation After Iodine-125 Plaque
Brachytherapy for Iris Melanomas
2176
Mostafa Heydarian
A Noninvasive Eye Fixation and
Monitoring System for the Treatment
of Choroidal Melanoma (CM) Using the
Gamma Knife Perfexion (GK)
2177
Bree Eaton
Hypofractionated Radiosurgery
for Large Intact or Resected Brain
Metastases
2178
Daniel Kim
Outcomes of Patients Treated With
A Second Course of Stereotactic
Radiosurgery for Locally or Regionally
Recurrent Brain Metastases After Prior
2179
Peter Gerszten
A Multi-national Report on Methods
for Institutional Credentialing for Spine
Radiosurgery
2180
Henry Park
Skull Base Chordoma and Chondrosarcoma: An Update of
National Radiotherapy Patterns and
Survival Outcomes in the Modern Era
112
2181
Jonathan Schoenfeld
Melanoma Brain Metastases Treated
With Brain-Directed Radiation Followed by Ipilimumab
2182
Yazan Abuodeh
Review of Patients With Brain Metastasis Treated With Fractionated
Stereotactic Radiation Therapy to
Surgical Resection Cavity
2183
Young Hee Park
Comparison of Five Prognostic Indices
in Patient With Brain Metastases Who
Treated With Radiotherapy
2184
Jeannie Han
The Significance of Optic Nerve
Involvement by Skull Base Meningioma and Its Impact on Radiographic Control After Treatment
With Stereotactic Radiosurgery or
Fractionated Stereotactic Radiation
Therapy
2185
Arshin Sheybani
High-dose Hyperfractionated Stereotactic Photon Radiation Therapy
for Skull Based Chordomas
2186
Byoung-Hyuck Kim
Reduced-dose Radiotherapy by the
Chemoresponsiveness for the Primary
Central Nervous System Lymphoma
2187
Francesca Caparrotti
Whole Brain Radiotherapy With Simultaneous Integrated Boost to 1-4
Brain Metastases: A Prospective Study
2188
Kevin Shiue
High vs. Standard Isodose Lines Has
Equivalent Efficacy in Gamma Knife
Treatment of 1-3 Brain Metastases
2189
Alexander Louie
Multidisciplinary Assessment and
Reporting of Fitness to Drive in Brain
Tumor Patients: A Gray Matter
2190
Madeera Kathpal
Use of a Non-coplanar Half-beam
Block on the Lower Spinal Field to
Decrease the Maximum Bowel and
Cumulative Dose iIn Craniospinal
Irradiation
2191
Hubert Pan
Frameless, Real-Time, Surface Imaging
Guided Radiosurgery (SIG-RS): Clinical
Outcomes for Brain Metastases
2192
Itai Pashtan
Proton Radiosurgery for Management
of Brain Metastases
2193
David Roberge
“Tri-modality” Therapy for Large Brain
Metastases
2194
Akifumi Miyakawa
Fractionated Stereotactic Radiotherapy for Metastatic Brain
Tumors Recurring After Gamma Knife
Radiosurgery: Acceptable Toxicity and
Improved Local Control
2195
Nils Arvold
Physician Recommendations for Steroid and Anticonvulsant Use Following Stereotactic Radiosurgery
2196
Tomohiko Matsuyama
Fractionated Stereotactic Radiation
Therapy (FSRT) For Brain Metastases
From Non-small Lung Carcinoma;
Relationship Between the Number of
Metastases and Intracranial Relapse
2197
Paul Rava
Stereotactic Radiosurgery As Salvage
for Brain Metastases from Small Cell
Lung Cancer
2198
Paul Rava
Associating Risk With Survival and
Brain Recurrence in Patients With
Non-small Cell Lung Cancer Treated
Aggressively for Synchronous Brain
Metastases
2199
Roshan Prabhu
Clinical Outcomes for a Novel 6 Degrees of Freedom Image Guided Immobilization and Localization
Method for Frameless Radiosurgery for
Brain Metastases
2200
Lijun Ma
How Millimeter Margins Impact
RTOG9005 Tolerance Dose Levels for
Intracranial Stereotactic Radiosurgery
2203
Jonathan Leeman
Linear Accelerator Based Stereotactic
Radiosurgery for the Treatment of
Brainstem Metastases
2204
John Flickinger
Subtraction-fusion of New-minus-old
Magnetic Resonance Images Can
Identify Additional Brain Metastases
in 24 percent of Repeat Radiosurgery
Procedures
2205
Diandra Ayala-Peacock
Predictive Factors for Distant Brain
Failure After Primary Radiosurgical
Management of Brain Metastases
2206
Edward Marchan
Multileaf Collimator-based Linac
Radiosurgery for Arteriovenous Malformations: The Emory Experience
2207
Sameer Nath
TRIC or Tumor: Regrowing Lesions
Following Radiosurgery for Brain Metastases - Proposal For a Histopathologic Scale based on Correlation With Survival
2208
Stefan Becker
A New Mathematical Model to Simulate the Progression of Brain
Metastasis
2209
Carmen Tundisi
Is the Graded Prognostic Assessment
(GPA) Reliable for Patients Previously
Treated for Brain Metastases?
2210
Eric Ojerholm
Gamma Knife Radiosurgery to Four
or More Brain Metastases in Patients
Without Prior Intracranial Radiation
or Surgery
2211
David Roy
Stereotactic Radiosurgery and Radiotherapy for the Treatment of
Brain Metastases in Thyroid Carcinoma
2201
Dong Soo Lee
Early Volumetric Change and Treatment Outcomes After Palliative Radiotherapy for Brain Metastasis
2212
Lauren Tait
Outcomes of Gamma Knife Radiosurgery in Synchronous vs. Metachronous Small Cell Lung Carcinoma Brain Metastases
2202
Kristina Young
A Retrospective Review of SBRT for
Larger Brain Metastases or Post-resection Cavities
2213
Ryan Funk
The Washington University Experience
of Gamma Knife Radiosurgery for Aggressive Meningioma
113
CENTRAL NERVOUS SYSTEM/
continued
2214
Daniel Bernad
Prophylactic Cranial Irradiation in
Patients With Limited Stage Small Cell
Lung Cancer: A Pilot Study Investigating the Effects of Radiation
Therapy on Neurocognitive Function
2215
Maya Mathew
Ipilimumab in Melanoma With Limited
Brain Metastasis Treated With Stereotactic Radiosurgery
2216
Susannah Yovino
Eliminating or Modifying Vertex Fields
Significantly Reduces Normal Tissue
Dose in Brain Tumor Patients
2217
Valentina Ovalle
Radiosurgery of AVMs: A Single Center
Experience in Chile, 1996 - 2010
2218
Sean Szeja
Frameless Hypofractionated Stereotactic Radiation Therapy for
Brain Metastases
2219
Yasuaki Harasaki
Safety and Efficacy of Vemurafenib
Combined With Stereotactic Radiosurgery for Brain Metastases in
BRAF+ Melanoma
2220
Marc Leyrer
Radiation-Induced Taste and Smell
Toxicity: A Dose Volume Histogram
Analysis of a Prospective Observational Study
2221
Ashwatha Narayana
Use of Vemurafenib, a BRAF Inhibitor
Along With Radiation Therapy in
Melanoma Brain Metastasis
2222
Peyman Kabolizadeh
Fractionated Stereotactic Radiosurgery
for Large Brain Metastases
2223
Donald Cannon
Impact of Radiotherapy and Extent of
Resection in Choroid Plexus Carcinoma: An Analysis of the Surveillance Epidemiology and End
Results (SEER) Database
2224
Hany Soliman
Outcomes for Post-surgical Hypofractionated Stereotactic Cavity
Radiotherapy (HSCRT) As Salvage for
Patients With Prior Whole Brain Radiation (wbrt) As Compared to
Upfront Adjuvant Hscrt
GASTROINTESTINAL CANCER
2225
Yoshiki Kajiya
Hyperbaric Oxygen Therapy for Reducing Adverse Events of Chemoradiotherapy for Esophageal
Cancer
2226
Laurent Quero
Evaluation of Early Response to
Concomitant Chemoradiotherapy
by Interim 18-FDG PET-CT Imaging
in Patients With Locally Advanced
Oesophageal Carcinomas
2227
Connie Yip
CT Prognostication in Oesophageal
Cancer Treated With Definitive Chemoradiation: Is Still Relevant
2228
Noriko Kobayashi
Tumor Response After Small Dose of
Chemoradiotherapy in Patients With
Esophageal Carcinoma
2229
Hae-jin Park
The Influence of Circumferential
Resection Margin Status on Loco-Regional Recurrence in Esophageal Squamous Cell Carcinoma
2230
Feng-Ming Wang
5-beam Simplified Intensity Modulated Radiotherapy for Patients
With Cervical Esophageal Carcinoma
2231
Shigehiro Kudo
Preliminary Result of a Multicenter
Phase II Study of Chemoradiotherapy
With Docetaxel for Elderly Patients
With Stage II/III Esophageal Carcinoma
2232
Ryuta Koike
Definitive Chemo-radiotherapy (CRT)
Using Intensity Modulated Radiotherapy (IMRT) Boost for Cervical
Esophageal Cancer
2233
Hitoshi Ito
Radiation therapy for Stage IA Esophageal Squamous Cancer
2234
Yoshinori Ito
Phase II Trial of 5-fluorouracil In Combination With Cisplatin and Concurrent Radiotherapy (50.4 Gy)
With Elective Nodal Irradiation for
Clinical Stage II/III Esophageal Cancer
2235
Kazushige Atsumi
Prognostic Value of FDG-PET In
Definitive Chemoradiotherapy for
Esophageal Cancer
2236
Shuchai Zhu
Characteristics of the Lymph Node
Metastases and Their Affect in Target
Region Delineation in Prophylactic
Postoperative Radiotherapy for Thoracic Esophageal Carcinoma
2237
Samuel Cooper
Cervical Esophageal Cancer: A Population Based Study
2238
Yufeng Cheng
Tumor-stroma Ratio is an Independent
Predictor for Survival in Esophageal
Squamous Cell Carcinoma
2239
Srinivas Chilukuri
Prospective Study Evaluating Image
Guided Volumetric Modulated Arc
Therapy With Concurrent Weekly
Cisplatinum for Inoperable Thoracic
Esophageal Cancer
2240
Connie Yip
CT Tumour Heterogeneity in Prognostication of Primary Oesophageal Cancer Treated With
Definitive Chemoradiation
2241
Kristin Kowalchik
Early Outcomes and Toxicity in Patients
Treated With Bimodality or Trimodality
Therapy for Esophageal Carcinoma
With Intensity Modulated Radiation
Therapy (IMRT)
2242
Roberto Innocente
Salvage Treatment in Locoregional
Recurrent Esophageal Carcinoma (EC)
Using Intensity Modulated Radiation Therapy -Helical Tomotherapy (IMRT-HT)
2243
Joseph Killoran
Application of FLT PET to Radiotherapy
Treatment Planning of Esophageal
Cancer
114
2244
Abraham Wu
Definitive Chemoradiation for Adenocarcinoma of the Esophagus
and Gastroesophageal Junction
2245
Takayuki Hashimoto
Concurrent Chemo-proton Therapy
Using 5-Fluorouracil and Cisplatin for
Esophageal Cancer
2246
Wei Lu
Pre-Chemoradiotherapy FDG PET/CT
Can Not Identify Residual Metabolically Active Areas in Patients
With Locally Advanced Esophageal
Cancer
2247
Yuji Murakami
Treatment Results of Definitive Radiation Therapy for Elderly Patients
With Esophageal Squamous Cell
Carcinoma
2248
Ligang Xing
Tumor 18F-FDG Heterogeneity Assessed by PET Image Texture
Analysis and Its Impact on Target
Delineation for Esophageal Squamous
Cell Carcinoma
2249
Yuichi Ishida
Neoadjuvant Concurrent Chemoradiotherapy Followed by
Definitive High-dose Radiotherapy or
Surgery for Operable T3 Squamous
Cell Carcinoma of Thoracic Esophagus
2250
Wei Wang
Comparison of the Planning Target
Volume Based on Three-dimensional
CT and Four-dimensional CT Images
off Thoracic Esophageal Cancer
2251
Shilpen Patel
Tumor Length As a Prognostic Factor
in Esophageal Cancer Management
2252
Bhupesh Parashar
Adenocarcinoma Is Associated With
Improved Survival Compared to
Squamous Cell Carcinoma in Patients
With Esophagus Cancer Treated With
Radiation: A Seer Analysis
2253
Ravi Shridhar
Lymph Node Dissection in Esophageal
Cancer After Neoadjuvant Radiotherapy: A SEER Database Analysis
2254
Feng-Ming Hsu
Changes of Pulmonary Fluorodeoxyglucose Uptake After
Neoadjuvant Concurrent Chemoradiation in Predicting
Postoperative Pulmonary
Complications for Patients With
Esophageal Cancer
2263
Ravi Shridhar
Increased Survival Associated With
Surgery and Radiation Therapy in
Metastatic Gastric Cancer: A Seer
Database Analysis
2264
Junichi Fukada
Inter- and Intra-fraction Gastric Motion Study: Impact of Breathing and
Stomach Filling
2255
Jeremy Tey
Clinical Outcome of Palliative
Radiotherapy in Locally Advanced,
Symptomatic Gastric Cancer in the
Modern Era
2256
Hua Ren
Preliminary Results of Ongoing Phase
II Study of Postoperative Intensity
Modulated Radiotherapy (IMRT) Combined With Capecitabine for High
Risk Gastric Cancer Patients
2257
Xin Wang
A Phase I Study of Concurrent
Capecitabine and Intensity Modulated
Radiotherapy (IMRT) As Adjuvant Treatment for Locally Advanced Gastric Cancer
2258
Li Zhang
Comparing Capecitabine Plus
Oxaliplatin vs. Capecitabine Plus
Oxaliplatin With Concurrent
Capecitabine Radiotherapy in Completely Resected Gastric Cancer
2259
Jean Owen
Sociodemographic Factors Associated
With Management of Gastric Cancer:
QRRO/CURE Results
2260
Aditi Aggarwal
Megavoltage CT (MVCT) Based Evaluation of Internal Target Volume
in Patients Undergoing Tomotherapy
Based Image Guided Intensity Modulated Radiation for Gastric Cancers
2261
Ligang Xing
Phase I Study of Docetaxel, 5-fluorouracil and Cisplatin With Concurrent Radiotherapy for Unresectable Locally Advanced Gastric
Adenocarcinoma
2262
Shilpen Patel
Analysis of Treatment Modalities for
Gastric Adenocarcinoma
2265
Gene-Fu Liu
Clinical Outcomes for Gastric Cancer
Following Adjuvant Chemoradiation
Utilizing Intensity Modulated Radiation Therapy
2266
Richard Lee
Proton Therapy May Allow Elective
Nodal Coverage in the Setting of Neoadjuvant Radiotherapy for Pancreatic Head Cancers Without
Significantly Increasing Normal Tissue
Exposure
2267
Roger Ove
Chemoradiation in the Management
of Pancreatic Neuroendocrine Tumors
(PNET)
2268
Malolan Rajagopalan
Pathologic Response With Neoadjuvant Chemotherapy and
Stereotactic Body Radiotherapy for
Borderline Resectable and Locally-advanced Pancreatic Cancer
2269
Akihito Nishioka
Safety and Efficacy of Enzyme-Targeting Radiosensitization
With Intraoperative Radiotherapy for
Locally Advanced Pancreatic Cancer
2270
Chi Lin
Borderline Resectable Pancreatic
Adenocarcinoma: Tumor Volume and
CA19-9 Reduction Following Neoadjuvant Chemotherapy and
Fractionated Stereotactic Body Radiotherapy Correlates With Pathologic Response
2271
Amy Farkas
Pancreatic Tumor Motion and Required Margins to Account for Motion
2272
Maged Ghaly
Duodenal Sparing Stereotactic Body
Radiation Therapy for the Treatment of
Locally Advanced Pancreatic Cancer
115
GASTROINTESTINAL CANCER/
continued
2273
Yolanda Tseng
Dosimetric and Clinical Predictors of
Nausea and Vomiting: An Exploratory
Analysis of a Prospective Phase I/II
Trial With Neoadjuvant Accelerated
Short Course Radiation Therapy With
Capecitabine for Resectable Pancreatic
Cancer
2274
Thomas Brunner
A Comparison of Four Target Volume
Definitions for Pancreatic Cancer: Two
Concepts Including the Lymphatics
(RTOG And ARO) and Two Concepts
Only Treating the Primary Tumour
(Michigan and UK-SCALOP)
2275
Severine Racadot
Dummy Run in the Phase Iii Lap07
Pancreatic Cancer Trial: First Evaluation
of Quality of Radiotherapy Planning
2276
Keun Yong Eom
Dose-Volumetric Parameters Affect the
Development of Diabetes Mellitus in
Patients Treated with Post-operative
Chemoradiotherapy Following Pancreaticoduodenectomy
2277
Aaron Wild
SBRT as a Novel Treatment Option for
Locally Recurrent Pancreatic Cancer
After Failure of Definitive Multimodality Therapy:
A Multi-institutional Case Series
2278
Lindsay Sales
Neoadjuvant Chemoradiation in the
Treatment of Local-Regional Pancreatic Adenocarcinoma
2279
Eric Mellon
Outcomes of Adjuvant Radiotherapy
and Lymph Node Dissection in Pancreatic Cancer: A Seer Analysis
2280
Ahmet Tunceroglu
Dose-painted Intensity Modulated
Radiation Therapy May Offer Improved
Morbidity As Compared to 3-D CRT
2281
Cengiz Gemici
Salvage Chemoradiotherapy for Loco-regional Recurrence After
Adjuvant Gemcitabine in Patients With
Resected Pancreatic Adenocarcinoma
2282
Wungki Park
A Loss of Function Genetic Screen
Identifies Determinants of Sensitivity
to PARP Inhibitor ABT-888 in Pancreatic
Cancer
2293
Sung hoon Kim
The Impact of Beam Angle Configuration of Intensity-modulated
Radiotherapy on the Normal Liver in
Advanced Hepatocellular Carcinoma
2283
Chiyoko Makita
Clinical Outcomes of Proton Beam
Therapy for Cholangiocarcinoma
2294
Jean-Emmanuel Bibault
Stereotactic Body Radiation Therapy
for Hepatocellular Carcinoma: A Prognostic Factors Analysis
2284
Brandon Barney
Clinical Outcomes and Toxicity using
Stereotactic Body Radiotherapy (SBRT)
for Advanced Cholangiocarcinoma
2285
Tae Ryool Koo
Extrahepatic Bile Duct Cancer: Analysis
of Treatment Outcomes and Patterns
of Failure
2286
Tomoki Kimura
The Treatment Results and Dosimetric
Analysis of Stereotactic Body Radiation
Therapy (SBRT) With Transarterial
Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)
2287
Zhao-Chong Zeng
Is It Time to Adopt EBRT As an NCCN
Strategy for Intermediate/Advanced
HCC?
2288
Zhi-Yong Yuan
CyberKnife Stereotactic Body Radiation Therapy for Liver Metastases
2289
Chie Toramatsu
The Role of Spot Scanning Proton
Therapy in the Treatment of Large
abdominal tumors: A comparative
Planning Study of Hepatocellular
Carcinoma
2290
RyoongJin Oh
Tolerance of Cirrhotic Liver Comparing
With Normal Liver to Stereotactic Body
Radiotherapy
2291
Harriet Eldredge
The Predictive Value of Functional Tumor Volume and Total Lesion Glycolysis in Patients With Liver Metastases From Uveal Melanoma Undergoing 90Yttrium Selective Internal Radiation Therapy
2292
Jeong Il Yu
Predictive Factors for Child-Pugh Score
Elevation in Hepatocellular Carcinoma
Patients Treated With Conformal Radiation Therapy: Dose-Volume
Histogram Analysis
2295Withdrawn
2296
Bree Eaton
Image-based Dosimetry for 90Y Selective Internal Radiation Therapy
(SIRT) of Hepatic Metastatic Melanoma: Dose-Volume Analysis
Predict FGD-PET Response
2297
Erik Lappinen
Combination of Surgery and Stereotactic Radiotherapy (SRT) with
3-D SPECT/CT Treatment Planning for
Primary and Metastatic Liver Tumors
2298
Yousri Rostom
Efficacy and Safety of Three-dimensional Conformal
Radiotherapy in Treatment of Portal
Vein Thrombosis in Hepatocellular
Carcinoma Patients
2299
Fumiaki Isohashi
Patterns of Radiotherapy Practice for
Bile Duct Cancer in Japan: Results of
the Japanese Radiation Oncology
Study Group (JROSG) Survey (2000-2008)
2300
Shigeo Takahashi
Portal Vein and Bile Duct Toxicity
Following Stereotactic Body Radiation
Therapy (SBRT) for Hepatocellular
Carcinoma (HCC)
2301
Chisa Hashizume
Novalis Stereotactic Body Radiotherapy (SBRT) for Hepatoma
and Liver Metastasis: Evaluation of the
Optimal Dose
2302
Pramod Gupta
Outcomes of Adjuvant Chemoradiation in Resected Gall Bladder Carcinoma: A Single
Institution Experience from North
India
116
2303
Seung Heon Lee
Promising early results of Stereotactic
Body Radiation Therapy for Hepatocellular Carcinoma With Respiratory Gated Radiation Therapy
2304
Jung Ho Im
Higher Radiation Dose May Benefit
Patients With Extrahepatic Bile Duct
Cancer Undergoing Curative Resection
2305
Ann Shing Lee
Individualized Hypofractionated
Radiation Therapy (IHRT) for Advanced
Hepatocellular Carcinoma (HCC):
Single Institution Experience With 98
patients
2306
Yi Rui Zhai
Outcomes of Intraoperative Electron
Radiotherapy (IOERT) Combined With
Radical Surgery for Early Stage Hepatocellular Carcinoma: A Pilot
Study
2307Withdrawn
2308
Po-Ming Wang
Results From a Phase II Non-Randomized Trial on 145 Patients
With Hepatocellular Carcinoma
Treated With Volumetric Modulated
Arc Therapy
2309
Martin Fuss
Transarterial Ethiodol-based Hepatocellular Carcinoma (HCC)
Embolization (TACE): Impact on
Image-guidance for SBRT and HFxRT
2314
Jennifer Wo
Phase I Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and
Capecitabine for Resectable Pancreatic
Cancer
2315
Jun Won Kim
Clinical Features of Hepatocellular Carcinoma Patients Undergoing Resection After Concurrent Chemoradiotherapy
2316
Caitlin Schonewolf
Patterns of Failure in Colorectal Patients With Liver Metastases Following Yttrium-90 Radioembolization
2317
Aaron Wild
Concurrent vs. Sequential Sorafenib
Therapy in Combination With Radiation for Hepatocellular Carcinoma: A Preclinical Study
2327
Ning Li
Phase I Clinical Study of Concurrent
Chemoradiation With Hydroxycamptothecin for Unresectable or Locally Relapsed
Rectal Cancer
2318
Lauren Hertan
Adjuvant Radiation Therapy in Resected Ampullary Carcinoma:
Impact on Survival Outcomes
2328
NingNing Lu
A Long-term Survival Analysis for
Phase II Study of Postoperative Concurrent Capecitabine and Radiotherapy for Patients With Stage
II/III Rectal Cancer
2319
Chiao-Ling Tsai
Investigation on Sonic Hedgehog
Signaling Pathway for Radiation Sensitization in Hepatocellular Carcinoma
2329
Ji Zhu
The Strategy of Chemoradiotherapy
First for Synchronous Distant Metastases Rectal Cancer: A Phase Ii
Clinical Trial
2320
Sheen Cherian
Stereotactic Radiation (SBRT) for
Primary Liver Malignancie
2330
David Chia
Efficacy of Palliative Radiation Therapy
in Symptomatic Rectal Cancer in the
Modern Era
2321
Hyunsik Yoon
Dosimetric Analysis of Gastroduodenal
Toxicity by Endoscopy in Cirrhotic
Patients After Radiotherapy for Hepatocellular Carcinoma
2311
Shixiong Liang
Evaluation of the Prognostic Value of
Different Staging System for Hepatocellular Carcinoma Undergoing
Conformal Radiotherapy
2322
Ki Mun Kang
Preliminary Report of Stereotactic
Body Radiotherapy With Respiratory
Motion Tracking for Liver Tumors
2313
Michelle Stinauer
Toxicity of combined SBRT and Selective Internal Radiation Therapy
for Liver Metastases
2325
Jee Suk Chang
Propensity Score Analysis of Anastomotic Leakage After Rectal
Cancer Resection: Risk Factors and
Radiation Effects
2326
May Abdel-Wahab
Does Radiation Improve Survival of
T2N1 or T3N0 Rectal Adenocarcinomas
in Population-based Series?
2310
Ping Li
Clinical Outcomes of γ-ray Stereotactic
Body Radiation Therapy for Patients
With Primary Hepatic Carcinoma of
Stage I/II
2312
Chun-Ming Huang
Clinical Experience of Helical Tomotherapy for Unresectable Hepatocellular Carcinoma
2324.5
Hee Ji Han
Radiotherapy Outcome of Advanced
Hepatocellular Carcinoma Greater
Than 10 cm
2323
Mark Ziegler
Efficacy of Radioembolization Treatments With Yttrium-90 Microspheres for Hepatocellular Carcinoma and Liver Metastases
2324
Mark Lobo
Retrospective Analysis of the Yttrium-90 Microspheres in Hepatocellular Carcinoma: The University of Virginia Experience
2331
Jonathan Whaley
Clinical Utility of Integrated FDG PET-CT Imaging in the Clinical Management and Radiation Treatment
Planning of Locally Advanced Rectal
Cancer
2332
Benhua Xu
The Preliminary Results of Intense
Neoadjuvant Chemoradiotherapy for
Locally Advanced Rectal Cancer: A
Prospective Non-randomized Phase
II Study
2333
Yan-yang Wang
Is Belly board Still Needed in IMRT for
Rectal Cancer? The Change of Bladder
Volume Affects the Determination
117
GASTROINTESTINAL CANCER/
continued
2334
Jessica Smith
Clinicopathologic Comparison of
High-dose-rate Endorectal Brachytherapy and Conventional
Chemoradiotherapy Among Patients
With Locally Advanced Low Rectal
Cancer
2335
Konstantin Lavrenkov
Experience Update of Neoadjuvant
Chemo-radiotherapy for Locally
Advanced Rectal Cancer Using UFT
and Leucovorin
2336
Chia-Chun Wang
Pre-operative Prone-position
Volumetric Modulated Arc Therapy
With Concurrent Bevacizumab and
Chemotherapy in Locally Advanced
Rectal Cancer
2337
Yong Cai
Phase II Trial of Modified Short-time
Preoperative Radiotherapy in Resectable Mid-low Rectal Cancer
2338
Ching-Wei Tzeng
Intraoperative Radiation Therapy for
Locally Advanced Primary and Recurrent Colorectal Cancer: Ten-Year Institutional Experience
2339
Luke Peng
SEER-based Analysis of the Impact
of Preoperative or Postoperative
Radiotherapy on Survival Outcomes
for T3N0 Rectal Cancer
2340
Tzu-I Jonathan Yang
Predictors of Hematologic Toxicity
During Pelvic Radiotherapy
2341
Daniel Bernad
Late Effects From Pre-operative
Endorectal Brachytherapy and Total
Mesorectal Excision in Rectal Cancer
Patients: Analysis on Bowel, Urinary
and Stoma Function
2342
Jinhong Jung
Clinical Results of Stereotactic Body
Radiation Therapy for Lung Metastases
From Colorectal Cancer
2343
Kara Leonard
The Role of Local Radiotherapy in the
Treatment of Metastatic Rectal Cancer
2344
Leire Arbea
Four-week Neoadjuvant Intensity
Modulated Radiation Therapy With
Concurrent Capecitabine and Oxaliplatin in Locally Advanced Rectal
Cancer Patients: A Single Institution
Experience With Long-term Follow-up
2354
Michael Chuong
Comparative Outcomes of Intensity
Modulated Radiation Therapy vs. 3-D
Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal
Canal
2345 Maria Gambacorta
Atlas-based Auto-segmentation Clinical Validation of Pelvic Volumes
And Normal Tissue in Rectal Tumors
2355
Rosanna Yeung
One vs. Two Cycles of Mitomycin C in
Concurrent Chemoradiation for Treatment of Anal Canal Carcinoma:
An Analysis of Outcomes and Toxicity
2346
Marsha Laufer
Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at National Comprehensive Cancer
Network (NCCN) Centers
2356
Omar Mahmoud
A Comparative Study of Conventional
Radiotherapy vs. Intensity Modulated
Radiotherapy in the Management of
Patients With Anal Canal Cancer
2347
Aryavarta Kumar
Peri-operative Complications in
Patients With Inflammatory Bowel
Disease Who Received Chemoradiation for Colorectal Malignancy
2357
Veronique Vendrely
French Multicentric Clinical Evaluation
of Helicoidal Tomotherapy for Anal
Cancer in a Cohort of 69 Consecutive
Patients
2348
Jared Sturgeon
Definitive Chemoradiation for Squamous Cell Carcinoma of the
Rectum
2349
Naichang Yu
Interfractional Rectal Motion During
External Beam Radiation Therapy for
Patients With Rectal Cancer
2350
Joshua Meyer
Young Age at Diagnosis Increases Risk
of Lymph Node Positivity in Early-stage
Rectal Cancer
2351
Jun Won Kim
Molecular Markers Aid Prediction of
Treatment Failure After Surgical Resection and Adjuvant Chemoradiation for Locally Advanced
Rectal Cancer
2352
Jose Bazan
Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Patients
Receiving Pelvic IMRT and Concurrent
Chemotherapy
2353
Fleure Gallant
Association of Dosimetric Parameters
and Acute Hematologic Toxicity in
Anal Canal Patients Treated with
Chemoradiation using 3-D Conformal
vs. Intensity Modulated Radiotherapy
Techniques
2358
Sheela Hanasoge
Re-irradiation for Cancers of the
Rectum and Anal Canal: The Emory
University Experience
2359
Joost Nuyttens
Inguinal Node Recurrence to the
Untreated Groin in Patients With Anal
Carcinoma
2360
Lisa Kachnic
Dose-painted Intensity Modulated
Radiation Therapy for Anal Cancer:
No Differences in Treatment Toxicity
and Early Outcomes Between Human
Immunodeficiency Virus Positive and
Negative Patients
2361
Suzanne Sachsman
Analysis of HIV Negative and Positive
Patients With Anal Squamous Cell
Carcinoma Treated With Definitive
Chemo-radiation Therapy at LAC/USC:
An Update
2362
Sindu Vivekanandan
Split-course Chemoradiotherapy: An
Effective Alternative Treatment of Anal
Cancer in Elderly Patients
2363
Craig Baden
(IMRT) vs. Three-dimensional Conformal Radiation Therapy (3-D
CRT) for Squamous Cell Carcinoma of
the Anal Canal: Average Weekly Radiation Dose and Clinical Outcomes
118
2364
Vaiibhav Patel
The Use of Gamma Knife Radiosurgery
in Gastrointestinal Brain Metastasis: A
Single Institution Experience
2365
Evan White
Reduced Toxicity in Inflammatory
Bowel Disease Patients Treated With
(IMRT)
2366
Nitika Thawani
Reduced Myelotoxicity in pelvic malignancies With Bone Marrow
Sparing IMRT
2367
Chi Lin
Comparison of Prognostic Factors and
Survival Outcome Between Primary
Malignant Melanoma in Gastrointestinal Track and Cutaneous
Malignant Melanoma
GENITOURINARY CANCER
2368
Ryan Burri
Rectal Balloons and the Risk of Secondary Rectal Malignancy After
IMRT for Prostate Cancer
2369
Steven Finkelstein
White Blood Cell Counts Remain
Stable Following Standard Radiation
Approaches for High-risk Adenocarcinoma of the Prostate
2370
Damien Weber
Intensity Modulated Proton and Photon Therapy for Early Prostate
Cancer With or Without Transperineal
Injection of a Polyethylen Glycol Spacer: A Treatment Planning Comparison Study
2373
Daniel Adam Jones
Neurovascular Bundle (NVB) Sparing
Technique In Prostate Brachytherapy
2374
Hiromichi Ishiyama
High-dose-rate (HDR) Brachytherapy
and Hypofractionated External Beam
Radiotherapy Combined With Long-term Hormonal Therapy for
2375
Kotaro Terashima
Can Belly Board Reduce Respiratory-induced Prostate Motion
in the Prone Position? Assessed by
Cine-magnetic Resonance Imaging
2376
Masahiro Morimoto
Comparison of Acute Genitourinary
and Gastrointestinal Adverse Events
of Localized Prostate Cancer Treated
With Monotherapy Using Intensity Modulated Radiation Therapy
or Three-dimensional Conformal Radiation Therapy or Permanent
Implant Brachytherapy
2377
John Hegde
Preoperative 3-Tesla Multiparametric
Endorectal MRI Findings and the Odds
of Upgrading and Upstaging at Radical
Prostatectomy in Men With Clinically
Localized Prostate Cancer
2378
Kamran Ahmed
Role of Stereotactic Body Radiation
Therapy in Oligometastatic, Hormone
Refractory Prostate Cancer
2379
Takashi Mizowaki
Interim Outcomes of a High-dose
Whole Pelvic IMRT for Very High-risk Group of Patients With Locally Advanced Prostate Cancer
2371
Waleed Mourad
Long-term Outcomes of Postprostatectemy Salvage Radiation
Therapy (PsRT) Dose Intensification
(81Gy)
2380
Alan Katz
Offers A Safe, Non-Invasive Treatment
for Prostate Cancer Patients Over 70
Years Old
2372
Waleed Mourad
Dosimetric and Biological Impacts of
Simultaneous Integrated Brachytherapy Boost (SIBB) Delivered
Via Pd103 Seeds followed by External
Beam Radiotherapy (EBRT) on Prostate
Cancer
2381
Jonathan Andrew Haas
Low-Intermediate Risk Prostate Cancer
2382
Ravinder Clayton
Utilization of Radiation Therapy in
Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice
2383
Israel Fortin
Fiducial Markers (fm) in the Prostate
Bed for Post Prostatectomy External
Beam Radiation Therapy: Improved
Accuracy As Compared to the Use of
Surgical Clips
2384
Shawn Malone
Preliminary Results of a Randomized
Trial of Optimal Timing of Dose Escalated (76 Gy) Radiation and 6
Months ADT in Prostate Cancer
2385
Vikram Velker
Predictors of Prostate Bed Contouring
Variability: An International Contouring Challenge
2386
Hiraku Sato
Comparison of Soft-tissue Matching on Daily Cone-beam
Computed Tomography and Fluoroscopy-based Bony-structure
Matching in the Target Localization for
the IMRT of Prostate Cancer
2387
Yutaka Shiraishi
Assessment of Late Rectal Toxicity After I-125 Prostate Brachytherapy
Using Equivalent Uniform Dose
2388
Breanne Terakedis
The Effect of Prostate MRI on Cancer
Staging and Radiotherapy Treatment
Recommendations
2389 Magali Lecavalier-Barsoum
Hypofractionated IMRT With Simultaneous Integrated Boost for
High-risk Prostate Cancer Patients:
Acute Toxicity Report
2390
Hong Ye
A Matched Pair Analysis of Long-term
Clinical Outcomes and Toxicities for
Low-risk Prostate Cancer Patients
Treated With Low-dose-rate or High-dose-rate Brachytherapy
2391
Shinichi Takahashi
Optimal Acquisition Parameter Selection for CT Simulators Reducing
Seed Artifacts in Permanent Seed
Implants
2392
Michael Dominello
Decreases Incidence of Acute Rectal
Toxicity in the Treatment of Low- and
Intermediate-risk Prostate Cancer
119
GENITOURINARY CANCER/
continued
2393
Christophe Hennequin
18(F)choline PET/CT and Prostate MRI
for Staging of Biochemical Relapse
After Radiotherapy of Prostate Cancer
2394
Magali Quivrin
Multiparametric MRI-based Dosimetric
Parameters Best Predict Short-term
Time Course of PSA After Iodine 125
Permanent Prostate Implantation for
2395
Andrew Lee
Patient Quality of Life After Proton
Therapy (1.8 vs 2 Gray Equivalents) for
Prostate Cancer
2396
Jeremy Karlin
An Exploratory Analysis of Prostate
Brachytherapy Cases Using the
Proposed Activity-Based Medical Event
Definition
2397
Eric Vigneault
The Long-term Experience of Permanent Seed Implant Monotherapy in Low- and Intermediate-risk Prostate Cancer
2398
Shigeyuki Takamatsu
Clinical Assessment of Proton Therapy
of Prostate Cancer Patients With Auto
Activation PET/CT
2399
Constantine Mantz
Real-time Target Tracking Prostate
SBRT: Quality of Life and Disease
Outcomes From a Phase II Trial Utilizing Varian Trilogy and the Calypso
4-D Localization System
2400
Shinji Kariya
High-dose-rate Brachytherapy Combined With External Beam Radiotherapy for Localized Prostate
Cancer: Clinical Predictive Factor for
Biochemical Relapse-free Survival
2401
Manabu Aoki
PSA Response to Tri-modality (HDR
Brachytherapy, Hypofractionated 3-D
CRT, Neoadjuvant/Adjuvant Androgen
Therapy) Predicts Biochemical Progression Free Survival in Localized
Prostate Cancer
2402
Colleen Lawton
RTOG Protocol 05-18: A Phase III Randomized Trial to Evaluate the Efficacy of Zometa for the Prevention
of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy (RT) and Long-term
Lutenizing Hormone-releasing Hormone (LHRH) Agonist
2403
Ovidiu Marina
Dose-Escalated Adaptive Image
Guided Radiotherapy vs. High-dose-rate Brachytherapy Monotherapy for Gleason 7 Intermediate-risk Prostate Cancer: A
Matched-pair Analysis
2411
Kevin Diao
Comparative Patient-reported Quality
of Life (QOL) During Radiation Therapy
(RT) in Patients Receiving Definitive RT
vs. Post-prostatectomy RT for Prostate
Cancer
2412
Harold Wallace
Autoscan Transperineal Ultrasound of
the Pelvis for Prostate Gland Localization: A Feasibility Study
2413
Catherine Duarte
Impact of Race on Prostate Cancer
Treatment Selection and
Cause-Specific Mortality: A SEER
Database Analysis
2404
Julia Luisa Munoz Garcia
Metabolic Alterations After Normalization of Testosterone Levels
in Patients With Prostate Cancer
Treated With Androgen Deprivation
2414
Ovidiu Marina
Mean Per-core Biopsy Volume As
a Predictor of Failure for Gleason 7
Prostate Cancer Patients Undergoing
High-dose-rate Brachytherapy (HDR)
2405
Shelly X. Bian
The Influence of Age and Cormorbidity
on the Benefit of Adding Androgen
Deprivation to Dose-Escalated Radiation in Men With Intermediate
Risk Prostate Cancer
2415
Abdenour Nabid
Adherence to Long-term Androgen
Blockade in Localised High-risk Prostate Cancer and Causes of Noncompliance
2406
Michael Bernstein
PSA Bounce Predicts for a Favorable
Prognosis Following Brachytherapy,
but an Unfavorable Prognosis After
External Beam Radiotherapy:
A Meta-analysis
2407
Jennifer Croke
Impact of Radical Prostatectomy on
Rectal Position and Implications for
CTV Definition for Post-operative
Prostate Radiotherapy
2408
Jose Hinojosa Gomez
C11-Acetate Positron Emission
Tomography (PET) for Prostate Cancer
Patients Undergoing Radiotherapy
2409
Anshu Jain
Predicting the Risk of Secondary
Malignancies Associated With Pelvic
Nodal Irradiation in the Treatment of
Prostate Cancer
2410
Nikul Sheth
Validation of Inverse Planning
Simulated Annealing Class Solution for
Prostate High-dose-rate Brachytherapy
2416
Whoon Jong Kil
Hypofractionated Proton Radiotherapy for Low- and Intermediate-risk Prostate Cancer Is
Not Associated With Post-Treatment
Testosterone Suppression
2417
Juan Salinas
Early Results of Hypofractionated
VMAT IGRT in Prostate Cancer
2418
Gregor Spira
More Space More Dose: Dose Report
of the First Patients With Intermediate
and High-risk Prostate Cancer Treated
in Cologne With Spaceoar Hydrogel
Before HDR-brachytherapy Boost and External Beam IMRT
2419
Viola Chen
for Clinically Localized Prostate Cancer: The Georgetown Experience
2420
Jose Lopez Torrecilla
Construction of Nomograms for
Predicting the Development of
Metastases and Biochemical Failure
in Cancer of Prostate Treated With
Radiotherapy From Patients of Spanish
Cancer Prostate Register (recap)
120
2421
Thomas Sheldon
Transperineal Ultrasound/CT Fusion
for LDR Prostate Brachytherapy Post-planning
2422
Richard Gewanter
Does Low PSA Predict for Worse Outcome in Patients With Gleason
8-10 Localized Prostate Cancer Treated
With Radiotherapy?
2423
Ferran Ferrer
Interfraction Motion in Image Guided
Radiotherapy for Prostate Cancer.
Protocol code: IGRT-Prostate 1-09
2424
Juanita Crook
In-vivo Validation of Ultra-sound (US)-based High-dose-rate (HDR)
Prostate Brachytherapy (BT) Planning:
Comparison of US Needle Tip Reconstruction to CT Gold Standard
2432
Takeshi Tamura
Improvement of Pollakisuria after
(IMRT) for Prostate Cancer: Association
With Prostate Volume
2433
Emile van Lin
MR-guided Focal Cryoablation of
Prostate Cancer Recurrence Following
Radiotherapy: Feasibility and Early
Results
2434
Shea Wilcox
Efficacy of Androgen Deprivation in
Combination With Dose-Escalated
Image Guided Intensity Modulated Radiotherapy for Prostate Cancer: 5
Year Outcomes From a Single Institution
2425
Michael Peroski
Prostate Brachytherapy Outcomes in a
Rural Community Cancer Center
2435
Koyo Kikuchi
Three-dimensional Summation of
Rectal Doses During Combined Seed
Implant Brachytherapy and External
Beam Radiotherapy for Prostate
Cancer
2426
Richard Marshall
Long-term Treatment Outcomes and
Morbidity Following the Brachytherapy Management of Localized Prostate Cancer
2436
Roberto Bortolus
High-risk Prostatic Cancer: Radiotherapy and Concomitant
Docetaxel. Guone (North-East Uro-oncology Group) Experience
2427
Armando Felix
Morbidity Results in a Prospective
Randomized Trial of Hypofractionation
vs. Standar Fractionation for Prostate
Cancer Using Conformal Radiotherapy
2437
Jerry Liu
Adjusted Intermediate- and High-risk
Stratification for Prostate Cancer Is
More Prognostic Than Current NCCN
Risk Grouping
2428
Goura Kishor Rath
Impact of Beam Energy Variations
and Setup Error in the Treatment of
Prostate Cancer
2438
Filippo Alongi
Moderate Hypofractionation and
Simultaneous Integrated Boost With
Volumetric Modulated Arc Therapy by
Rapidarc for Prostate Cancer: Report of
Feasibility and Acute Toxicity
2429
Jason Wong
First Report on Seed Migration to the
Lung With the Use of a Thinner I125
Radioactive Seed Within 20 Gauge
Needles for Permanent Seed Prostate
Brachytherapy
2430
Boris Naydich
Comparative Dosimetric Analysis of
Computer vs. Nomogram Based Intra-Operative Planning for Prostate
Seeds Implants
2431
Vinita Takiar
MRI-based Sector Analysis Enhances
Prostate Pd-103 Brachytherapy Quality
Assurance in a Phase II Prospective
Trial of Intermediate-risk Patients
2442
Fazilet Dincbas
Rectum and Bladder Dose Variations
During the Course of Image Guided
Radiotherapy for Postoperative Prostate Cancer
2443
Lisa McGee
Impact of Proton Therapy to the
Prostate Alone vs. the Whole Pelvis
on Patient-Reported Outcomes and
Toxicities in High-risk Prostate Cancer
Patients
2444
Sujay Vora
Nine-year Outcome and Toxicity in Patients Treated with IMRT for Clinically Localized Prostate Cancer
2445
Jonathan Tward
Demographics and Comparative Effectiveness of Surgery and Radiation
Therapy in Men With Gleason Pattern 5
Prostate Cancer
2439
Thomas Pugh
Prospective Quality of Life and Toxicity
between Passively Scattered and Spot-Scanning Proton Therapy for
Prostate Cancer
2440
Richard Stock
The Relative Effects of Biologically
Effective Dose (bed) vs. Adjuvant Androgen Suppression (as) on Biochemical Control and Post-treatment Biopsy Results Following the Brachytherapy Management of Prostate Cancer
2441
Nancy Mendenhall
The Value of Dose Constraints in
Minimizing Rectal Toxicity in Patients
Receiving Radiation Therapy for
Prostate Cancer: Three-year Analysis of
Toxicity Outcomes in Two Prospective
Trials of Image Guided Proton Therapy
for Early- and Intermediate-risk Prostate Cancer
2446
Gael Drean
Voxel-based Analysis of Dose for
Toxicity Prediction in Prostate Cancer
Radiotherapy
2447
Juan Ospina
Random Forest Are Strong Competitors of Published NTCP
Models for Rectal and Bladder Toxicity
Prediction
2448
Christopher King
Critical Utility of Ultrasensitive PSA for
High-risk Patients Eligible for Adjuvant
Radiotherapy Following Radical
Prostatectomy
2449
Vladimir Turkevich
Clinical Experience With the Use of the
Exablate Magnetic Resonance Guided
Focused Ultrasound Surgery (MRGFUS)
System for Focal Treatment of Low-risk
Prostate Cancer
2450
Andrew Hollander
Interfraction Motion of the Full Seminal Vesicles in Prostate Radiotherapy Using a Daily Endorectal
Balloon
121
continued
2451
Sinisa Stanic
Analysis of True Delivered Dose to
the Prostate Fossa Utilizing Daily
Cone Beam CT in Postprostatectomy
Patients Who Failed Salvage Intensity
Modulated Radiation Therapy
2452
James Welsh
Evidence Supporting the Assertion
That the Current Definition of Medical
Events Is Imperfect for Prostate Permanent Implant Brachytherapy
2453
Robert Fratamico
Toxicity Analysis of Prostate Seed
Implant (PSI) Combined With Photovaporization of the Prostate
(PVP) to Treat Prostate Cancer (PC) in
Men With Bladder Outlet Obstruction
(BOO) Compared to PSI Alone in Men
Without BOO
2454
Mark Ranck
Refining Intermediate-risk Prostate
Cancer: An Analysis of Prostate
Biopsy Pathology and Implications for
Hormone Therapy With Dose Escalated
Radiation
2455
Derek Suderman
Comparison of Adjuvant vs. Salvage
Radiotherapy After Prostatectomy: A
Population Based Analysis
2456
William Foster
Impact of Implantation Technique on
Biochemical Disease-free Survival in
I-125 Treated Prostate Cancer Patients
2457
Maged Ghaly
Phase I Dose-escalation Study of
(SBRT) for Localizes Prostate Cancer
2458
Yi Le
Development of a Non-template
based Permanent Prostate Brachytherapy Treatment Planning
System for Penile Bulb Avoidance
2459
Apsara Windsor
Endorectal Balloons in
Post-prostatectomy Radiotherapy:
Improved Stability of Clinical Target
Volumes and Reduction of Geographical Miss
2460
Yeohan Song
ERG Gene Fusions As a Prognostic
Tumor Biomarker in Prostate Cancer
Patients Treated With Salvage Radiotherapy
2461
Steven Frank
Prostate Brachytherapy Long-term
Outcomes, Quality of Life and Patient-reported Satisfaction: The MD
Anderson Cancer Center Experience
2462
Akihiro Hayashi
Elevation of Baseline PSA Levels after
Intensity Modulated Radiotherapy
(IMRT) for Prostate Cancer: Discrimination From Biochemical
Failure
2463
Jared Robbins
Outcomes for Hormone-Naïve Patients
Who Achieved Undetectable PSA After
Salvage Prostate Bed Radiation Treatment Post-prostatectomy
2464
Carlo Greco
Feasibility and Preliminary Rectal
Toxicity Data of Transperineal Polyethylene Glycol Gel Spacer Implantation Prior to Hypofractionated VMAT in Prostate
Cancer
2465
Zvi Symon
Do Prostate Cancer Patients With
Extremely High PSA Benefit From
Radiation Therapy? A Population
Based Study
2466
Taisuke Inomata
The Excellent Biochemical Failure
Free Survival Rate of High-dose-rate
Brachytherapy Combined With External Beam Radiation Therapy in
Patients With Prostate Cancer
2470
Lev Tsvang
Pelvic Volumetric Modulated Arc
Therapy With Hypofractionated Concomitant Integrated Prostate
Boost: An Isoeffective Dose Comparison
2471
Brett Cox
Aggressive Intrafraction Motion
Management Is Required for SBRT for
2472
Brandon Nguyen
Catheter Geometries for Prostate
Tumor Targeted HDR Brachytherapy
2473
Takuya Nishimura
Exceptionally High Incidence of Symptomatic Grade 2 - 4 Late Rectal
Toxicity in Radiotherapy of Prostate
Cancer in 2.2 Gy Hypofractionation Using Image Guided Intensity Modulated Radiation Therapy
2474
Takuya Kaminuma
Comparison of the Objective and
Subjective Assessments of Urinary
Condition in Hypofractionated
Carbon-ion Radiotherapy for Localized
Prostate Cancer
2475
Kristina Sjödin
Quality of Life Assessment in Patients
Receiving a Spacer Between Prostate
and Anterior Rectal Wall to Optimize
Radiotherapy of Localized Prostate
Cancer
2476
Hussam Hijazi
Early Toxicity Comparison of Three Different Brachytherapy Boost Fractionation Schemes for Prostate
Cancer
2467
Ryan Smith
Prediction of True Dosimetric Parameters Over the Life of the Implant in Prostate Brachytherapy
2477
MRI-based Evaluation of Interfraction Motion in Post-Prostatectomy Radiation Therapy
(PPRT) With Daily Endorectal Balloon
(ERB)
2468
Amit Jotwani
Rectum and Bladder Dose Variations
During Prostate IGRT: An Evaluation
of Bowel and Bladder Preparation
Protocol
2478
Nathan Tonlaar
Image Guided Adaptive Radiotherapy
for Prostate Cancer: Toxicity Comparison for 3-D Conformal vs.
Intensity Modulated Beams
2469
Kristina Maletz
Identifying Prostate Cancer Subgroups
With Decreased Survival Following Adjuvant Androgen Deprivation
Therapy
2479
Amarjit Sen
for Low-risk Prostate Cancer: Plan
Comparison Between Rapidarc With
Real Time Tracking by Calypso Beacons
and Helical Tomotherapy
122
2480
Usama Mahmood
Decreasing Utilization of Brachytherapy for the Treatment of
Prostate Cancer: A National Patterns of
Care Analysis Using NCCN Risk Categorization
2490
Ana Paula Galerani
PSA Levels After Salvage High-dose-rate (HDR) Brachytherapy
in Patients With Locally Recurrent
Prostate Cancer After External Beam
Radiotherapy
2481
Joelle Helou
Intraprostatic Boost Using Highdose-rate Brachytherapy (HDR-BT)
According to Gross Tumor Volume
(GTV) Location for Prostate Cancer: A
Dosimetric Feasibility Study
2491
Moshiur Anwar
Role of Endorectal MRI And MRSI in
Defining the Dominant Intraprostatic Lesion in Prostate
Cancer: Quantitative Analysis of Imaging Contour Compared to Whole-mount Histopathology
2482
Seth Blacksburg
The Potential Impact of Medications
on Biochemical Control Following
Definitive Management of Prostate
Cancer
2483
Tamim Niazi
What Daily Image Guidance Is Needed
for Prostate Cancer Patients Post Radical Prostatectomy? Data From a
pilot phase II study
2484
Felix Sedlmayer
EBRT of Prostate Cancer: Does Rectal
Spacer Application Show Influence
on Inter- and Intra-fraction Prostate
Mobility?
2485
David Cuthbert
Dose Conformality and Acute Toxicity
Analysis in Patients With Prostate Adenocarcinoma Treated With Volumetric Modulated Arc Therapy
(VMAT) vs. Conventional Intensity
Modulated Radiation Therapy (IMRT)
2486
Sarah Kerns
Genome Wide Association Study to
Identify Genetic Variants Associated
With Urinary Symptoms Following
Radiotherapy for Prostate Cancer
2487
David Bowes
A Randomized Trial Comparing Seed
Loss and Displacement of Anchorseeds to Standard Uncoated
Loose Seeds
2488
John Hayes
HDR Boost Combined With Short-term
Androgen Blocade Produces Excellent
Long Term Outcome in High-risk
Prostate Cancer
2489
Francisco Gomez-Veiga
Low-dose-rate Brachytherapy for the
Treatment of Post Prostatectomy Local
Recurrence. A Phase II Trial
2492
Eric Ko
Association of Genetic Factors With
PSA Response in Prostate Cancer
Patients Receiving Definitive Radiotherapy
2500
Marie Hjalm-Eriksson
Long-term Effects on Quality of Life
After Treatment of localized Prostate
Cancer, A Comparison of Four Different
Treatment Modalities
2501
Adrian Anton
Dosimetry Evaluation of MIM Symphony LDR Brachytherapy Treatment Planning for Prostate Seed
Implant (PSI)
2502
Kenneth Tokita
Acute Normal Tissue Toxicities for 148
Combined Therapy Prostate Carcinoma Patients
2503
Marie Charissoux
Updated Results of the Montpellier
IMRT Prostate Cancer Cohort: Focus on
Elderly Patients
2493
Monica Shukla
Pre-radiotherapy PSA Is Predictive of
Biochemical Progression Free Survival
Following Post-prostatectomy Salvage
Radiotherapy
2494
Nita Patel
Correlation Between PSA Bounce, Time
to Nadir and Biochemical Failure in
Patients With Prostate Cancer Treated
With a Combination of HDR-Brachytherapy and Hypofractionated External Beam
Radiotherapy
2495
Young Kwok
Long-term Follow-up of Combined
Modality Therapy With Pelvic External
Radiation Followed by Cs-131 Brachytherapy Boost in Men with
2504
Rafi Kabarriti
Predictive Value of Psa Trend During
snd After Post Prostatectomy Salvage
Radiation Therapy
2505
Gilles Crehange
Duration of Androgen Deprivation
Combined With Radiotherapy Does
Not Jeopardize Time to Castration
Resistance iIn Men With Unfavorable
Intermediate- and High-risk Prostate
Cancer
2506
Benjamin Guix
Dose Escalation With High-dose 3-D
Conformal (HD-3-D CRT) or Low-dose
3-D Conformal Radiotherapy (LD-3-D
CRT+HDR-B) For Intermediate- or
High-risk Prostate Cancer: Higher
Disease Control and Survival With
Lower Toxicity
2496
Elizabeth Ester
Intermediate-risk Prostate Cancer
Treated With Definitive Low-dose-rate
Brachytherapy
2507
Dorothy Boo
In Support of Brachytherapy for Young
Men with Prostate Cancer
2497
Michael Repka
Do Loose Sources vs. Stranded
Improve Postimplant Dosimetry for
Prostate Seed Implants?
2508
Waleed Mourad
The Impact of Sequence of Bimodality
Approach on Low-risk Prostate Cancer
Outcomes
2498
Douglas Kelly
Dose Painting a Prostate Peripheral
Zone Boost With Helical Tomotherapy
IMRT
2509
Gilles Crehange
Prostate Metabolism After the Completion of Exclusive Radiation Is
More Depleted After Seeds Brachytherapy Compared to External
Beam Radiotherapy for Prostate Cancer Patients
2499
Olivier Chapet
Injection of Hyaluronic Acid (HA) to
Better Preserve the Rectal Wall in
Prostate Hypofractionated Radiotherapy (HFR)
123
continued
2510
Richard Lee
Association Between Biochemical
Outcome and Pre-salvage Radiation
Therapy PSA Is Not Different for Obese
and Non-obese Men
2511
Michael Leapman
Hematuria After Prostate Brachytherapy
2512
Lester Greer
Dosimetric Comparison of Photon Stereotactic Ablative Radiotherapy
(SABR) and Proton SABR in the Treatment of Prostate Cancer Patients
2513
Laura D’Alimonte
Variability of Bladder Volumes in Men
Receiving Radiotherapy to the Prostate
2514
Randal Henderson
Three-Year Analysis of Urinary Toxicity
in Two Prospective Trials of Image
Guided Proton Therapy for Early- and
Intermediate-risk Prostate Cancer:
Outcomes in Men With Moderate to
Severe Pretreatment Urinary Obstructive Symptoms
2515
Sindy Magnan
Long Term Experience of HDR Brachytherapy Boost for Localized
Prostate Cancer
2516
Sameer Keole
Initial Report of Toxicities in Men With
Prostate Cancer Treated With Uniform
Scanning Protons
2517
Moshiur Anwar
Comparison of PSA Kinetics Between
Hypofractionated Stereotactic Body
Radiotherapy, Conventionally Fractionated External Beam Radiation
and High-dose-rate Brachytherapy
2518
Daniel Schroyer
Dosimetric and Clinical Comparison
of Anchor Seeds (AS) vs. non-Anchor
Seeds (NAS) Using Real-time US Dosimetry and Day 30 CT Dosimetry
for Low-dose-rate Prostate Brachytherapy
2519
David Berlach
Iodine and Palladium Implants of
High-risk Prostate Cancers Both
Achieve Excellent Biochemical Failure
Free Survival
2520
Brian Moran
Preliminary Results of a Prospective,
Randomized Trial Evaluating Quality of
Life Outcomes After Prostate Brachytherapy Using 18g vs. 20g
Needles/Seeds
2521
Grant Hunter
Competing Risk Analysis for Causes of
Death in Men With High-risk Prostate
Cancer
2522
Onyi Offor
PSA Halving Time Of ≤2 Weeks and
Post-RT PSA Nadir <0.1 ng/ml Are
Associated With Excellent Biochemical
Control for High-risk Prostate Cancer:
Implications Regarding the Need For
Long-term ADT With Dose Escalated
RT
2523
Stephanie Markovina
Serum Testosterone Levels in Men
Treated With Intensity Modulated
Radiation Therapy for Prostate Cancer
2524
Lili Chen
Dosimetric Evaluation of Inter-factional Motion For Image
Guided Prostate IMRT
2525
Andre Martin
Does Phoenix Failure Definition Apply
to EBRT + HDR Brachytherapy Boost in
Prostate Cancer?
2526
Carolyn Kim
Incidence and Predictors of Acute And
Chronic Rectal Bleeding As Reported
by Patients Through Epic Questionnaire for Prostate Brachytherapy Using Cesium
2527
Carolyn Kim
Is There a Secondary Spike in Urinary
Symptoms With Cs131 Prostate
Brachytherapy? A Longitudinal Analysis With Patient Reported Epic
Survey and AUA Score
2528
Robert Meier
Long-term Outcomes of Stereotactic
Body Radiotherapy for Organ-confined
Prostate Cancer
2529
Sharon Lu
Comparison of Acute and Late GI and
GU Toxicity Following Whole-pelvis vs.
Prostate-only IMRT With Daily Image
Guidance
2530
William Lorentz
Role of Multiparametric MRI in Defining Lesions for Targeted Dose
Escalation in Prostate Cancer
2531
Oleg Sostin
Impact of Real-time Tumor Tracking
and Fraction Size on Treatment-related
Morbidity in Prostate Cancer Patients
Treated With IMRT
2532
Awad Ahmed
A Novel Methodology to Predict Late
Urinary Toxicity Following Prostate
Radiotherapy Based on Bladder Wall
Dosimetry
2533
Ananya Choudhury
Tumour Necrosis Predicts Benefit From
Hypoxia-modifying Therapy in High-risk Bladder Cancer
2534
Olivier Riou
Combined Chemoradiotherapy With
Gemcitabine and Cisplatinum for
Organ Preservation in Muscle-invasive
Bladder Cancer: Long-term Results of
a Phase I Trial
2535
Meral Kurt
The Effect of Her2/Neu Protein
Overexpression on the Prognosis of
Patients With Invasive Bladder Cancer
Who Were Treated With Definitive
Radiotherapy
2536
Kate Noa
Adjuvant Radiation for Bladder Cancer:
A Dosimetry Study
2537
Michael Folkert
Second Cancer Risk Following Radiation Therapy for Seminoma: A
Single-institution Retrospective Study
2538
Leah Katz
Impact of Radiation Field Design on
Inadvertent Cardiac and Kidney Dose
Delivered During Treatment for Stage
I/II Seminoma
2539
Jennifer Vogel
Radiation Therapy in Management of
Malignant Pheochromocytoma
2540
Jennifer Ho
The Role of Radiotherapy in Adrenocortical Carcinoma
124
2541
Ron Allison
Current Management of Penile Cancer
2542Withdrawn
2543 Maria Cascales Garcia
Conservative Treatment of Penile
Cancer: Retrospective Analysis of
One Cohort of Patients Treated With
Brachytherapy
2544
Alexander Louie
Photodynamic Therapy for Bowen’s
Disease of the Penis
2545
Daniel Pham
Analysis of Potential Surrogates for
Kidney Motion Verification Imaging
and Its Implications for Stereotactic
Radiotherapy of the Kidney
2546
Richard Speight
Producing a VMAT Class Solution for
Adjuvant Pelvic Radiotherapy for
Penile Cancer
2547
David Ly
Demographics, Prognostic Factors and
Treatment Outcomes of Adrenocorticotrophic Carcinoma: A
SEER Database Analysis From 1988-2008
2548
Jonathan Paly
Outcomes for a Multi-institutional
Cohort of Patients Treated With
Intra-operative Radiation Therapy
for Advanced or Recurrent Renal Cell
Carcinoma
2549
Chi Zhang
A SEER Database Analysis of Urethral
Cancer Management
2550
Kapila Kalakota
Outcomes in Stage I and IIA-B Testicular Seminoma Patients Treated
With Dog-leg Field Radiotherapy
(DLRT)
GYNECOLOGICAL CANCER
2551
Brandon Barney
Intraoperative Electron Beam Radiotherapy (IOERT) in the Management of Locally Advanced or
Recurrent Cervical Cancer
2552
Hani Gaballa
Cancer of the Cervix: Dosimetric
Comparisons of Dose Prescription to
Applicator Point a vs. Dose Prescription to CTV
2553
Kimiko Hirata
Clinical Efficacy of Alternating Chemoradiotherapy With Moderate-Dose Brachytherapy for
High-risk Patients of Cervical Cancer
2554
Rahul Krishnatry
Comparison of Two Contouring
Methods of Bone Marrow on CT and
Correlation With Hematological Toxicities (HT) in Non Bone Marrow
Sparing Pelvic IMRT (NBM-IMRT) With
Concurrent Cisplatin for Cervical
Cancer
2555
Miho Watanabe
New Approach to Relief Pain and
Distress during High-dose-rate Intracavitary Irradiation for Cervical
Cancer
2556
Goro Kasuya
Outcomes of Postoperative Radiotherapy for Early-stage Uterine
Cervical Cancer
2557
Tamer Refaat
Pulsed Dose Rate and Image Guided
Brachytherapy: Outcomes and Comparison to ICRU 38 Reference
Point
2558
Vasu Tumati
Can Be Dosimetrically Equivalent to
High-dose Brachytherapy As a Boost
for Locally Advanced Cervical Cancer:
A New Clinical Trial Concept
2559
Fernanda Herrera
Simultaneous Integrated Boost in
Cervix Cancer: The Impact of Organ
Motion and Tumor Regression
2560
Frederique Vasseur
Long Follow-up of Pulsed-dose-rate
Brachytherapy for Cervical Carcinoma:
Analysis of Oscar Lambret Center
Experience on 125 Patients Treated
From 1999 to 2008
2561
Lichun Wei
The Relationship Between the Late
Toxicity and the Dose of Rectum and
Bladder of the Patients With Local
Advanced Cervical Cancer Treated
With CT Image Guided High-dose-rate
Brachytherapy
2562
Yu-Jen Chen
A Novel Vagina Enhancement Modality
Aids Vaginal Mucosa Delineation and
Improves Dosimetric Parameters in
Female Pelvic Intensity Modulated
Radiotherapy
2563
Jasleen Khanuja
Effect of Rectal Distension on Successful High-dose-rate Dwell Optimization in the Treatment of
Cervical Cancer
2564
Keiko Murofushi
The Impact of Vicril Mesh Sheet Placed
on Pelvic Wall for Reducing the Irradiated Bowel Volume in RapidArc
of Cervical Cancer: Planning Study
2565
Grant Clark
A Dosimetric Comparison of Tandem
and Mini-ovoid Applicator vs. Vaginal
Cylinder With Tandem in the 3-D HDR
Era of Cervical Cancer Brachytherapy
2566
Noamie Vulquin
MRI Guided Cervical Cancer Brachytherapy: Inter- and Intra-observer Variation In HR-CTV
Delineation In T2-weighted And
Gadolinium-enhanced T1-weighted
Images
2567
Neeta Kannan
Complete Metabolic Response
After Definitive Radiation Therapy for
Cervical Cancer: Patterns and Factors
Predicting for Recurrence
2568
Akiko Nakagawa
The Efficacy of Reducing Point a Dose
in Image Guided Brachytherapy for
Stage I-II Cervical Cancer of the Atrophic Small Uterus
125
GYNECOLOGICAL CANCER/
continued
2569
Rafael D’Ambrosi
Impact of Radiological Lymph Node
Stage and Extended Field Radiotherapy on Survival in Cervical
Cancer
2570
Yuan Rao
A Clinically Useful Watershed-based
Method of Auto-Segmenting Apparent
Diffusion Coefficient (ADC) Maps of
Cervical Cancer
2571
Shalini Vinod
The Use of Cervical Cancer MRI Contouring Guidelines in Clinical
Practice
2572
Jin Hee Kim
A Comparison of Outcomes Between
Concurrent Chemoradiotherapy and
Radiotherapy Alone in Cancer of the
Uterine Cervix: A Single Institutional
Experience
2573
Jose Perez-Regadera
Impact of Value of Squamous Cell Carcinoma Antigen (SCC) in the
Survival of Advanced Cervical Cancer,
Managed With Chemo-radiotherapy
(CT-RT)
2574
James Anderson
The Impact of Tandem and Ovoids
Displacements on High-dose-rate
(HDR) Plans
2575
Helen Chen
Prognostic Value of Human Copper
Transporter 1 (HCTR1) in Cervical
Cancer Patients Treated With Radical
Hysterectomy and Adjuvant Chemoradiotherapy or Salvage
Chemoradiotherapy at Recurrence
2576
Dominique Rash
Pelvic and Para-aortic Lymph Node
Response to Chemoradiation Therapy
in Patients With Locally Advanced
Cervical Cancer: Does a Higher Boost
Dose Impact Nodal Control?
2577
Pramod Julka
Acute Gastrointestinal and Genitourinary Toxicities in Locally Advanced Carcinoma Cervix Treated
With Intensity Modulated vs. Conventional Pelvic Radiotherapy: Results From a Prospective Randomized Study
2578
Jacqueline Esthappan
A Novel MRI Technique for Adaptive
Cervix Cancer Brachytherapy
2579 Anand Narayan
Chinnachamy
Correlation of EQD2, Local Control and
Early Toxicity Following Image Guided
IMRT and Interstitial Brachytherapy in
Patients With Cervical Cancer
2580
Daya Nand Sharma
Interstitial Brachytherapy With and
Without Central Tandem in the
Treatment of Cervical Carcinoma: A
Dosimetric Study
2581
Hayeon Kim
Calculation of Equivalent Dose to
Target Volume and Critical Organs for
Combination of IMRT and MRI Guided
High Dose Rate Brachytherapy Using
Deformable Image Registration in
Cervical Cancer
2582
Anthony Apicelli
Adaptive MRI Image Guided HDR
Brachytherapy Treatment Planning for
Cervical Cancer
2583
Christopher Tinkle
Inverse Planned High-dose -rate
Brachytherapy for Locoregionally
Advanced Cervical Cancer: The UCSF
Experience With 4-year Follow-up
2584
Supriya Chopra
Evaluation of Correlation Between
Dose Volume Parameters and Clinically
Significant Bowel Toxicity After Postoperative Radiation for Cervical
Cancers
2585
Eva Christensen
Personalization of Fractionation
Schedule for Cervical Cancer
Brachytherapy Using Biologically Effective Dose and 3-D Treatment Planning
2586
Jyoti Mayadev
CT Based Image Guided Brachytherapy
for Locally Advanced Cervical Cancer:
The Time Required for Optimal Implantation to Delivery
2587
Philippe Nickers
Tomotherapy of Locally Advanced
Cervix Carcinoma: Clinical Validation of
3 mm CTV-PTV Expansion
2588
Somorat Bhattacharjee
Stereotactic Robotic Radio Surgery
Improves Local Control Rates With Second Line Chemotherapy in Unfavourable Locally Recurrent Unresectable Gynaecologic Malignancies
2589
Henrik Hansen
Results of PET/CT Planned IMRT and
Concomitant Boost to Lymph Node
Metastasis in Patients With Cervical
Cancer
2590
Hidehiro Eto
Usefulness of Small Pelvic Field for
Stage IB-IIA Uterine Cervical Cancer
Patients With Intermediate Recurrent
Factors
2591
Null- Erpolat
Dosimetric Parameters of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With Concurrent Cisplatin and Pelvic
Radiotherapy: Turkish Oncology Group
Gynecological Tumor Subgroup Study
2592
Ying Zhang
Relationship of Imaging and
Pathological Gross Tumor Volume Determined by Whole-mount Serial
Sections Technique in Primary Cervical
Cancer
2593
Andrzej Roszak
Correlation Between Proliferation
Activity, Glucose Metabolizm and Tumor Volume in Patients With Cervical Cancer, Measeured by 18F-FLT-PET and 18F-FDG-PET- Preliminary Results
2594
Shanmuga Vallinayagam
Can VMAT-based SBRT Be an Option in
Patients Unsuitable for Intra Cavitory
Brachytherapy in Locally Advanced
Cancer Cervix?
2595
Narek Shaverdian
Impact of Concomitant Chemotherapy
on the Effects of Treatment Prolongation in Cervical Cancer
2596 Susan Msadabwe Chikuni
Comparison of Two Dose Fractionation
Regimens of High-dose-rate Brachytherapy in the Treatment of
Cervical Cancer: The University of
Alabama at Birmingham Experience
126
2597
Pawel Dyk
Toxicity Following Adaptive MRI Image
Guided HDR Brachytherapy and IMRT
in the Treatment of Cervical Cancer
2598
Javier Lopez-Araujo
The Importance of Overall Treatment
Time in the Era of Concurrent Chemoradiation Therapy for Locally
Advanced Cervical Cancer
2599
Sui Shen
Inter-fractional Variation of Hot Spot
Locations for Organs At Risk in High-dose-rate Brachytherapy for
Cervical Cancer
2600
Yarah Haidar
Dosing to Point a with Image Guided
Brachytherapy and the Probability of
Normal Tissue Excessive Dose in Cervical Cancer
2601
Philip Poorvu
Duodenal and Other Gastrointestinal
Toxicity in Cervical and Endometrial
Cancer Treated With Intensity Modulated Radiation Therapy to
Paraaortic Lymph Nodes
2602
Tony Eng
Significant Rectal and Bladder Dose
Reduction Using Intra-vaginal
Balloons During High-dose-rate (HDR)
Intracavitary Brachytherapy (ICBT) for
Cervical Cancer
2603
Sunao Tokumaru
Concurrent Chemoradiotherapy for
Uterine Cervical Cancer: Correlation
of MRI Findings With Histopathologic
Results
2604
Qifeng Wang
Evaluation of Intra- and Inter-fraction
Movement of the Cervix and the Uterine Body During Intensity Modulated Radiation Therapy
2605
Ravindra Yaparpalvi
Is Re-planning at Every T and O Insertion Necessary When Cervix HDR
ICBT Is Performed Under Identical
Conditions in a Brachytherapy Suite?
2606
Bae Kwon Jeong
Characteristics and Prognosis of
Patients With Cervical Cancer Who
Show an Unusual Level of Squamous
Cell Carcinoma Antigen at Diagnosis or
Recurrence
2607
Larissa Lee
Combined Chemotherapy and Radiation (RT) Improves Survival for
Node-positive, High-grade Endometrial Cancer
2608 Withdrawn
2609
Melissa Young
Adjuvant Carboplatin/Paclitaxel and
Vaginal Brachytherapy for Locally
Advanced Endometrial Cancer
2610
Huma Chaudhry
(SBRT) for Single Small (< 5 cm)
Extracranial Ovarian or Uterine Cancer
Metastases: Promising Local Control
and Normal Tissue Tolerance With 5
Fraction Approach
2611
Ismael Membrive Conejo
Dosimetry Comparison Between
Custom and Standard Dosimetry in
the Treatment of the Vaginal Cuff With
HDR Brachytherapy
2612
Steven Register
The Role of Adjuvant Radiation in
Stage III Endometrial Cancer
2613
Weisi Yan
SEER Analysis of Adjuvant Pelvic Radiation Therapy or Vaginal Brachytherapy in Treating Patients
With High-risk Stage I or Stage II Papillary Serous, Clear Cell and High-grade Endometrioid Carcinoma
2618
Sarah Milgrom
Lymph Node Involvement: Indicator or
Instigator of Poor Outcome in Stage III
Endometrial Cancer?
2619
Mira Shah
Sexual Function in Patients With Endometrial Carcinoma After Hysterectomy and Adjuvant Therapy
2620
Andy Chen
Clinical Outcomes of Three-Dimensional vs. IMRT Post-operative Pelvic Radiation for
Gynecologic Malignancies
2621
Shyamal Patel
Organ at Risk Interfraction Dose
Variance in Relationship to Insertion
Angle of a Vaginal Cylinder for HDR
Brachytherapy
2622
Jonathan Frandsen
Survival Analysis of Endometrial
Cancer Patients With Cervical Stromal
Involvement
2623
Himanshu Nagar
Outcome Determinants in Uterine
Papillary Serous Carcinoma Based on
Clinico-pathological and Treatment
Factors
2624
Hualei Li
Retrospective Review of Patients With
Carcinosarcoma of Uterus Confined to
Pelvis-outcome Analysis
2614
Jessica Zhou
Single or Multi-channel Vaginal Cuff
HDR Brachytherapy - Is Replanning
Necessary Prior to Each Fraction?
2625
Kanokpis Townamchai
Clinical Outcomes With Dose Escalation Using Intensity Modulated
Radiotherapy for Node-positive Endometrial and Cervical Cancer
2615
Caitlin Gomez
Combined Chemotherapy and Radiation Results in Improved Outcomes in High-risk Endometrial
Cancer Patients
2626
Raphael Yechieli
Adjuvant Radiation Therapy for
Patients With Type II Endometrial Carcinoma: Impact on Tumor Recurrence and Survival
2616
Lijia Aviles
Factors Influencing Outcome After
Relapse of Endometrial Cancer: Role of
Brachyterapy in the Salvage treatment
2627
Ann Klopp
Management of Node Positive Endometrial Cancer With Multimodality Adjuvant Therapy
2617
Nathalie Rochet
Consolidative Whole Abdomen Radiotherapy After Surgery and
Carboplatin-Taxol Based Chemotherapy for Advanced Epithelial
Uterine Endometrial Malignancy:
Feasibility and Clinical Outcomes
2628
Lihong Zhu
Urinary Catheterization Increases
the Dose to Bowel During Vaginal
Brachytherapy
127
GYNECOLOGICAL CANCER/
continued
2629
Saif Althaqfi
Assessing Efficacy of Adjuvant
Vaginal Vault Brachytherapy Among
Intermediate-risk Stage I Endometrial
Cancer Patients
2630
Aditya Juloori
Radiation Therapy in the Management
of Carcinosarcoma of the Uterus
2631
Alfred Chung
Uterine Adenosarcoma and the Role of
Radiotherapy: A Retrospective Study
2632
Lane Rosen
An Optimization Study and Comparison of a Multichannel Vaginal
Cylinder vs. Single Channel Cylinder
Applicator in High-dose-rate Brachytherapy
2633
Bryan Macrie
Patterns of Recurrence and the Role
of Radiotherapy in Ovarian Clear Cell
Adenocarcinoma
2634
Felipe Rey
Dosimetric Impact of Daily MRI Guided
Adaptive HDR Interstitial Brachytherapy for GYN Cancers
2635
Charu Sharma
Patterns of Care in Locally Advanced
Vulvar Carcinoma
2636
Austin Kirschner
Outcomes and Evaluation of the Role
of Radiation and Surgery in Vaginal
Melanoma
2637
Susan Hiniker
Primary Squamous Cell Carcinoma of
the Vagina: Prognostic Factors, Treatment Patterns and Outcomes
2638
Nikhilesh Patil
MRI Guided High-does-rate Vaginal
Interstitial Brachytherapy for Locally
Recurrent Endometrial Cancers
2639
Ericka Wiebe
Integration of CT-planned Interstitial
Brachytherapy Boost in Advanced
Gynecologic Malignancies
2640
Suzanne Evans
Surveillance, Epidemiology and End
Results (SEER) Database Analysis of
Verrucous Carcinoma of the Vulva
2641
Eugene Koay
Definitive Radiation Therapy of Locally
Advanced Squamous Cell Carcinoma
of the Vulva: Factors Associated With
Vulvar Disease Control
2642
Junzo Chino
Multi-catheter Vaginal Balloon Brachytherapy: One Year’s Clinical
Experience
2643
Ashley Ruby
for Gynecologic Malignancies
HEAD AND NECK CANCER
2644
Ryuji Murakami
Clinical Nodal Staging and Clinical
Target Volume for Preoperative Concurrent Chemoradiotherapy in
Patients With Advanced Oral Cancer
2645
Szu-Yuan Wu
Irradiation Induced Nf-kb Dependent
Vimentin Expression Is Related With
the Evading Radiation Induced Apoptosis in Betel Quid Chewing
Related Oral Squamous Cell Carcinoma
Cells
2646
Ryo-ichi Yoshimura
Results of Low-dose-rate Interstitial
Brachytherapy Using Au-198 Grains in
T1-2 Tongue Cancer Patients
2647
Kang-Hsing Fan
Retrospective Analysis: Postoperative
CCRT Improved Treatment Outcome of
Oral Cavity Cancer With Multiple Nodal
Metastases But Without Extracapsular
Spreading
2648
Lilie Wang
Feasibility of Optimizing IMRT Plans-based on Measured Mucosal
Dose to Adjacent Metallic Dental
Fillings for Head and Neck Cancer
Patients
2649
Kanako Takayama
Proton Beam Therapy Combined With
Intra-arterial Infusion Chemotherapy
for Locally Advanced Tongue Cancer
2650
Min Yao
Recurrence Before Postoperative
Radiotherapy in Head and Neck Squamous Cell Carcinoma
2651
Yao Yu
Association Between Number of
Positive Lymph Nodes and Outcome
Among Patients Treated by Surgery
and Post-operative Radiation Therapy
for Head and Neck Cancer
2652
Pablo H. Montero
Neck dissection Without Postoperative
Radiotherapy in Select Patients With
Oral Cavity Carcinoma and pN1 neck
2653
Christine Chin
Can Meaningful and Durable Loco-regional Control Be Achieved for
Oral Cavity Squamous Cell Carcinoma
(OCSCC) Treated With Definitive Radiation Therapy (RT)?
2654
Peter Hofner
A MicroRNA Link Between Tumor Invasion and Radioresistance in Head
and Neck Squamous Cell Carcinoma
2655
Prashant Desai
Radiological-pathological Correlation
for Cervical Lymph Nodes in Oral Cavity Cancers: Implications for Radiation Field Reduction
2656
Felix Ho
IMRT vs. Conventional Radiotherapy
for Post-operative Treatment of Oral
Cavity Squamous Cell Carcinoma
(OCSCC)
2657
Christine Chin
Surgery Improves Outcome in Recurrent Squamous Cell Carcinoma
of the Oral Cavity
2658
Wade Thorstad
Surgical Treatment Intensification for
HPV Negative Oropharyngeal Squamous Cell Carcinoma (OSCC)
2659
Tony Wang
Correlation of Planned Dose to Area
Postrema and Dorsal Vagal Complex
With Clinical Symptoms of Nausea and
Vomiting in a Series of Oropharyngeal
Cancer (OPC) Patients Treated With
Radiation Alone Using IMRT
2660
G. Brandon Gunn
Symptom-free Cure Following
Unilateral Radiation Therapy for Tonsil
Cancer: A Patient-reported Outcomes
(PRO) Benchmark
128
2661
Giuseppe Sanguineti
Mid-treatment Volumetric Change of
Parotids Is an Independent Predictor
of Long-term Xerostomia
2662
Francesco Ricchetti
PEG Dependence After IMRT for Oropharyngeal Cancer: Different
Impact of CHT, Oral Mucosa and
Superior Constrictor Dose-volume
Parameters Between Short (>3months)
and Long (>7months) Dependence
2671
Matthew Newcomb
Comparison of Weekly and 3-Weekly
Cisplatin-based Radiochemotherapy
Regimens for the Treatment of Patients
with Stage III/IV Squamous Cell Head
and Neck Cancer
2672
David Fried
Dosimetric Effect of Sparing the
Primary Site for Oropharyngeal Squamous Cell Carcionoma After
Transoral Laser Microsurgery
2663
Klaudia Hunter
Aspiration Pneumonia After Chemo-IMRT of Head and Neck Cancer
and Its Clinical and Dysphagia-related
Predictors
2673
Samir Patel
Transoral Laser Microsurgery (TLM)
Followed by Radiation Therapy (RT)
for Oropharyngeal Tumors: The Mayo
Clinic Arizona (MCA) Experience
2664
Nadine Housri
African Americans Face Significant
Delays to Treatment After Diagnosis of
Orophyaryngeal Carcinoma
2674
Michelle Mierzwa
HPV Positive Squamous Cell Carcinoma of the Oropharynx is
Adequately Treated With Radiotherapy
Alone
2665
Beth Beadle
Impact of Metformin on Outcomes
in Patients With Oropharynx Cancer
Treated With IMRT
2666
Andrew Baschnagel
Predictors of Recurrence After Intensity Modulated Radiation Therapy
With Concurrent Chemotherapy for
Locally Advanced Head and Neck
Carcinomas
2667
Ebru Karakaya
Is a Routine Neck Dissection Necessary
Following Chemoradiotherapy for
N2 Head and Neck Squamous Cell
Carcinoma?
2675
Adam Garsa
Total Metabolic Tumor Volume Predicts
Outcomes in p16 Positive and Negative Oropharyngeal Squamous
Cell Carcinoma
2676
Chad Tang
Radiologic Assessment of Lymph Node
Involvement in HPV/p16+ Oropharyngeal Cancers
2677
Zoran Rakusic
Impact of Human Papillomavirus on
Clinicopathological Characteristics of
Oropharyngeal Carcinomas
2678Withdrawn
2668
Nicolas Lescut
Assessment of a Predictive Score for
Indications of Prophylactic Enteral
Nutrition in Head and Neck Cancer
Patients Treated by Radiotherapy or
Chemoradiotherapy
2669
Hyebin Lee
Tumor Volume Reduction Rate During
Definitive Radiation Therapy: A Potential Prognosticator In Oropharynx Cancer
2670
Iain Nixon
The Impact of Histopathologically
Measured Gross Tumor Volume on
Outcome in Patients Treated Surgically
for Oropharyngeal Squamous Cell
Carcinoma
2679
Paul Romesser
Metabolic Tumor Volume Is Superior
to Gross Tumor Volume in Predicting
Outcomes in Patients With Oropharyngeal Cancer Treated With
IMRT
2680
Nadeem Riaz
Loco-regional Patterns of Failure in
Oropharyngeal Carcinoma:
Implications for Treatment De-escalation
2681
William Silveira
Diffusion-Weighted Imaging Compared to 3-Month PET/CT to Predict Response in the Irradiated
Neck
2682
Steven Frank
Intensity-Modulated Proton Therapy
for Head and Neck Cancer: The First
Clinical Experience
2683
Robert Semrau
Prognostic Importance of
HPV-association in Locally Advanced Inoperable Oropharyngeal Cancer
2684
Ajeet Gandhi
Re-irradiation in Head and Neck Cancers: An Indian Tertiary Cancer
Centre Experience
2685Withdrawn
2686
Anne-Marie Charpentier
The Dosimetric/Clinical Impact on
Parotids of Weight Change During
Head and Neck IMRT
2687
Aryavarta Kumar
A Dosimetric Analysis of IMRT vs. 3-D
Planning and Its Impact on Acute
Grade 3 Dysphagia and Xerostomia
in Oropharyngeal Cancer Patients
Treated With Chemoradiotherapy
2688
Jimmy Caudell
Interim Analysis of a Phase II Trial to
Examine Use of Post-Chemotherapy
Volumes After Neo-adjuvant Treatment of Squamous Cell Carcinomas of the Head and Neck
2689
Michael Bishop
Adaptive Planning of Intensity
Modulated Radiation Therapy for
Head and Neck Cancers for Improved
Accuracy of Delivered Dose in Patients
With Clinically Significant Anatomical
Change Due to Therapy
2690
Trevor Bledsoe
Oropharyngeal Squamous Cell Carcinoma (OPSCC) With Known
Human Papillomavirus (HPV) Status
Treated With Definitive Chemoradiotherapy: Patterns of
Failure and Toxicity Outcomes
2691
Michael Rutenberg
Salivary Preservation Using Submandibular Gland Transfer and
Salivary Gland Sparing IMRT in
Definitive Chemoradiotherapy for
Oropharyngeal Cancer
129
HEAD AND NECK CANCER/
continued
2692
Joanne Jang
Factors Associated With Prolonged
Gastrostomy Tube Usage in Patients
With Oropharyngeal Cancer Treated
With Chemoradiation
2693
Matthew Palmer
The Optimal Timing for Off-line
Adaptive Planning for Bilateral Head
and Neck IMPT Is Week 4
2694
Gordon Guo
Dosimetric Predictors of Long Term
Dysphagia in Oropharyngeal Cancer
After IMRT in a Population-based
Cohort
2695
Edwin Crandley
Impact of p16 Status on the Patterns
of Failure in Patients Treated With
Definitive Intensity Modulated
Radiation Therapy (IMRT) for
Oropharyngeal Squamous Cell
Carcinoma (OPSCC)
2696
Pranshu Mohindra
Squamous Cell Carcinoma of the
Oropharynx: 20-year Outcome Results
From the University of Wisconsin
2697
Joseph Lee
Outcomes of Concurrent Chemoradiotherapy (CRT) vs. Induction Plus CRT (ICRT) for Oropharynx Carcinoma
2698
Ryan Lee
Oropharyngeal Cancer Patients and
Mandibular Dose Distributions Following Intensity Modulated Radiation Therapy
2699
Nadeem Riaz
Recursive Partition Analysis Identifies
Oropharyngeal Cancer Patients at High
Risk for Distant Metastasis
2700
Sujith Mullapally
Image Guided Radiotherapy in Head
and Neck Cancer: Static Dose vs. Dynamic Volumes: The Need for Adaptive Innovation
2701
Takeshi Kodaira
Clinical Efficacy of Helical Tomotherapy for Nasopharyngeal Cancer Treated With Definite Concurrent Chemoradiotherapy
2702
Junlin Yi
The Role of Concurrent Chemoradiotherapy for Locally
in the Era of Intensity Modulated
Radiotherapy
2703
Sefik Igdem
Pretreatment SUVmax As a Prognostic
Factor in Patients With Nasopharyngeal Cancer Treated With
IMRT
2704
Jianji Pan
Outcomes of Chemotherapy-based
Multimodality Treatment for Metastatic Nasopharyngeal Carcinoma
Patients With a Good Performance
Status
2705
Jenny Ling-Yu Chen
for T4 Nasopharyngeal Carcinoma:
Treatment Outcomes, Patterns of
Recurrence and Feasibility of Salvage
Treatment for Locoregional Recurrence
2706
Yu-Wei Lin
Impact of Reduced-volume Intensity-Modulated Radiation
Therapy on Disease Control for Nasopharyngeal Carcinoma
2707
Kazuhiko Tsuchiya
Retrospective Comparison Between
Cisplatin Plus Fluorouracil and Weekly
Cisplatin in Concurrent Chemoradiotherapy Setting for Stage
II-IV Nasopharyngeal Carcinoma: Hokkaido University Hospital Experience
2708
Lin Ma
Treatment of Nasopharyngeal Carcinoma With Helical Tomotherapy:
A Retrospective Study of 121 Cases
2709
Daniel Golden
Outcomes of Induction Chemotherapy
and Concurrent Chemoradiation for
Nasopharyngeal Carcinoma
2710
Xiaomin Ou
Preliminary Results of 18F-FMISO PET
In Evaluating Tumor Hypoxia and
Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma
2711
Muhammad Fareed
With Simultaneous Modulated Accelerated Boost Technique in
Patients With Nasopharyngeal
Carcinoma: King Fahad Medical City
Experience
2712
Qin Lin
Comparison of 18F-FDG PET/CT and
Conventional Imaging in Clinical N
Staging of Nasopharyngeal Carcinoma
and the Impact of PET/CT N Staging
on Clinical Treatment
2713
Yu-Wen Wang
Partial Volume Correction in FDG PET/
CT Enhances the Efficacy of Detecting
the Equivocal Size Range for Lateral
Retropharyngeal Nodal Metastases of
Nasopharyngeal Carcinoma
2714
Lin Kong
Neoadjuvant Chemotherapy With
TPF Regimen Followed by Concurrent
Chemoradiation for Locoregionally
Advanced Stage Nasopharyngeal
Carcinoma
2715
Yunsheng Gao
Maximal Diameter of Lymph Node Was
Not a Prognostic Factor for Stage II
Nasopharyngeal Carcinoma Treated by
Radiotherapy Alone
2716
Junxin Wu
Study of Hippocampal Formation
Protection as the Organ at Risk in IMRT
for Nasopharyngeal Carcinoma
2717
Jin Wang
Sensorineural Hearing Loss in
Nasopharyngeal Carcinoma Patients
Treated With Combined Intensity
Modulated Radiation Therapy and
Cisplatin-based Chemotherapy
2718
Zhang Peng
Studies on the Expression of P53,
MDM2, eIF4e, EGFR in Nasopharyngeal
Carcinoma and Its Correlation With the
Nasopharyngeal Carcinoma Biological
Behavior and Prognosis
2719
David Wilson
The Prognostic Significance and
Relationship Between p16, Human
Papillomavirus (HPV) and Epstein-Barr
Virus (EBV) in the Tumors of Adult Non-Asian Patients With Nasopharyngeal Squamous Cell Carcinoma (NPSCC)
130
2720
Yan Sun
The Clinical Outcomes of Radiotherapy
With RapidArc in Local-Regionally
2721
Xu Peng
Clinical Study of the Necessity of
Multiple Replanning During the
Course of Intensity Modulated
Radiotherapy for Patients With Locally
2722
Klaudia Hunter
Non-Intensity Modulated Proton vs.
Intensity Modulated Photon Planning
for Complex Head and Neck Tumors
2723
Haijun Lu
Outcome of Intensity Modulated
Radiotherapy Combined With Concurrent Chemotherapy for Recurrent Nasopharyngeal Carcinoma
2724
BaoQing Li
Improved Survival With Chemoradiotherapy Compared to
Radiation Therapy Alone for Asian-Americans: Results From the
California Cancer Registry
2725
Hideki Nishimura
Patterns of Local Recurrence and
Metachronous Malignancy Following
Radiation Therapy for Stage I or II
Hypopharyngeal Carcinoma: Role
of Close Observation and Multidisciplinary Approach
2726
Michio Yoshimura
Using Simultaneous Integrated Boost
for Hypopharyngeal Cancer
2727
Takeshi Yanagi
Usefulness of Induction Chemotherapy Followed by Chemoradiation in the Treatment of
Hypopharyngeal Carcinoma
2728
Gary Mok
Does IMRT for Hypopharyngeal Cancer
Improve Loco-regional Control? A
Comparison to 3-D Conformal Radiotherapy
2729
Chance Matthiesen
A Comparative and Dosimetric Analysis Regarding the Practical Use
of 3-D Conformal, IMRT, Rapid Arc and
Proton Therapy for the Treatment of
Early-stage T1/T2 Glottic Laryngeal
Cancer
2730
Hideo Kawaguchi
Efficacy and Safety of High Dose Accelerated Hyperfractionated
Radiotherapy Alone for Early Glottic
Carcinoma
2731
Richard Cassidy
Primary Subglottic Carcinoma: The University of Florida Experience
2732
Jomon Raphael
A Prospective Single Arm Study on the
Feasibility and Response of Concurrent
Docetaxel With Radiotherapy in Locally
Advanced Head and Neck Malignancy
2733
Evangelia Katsoulakis
Outcomes of Radiotherapy for Hypopharyngeal Squamous Cell Carcinoma: A Single Institution’s Experience
2741
Joseph Tung-Chieh Chang
The Health Related Quality of Life for
Hypopharyngeal and Laryngeal Caner
Patients Received Organ Preservation
Treatment
2742
Peter Ahn
Primary Treatment With External
Beam Radiation vs Partial and Radical
Pharyngectomy for Hypopharyngeal
Carcinoma: A SEER analysis
2743
Christopher Barker
Multivariable Analysis of Factors Associated With Outcome in Localized
Sinonasal Mucosal Melanoma (SM)
2744
David Fried
Patterns of Local Recurrence for Sinonasal Malignancies
2734
Hong Zhang
Pyriform Sinus Cancer in the US: A
Population-based Study of 5,601
Patients Over Three Decades
2745
Robert Malyapa
Outcomes of Nasal Cavity and Paranasal Sinus Cancers Treated With
Proton Therapy
2735
Ben J.M. Heijmen
Cone Beam CT (CBCT) Guided Tumor
Positioning for Laryngeal Cancer
Patients With Large Interfraction Time
Trends in Tumor Set-Up
2746
XiYin Guan
Clinical Significance of Lymph Node
Metastasis in Sinonasal Squamous Cell
Carcinoma Treated With IMRT/3-D CRT
2747
Anouchka Modesto
Esthesioneuroblastomas: Bi Centric R0
review of Clinical Features, Multimodal
Treatment and Long-term Outcome
2736Withdrawn
2737
Jorgen Johansen
Radiation Treatment of T1-T2N0 Squamous Cell Carcinoma of the Glottic Larynx in the Modern Era
2738
Nadeem Riaz
Is IMRT Associated With Inferior
Outcomes for T1-2N0 Squamous Cell
Carcinoma of the Larynx?
2739
Man Hu
Excellent Laryngeal Preservation Can
Be Achieved With IMRT For Loco-regionally Advanced Laryngeal
Cancer
2740
Shlomo Koyfman
Outcomes in Human Papillomavirus
(HPV-) Unrelated Locally Advanced
Squamous Cell Cancers of the Head
and Neck (LA-HNC) Treated With Definitive Chemoradiotherapy (CRT)
2748
Azusa Hasegawa
Combined Chemotherapy and Carbon
Ion Radiotherapy for Mucosal Malignant Melanoma of the Head and
Neck
2749
Tyler Hollen
Esthesioneuroblastoma of the Nasal
Cavity
2750
Waleed Mourad
Outcomes of Parotid Gland Tumors
Treated With Surgery and Post-operative Radiation Therapy
2751
Xiaofeng Yang
Ultrasound Histogram Assessment
of Acute and Late Parotid Gland
Injury Following Head and Neck
Radiotherapy
2752
Youssef Zeidan
Postoperative Radiation Therapy for
Minor Salivary Glands Carcinomas
of the Head and Neck: Long-term
Outcomes
131
continued
2753
Rebecca Israel
Patterns of Practice in the Treatment of
Adenoid Cystic Carcinoma Compared
With NCCN Guidelines: A National
Survey
2754
Rebecca Israel
Neutron Radiotherapy for Treatment of
Adenoid Cystic Carcinoma and Other
Primary Salivary Gland Malignancies: A
Patterns of Practice Survey
2755
Michael Herman
Elective Neck Management for High-grade Salivary Gland Carcinoma
2756
Petra Stegmaier
Xerostomia: Association Between Saliva Production and Patient Reported Grading
2757
Lucas Resende Salgado
Definitive Photon Radiotherapy in the
Treatment of Unresectable Salivary
Gland Tumors
2758
Lucas Resende Salgado
Surgery Followed by Post-operative
Radiation Therapy for Minor Salivary
Gland Tumors
2759
Pretesh Patel
Postoperative Radiotherapy for Salivary Gland Tumors: Factors Associated With Treatment Failure and
Toxicity
2760
Anisha Noble
High Risk Factors Associated With
Disease Recurrence in Patients With
Salivary Gland Cancer Treated With
Surgery +/- Adjuvant Radiotherapy or
Chemoradiotherapy
2761
Kyle Arneson
The Role of Radiation in Carcinoma Ex
Pleomorphic Adenoma
2762
Jung Hun Oh
A Novel Modeling for Salivary Toxicity
Based on Salivary Flow Recovery Over
Time in Head and Neck Cancer Patients
Treated With Radiotherapy
2763
Nadeem Riaz
Long Term Outcomes of Post-operative
Radiation Therapy for Major Salivary
Gland Tumors
2764
Paul Romesser
External Beam Radiotherapy in Advanced Or Recurrent Non-Anaplastic Thyroid Cancer an
Updated Experience
2765
Shruthi Arora
Outcomes in Poorly-differentiated and
Anaplastic Thyroid Cancers Treated
With Radiation: A Seer Analysis
2766
Viktoras Rudzianskas
Interstitial High-dose-rate Brachytherapy for Recurrent and Previously
Irradiated Head and Neck Cancer
2767
Azmi Kumaravelu
Toxicity and Response Assessment
With Prolonged Infusion Gemcitabine
and Gefitinib With Intensity Modulated
Radiation Therapy in Recurrent Head
and Neck Squamous Cell Carcinoma:
A Pilot Study
2768
Christopher Hallemeier
Adjuvant Hypofractionated Intensity
Modulated Radiotherapy (IMRT) After
Resection of Regional Lymph Node
(LN) Metastases in Patients With Malignant Melanoma of the Head and
Neck
2769
Waleed Mourad
The Role of Chemo-radiotherapy
(CRT) in the Management of Patients
With Squamous Cell Carcinoma of the
Head and Neck (SCCHN) ± HPV With
Coexisting HIV
2770
Waleed Mourad
Pattern of Failure of Head and Neck
Malignancy (HNM) With Perineural
Invasion (PNI)
2771
Gabriela Studer
Late Term Tolerance Following Radiation Using Intensity Modulation
in >700 Head Neck Cancer Patients
2772
Luis Perez-Romasanta
Tumor Volume Delineation In Head
and Neck Cancer With 18-Fluor-Fluorodeoxiglucose Positron
Emission Tomography: Adaptive
Thresholding Method Applied to
Primary Tumors and Metastatic Lymph
Nodes
2773
Charles Woods
A Phase II Study of Definitive Radiotherapy With Concurrent Erlotinib and Docetaxel in Locally-advanced Squamous Cell
Carcinoma of the Head and Neck (LA-SCCHN)
2774
Arif Ali
A SEER-based Probability Model Using
HPV Status and Lymph Node Levels
to Predict Primary Head and Neck
Tumor Site for Squamous Cell Cancer
Confined to Cervical Lymph Nodes
2775
Klaudia Hunter
Dosimetric Predictors of Neck Spasm
Following Chemoradiation for Head
and Neck Cancer
2776
Hani Ashamalla
The Anatomical Biological Value (ABV)
on Pretreatment PET/CT Predicts
Response and Survival in Locally
Advanced Head and Neck Cancer
2777
Kazufumi Kagawa
Clinical Significance of Salvage Surgery
for Recurrent Pharyngeal or Oral Cancer After Definitive Radiation
Therapy
2778Withdrawn
2779
John Vargo
The Impact of Treatment Duration and
Volume on Toxicity Following SBRT for
Locally-Recurrent, Previously Irradiated
Head and Neck Cancer
2780
John Vargo
Treatment Duration > 2 Weeks
Negatively Impacts Disease Control
Following SBRT for Locally-recurrent,
Previously-irradiated Head and Neck
Cancers
2781
Christopher Balamucki
Impact of Radiographic Findings on
Prognosis for Skin Cancer of the Head
and Neck With Clinical Perineural
Invasion
2782
Sven Steen
Accuracy and Utility of a Screening
FDG PET/CT 12 Months Post-Radiation
for Head and Neck Squamous Cell
Carcinoma
132
2783
Jessica Wobb
A Matched Analysis Evaluating the
Role of Triple-agent Induction Chemotherapy in the Context of Intensity Modulated Radiation Therapy
and Concurrent Chemotherapy for Locally Advanced Head and Neck
Cancer
2784
Nataliya Kovalchuk
Comparison of Deformable vs. Rigid
PET/CT Registration in Head and Neck
Cancer (HNC) Patients Undergoing
Post-operative Radiation Therapy
(PORT)
2785
Rohan Deraniyagala
Proton Therapy for Skull Base Chordomas: An Outcome Study
From the University of Florida Proton
Therapy Institute
2793
Takuya Yamazaki
Retrospective Analysis of Definitive
Radiotherapy for Neck Node Metastasis Fron Unknown Primary
Tumor: Japanese Radiation Oncology
Study Group Study
2794
Niranjan Bhandare
Evaluating the Association Between
Pre- and Post-radiation Therapy Otitis
Media With Effusion and the Incidence
of Sensory-neural Hearing Loss in
Head and Neck Cancer Patients
2795
Irene Karam
Retrospective Comparison of Two
Feeding Tube Approaches for Head
and Neck Cancer Patients Receiving
Concurrent Chemo-radiation Therapy
2786
Julie Bradley
Patient and Tumor Characteristics and
Pre-treatment Swallowing Frequency
and Duration in Head and Neck Cancer
Patients
2796
Jason Kehrer
Implementation of Intensity Modulated Radiation Therapy in the
Treatment of Carcinoma of the Nasopharynx and Oropharynx: a Retrospective Single-institution
Analysis
2787
Gregory Vlacich
Dose to the Inferior Constrictor Predicts Persistent Dysphagia With
Definitive ChemoIMRT in Locally-advanced Head and Neck
Cancer (LAHNC)
2797
Sang-June Park
Comparative Dosimetry of an Extensive Scalp Lesion: High-dose-rate
Brachytherapy, Electronic Brachytherapy and Volumetric Modulated Arc Therapy
2788
Masaharu Hata
Radiation Therapy for Primary Carcinoma of the Eyelid: Tumor Control and Visual Function
2798
Isabel Prieto
Fentanyl Pectin Nasal Citrate (FPNC),
To Control Breakthrough Pain (BP) And
Improve Dysphagia, in Head and Neck
Cancer Patients Receiving Radiotherapy (RT)
2789
James Douglas
Fast Neutron Radiotherapy for the
Treatment of Major Salivary Gland
Neoplasms
2790
Lanea Keller
p16 Status, Pathologic and Clinical
Characteristics, and Long-term Outcomes in Unknown Primary Carcinomas of the Head and Neck
2791
Michinori Yamamoto
Clinical Usefulness of Immediate
Imaging Using a 64-Multidetector
Computed Tomography (MDCT) in
Treatment Planning of Patients With
Head and Neck Neoplasm
2792
Sewit Teckie
Ultra-high-dose Stereotactic Body
Radiation Therapy (SBRT) Is Feasible
for Tumors in the Head and Neck (HN)
2799Withdrawn
2800
Paul Romesser
Prognostic Utility of Pretreatment
Metabolic Tumor Volume, Gross Tumor
Volume, Maximum Standardized
Uptake Value in Head and Neck Cancer
Patients Receiving IMRT
2801
Nigel Anderson
Correlation of Oral Cavity Dose, Acute
Mucositis and PEG Dependency for
Head and Neck IMRT
2802
Pinaki Dutta
The Role of Post-operative PET/CT
Imaging in Head and Neck Cancer
Patients Prior to the Initiation of Adjuvant Radiation Therapy
2803
Lauren Kropp
Incidental Perineural Invasion in
Cutaneous Carcinoma of the Head and
Neck: The University of Florida Experience With Postoperative Radiotherapy After Mohs Resection
2804
Karen Chu
Evaluating the Prognostic Impact of
Lean Body Mass on Head and Neck
Cancer Outcomes
2805
David Berlach
High-dose-rate Intraoperative
Radiotherapy Combined With Neck
Dissection to Salvage Isolated Cervical
Nodal Recurrences
2806
Samy El-Sayed
Patterns of Failure in Patients Treated
With Intensity Modulated Radiation
Therapy (IMRT) Using Helical Tomotherapy (HT) for Head and Neck
Squamous Cell Carcinoma (HNSCC),
Results of a Prospective Trial
2807
Masayuki Fujiwara
Hypothyroidism After Radiation
Therapy For Head and Neck Cancer
– The Retrospective DVH Analysis of
75 Patients: The Volume of Thyroid
Gland Spared From Doses Can Be a
New Dose Constraint for Treatment
Planning?
2808
Patricia Daly
Can We Avoid Bilateral Radiotherapy in
Head and Neck Carcinoma of Unknown Primary in the PET-CT Era?
2809
Christian Hansen
Changes in Dose for Head and Neck
Cancer Patients As a Consequence of
Orthopedic Metal Artifact Reduction
2810
Dian Wang
High Negative Predictive Value of
FDG-PET/CT in Assessment of Tumor
Response Following Radiation Treatment for Head and Neck Carcinomas: Long-term Update
2811
Nhu Tram Nguyen
Restrospective Study of Hypofractionated Palliative Radiotherapy for Advanced Head and
Neck Cancers 0-7-21
133
continued
2812
Senzo Taguchi
The Treatment Outcome of Squamous
Cell Carcinoma of the External Auditory Canal and Middle Ear: A Single-institution Experience
2813
John Buatti
Early Evaluation of Response to
Chemoradiation in Head and Neck
Squamous Cell Cancer (HNSCC) With
F-18 Fluorothymidine Positron Emission Tomography (FLT PET)
2814
David Wilson
Prognostic Significance and Relationship Between p16 and Human
Papillomavirus (HPV) in Tumors of
Patients With Pharyngeal Squamous
Cell Carcinoma (SCC)
2815
Ryan Cotter
Does Response to Induction Chemotherapy (IC) Predict Outcome
After Concurrent Chemoradiotherapy
(CCRT) in Locally-advanced Head and
Neck Cancer (LAHNC)?
2816
Sudha Amarnath
Early Patient Outcomes With Adaptive
Radiation Therapy in Head and Neck
Cancers: The University of Washington
Experience
2817
Tarita Thomas
Brachial Plexus Dose Tolerance in Head
and Neck Cancer Patients Treated With
Sequential Intensity Modulated Radiation Therapy
2818
Carryn Anderson
Accuracy of F-18 Fluorodeoxyglucose
PET/CT 3 Months After Completion of
Radiation Therapy for Head and Neck
Squamous Cancer
2819
Sara Alcorn
Assessing Utility of Daily Cone Beam
CT in Head And Neck Cancers: The
Effect of Disease Site
2820
Shiva Das
The Role of Intrinsic Fluctuation in
Glucose Metabolism in the Use of FDG-PET in Assessing Metabolic
Response to Chemoradiation in Head
and Neck Cancer
2821
Hussain AlHussain
Correlation of Neck Nodal Levels With
the Risk of Distant Metastasis in Patients With Head and Neck Squamous Cell Carcinoma
2829
Trevor Bledsoe
Safety and Efficacy of Definitive Split-Course Hypofractionated Radiotherapy in High-risk Patients
With Head and Neck Cancer
2822
Isaac Kaufman
Limitations of CT and MRI in Evaluation of Individual Neck Levels
and Overall Nodal Staging of Head and
Neck Cancer
2830
Nigel Anderson
Dose Volume Response in Acute
Dysphagia and PEG Dependence: Validating QUANTEC Recommendations for Head and IMRT
2823
Jason Sun
Development of a Correlative CT/
Nasoendoscopy-based Head and Neck
Anatomy Atlas at the University of
Washington
2831
Jeanette Zhang
Correlating Planned Radiation Dose to
the Cochlea With Primary Site and
Tumor Stage in Head and Neck
Patients Treated With Intensity
Modulated Radiotherapy
2824
Surbhi Grover
A Single-institution Experience With
Induction Chemotherapy (ICT) Followed by Chemoradiation (CRT)
Versus CRT for Definitive Treatment
of Locally-advanced Squamous Cell
Carcinoma of the Head and Neck (LA-SCCHN)
2825
Maria E. Rodriguez-Ruiz
Induction Chemotherapy (I-CHT)
Followed by Intensity Modulated
Radiation Therapy Using Simultaneously Integrated Boost
(IMRT-SIB) and Concomitant Chemotherapy and Cetuximab
(C-CHT) for Locally-advanced Squamous Head and Neck Carcinomas
(SHNC)
2826
Kyle Wang
SUVmax on Initial Post-treatment PET-CT Predicts Local Failure in Patients With Previously-irradiated, Recurrent Head and Neck Cancer
Treated With SBRT
2827
Felipe Rey
Weight Loss During Head and Neck Radiation: Risk Factors and Implications on Treatment Outcome
2828
William Magnuson
Impact of Node Negative (n0) Target
Volume on Parotid Gland Dose Sparing
in HNSCC
2832
Andrew Hoover
Diagnostic Value of 3-Month F-18
Fluorodeoxyglucose PET/CT Among
Head and Neck Cancer Patients With
and Without Gross Disease at Initiation
of Radiation Therapy
2833
Moein Alizadeh-Kashani
The Role of PET-CT After Chemoradiation in Partially Regressed
Nodal Disease
HEALTH SERVICES RESEARCH
2834
Abigail Stockham
Results of a Questionnaire for Diagnosis and Treatment of Brain
Radiation Necrosis
2835
Jordan Gutovich
Predictors of Radiation Oncology
Resident Research Productivity
2836
Lukasz Mazur
Association Between Workload and
Errors in Clinical Radiation Oncology
2837
Benjamin Mou
Population-based Analysis of Preoperative Radiotherapy Utilization
for Patients With Rectal Cancer
2838
Jessica Church
Quality Assurance in Clinical Radiation
Therapy: A Qualitative Assessment of
the Impact of Physician Attendance on
the Number/Nature of Peer Review-defined Changes to Planned
Cases
134
2839
Robert Adams
Multipronged Quality Initiatives In
Radiation Oncology: Feasibility, Staff
Satisfaction and Initial Outcomes
2840
Christine Min
Whole Breast Hypo-fractionated Radiation Therapy: Outcomes, Toxicities and Cost-benefit Analysis
2841
Gaurav Bahl
A Population-based Study on the
Uptake and Utilization of Stereotactic
Radio-surgery (SRS) for Brain
Metastasis in a Canadian Province
2842
Anushree Vichare
Performance Assessment for the
Advancement of Radiation Oncology Treatment (PAAROT): A Practical Approach for Informing
Practice Improvement
2843
Sarah Hegarty
Predictors of Post-prostatectomy
Radiotherapy Use: A Population-based
Study Using SEER-medicare Data
2844
Clayton Hess
CyberKnife Stereotactic Radiotherapy (SRT) for Solitary, Variably-Symptomatic, Intracranial
Meningiomas: Clinical Outcomes, Cost
Effectiveness and Prescribing Habits
2845
Andrea Russo
Advancing Age Within Established
Gleason Score Categories and the Risk
of Prostate Cancer Specific Mortality
2846
Colin Champ
Dietary Recommendations During
Cancer Treatment: Consistently
Inconsistent?
2847
Daniel Golden
The Radiation Oncology Fourth-year
Medical Student Clerkship: A Targeted
Needs Assessment
2848
Nitesh Paryani
Medical Student Understanding of the
ACGME Core Competencies: A Survey
of Residency Applicants
2849
Andrew Camarata
A Surveillance, Epidemiology and End
Results Registry (SEER) Analysis of
Treatment in Prostate Cancer: Practice
Trends With regard to Certificate of
Need Policy
2850
Kevin Albuquerque
Challenges and Cost of Non-interconnectivity in Re-treatment
With Radiation-Results of a National
Survey
2861
Mikel Eguiguren Bastida
A Survey of the Perceived Quality of
Patient Care in a Radiation Oncology
Service: Results From 2002 to 2011
2851
Raymond Bernard Wynn
Translating SBRT from Academic
to Community Practice: The UPMC
Experience
2862
Jennifer Johnson
Improvement in IMRT Quality Assurance Rates: A Quality Improvement Project at a Large Academic Institution
2852
Yoshiko Doi
The Frequency of Adverse Events by
Radiation Therapy for Atomic Bomb
Survivors With Cancer
2863
Anna McCullough
Integration of Tobacco Cessation Services Into a Radiation Oncology
Clinic
2853
Lucille Lee
Operational Process for Treatment
Pathways in Radiation Medicine
2864
Yee Ung
Cancer Care Ontario’s Lung Cancer Disease Pathway Management Initiative: A Novel Approach to Provincial Quality Improvement
2854
A. William Blackstock
Impact of Marital Status and Race
on Survival for Patients With Colon
Cancer: An Analysis of Data From the
Surveillance, Epidemiology and End-Results (SEER) Program
2855
Muhammad Qureshi
Gross Tumor Volume Presentation
in Different Race/Ethnic Groups As a
Determinant of Treatment Outcome
in Head and Neck Cancer Patients
Treated With Definitive Radiotherapy
2856
James Murphy
Increasing Use of Technology With
Palliative Radiotherapy
2857
Kristina Mirabeau-Beale
Metachronous Cancer Diagnosis in
Men with Prostate Cancer and the Risk
of Prostate Cancer-specific Mortality: A
Competing Risks Analysis
2865
Marie Andree Fortin
Online Optimization of Radiotherapy
Patient Scheduling
2866
Todd Pawlicki
Investigation of RFID-based Workflow
Analysis
2867
William Stokes
Control of Cardiovascular Risk Factors
In Cancer Survivors Compared to Non-Cancer Controls, Measured Outcomes From a Population-based
Study
2868Withdrawn
2869
Nathan Sheets
Trends in Use of Post-prostatectomy
Therapies for Prostate Cancer: A SEER-Medicare Analysis
2858
Daniel Gomez
Treatment Modality and Other Prognostic Factors for Overall Survival
in Stage III Non-small Cell Lung Cancer
(NSCLC): A Population-based Analysis
2870
Anamaria Yeung
Making Patient Safety a Priority: Standardizing Workflow from CT Simulation to Radiotherapy Start to Allow Adequate Time for Safety Checks
2859
Daniel Gomez
Patient Selection for Treatment Modality In Stage III Non-small Cell
Lung Cancer: A Population-based
Analysis
2871
Nirav Kapadia
Patterns of Practice and Outcomes for
Stage I Non-small Cell Lung Cancer
(NSCLC): Analysis of SEER-17 Data
1999-2008
2860
Tomas Dvorak
Assessment of Compliance With NCCN
Guidelines for Breast Cancer Patients
Treated at a Comprehensive Cancer
Center
2872
Inge Aivas
Improving the Efficiency of Radiotherapy Delivery by Resource
Optimization
135
HEALTH SERVICES RESEARCH/
continued
2873
Jean Archambault
Radiotherapy Safety and Tolerance in
90+ Years Patients
2874
Shlok Gupta
The Effect of the Adoption of Concomitant Chemoradiotherapy on
Outcomes for Cancers of the Upper
Aerodigestive Tract in Ontario
HISTORY
2875
Sanjay Aneja
A 35-Year History of Radiation Therapy
Utilization Across the United States
2876
Shushan Rana
Scholastic Activity Among Radiation
Oncology Residents at U.S. Academic
Institutions: A Benchmark Analysis of
H-Index
2877
Raphael Pfeffer
Radiation Epilation for Tinea Capitis: A Historical Review
2878
Emma Holliday
Gender Differences in Publication
Productivity, Academic Position and
Career Duration Among Current Academic Radiation Oncology Faculty
2879
Herbert Torres
History of Respiratory Tumor Motion
Assessment from Radiation Oncology
Perspective
LUNG CANCER
2880
Michael Stauder
Radiologic Tumor Regression and Correlation With Pathologic Findings
After Neoadjuvant Therapy for Non-small Cell Lung Cancer
2881
Abdallah Mohamed
Feasibility of Hypofractionated Radiotherapy (RT) for End-of-life
Palliation: Preliminary Results From a
Prospective Randomized Study
2882
David Palma
Predicting Symptomatic Radiation
Pneumonitis After Concurrent Chemoradiotherapy for Non-Small Cell
Lung Cancer: Results of an International Individual Patient Data
Meta-analysis
136
2883
Max Dahele
Hypofractionated Stereotactic Radiotherapy for Large and Central
Lung Tumors
2884
Xueying Qiao
Prospective Study of Simultaneous
Integrated Boost Conformal Radiotherapy in Locally Advanced
Central Non-small Cell Lung Cancer
2885
Osamu Fujii
Involved-Field Radiotherapy Using
Protons or Carbon Ions for N1-2M0
Non-Small Cell Lung Cancer: A Retrospective Study
2886
Takeaki Ishihara
Lung Cancer In Octogenarians
2887
Yukinori Matsuo
Impact of Overall Treatment Time on
Local Control After Stereotactic Body
Radiation Therapy for Lung Cancer
2888
Voichita Bar Ad
Treatment-related Esophagitis for Patients With Locoregionally Advanced
With Involved-field Radiotherapy and
Concurrent Chemotherapy
2889
Chisa Hashizume
Novalis Stereotactic Body Radiotherapy (SBRT) for Stage I
Non-small Cell Lung Cancer (NSCLC):
Analysis Based on the New TNM
Classification and Difference Due to
Histology
2890
Ji Hyun Chang
Induction Chemotherapy Plus Concurrent Chemoradiotherapy
(ICCRT) vs. Concurrent Chemoradiotherapy (CRT) in the
Treatment of Unresectable Stage III
Non-Small Cell Lung Cancer (NSCLC)
2891
Fumiya Baba
Clinical Experience wWith Respiratory-Gated Stereotactic Body
Radiotherapy (SBRT) for Lung Tumors
Using Audio Coaching
2892
Connie Yip
Pre-treatment FDG PET Tumour
Heterogeneity in Non-Small Cell
Lung Cancer is Associated With Poor
Response and Survival Following
Chemoradiotherapy
2893
Xiangpeng Zheng
Comparisons of Local Control and
Survival of Stereotactic Body Radiation Therapy vs. Surgery for
Stage I Non-small Cell Lung Cancer: A Meta-Analysis
2894
Suneil Jain
A Randomized Trial of Lung Stereotactic Body Radiation Therapy
(SBRT) Delivered Over 4 or 11 Days:
Acute Toxicity and Quality of Life
2895
Kitty Huang
Radiographic Changes After Lung
Stereotactic Ablative Radiotherapy
(SABR): Can We Distinguish Fibrosis
from Recurrence? A Systematic Review
of the Literature
2896
Joo Ho Lee
Radical Chemoradiotherapy As a Treatment of Choice for the Elderly
With Locally Advanced NSCLC
2897
Stephanie Casey
Impact of Respiratory Gating on Toxicity Outcomes for Locally
Advanced Lung Cancer Treated With
Radical Chemoradiotherapy
2898
Jordan Kharofa
Symptomatic Radiation Pneumonitis
in Elderly Patients Receiving Thoracic
Irradiation: Comparative Analysis of
Clinical and Dosimetric Predictors
2899
Maria Werner-Wasik
No Difference in Outcome Between
Biopsied vs. Non-biopsied Early-stage
Medically Inoperable Non-small Cell
Lung Cancer Patients Treated With
Volumetric Image Guided Stereotactic Body Radiation Therapy
(SBRT): Analysis of a Large Multi-institutional Database
2900
Lichung Ku
Novel Hybrid Volumetric Modulated
Arc Therapy (VMAT) for Stereotactic
Body Radiation Therapy (SBRT) of Lung
Tumors in Proximity to the Chest Wall
2901
Zuolin Xiang
A Dosimetric Model for Predicting
Radiation Pneumonitis After Stereotactic Ablative Radiotherapy for
2902
Shinya Takemoto
Changes of Pulmonary Function
and Correlation With Dose-volume
Parameters in Patients Undergoing
Stereotacic Body Radiotherapy (SBRT)
for Lung Cancer
2903
Brendan Prendergast
(SBRT) for Lung Malignancies: Preliminary Toxicity Results Using a
Flattening Filter-free Linear Accelerator
Operating at 2400 Monitor Units Per
Minute
2904
Andrew Evans
Sublobar Resection and Robotic Interstitial Brachytherapy for Early-stage Non-small Cell Lung Cancer
2905
Soha Atallah
Impact of Pre-treatment Growth Rate
on Outcome of Stage I Non-small Cell
Lung Cancer After Stereotactic Body
Radiotherapy
2906
Tetsuya Inoue
Stereotactic Body Radiotherapy Using
Gated Radiotherapy With Real-time
Tumor-tracking for Stage I Non-small
Cell Lung Cancer
2907
Liu Di
Induction Chemotherapy With Cetuximab, Vinorelbine-Cisplatin followed by Intensity Modulated
Thoracic Radiotherapy and Concurrent Cetuximab, Vinorelbine-Cisplatin in
Patients With Unresectable Stage III
2908
Hunter Boggs
Using Tomotherapy for Early-stage
NSCLC: The Utility of Mid-fraction CT
Scans to Assess Intra-fraction Tumor
Motion
2909
Edwin Crandley
Survey of Institutional Practices for
Internal Target Motion Management
in Lung Stereotactic Body Radiation
Therapy (SBRT)
2910
Masahiro Hiraoka
Realization of Dynamic Tumor Tracking
Irradiation with Real-time Monitoring
in Lung Tumor Patients Using a Gimbaled X-ray Head Radiation
Therapy Equipment
2911
Hong-Qing Zhuang
The Preliminary Results and Early
Response for Centrally Located Lung
Cancer Treated by Stereotactic Radiotherapy in Consecutive Daily Fractions
2921
Susan Guo
Outcomes of Hypofractionated Radiation Therapy in Poor Risk Non-small Cell Lung Cancer Patients
and Validation of RTOG 0213
2912
Jinming Yu
Impact of Intra-tumor 18F-FDG Uptake
Heterogeneity on Different Target
Delineation Methods by PET and CT
for Non-small Cell Lung Cancer
2922
Yi Hsuan Chung
The Impact of Anatomical Changes
During the Course of Intensity Modulated Radiotherapy (IMRT) for
Lung Cancer
2913
Gregory Videtic
Mature experience in Stereotactic
Body Radiotherapy for Early-stage
Medically Inoperable Lung Cancer at
Cleveland Clinic
2923
Radhe Mohan
IMRT vs. Passively Scattered Proton
Therapy (PSPT) for Locally-advanced
NSCLC: Impact of Changing Techniques and Technologies Over the
Course of a Randomized Trial
2914
Stephen Rosenberg
Variability of Tumor Motion in 4-D CT:
The Effects of Abdominal Compression
on Lung Tumor Displacement
2915
Wesley Russell
Predictors of Survival After Brain
Metastases From Non-small Cell Lung
Cancer
2916
Aruna Turaka
Role of Radiation Therapy for Malignant Thymoma: A Single-institution Experience
2917
Kaori Asai
Carcinoembryonic Antigen As a
Predictive Factor for Recurrence After
Stereotactic Body Radiotherapy in
Stage I Lung Adenocarcinoma
2918
Christopher Peters
Stereotactic Ablative Radiotherapy for
Lung Tumors using Helical Tomotherapy: A Cost-effective Treatment Regimen
2919
Shinji Tsudou
A Comparison of Lung Tumor Shadow
on Maximum Intensity Projection and
Average Intensity Projection of Respiratory Correlated Simulation CT
2920
Jonathan Whaley
Incidental Nodal Irradiation in Stage
III Lung Cancer Treated With Involved
Field Radiation: Comparison Between
3-D CRT and IMRT
2924
Xiangrong Qi
Analysis of Outcomes in Early Stage
Non-small Cell Lung Cancer Irradiation:
Fractionation Scheme Implications for
Stage I vs. Stage II Disease
2925
James Russo
(IMRT) in Advanced Inoperable Non-small Cell Lung Cancer: Toxicity,
Survival and Patterns of Failure
2926
Elizabeth Nichols
Marital Status Is an Independent
Predictor of Survival for Patients
Undergoing Definitive Chemoradiation for Stage III Non-small
Cell Lung Cancer (NSCLC)
2927
Kaoru Uchiyama
Invasive Thymoma: Results of Mediastinal and Low-dose Entire
Hemithorax Irradiation
2928
Ryuji Mikami
Preliminary Results of Definite
Radiotherapy for Stage II Non-small
Cell Lung Cancer at Tokyo Medical
University
2929
Lee Jeongshim
Intermediate Hypofractionated Radiotherapy for Lung Parenchymal
Tumor
2930
Masahiko Aoki
Radiation-induced Rib Fracture
After Hypofractionated Stereotactic
Body Radiotherapy for Patients With
Peripheral Lung Tumor: Impact of the
Maximum Dose and the Fraction Size
137
LUNG CANCER/ continued
2931
Marc Mahe
Acute Radiation Pneumonitis After
Conformal Radiation in Non-small Cell
Lung Cancers: A Large French Prospective Study on Predictive Factors
2932
Varun Chowdhry
Complications From CT-guided Needle
Biopsy for Patients Receiving Stereotactic Body Radiation Therapy
2933
Christopher Kelsey
Analysis of Prognostic Factors Affecting Local and Distant Recurrence
Following Surgery for Non-Small Cell
Lung Cancer: A Recursive Partitioning
Analysis
2934
Katsura Kosaki
Safety and Efficacy of Second Stereotactic Body Radiotherapy (SBRT)
for Local Recurrence of Non-small Cell
Lung Cancer (NSCLC) or Lung Metastasis Previously Treated With
SBRT
2935
Blake Currier
A MCNP5 Comparison of the Dose
Distribution From 169-Ytterbium LDR
Brachytherapy Sources Within Heterogeneous Tissue to TG-43 Guidelines
2936
Ping Wang
Prognostic Value of Serial FDG-PET/
CT Scanning in Stage I Non-small Cell
Lung Cancer Patients Treated With
Hypofractionated Radiotherapy
2937
Cory Knill
Dosimetric Effect of Patient Weight
Change on RapidArc Lung Treatments
2938
Xiong Wei
Pretreatment Poor Pulmonary Function Is Prognostic of Poor Overall
Survival in Patients With Stage III Non-small Cell Lung Cancer Treated
With External Beam Radiotherapy
2939
Malcolm Mattes
The Ratio of Lymph Node SUV to
Primary Tumor SUV on PET/CT Predicts
Nodal Pathology in Patients with Non-small Cell Lung Cancer (NSCLC)
2940
David Shultz
Anatomic and Metabolic Predictors
of Failure After Stereotactic Ablative
Radiotherapy for Non-small Cell Lung
Cancer
2950
Yuu Tajima
Dosimetric Evaluation of Compensator
Intensity Modulated Radiotherapybased Stereotactic Body Radiotherapy
for Stage I Non-small Cell Lung Cancer
2941
Ryan Herde
A Unique Geographical Analysis of
Lung Cancer Patients in the State of
Utah – Huntsman Cancer Hospital
Experience
2951
Hitoshi Ikushima
Treatment Effect of Neoadjuvant
Chemoradiation Therapy for Non-small
Cell Lung Cancer Evaluated by Multi-modality Imaging and Histopathological Analyses
2942
Jessica Freilich
Outcomes for Stage III Unresectable
Treated With Concurrent Chemotherapy and Radiation Therapy
to 70 Gy
2943
Kazuya Inoue
Feasibility and Efficacy of Salvage
Radiotherapy for Loco-regional Recurrence of Elderly Non-small Cell
Lung Cancer After Resection
2944
Yunfeng Cui
Can Use of an Atlas Decrease Contouring Variability in Non-small
Cell Lung Cancer Radiotherapy? Analysis of the RTOG 1106 Pre-clinical
Trial Planning Study
2945
Hideyuki Harada
Clinical Comparison of Proton Beam
Therapy and Stereotactic Body Radiotherapy for Medically Inoperable
2946
Monika Blake
Phase II trial: Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Locally Advanced Non-small Cell Lung Cancer Patients
2947
Genevieve Maquilan
Analysis of the Relationship Between
Response to Chemotherapy and
Response to Radiation Therapy in Patients With Non-small Cell Lung Cancer Receiving Sequential Treatment
2948
Jiandong Zhang
Radiotherapy in Combination With
Nimotuzumab in Elderly Patients With
Locally Advanced Squamous Cell Lung
Cancer: A Pilot Study
2949
Rikiya Onimaru
Using Real-time Tracking Radiotherapy
(RTRT) System for Patients With Lung
Cancer Aged 80 and Over
2952
Michael MacManus
Significant Numbers of Irradiated
Tumor Cells Enter the Circulation
Early During a Course of Fractionated
Radiation Therapy for Non-small Cell
Lung Cancer
2953
Kotoha Tatekawa
Changes in Volumes of Stage I Non-small Cell Lung Cancer (NSCLC)
During Stereotactic Body Radiotherapy (SBRT)
2954
Suzhen Wang
Comparisons of Clinical Target Volumes Defined on 3-D CT and 4-D CT
Images for the Mediastinal Metastatic
Lymph Nodes in Non-small Cell Lung
Cancer
2955
Vimoj Janardanan Nair
Higher Dose Thoracic Radiotherapy
is Associated With Improved Overall
Survival in Limited-stage Small Cell
Lung Cancer: Analysis of the 15 Year
Experience From a Retrospective
Cohort of 296 Patients at the Ottawa
Hospital Cancer Centre (TOHCC)
2956
Aparna Kesarwala
Feasibility of Proton Therapy for Elective Nodal Irradiation in Patients
With Locally Advanced Non-small Cell
Lung Cancer
2957
Zhongxing Liao
Heart and Lung Radiation and Overall
Survival in Non-small Cell Lung Cancer
Patients After Chemoradiotherapy
2958
Elisabetta Parisi
Accelerated Hypofractionated Radiotherapy Using Helical Tomotherapy for the Treatment of
Medically Inoperable Pleural Mesothelioma: IRST Preliminary Data
138
2959
Pierina Navarria
Lung Metastases in Oligometastatic
Patients: A New SBRT Approach Using
VMAT With Flattening Filter Free (FFF)
Beams
2970
Ato Wright
Non-small Cell Lung Cancer With Chest
Wall Invasion is Associated With High
Rates of Positive Margins and Local
Failure After Surgery
2981
Takahiro Kishi
Feasibility of Definitive Concurrent
Chemoradiotherapy for Patients Over
80 Years Old With Non-small Cell Lung
Cancer
2960
Andreas Rimner
The Role of EGFR and KRAS Mutations
in Locally-advanced Lung Adenocarcinoma Treated With Definitive Radiation Therapy
2971
Gonzalo Vazquez
Late Pulmonary Injury After Irradiation
for Lung Cancer at 5-year Follow-up
2982
Hongmei Wang
Improved Survival Outcomes in
Non-small Cell Lung Cancer Patients
With Incidental Concurrent Use of
Beta-blockers and Definitive Radiation
Therapy
2961
Kumiko Karasawa
Carbon Ion Radiotherapy for Lymph
Node Recurrence
2962
Shalini Garg
Patterns of Regional Failure in Stage III
Non-small Cell Lung Cancer Managed
With Neoadjuvant Chemoradiotherapy
and Resection
2963
David Peterson
A Prospective Study Measuring
Interobserver Variability of GTV With
FDG-PET-CT in Stage III Non-small Cell
Lung Cancer Using 3-D Analysis
2964
Sindhu Ramamurthy
A Study Comparing Clinical Outcomes
in Non-small Cell Lung Cancer
Patients Treated With Radical Thoracic
Radiotherapy Planned Using Pencil
Beam Algorithm and Collapsed Cone
Algorithm
2965 Withdrawn
2966
Aparna Kesarwala
The Role of Advanced Imaging in
Assessing Response to Definitive
Chemoradiation Prior to Prophylactic
Cranial Irradiation in Limited-stage
Small Cell Lung Cancer
2972
Sashendra Senthi
Patterns of Recurrence Following Stereotactic Ablative Body Radiotherapy (SABR) for Stage I-II
NSCLC: Initial Sites and Timing
2973
Naomi Nakajima
Prognostic Value of Pre-treatment
FDG-PET Parameter for Early-stage
With Stereotactic Ablative Radiotherapy
2974
Naoko Okano
The Efficacy of Three-dimensional
Non-coplanar Conformal Radiation
Therapy for T2N0M0 Non-small Cell
Lung Cancer Compared With Stereotactic Body Radiotherapy
2975
Brandon Mancini
Comparative Analysis of Stereotactic
Body Radiation Therapy for Multiple
Primary Non-small Cell Lung Cancer
2976
Dongryul Oh
Hypofractionated Radiation Therapy
for Central T1-3N0 Non-small Cell Lung
Cancer
2977
Andrea McKee
Initial Results of a NCCN Guideline-based Free Low-dose CT
Lung Cancer Screening Program
2967
Joost Nuyttens
Peripheral Early-stage Lung Tumors
Treated With Real-time Tumor Tracking
During Stereotactic Radiotherapy: A
6-year experience
2978
Joshua Siglin
Assessing Normal Tissue Motion on
Four-dimensional Computed Tomography Scan: Modeling the
Internal Risk Volume of the Esophagus
2968
Carmen Perez
Intensity Modulated vs. 3-D Conformal
Radiation Therapy for Limited-stage
Small Cell Lung Cancer
2979
William Silveira
Bronchial Obstruction From Non-small
Cell Lung Cancer: Factors Indicative of
Benefit from High-dose External Beam
Irradiation
2969
Raj Rajpara
Analyzing Locoregional Tumor Failure
in Association With Pre-treatment
FDG PET Parameters and Radiation
Dose Among Patients With Locally
Advanced Non-small Cell Lung Cancer
(NSCLC)
2980
Dongryul Oh
The Treatment Outcomes of
Concurrent Chemoradiotherapy for
Supraclaivcular Lymph Node Positive
2983
Wen Feng
Study on the Rationale of Postoperative Radiation Therapy Target Volumes in Completely Resected Stage IIIa (N2) Non-small Cell
Lung Cancer
2984
John Ng
Comparing Lung Dosimetry and
Secondary Malignancy Risks Associated With Stereotactic Body
Radiation Therapy (SBRT) Using Intensity Modulated Radiotherapy
(IMRT), Coplanar Volumetric-
Modulated Arc Therapy (VMAT) and
Non-Coplanar Volumetric-Modulated
Arc T
2985
Martin King
Evaluation of the Physiological
Response to Stereotactic Ablative
Radiation Therapy
2986
Tine B. Nielsen
Increasing Local Control in NSCLC
Patients With Inhomogeneous Dose
Distributions
2987
Karl Wurstbauer
Non-resected NSCLC: Tumor Size –Radiation Dose Related, Accelerated (1.8 Gy bid) Therapy– Definitive Results of a Prospective Study
2988
Lindsey Appenzoller
Automation of Lung Treatment Planning With the Varian Eclipse
Scripting Application Programming
Interface
2989
Sean Vance
Clinical Outcomes and Toxicity after
With or Without Adjuvant Chemotherapy for Stage I Non-small
Cell Lung Cancer (NSCLC)
139
LUNG CANCER/ continued
2990
Abdul Dar
Megavoltage Imaging: Patterns of
Tumour Regression and Predictive
Factor for Non-small Cell Lung Cancer
Undergoing Radiation Therapy on
Tomotherapy
2991
Jasper Nijkamp
Relating Acute Esophageal Toxicity to
Radiotherapy Dose Using 18FFDG-PET
in Concurrent Chemo-radiotherapy
for Locally Advanced Non-small Cell
Lung Cancer
2992
Nicholas Roman
Selection Bias in Lung Cancer Dose-escalation Protocols
2993
Yan Zhuang
Prognostic Factors for Overall Survival
in Stage IIIA/IIIB Non-small Cell Lung
Cancer After Definitive Radio-chemotherapy
2999
Sara Alcorn
Utility of Daily Cone Beam CT in
Predicting Setup Within Clinical CTV-PTV Margins in Lung Radiotherapy
3000
Brandon Mancini
for Patients With Clinically vs. Pathologically Diagnosed Non-small
Cell Lung Cancer: A Comparative
Analysis
3001
Deepinder Singh
Local Control Rates With Stereotactic
Body Radiotherapy (SBRT) for Primary
Lung Tumors: Single Institution Experience of 153 Consecutive Patients
3002
Shripal Bhavsar
Accelerated Hypofractionated
Radiotherapy in Early-Stage Non-Small
Cell Lung Carcinoma With Concurrent
Chemotherapy
2994
Aditya Juloori
Limited-Stage Small Cell Lung Cancer
in the Contemporary Period: Impact of
New Technologies on Outcomes
3003
Yoshiyasu Maehata
What Is the Cause of Immune Suppression in Stereotactic Body
Radiotherapy for Non-small Cell Lung
Cancer?
2995
Yoshiyuki Shioyama
Usefulness of Electron Density in
Gross Tumor Volume as a Prognostic
Factor in Stage I Non-small Cell Lung
Cancer Treated With Stereotactic Body
Radiotherapy
3004
Shervin Shirvani
Patterns of Failure for Limited-stage Small Cell Lung Cancer
Following Definitive Radiotherapy in
the Modern Era
2996
Jianxin Xue
High Dose to Large Volumes of
Pericardium May Be Associated With
Radiation-related Pericardial Effusion
and Survival in Patients With NSCLC
2997
Jonathan Grant
Impact of Chemotherapy Response
and Radiation Dose on Overall Survival
in Patients With Inoperable Non-small
Cell Lung Cancer Treated With Induction Chemotherapy Followed by
Concurrent Chemoradiotherapy
2998
Arjun Pennathur
Stereotactic Radiosurgery for Stage
I NSCLC in Medically Inoperable
Patients: A Prospective Multicenter
Phase II Study
3005
Mitsuhiko Oguri
Rib Fractures After Stereotactic Body
Radiation Therapy for Primary Non-small Cell Lung Cancer
3006
Sun Yi
Prospective Evaluation of Cardiac
Toxicity After Stereotactic Body Radiotherapy for Thoracic Tumors Using Echocardiographic Findings
3007
Orlan Macdonald
What is the Impact of External Beam
Radiotherapy (EBRT) Following Limited Resection of T1 or T2 Non-small Cell Lung Cancer (NSCLC)?
A SEER Analysis
3008
David Palma
Preliminary Statistical Dose Tolerance
Limits for Radiation Pneumonitis (RP)
When Treating Large Primary Lung
Cancers With Stereotactic Body Radiotherapy (SBRT)
3009
Paula McCloskey
Comparison of 3-D Conformal
Radiotherapy (3-D CRT) and Intensity
Modulated Radiotherapy (IMRT) in
Stage III Non-small Cell Lung Cancer
(NSCLC)
3010
Christoph Poettgen
Post-pneumonectomy Radical Accelerated Re-Irradiation and Concurrent Chemotherapy for Patients
With Contralateral Central Lung Cancer
Relapses
3011
Pierre Thirion
Implementation of Linac-based
(SABR) for Early-stage Non-operable
in Community-based Radiotherapy
Practice: A Trans-atlantic Hub-and-Spoke Experience
3012
Carl Peterson
Incidence of Second Primary Small Cell
Lung Cancer Following Non-small Cell
Lung Cancer Treated With and Without
Radiation Therapy: An Analysis of
SEER Data
3013
Thomas Dilling
Clinical and Dosimetric Predictors of
Radiation Pneumonitis (RP) in a Large
Series of Patients Treated With Stereotactic Radiotherapy (SBRT) to
the Lung
3014
Michael Corradetti
An Analysis of Survival After Prophylactic Cranial Irradiation for
3015
Victoria Ford
Role of FDG-PET As an Early Imaging
Biomarker of Esophagitis and Pneumonitis During the Course of
Radiation Therapy for Lung Cancer
3016
Rita Murphy
The Influence of the Inhomogeneity
Correction Factor on Dose Distributions in Lung Cancer Radiation
Therapy Treatment Plans: A Retrospective Study
3017
Vikren Sarkar
Dosimetric Implications of Abdominal
Compression for Lung SBRT Treatment
140
3018
Wenzhou Chen
Quantitative Evaluation of Impact
Upon Tumor Control Probability (TCP)
From Quality Assurance Criteria for
Non-small Cell Lung Cancer From
RTOG 1106 Study
3019
Joseph Lee
Predictors of Rib Fracture and Non-fracture Chest Wall Pain After
Lung Stereotactic Body Radiotherapy
(SBRT)
3020
Wenzhou Chen
Is Recontouring Organs-at-Risk (OAR)
for Adaptive Radiotherapy Plans for
Locally Advanced Lung Cancer Necessary? A Pre-activation Analysis
From Radiation Therapy Oncology
Group (RTOG) 1106
3021
Jason Hearn
Salvage Stereotactic Body Radiotherapy (SBRT) for Local Failure
After Upfront Lung SBRT: If at First You
Don’t Succeed...
3022
Amir Lavaf
The Role of Pretreatment PET/CT Parameters in Predicting Response
After Lung Cancer Treatment
3023
Katsuyuki Karasawa
Three-dimensional Non-coplanar
Conformal Radiotherapy With Middle
Fraction Dose for the Treatment of
3024
Yee Ung
Referral of Suspected Lung Cancer by
Family Physicians and Other Primary
Care Providers: A Clinical Practice
Guideline
3025
Jeremy Kilburn
Thoracic Re-irradiation In Patients With
As First or Second Course of Treatment
3026
Kevin Orcutt
Dose Escalation Using PET Imaging
for NSCLC While Maintaining RTOG
0915/0813 Criteria
3027
John Grecula
MR-Predictive Assay in Preoperative
Lung Cancer Therapy
3028
Taghrid Altoos
Assessment of Local Control Following
PET/CT Guided Adaptive Radiotherapy
for Locally Advanced Non-small Cell
Lung Cancer
3029
Iris Rusu
A Clinical Guide to Evaluate NonMonte Carlo Treatment Plans in Lung
SBRT
3038
Qing Chen
Dosimetric Evaluation of Flattening-Filter Free (FFF) Photon
Beams for Lung SBRT
3030
Stanley Kwong
Incidental Mediastinal Nodal Radiation
During Stereotactic Radiation for Lung
Tumors: Implications for High-dose
Treatment of Locally Advanced Disease
3039
Mike Soike
Long-term Follow-up and Patterns
of Failure for Patients With Medically
Inoperable Stage I Non-small Cell Lung
Cancer (NSCLC) Treated With
3031
John Greskovich
Improved Four Year Overall and
Local-Failure Free Survival in Stage
IIIA Non-small Cell Lung Cancer After
High-Dose, 3-D Conformal RT (3-D
CRT) +/- Chemotherapy (CT): A Single
Institution Experience
3040
Feng-Ming Kong
Role of Radiation Therapy in Small
Cell Lung Cancer (SCLC): Analysis of
SEER-17 Data
3032
Huanpeng Qi
Comparison of Internal Gross Tumor
Volume for Peripheral Lung Cancer
Based on Four-dimensional CT and
Three-dimensional CT Assisted With
Active Breathing Control
3033
Justin Rineer
The Impact of Changing Practice
Patterns on Outcomes in Stereotactic
Body Radiation Therapy (SBRT) for
Lung Tumors: The MD Anderson Cancer Center Orlando Experience
3034
Yuko Nakayama
Prognostic Value of Histopathological
Response to Preoperative Therapy for
the Patients With Non-small Cell Lung
Cancer
3035
Matthew Johnson
Survival and Toxicity After Standard
Dose 3-D Conformal Radiotherapy
or High-dose Intensity Modulated
Radiotherapy for Locally-advanced
3036
Nicholas Trakul
Improved Outcomes in Stage I NSCLC
Patients Treated in the Stereotactic
Ablative Radiotherapy Era:
A Population-based Analysis
3037
Sarah McAvoy
Reirradiation With Proton Beam
Therapy or Intensity Modulated Radiation Therapy for Non-small Cell
Lung Cancer: An Institutional Experience
3041
Salma Jabbour
Ambulatory Pulse Oximetry As a Clinical Aid in the Diagnosis of Radiation
Pneumonitis
3042
Yaping Xu
Concomitant Chemoradiotherapy
Phase II Study Comparing Pemetrexed/carboplatin With
Paclitaxel/Carboplatin in Patients With Unresectable Stage III Non-small Cell
Lung Cancer
3043
Huimin Xu
The Combination of Elevation of
Plasma TGF-β1 dDuring Radiotherapy
and Pre-radiation Cyfra21-1 Level Predicts Radiation-induced Lung
Toxicity in Patients With Non-small Cell
Lung Cancer
3044
Ben Wilkinson
Predictors of Local Recurrence After
Early-stage Non-small Cell Lung
Cancer
3045
Nan Bi
Comparison of the Effectiveness
of Radiofrequency Ablation with
Strereotactic Body Radiation Therapy
in Inoperable Stage I Non-small Cell
Lung Cancer: A Systemic Review and
Meta-analysis
3046
Chengbo Han
Relationship Between Pulmonary Artery Invasion and High-dose Radiation and Overall Survival in Patients with Non-small Cell Lung
Cancer
3047
Brian Lally
What Disparities Exist in Stage I Non-small Cell Lung Cancer?
141
LYMPHOMA
3048
Benjamin Goldsmith
A Novel Multileaf Collimator-based
Photon-Proton Involved-Field Technique for Treatment of Hodgkin’s Lymphoma of the Neck and Mediastinum
3049
Miran Blanchard
Evaluation of Limited-Volume
Involved-Nodal Radiotherapy (IN) and
(IMRT) in the Treatment of Hodgkin
Lymphoma (HL)
3050
Bradley Hunter
Pleural Effusions in Patients With
Hodgkin Lymphoma: Clinical Predictors and Associations With
Outcome
3051Withdrawn
3052
Evan Michaelson
Thyroid Malignancies In Survivors of
Hodgkin Lymphoma
3053
Julia Skliarenko
Pattern of Failure in Patients With
Stage I-ii Hodgkin Lymphoma Treated
With CMT: Implications of Partial Nodal
Region Coverage and the Need for
Adjacent Uninvolved Nodal Region
Coverage
3054
Matthew Vernon
Involved-field Radiation
Therapy Following TBI-containing
Myeloablative and Non-myeloablative
Conditioning Regimens in Hematopoietic Cell Transplant for
Non-Hodgkin Lymphoma: No Impact
on Relapse Rate
3055
Jennifer Dorth
Radiotherapy Dose-response Analysis
Ffor Diffuse Large B-cell Lymphoma
With a Complete Response to Chemotherapy
3056
Sarah Hamilton
Treatment and Outcomes of Patients
With Limited Stage Primary Cutaneous
B-cell Lymphoma
3057
Vladimir Valakh
Clinical Characteristics and Use of Radiation Therapy for the Management of Plasmablastic
Lymphoma (PBL): A Population Based
Study
3058
Zhen Tao
Dosimetric Comparison of Conventional Radiotherapy, Three-dimensional Conformal Radiotherapy and Intensity Modulated
Radiotherapy for Non-Hodgkin’s
Lymphoma in Pelvis
3059
Ximei Zhang
Elevated Beta2-microglobulin Level
is an Adverse Prognostic Factor for
Patients With Extranodal Nasal-type
NK/T-cell Lymphoma
3060
Ximei Zhang
Clinical Features and Treatment
Outcomes of Patients With Primary
Systemic Anaplastic Large Cell
Lymphoma: Report From a Single
Institution in China
3061
Ximei Zhang
Outcomes of ALK-negative Anaplastic
Large-cell Lymphoma are Superior
to Peripheral T-cell Lymphoma, Not
Otherwise Specified: Report From a
Single Chinese Institution
3062
Michio Iwabuchi
Treatment of Primary Central Nervous
System Lymphoma (PCNSL): Comparison of Whole-brain Radiotherapy and Partial-brain Radiotherapy
3063
Li-ming Xu
Prognostic Importance of Rituximab
and Radiotherapy in Patients With
Primary Mediastinal B-cell Lymphoma
Receiving Doxorubicin-containing
Chemotherapy
3064
Shinya Otsuka
Changes in Dose-volume Parameters
of Stereotactic Body Radiotherapy
(SBRT) for Stage I Lung Cancer by
Calculation Algorithms and Relationship With Outcome: Pencil
Beam Convolution With Batho Power
Law vs. Anisotropic Analytical Algorithm
3065
Saiji Ohga
Limited-stage Diffuse Large B Cell
Lymphoma in Head and Neck Treated
With CHOP or Rituximab -CHOP (R-CHOP) Plus Radiotherapy
3066
Cato Chan
Evaluation of Radiation Therapy for
NK-T Cell Lymphoma of the Head and
Neck
3067
Ting Zhao
Radiotherapy Improves the Prognosis
of Locoregionally Recurrent Extranodal
Nasal-type NK/T-cell Lymphoma
3068
JaYoung Kim
Predictive Value of Fluorine-18
Fluorodeoxyglucose Positron Emission
Tomography After Frontline Treatment and Consolidative Treatment in Patients With Extranodal
NK/T Cell Lymphoma
3069
Sang-wook Lee
Stage IE/IIE Extranodal NK/T Cell Lymphoma Arising From the Nasal
Cavity: Investigation of Computed Tomography Findings and Its Prognostic Values
3070
Mauricio Gamez
Extranodal Lymphoma and Radiation
Therapy: A Single Institution Experience
3071
Luluel Khan
A Single Institution Experience of
Extranodal Natural Killer/T cell Lymphoma of Nasal type
3072
Aaron Wagner
Mycosis Fungoides: Is There a Benefit
to Concurrent and Adjuvant Interferon With Total Skin Electron
Beam Therapy?
3073
Aruna Turaka
Results of Radiation Therapy for Primary Extranodal Lymphoma of
the Head and Neck: A Report of Case
Series
3074
Kiran Turaka
Vitreoretinal Lymphoma: Changing
Trends in Diagnosis and Local Treatment Modalities
3075
Matthew Hall
Radiation Therapy for Chloroma:
Treatment Outcomes and Prognostic
Factors
3076
Young Suk Kim
The Role Of Radiotherapy in the Management of POEMS Syndrome
142
3077
Guy Jones
Characterization of Unconventional
Response of Gray Zone Lymphoma to
Conventional Radiation Treatment
3078
Ji Hyun Kim
Extramedullary (EM) Relapse Following
Total Marrow and Lymphoid Irradiation (TMLI) in Patients Undergoing Allogeneic Hematopoietic
Cell Transplantation (HCT)
NON-MALIGNANT
3079
Waleed Mourad
The Impact of Radiotherapy (RT) Duration and Dose Per Fraction on
Long-term Outcomes in the Management of Benign Lymphoepithelial Cysts of Parotid
Glands in HIV Seropositive Patients
3080
Caleb Dulaney
Radiotherapy Prophylaxis for Heterotopic Ossification of the Elbow
Following Trauma or Recurrent HO
3081
Roshan Prabhu
Clinical Outcomes of Radiotherapy
as Initial Local Therapy for Graves’
Ophthalmopathy and Predictors of the
Need for Post-Radiotherapy Decompressive Surgery
3082
Jennifer Rosenberg
Long-term Outcomes of Patients
Treated With Gamma Knife Radiosurgery for Trigeminal Neuralgia
3083
Baldassarre Stea
Minimally Invasive Retrobulbar Episcleral Brachytherapy for Treatment
of Wet Age-related Macular Degeneration: Preliminary Results of a
Feasibility Study
PALLIATIVE CARE
3084
Brock Debenham
Multidisciplinary Prediction of Survival
in Advanced Cancer Patients
3085
Naoki Nakamura
Variability in the Point to Which Single
Direct Field Irradiation Is Prescribed for
Spinal Bone Metastases: A Survey of
Practice Patterns in Japan
3086
Marie-Adele Kress
Stereotactic Radiosurgery for Single
Brain Metastases From Non-small Cell
Lung Cancer: Progression of Extracranial Disease at Treatment
Correlates With Distant Intracranial
Control
3087
David Howell
Spare the Midline! Midline Scalp Dose
is Reduced Without Compromising
Brain Dose in Whole Brain Radiation
(WBRT) With Scalp Blocks. Whole
Brain Radiation Using Opposed Lateral
Fields With and Without Scalp Blocking: Dosimetric Considerations
3088
Carlo Furlan
Extended-field Tomotherapy for Multiple Painful Pelvic Bone Metastases in Breast Cancer Patients:
Feasibility and Toxicity
3089
Jeanny Kwon
Prognostic Factors for Patients With
Leptomeningeal Metastases From
Solid Tumor
3096
Vladimir Turkevich
Experience Of Treatment Painful Bone
Metastases With Magnetic Resonance
Guided Focused Ultrasound
3097
Mary Job
Rapid Response Radiation Therapist:
An Expanding Role in the Palliative Radiation Oncology Service in Australia
3098
Effective and Durable Palliation Using
a Novel Single Fraction Radiation
Therapy Approach for Merkel Cell
Carcinoma Metastatic Lesions
3099
John Suh
The Use of Spine Stereotactic Body
Radiation Therapy for the Treatment of
Spinal Cord Compression
3100
Franco Casamassima
Results of SBRT for 217 Consecutive
Oligometastatic Patients Treated With
Curative Intent
3101
Rachel Lei
A Prospective Investigation of Definitive Targeted Therapy for Solid
Malignancies With Oligometastases
3090
Nikola Cihoric
Clinically Significant Bleeding in Incurable Cancer Patients: Effectiveness of Hemostatic Radiotherapy
3102
Bevan Ly
Conventional vs. IMRT Planning for
Palliation of Bone Metastases: A Dosimetric Comparison
3091
Sonali Rudra
Patterns of Failure in Esophageal Cancer: What Is the Likelihood of
Limited Metastatic Failure?
3092
Daniel Golden
Linear-accelerator Based Stereotactic
Radiosurgery Outcomes for Melanoma
and Renal Cell Carcinoma Brain
Metastases
3093
Edward Jung
Repeated Stereotactic Radiosurgery
for Progressive Brain Metastases from
Melanoma After Initial Treatment
3094
Jovita Martin
Prompt Referrals and Timely Interventions Leads to Cost Effective
Palliation; Short vs. Long Course
Radiation for Response to Palliation: A
Single Institution Study in a Developing Country
3095
Taro Murai
Stereotactic Body Radiotherapy Using
Tomotherapy for Single or Multiple
Vertebral Metastases
3103
Ehsan Balagamwala
Higher Dose Spine Stereotactic Body
Radiation Therapy Is Associated With
Improved Pain Control in Radiosensitive Histologies
PEDIATRIC CANCER
3104
Nirav Kapadia
Assessment of Bone Growth Effects
Among Medulloblastoma (MB) Patients Treated With Electron vs.
Photon Spinal Irradiation
3105
Shalini Moningi
The Role of Adjuvant Therapy in the
Management of Low-grade Pediatric
Spinal Tumors: The Johns Hopkins
Experience
3106
Daniel Indelicato
Proton Therapy for Craniopharyngioma: Early Clinical
Outcomes
143
PALLIATIVE CARE/ continued
3107
Martin King
Parotid Gland As an Organ at Risk for
Craniospinal Irradiation
3108
Robert Marcus
One-year Quality of Life Results After
Proton Irradiation for Pediatric Brain
Tumors
3109
Ronica Hazariwala
The Role of Frameless Stereotactic
Radiosurgery in the Management
of Pediatric Central Nervous System
Tumors
3110
Michael Confer
Proton Radiotherapy for Pediatric
Craniopharyngiomas: Initial Results
3111
Christine Lauro
The Relationship Between Thyroid
Dose and Diagnosis of Primary
Hypothyroidism in Pediatric Brain
Tumor Patients Receiving Craniospinal
Irradiation
3112
Nataniel Lester-Coll
Proton Therapy for Sparing Fertility in
Girls Requiring Craniospinal Irradiation: Is Tthere a Role for
Ooophoropexy?
3113
Charles Hsu
Supratentorial Primitive Neuroectodermal Tumors (PNETs) and
Medulloblastoma in Children and the
Elderly: A Surveillance, Epidemiology
and End Results (SEER) Investigation of
Prognosis, Tumor Characteristics and
Predictors of Radiation Therapy
3114
Gustavo Ferraris
Impact of Radiation Techniques – 3-D
vs. IMRT – On Acute Toxicity and Local
Control in Patients With Rhabdomyosarcoma
3115
Zhong Su
Pediatric Chest Wall Ewing Sarcoma: A
Retrospective Dosimetric Study of 3-D
Conformal Proton Therapy and IMRT
3116
Kyle Denniston
Factors Influencing Five-year Overall
Survival in Patients With the Ewing
Sarcoma Family of Tumors
144
3117
Joanna Yang
Dose Painting Intensity Modulated
Radiotherapy for Pediatric Sarcomas
With Lung Metastases
3118
Jenna Kahn
Radiation Therapy in Management of
Sporadic and Neurofibromatosis Type
1 (NF1) Associated Malignant Peripheral Nerve Sheath Tumors
(MPNST)
3119
Monica Roca
Dosimetric Comparison of Photon and
Proton Radiotherapy for Unresectable
Ewing Sarcoma of the Pelvis
3120
Nancy El-Bared
Preoperative Intensity Modulated
Radiation Therapy for Retroperitoneal
Sarcoma
3121
Charlotte Demoor-Goldschmidt
Respiration Gated-radiotherapy for
Bilateral Pulmonary Radiation In Paediatric Cancers : Benefits on the
Liver
3122
Josefine S. Kornerup
Influence of PET Data on the Radiation
Therapy Planning of Pediatric Cancer
3123
Douglas Prah
Cardiac Sparing by Respiratory-Gating
During Whole Abdominal Irradiation Using 3-D CRT for Wilms’ Tumor
Patients
3124
Kavita Dharmarajan
for Palliation in Relapsed Neuroblastoma
3125
Hiroshi Fuji
Assessment of the Organ-dose Reduction and Secondary Cancer Risk
Associated With the Use of Proton
Beam Therapy and Intensity Modulated Radiation Therapy in Treatment of Neuroblastoma
3126
Miho Watanabe
Delayed Renal Dysfunction After
Total Body Irradiation in Pediatric
Malignancies
3127
Jordan Kharofa
Feasibility of Cardiac Sparing Splenic
Irradiation Using IMRT for Pediatric
Patients Enrolled on the COG High-risk Hodgkin’s Lymphoma Protocol AHOD0831
3128
Joella Wilson
A Comparison of Traditional vs.
Response-based Involved-field Radiotherapy on Clinical Target Volume and Organs at Risk for
Pediatric Rapid Early Responders with
High-risk Hodgkin Lymphoma
3129
Charlotte Birk Christensen
PET/CT in Radiation Therapy Planning
of Malignant Tumors in Children:
Impact on Gross Tumor Volume
3130
Chika Nwachukwu
Optimal Spot Scanning Treatment
Plans in Infants With Brain Tumors in
the Posterior Fossa
3131
Daniel Arsenault
Do Pediatric Patients Have Equal Access to Proton Beam Therapy?
3132
Justin Peacock
Optimal Spot Scanning Treatment
Plans for Centrally Located Infant Brain
Tumors
3133
Douglas Rahn
Clinical Outcomes of Palliative
Radiotherapy for Children: 5-year
Institutional Data
QUALITY OF LIFE
3134
Denise Rollmann
Double- Blind, Placebo-controlled Pilot
Study of Processed Ultra Emu Oil vs.
Placebo in the Prevention of Radiation
Dermatitis
3135
Ashley Burt
Comparison of Methods for Eliciting
Multiattribute Utilities for Prostate
Cancer
3136
Todd Carpenter
Quality of Life With Adjuvant Radiotherapy Following Transoral
Robotic Surgery (TORS) for Head and
Neck Cancer
3137
Silke Tribius
Dry Mouth and Sticky Saliva: Quality
of Life Domains Most Affected in the
Acute Toxicity Phase of Radiation
Therapy
3138
Arbind Dubey
Effect of Insomnia on Patient’s Well
Being During External Radiation in
Outpatient Radiation Oncology Clinic
3139
Andrew Lee
Multi-institutional Patient-reported
Quality of Life After Proton Therapy for
Prostate Cancer Compared to Non-treated Men
3140
Sumit Sood
(SBRT) for Clinically Localized Prostate
Cancer: Endoscopic Outcomes, Rectal
Toxicity and Quality of Life
3141
Tzu-I Jonathan Yang
Risk Factors Associated With Sacral
Fractures After Pelvic Radiotherapy for
Rectal Cancer
3142
Tsz Kin Lee
Systematic Review of Epic Quality
of Life Data After Prostate Cancer
Treatment
3143
Afshin Rashtian
Radiation Dose to the Parotid Glands
in Patients Receiving Whole Brain
Radiation Therapy (WBRT)
3144
Cristina Cigarral Garcia
Psychosocial Distress Among Patients
With Lung Cancer: An Approach to
Assessment and Intervention
3145
Piotr Milecki
Comparison of Quality of Life in
Patients With Locally Advanced Head
and Neck Cancer Prior and 1 Year After
the Completion of Radiotherapy
3146
Shrinivas Rathod
Change in Health Related Quality of
Life Scores Predict Survival in Head
Neck Squamous Cell Carcinoma
Treated With Definitive High Precision
Radiation Therapy: Evidence From a
Prospective Study
3147
Anna Likhacheva
Patient-reported Acute Symptoms
During Chemoradiation for Cervical
Cancer
3148
Rashmi Koul
Determinants of Quality of Life and
Depression in Patients Undegoing
External Beam Radiation
3149
Sherry Soeder
Outcomes of Spine Stereotactic
Body Radiation Therapy in Patients
Previously Treated With Conventional
Radiation
3150
Curtis Bryant
Does Race Influence Quality of Life,
Toxicity or Early Relapse Following
Proton Therapy in Men With Prostate
Cancer?
3151
Todd Adams
Markov Model Comparing Breast Conserving Therapy With Mastectomy
3152
Raju Raval
Gabapentin Therapy for Prevention
and Management of the Pain Syndrome in Oropharyngeal Carcinoma Patients Treated With
Radiation: A Retrospective Study of
the Johns Hopkins Experience
3158
Christopher Barker
Tolerance and Efficacy of Extra-cranial
Radiotherapy During Ipilimumab Immunotherapy for Metastatic Melanoma
3159
Josephine Kang
Management of Atypical Lipomas With
Radiation
3160
Nora Kramkimel
Preliminary Results of the Use of
Helical Tomotherapy (HT) in Advanced
Non-Melanoma Skin Cancers: The
Institut Curie Experience
3161
James Jackson
Melanoma Brain Metastases: The
Impact of Nodal Disease
3162
Omitting Post Operative Radiotherapy
in Selected Cases of Merkel Cell Carcinoma: When is it safe?
3153
Elizabeth Klein
Quality of Life in Neuro-oncology:
Presence at National Meetings
3154
May Abdel-Wahab
Does Radiation Technique Influence
Peg Dependence? A Comparison
Between Intensity Modulated Radiation Therapy and Three-dimensional Conformal
Techniques
3155
Lin Wang
The Impact of Cystoscopy on the
Quality of Life in Men Undergoing
Permanent Prostate Brachytherapy
3156
Alireza Fotouhi Ghiam
Hyperbaric Oxygen Treatment,
Alpha-tocopherol and Ascorbic
Acid Are Effective for Reducing Late
Radiation-induced Side Effects of
Pelvic Radiotherapy
3157
Ehsan Balagamwala
Treatment of Three or More Contiguous Vertebral Bodies With
Spine Stereotactic Body Radiation
Therapy
SARCOMA AND SKIN CANCER
3163
Yoshitaka Miki
Impact of Chemoradiotherapy Using
Docetaxel for Treatment of Scalp
Angiosarcoma
3164
Anna Cooper
Primary Soft-tissue Sarcomas: Predictors of Local Disease Recurrence,
Distant Metastasis and Overall Survival
After Limb-sparing Surgery and Radiotherapy
3165
Niraj Mehta
Safety and Efficacy of Stereotactic
Body Radiation Therapy for Pulmonary Metastases From High-Grade Sarcomas
3166
Josephine Kang
Management of Metastatic Melanoma
With Stereotactic Body Radiotherapy
3167
Jessica Rooney
Post Operative Radiation Therapy
in Merkel Cell Carcinoma: The Mayo
Clinic Experience
3168
Mersiha Hadziahmetovic
Multifocal Scalp Angiosarcoma
With Regional Metastases: SCUBA
Technique for Homogenous Scalp and
Regional Nodal Irradiation
145
QUALITY OF LIFE/continued
3169
Matthew Spraker
An Analysis of Patient Characteristics
and Clinical Outcomes in Primary
Pulmonary Sarcoma
3170
Ashley Burt
Treatment of Chest Wall Sarcomas:
A Single Institution Experience Over
Twenty Years
3171
Jun Won Kim
High Dose Radiotherapy After
Surgical Resection for the Management of Chordoma of the Skull Base:
Early Clinical Experience With Helical
Tomotherapy
3172
Fazilet Dinçbaş
The Prognostic Factors And Results
of Neoadjuvant Treatment Protocol
in Extremity Soft Tissue Sarcomas: A
Monoinstitution Results
3173
Andrew Sharabi
Analysis of Cone Beam-CT Shifts in
Image Guided Radiation Therapy for
Abdominopelvic Soft Tissue Sarcomas
3174
Mark Stavas Stavas
Treatment Approach and Outcomes in
Patients With Extra-cranial Hemangiopericytoma
3175
Darwin Yip
Electron Therapy for Non-Melanoma
Skin Cancers: Computer Simulated
Bolus vs. Actual Physical Bolus for
Treatment Planning
3176
Monica Serban
Dose Escalation Based on MR-PET/CT
for Soft Tissue Sarcoma
3177
Shilpa Vyas
Initial Experience With Three-dimensional Topographic
Applicator Brachytherapy for Treatment of Non-melanoma Skin
Cancers on the Nose and Ear
INFORMATICS/
BIOINFORMATICS
RADIATION AND CANCER
BIOLOGY
3178
Ewa Szumacher
Opinions From the Experts: What
Prostate Cancer Patients Should Know
About Post-operative Radiotherapy
3179
Yutaka Ando
How did the particle therapy grow in
Japan? Current Status of Proton and
Carbon Ion Radiotherapy From 1979 to
2011 in Japan
3188
Andrew Vaughan
Next Generation Sequencing as a Tool
to Track Low-dose Effects Linked to
Transformation
3180
Ajay Tejwani
Assessing The “Readability” of Websites
Regarding Lung Cancer Diagnosis and
Treatment Information
3190
Samuel Bakhoum
Examining the Cellular Mechanisms
of Chromosomal Instability As Means
for Enhanced Radiation-induced
Cytotoxicity
3181
Sachin Jhawar
All Atwitter About Radiation Oncology: A Content Analysis of
Radiation Oncology-Related Traffic on
Twitter
3182
Russell Fuhrer
Quality Control Trigger: A Quality Assurance Process in Radiation Oncology
3183
Ajay Kapur
An Audit Of Treatment Overrides in a
Paperless Radiation Medicine Department
3184
James Sinicki
Your Safety, Our Commitment: A
Standardized Error Reporting Enabling
a Culture of Patient Safety
3185
Ankit Agarwal
Medical Student Education in Radiation Oncology: A Multi-year
Analysis of the Oncology Education
Initiative
3186
Pin-Chieh Wang
Implementation of a Comprehensive
Radiation Therapy Registry: Focus on
Feasibility and Reliability
3187
Andrew Sharabi
Automated Cross-referencing of
Radiation Prescriptions to Diagnosis:
A Proposed Mechanism to Improve
Patient Safety
3189
ShengJun Ji
Whole Brain Irradiation Induced
Decrease of Histone H3 Acetylation in
Hippocampus of Rats
3191
Jacqueline Williams
Revisiting Inflammation As a Target for
Normal Tissue Damage Mitigation: Interplay Among Interleukin Expression, Parenchyma and Inflammatory Cells in Lung Effects
3192
Shin-ichiro Masunaga
Radio-sensitivity of Pimonidazoleunlabeled Intratumor Quiescent Cells
to Gamma-rays, Accelerated Carbon
Ion Beams and Boron Neutron Capture
Reaction
3193
Cheng-Chia Wu
The Role of Prostate Cancer 20-HETE in
Tumor Vasculature
3194
Thomas Klein
Ras Promotes Non-autonomous Cell
Death in Response to Radiation: Insights From a Novel Drosophila-Based Model of Radiotherapy
3195
Tao Wang
ERK1 Meddiated Epithelial-Mesenchumal Transition
and Neuroendocrine Development in
Prostate Cancer Cells that Survive High
Dose Ionizing Radiation
3196
Guillem Pratx
Radioluminescence Microscopy: A
New Tool to Characterize Heterogeneous Radiopharmaceutical
Uptake in Living Cells
146
3197
Zhibin Huang
The Kinetics of Repair of Sublethal
Damage in Rat Cervical Spinal Cord
During Fractionated
Irradiation - Application of the gLQ
Model with Reciprocal Time Pattern
3198
Pamela Boimel
MicroRNA-375 Expression Correlates
With Increased Radiosensitivity, Decreased Invasion and Improved
Patient Survival in Head and Neck
3199
Catherine Park
Ionizing Radiation Modifies Tissue Tension, Mechanosignaling and Apoptosis in Human Breast
3200
Kumara Swamy
Evaluation of Immunological Changes
in Patients Treated With SBRT and
Radiotherapy: A Prospective Cohort
Study
3201Govindarajan
Mallarajapatna
Apparent Diffusion Coefficient (ADC)
Value on MR Imaging As a Marker
of Treatment Response in Prostate
Cancer
3202
Ping Wang
PI3K/AKT Signaling Pathway in the
Regulation of Non-small Cell Lung
Cancer Radiosensitivity After Hypofractionated Radiotherapy
3203
Jing Huang
Convergence of Divergent Tumors: A
Systems Biology Approach of Tumor-specific Signaling
3204
Masahiko Okamoto
Radiation-induced HIF-1α Induces
Radioresistance and Enhances the Migration Abilities in Glioblastoma
Cells Through Pten-src-hif-1α Signaling
Axis
3205
Brandon Dyer
Hypoxic and Reperfusive Responses
Are Selectively Altered During Non-small Cell Lung Cancer Progression
3206
Hitoshi I shikawa
The Impact of Radiation-induced
Up-regulations of Ifn-γ on Local Tumor
Control of Malignant Melanoma in
Vivo
3207
Carsten Herskind
A Role for a Bystander Effect in Cell
Inactivation After Large Single Doses?
3218
Anne Kiltie
Differential Roles of DNA Repair Proteins in the MMEJ Phenotype
3208
Karl Butterworth
Differential Mechanisms of Cellular
Radiobiological Response Following Exposure to Intensity Modulated Radiation Fields
3219
Sara Samiee
Dicentric Chromosome Assay: A Potential in Vitro Biomarker for
Radiosensitivity
3209
Vivek Patel
IMP1 Consensus Recognition Elements
Identify Transcripts Affecting Tumor
Cell Survival After Ionizing Radiation
3210
Iman Washington
p21 Functions to Prevent Radiation-Induced Myocardial Injury in
Mice
3211
Michael Epperly
Irradiation Induction of mRNA for
Redox-Sensitive Promoters and
Inflammatory Cytokines in Conditional
Manganese Superoxide Dismutase
(MnSOD) Tet On -/- Mouse Bone Marrow Stromal Cells
3212
Adam Schmitt
O6-methylguanine DNA Damage Signals Through Nfkb1/p50 to
Potentiate DNA Strand Break-induced
Cytotoxicity
3213
Sarah Krueger
The Role of Bone Marrow-derived Progenitor Cells in the Systemic
Response to Radiation-induced Lung
Damage
3214
Michael Epperly
Irradiation-induced Inhibition of Bone
Repair in SAMP6 and SAMR1 Mice
3215
David Fried
Estimating the Alpha/Beta Ratio for Radiation-Induced CT Density
Changes in Patients Receiving Thoracic
Radiation: Comparison of Data from
SRS and Conventional Fractionation
3216
Ikuno Nishibuchi
Reorganization of Damaged Chromatin by the Exchange of Histone
Variant H2A.Z-2
3217
Liping Liang
MiR-223 Modulates Radiosensitivity of
U87-MG Cells Through Targeting ATM
3220
Hui Zhang
SIRT2 Directs the Replication Stress Response Through CDK9 Deacetylation
3221
Sara Chiblak
Photon vs. Proton vs. Carbon Irradiation of Glioma Initiating Cells
3222
Michael Epperly
Oral Delivery of Mitochondrial
Targeted GS-Nitroxide JP4-039 Protects Fanconi Anemia (FA) D2 -/Mice From Irradiation Mucositis
3223
Michael Epperly
Induction of MnSOD Expression in
MnSOD Tet On -/- Murine Bone Marrow Stromal Cell Lines Correlates
With Temporal Radiation Resistance
3224
Michael Epperly
Elevated Pulmonary MnSOD and
Endothelial Gene Expression Heralds
the Onset of Irradiation Fibrosis
3225
Matthew Janko
IL-1 Generated Subsequent to
Radiation-induced Tissue Injury
Contributes to the Pathogenesis of
Radiodermatitis
3226
Michael Bassetti
CD24 Regulates Radiation Induced
Lung Damage and Neutrophil Accumulation
3227
Ola Maria
Mesenchymal Stem Cells for Recovery
From Radiation-induced Lung Injury
3228
Michael Epperly
MMS350: A Novel Bifunctional Sulfoxide With Radiation Protection
and Mitigation Properties
3229
Julie Goff
Identification of Ionizing Irradiation
Damage Mitigators by Evaluation of
Clonogenic Survival of Human Umbilical Cord Blood Progenitor Cells
147
BIOLOGY/continued
3230
Liangjie Yin
A Potent Amino Acid Mixture to Mitigate Radiation-induced Gastrointestinal Toxicity
3231
Abigail Milby
Phase I Randomized Trial of Dietary
Flaxseed in Non-small Cell Lung Cancer Patients Receiving Chemoradiation
3232
Jun Won Kim
Development of a Porcine Skin Injury
Model and Characterization of Dose-dependent Response to High-dose Radiation
3233
Zhenhuan Zhang
The Antitumor Effects of MRx102:
Novel, Potent and Synergistic
3234
Ross Mikkelsen
Polymorphisms In Genes Involved in
Nitric Oxide (NO) Signaling and the
Risk for Late Normal Tissue Injury From
Radiation Therapy (RT)
3241
Sei Sai
The Role of XRCC4 in Sensitizing
Human Colon Cancer Stem-Like Cells
to X-ray or Carbon Ion Beam
3242
Paul Romesser
Correlation of Brachial Plexus Dose
With Gross Tumor Volume in Head and
Neck IMRT
3243
Hiromitsu Iwata
Compatibility of the Repairable Conditionally-repairable, Multi-target
and Linear-quadratic Models in Converting Hypofractionated Radiation Doses to Single Doses
3244
Mahmoud Moustafa
Comparison of Photon versus Carbon
Irradiation in Pancreatic Cancer
3245
Masatoshi Hasegawa
Gene Expression Profiles Induced by
Carbon Ion Beams and X-rays in Human Brain Tumors
3246
Masayuki Matsuo
Chronic and Cyclic Hypoxia in Fractionated Radiation Therapy
3253
Shihong Ma
Depletion of Regulatory T Cells Does
not Influence the Inflammatory
Response Induced by High-dose
Irradiation
3254
In Ah Kim
Enhancement of the Radiosensitizing
Effect of Temozolomide: Targeting
EGFR-associated Signaling in Malignant Glioma Cells
3255
Satoshi Harada
Imaging of Premetastatic Sites and
Prophylaxis of Metastasis Using
Radiosensitive Nanocapsules Via
Radiotherapy
3256
Andrew Wang
Development of a Novel Nanoparticle
Formulation of Cisplatin to Improve
Chemoradiotherapy
3257
David Guttmann
Preclinical Investigation of Hsp27 LNA
As a Novel Radiosensitizer in Head and
Neck Cancer
3258
Withdrawn
3235
Jennifer Sattler
Potentiation of Radiation-induced Cell
Death in PC3 Prostate Cancer Cells by
Genistein and the Soy Food Miso
3247
Sean McDermott
Potential of Dynamic 18F-FDG PET Parameters for Use in Biological Adaptive Treatment Planning
3259
Caitlin Abidin
Autophagy Inhibition by Chloroquine
Radiosensitizes Colorectal Cancer Cells
to Radiation Therapy
3236
Zeljko Vujaskovic
Cerium Oxide Nanoparticles Protect
Lung from Radiation-induced Injury in
CBA/J Mice
3248
Yuan-Chia Kuo
Liposome-based Nanoprobe With
Antibody Conjugation Combined
With MRI Contrast Encapsulation As a
Potential Diagnostic and Therapeutic
Agent for Human Head and Neck
Cancer Cells
3260
Noriyuki Okonogi
Cranial Irradiation Induces Migration
of Bone Marrow Derived Microglia
(BMDM) to the Cerebellum in Adult
C57BL/6 Mice
3237
Leo Gerweck
Out of Field Cancer Risk in Mice Following Exposure to a Clinical Proton
Beam
3238
Rui Sun
Effect of Low-dose Radiation on Cognitive Function of Rats at Different
Ages
3239
Joshua Walker
Effects of Total Body Irradiation on
T-Cell and B-Cell Subsets as Well as
Macrophage in Rhesus Macaque
3240
Thomas Schmid
Relative Biological Effectiveness of
Single-shot Irradiation With Laser-driven Nanosecond Proton
Bunches
3249
Chun-Chieh Wang
Diffusion-weighted MRI and FDG PET/
CT As Predictors of Tumor Treatment
Response in Patients With Cervical
Cancer Receiving Chemoradiotherapy
3250
Yi-ping Lin
Detecting a Geometric Miss by
Dynamic Contrast-enhanced Magnetic
Resonance Imaging
3251
Chiwei Hung
Multifunctional Molecular Probes for
Targeting and Imaging of Epidermal
Growth Factor Receptor
3252
Magdalena Bazalova
X-ray Imaging beyond Transmission
CT: Detecting Low Concentrations of
Gold Nanoparticles
3261
Hiroki Ushjima
Radiosensitizing Effects of mTOR Inhibitor (Temsirolimus) under Normoxic/Hypoxic Conditions
3262
Takahiro Oike
Garcinol, a Histone Acetyltransferase
Inhibitor, Radiosensitizes Cancer Cells
by Inhibiting Non-homologous End
Joining
3263
Michael Foote
Nanoparticle Formulation of KU55933
as a Novel Radiosensitizer
3264
Lujun Zhao
Inhibition of TGF-β1 Signaling With
Halofuginone Can Enhance the Anti-tumor Effect of Irradiation in Lung
Cancer Xenograft
148
3265
Paul Medin
Unexpected Paralysis in a Swine Model
Suggests a Tolerance Constraint for
Single-fraction Spinal Nerve Irradiation
3266
Yuya Yoshimoto
Requirement of Anti-tumor Immunity
and Enhancement by CTL-associated
Antigen-4 Blockade on Therapeutic Efficacy of Radiation Therapy in a
Mouse Tumor Model
3267Withdrawn
3268
Koh-ichi Sakata
The Combination of Olaparib and
Camptothecin Effectively Sensitize
Radiation
3269
Corey Speers
Intra-treatment Changes in RAD51
Foci Formation Predict Radiosensitization by PARP1 Inhibition
in Breast Cancer Cell Lines
3270
Naoya Ishibashi
An Iodine Labeled Porphyrin As a New
Radiosensitizer in Vitro and Vivo, Combining Photodynamic Therapy
(PDT) and Photon Activation Therapy
(PAT)
3271
Joshua Dilworth
Pulsed Low-dose-rate vs. Standard
Irradiation in Orthotopic Glioblastoma
Multiforme: Dose Escalation, Functional Imaging and the Small
Animal Radiation Research Platform
3272
Roberto Diaz
Ganetespib, an HSP90 Inhibitor, Sensitizes Colorectal Cancers to the
Effects of Ionizing Radiation
3273
Te Vuong
Targeted Treatment With Anti-egfr
Antibodies and Radiation Therapy for
Patients With Squamous Cell Carcinoma of the Anal Canal: Rationale
for a New Treatment Strategy
3274
Jenna Kahn
The mTORC1/mTORC2 Inhibitor
AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells
3275
Jennifer Yu
Hyperthermia Sensitizes Glioblastoma
Stem Cells to Radiation
3276
Gopal Abbineni
S-PAC-1, A Small Molecule Activator of
Procaspase 3, Sensitizes Human Breast
Cancer and Other Cell Lines To Ionizing
Radiation
3277
Savita Dandapani
Potential Role of Novel Wnt Modulator
ICG-001 As a Radiosensitizer In
Glioblastoma Cell Lines
3278
Ning Cao
Monitoring the Radiosensitizing
Effects of Implantable Micro-oxygen
Generator in Pancreatic Cancer
Xenografts
3279
Randall Kimple
Direct-from-patient Tumorgrafts of
Head and Neck Cancers: Preclinical
Models for Evaluating Chemoradiation
3280
Christopher Corso
Evaluating the HSP90 Inhibitor `
Ganetespib as a Radiosensitizing
Agent in Breast Cancer Models in Vitro
3281
Susan Higgins
The Standardized Herbal
Formulation PHY906 Decreases the
Toxicity of Abdominal Irradiation in
Mice
3282
Masao Nakayama
Novel Radiosensitization Through
Reactive Oxygen Species Generation
Using Titanium Peroxide Nanoparticle
Compounds Against Pancreas Cancer
3283
Guangying Zhu
New Gene Miip Enhances
Radiosensitivity of Lung
Adenocarcinoma Cell in Vitro and in
Vivo
3284
Florence Perillo-Adamer
Glioblastoma Expressing MGMT:
Contribution of PaTrin-2 in
Radiotherapy With Temozolomide
3287
Hiroaki Akasaka
Efficacy of Surgically Implanted Flexible Spacer in Particle Therapy:
A Novel Strategy Making Temporal
Space Between Tumor and Adjacent
Organs
3288
Bryan Allen
High Dose Ascorbate Enhances
Chemo-radio-sensitization in GBM
3289Withdrawn
3290 Withdrawn
3291
Gilda Hillman
Radioprotective Effects of Soy Isoflavones on Normal Lung Tissue
Could Translate to Improve Radiotherapy Outcome of Lung Cancer
3292
Aisha Fasih
Metformin As a Radiosensitizer in
Pancreatic Cancer Cells
3293
Gilda Hillman
Enhanced Therapeutic Efficacy by Radiotherapy Combined With Axitinib
in a Pre-clinical Model of Lung Carcinoma
3294
Zili Tang
Glioma Invasion Confers Radioresistance
3295
Natalie Cummings
Preclinical Evaluation of a Polymeric
Nanoparticle Micelle Formulation of
Paclitaxel (genexol-pm) As a Radiosensitizer
3296
Michael Siedow
Anti-EGFR/Radiation Therapy Enhanced Through Galectin-1 Suppression in Nsclc
3297
Dennis Hallahan
A New Use of Radiation to Ignite an
Immune Response to Cancer
3285
Mohamed Abazeed
Development of a High-throughput
Platform for Measuring Radiation
Response
3298
Claudius Melzig
Beneficial Effects of Combined
Antiangiogenesis and Heavy Ion
Radiotherapy
3286
Dhwani Parikh
Des-methyl, Des-amino pateamine A, a
Synthetic Analogue of Marine Natural
Product Pateamine A, Sensitizes Non-small Cell Lung Cancer Cells to Radiation and Enhances BAX
Expression
3299
Blaz Groselj
The HDAC Inhibitor Panobinostat Promotes Expression of ∆133p53 Variants in TP53 Wild Type Bladder
Cancer Cells
149
BIOLOGY/continued
3300
Ying Dai
Combined ALK-inhibtion and Radiotherapy in Lung Cancer
3301Withdrawn
3302
William McBride
Investigation of Radiation Therapy
Response Enhancement of DC Magnetic Fields
3303
C.M. Charlie Ma
In Vivo Investigation of Non-thermal
Pulsed Focused Ultrasound for Prostate and Breast Cancer Therapy
3304
Roger Macklis
Alpha Particle Radiobiology for
Radium-223 (“Alpharadin”): The
Fortuitous “Goldilocks” Effect Observed
for Hormone-Resistant Metastatic
Prostate Cancer
3305
Yaacov Lawrence
NCI-RTOG Translational-program
Strategic Guidelines for the Early Stage
Development of Radiosensitizers
3306
Philip Blumenfeld
The Lag-time in Initiating Clinical Testing of New Drugs in Combination
With Radiation Therapy, a Significant
Barrier to Progress in Radiation Oncology
3307
Mitra Heravi
Combination of Ionizing Radiation and
DNA/ EGFR Binary Targeting Molecule
Delays DNA Double Strands Repair
3308
Tod Speer
Feasibility of the Systemic Cure of
Cancer With Targeted Radionuclide
Therapy (TRT)
3309
Chaitanya G. Joshi
Transcriptome Analysis of Human Buccal Mucosal Cancer
3310
Janet Horton
Gene Expression Response to Ionizing
Radiation in Luminal and Basal Breast
Cancer Cell Lines
3312
William Hall
C-Reactive Protein (CRP): Initial Exploratory Study of an Inflammatory Biomarker for Prostate
Cancer Radiotherapy
3313
Jan Akervall
Gene Expression Characterization of
Chemoradiation Treatment Failure in
HPV16 Positive Head and Neck Squamous Cell Carcinoma
3314
Dukagjin Blakaj
Characterization of Human Papillomavirus 16 Variants in Head
and Neck Squamous Cell Carcinoma
Patients
3315
George Wilson
The Role of CD44-Associated Stem
Cells in the Recovery of Head and Neck
Squamous Cell Carcinoma Following
Radiation
3323
Anne Kiltie
Predictive Biomarkers for Gemcitabine
As a Chemoradiosensitiser in Bladder
Cancer
3324
John Jarboe
Marcks Regulates Growth, Radiation
Sensitivity and Is a Novel Prognostic
Factor for Glioblastoma
3325
Jennifer Jones
nanoFACS: A New Tool for Studying
Tumor- and Treatment-Associated
Exosomes and Microparticles
3316
Nelson Leong
Single Nucleotide Polymorphisms
(SNPs) Associated With Late Radiation Urinary Toxicity After Prostate Brachytherapy
RADIATION PHYSICS
3317
Matthew Parliament
Single-Nucleotide Polymorphisms
(SNPs) Associated With Radiation
Proctitis From Genome-wide False
Discovery Rate Analysis
3327
Bassel Kassas
Assessment of Using Endorectal Balloon in Prostate Radiotherapy on
Daily Kilovoltage Cone Beam Computed Tomography Localization
3318
Scott Bratman
Cell-free DNA As a Biomarker of Residual Disease Following Radiotherapy for Non-small Cell Lung
Cancer
3328
Ivan Buzurovic
Effects of Tumor Tracking Errors to the
Quality of Radiation Treatment
3319
Bassem Zaki
Determination of Predictive Markers
of Chemoradiation Sensitivity and
Resistance of Rectal Tumors
3320
Michael Chin
Hyperspectral Imaging for Early Prediction of Chronic Microvascular
Injury in Irradiated Skin
3321
Wendy Woodward
EZH2 Expression Correlates With Locoregional Recurrence After Radiation in Inflammatory Breast
Cancer
3311
Tomasz Rutkowski
The Role of Biochemical Markers in
Prediction of Radiotherapy Failure for
Patients With Head and Neck Cancer
150
3322
Dong Wook Nathan Kim
Loss of Tumor Suppressor DAB2IP Correlates With Decreased Biochemical
Recurrence Free Survival in High-risk
Prostate Cancer Patients Treated With
Radiation Therapy
3326
John McGary
Electromagnetic Tracking for TomoTherapy Systems
3329
Shinichi Ueda
Evaluation of Prostate Motion and
Optimum Planning Target Volume
(PTV) Margin in Prostate Intensity
Modulated Radiation Therapy (IMRT)
Based on Fiducial Markers Using Two
Modern, Online Image Guided Radiation Therapy (IGRT) Systems
3330
Ryan Foster
An Analysis of SBRT Localization Errors
and Intrafraction Motion Using CBCT
3331
Kiyonori Shirai
Maximum Intensity Projection (MIP)
and Average Intensity Projection (AIP)
in Image Guided Stereotactic Body
Radiotherapy (SBRT) for Lung Cancer
3332
Anoop Haridass
Customised MoldCare Head Cushions
Reduce Patient Movement During
Intracranial Cyberknife Radio Surgery
3333
Mingyao Zhu
Is the Prostatic Bed a Rigid Structure?
Evaluation Using Real-time Electromagnetic Tracking
3334
Troels Bjerre
A Feasible Real-time Multi-plane MRI-linac Guidance Strategy
3335
Irina Vergalasova
Impact of Patient Anatomy Variations
on a Fourier Technique for Markerless
4D-CBCT
3336
Masahiro Yamada
Dependency of Imaging Conditions on
a Marker Detectability Using kV X-ray
Images in the Tracking Irradiation With
Vero 4-D RT (MHI-TM2000)
3337
Shifeng Chen
Respiratory-induced Setup Errors
Should Be Considered for Patients
With Tumor Affected by Respiratory
Motion and Treated With free
breathing IGRT: A pilot study on
Patients With Pancreatic Head tumor
3338
Jean Peng
The Assessment of Interfraction and
Intrafraction Setup Error With Open
Thermoplastic Masks for Head and
Neck Cancer Using CBCT and 3-D
Surface Imaging System
3339
Songbing Qin
Motion Pattern for Liver Tumor and Its
Correlation to External Surrogates
3340
Jason Samuelian
High-field Open 1.0 T Magnetic
Resonance Imaging Simulation for
Radiation Treatment Planning in
3341
Jin Wang
Positioning Accuracy and Efficacy of
Different Correction Protocols Based
on kV-Cone beam CT Guidance for
Abdominal Pelvic Radiotherapy
3342
Norio Katoh
Real-time Tumor-tracking
Radiation Therapy for Lymphoma Of
The Stomach
3343
Chi Wah Kong
Amplitude Restricted RPM Technique
for Lung Cancer Radiotherapy
3344
Zejian Liu
Evaluation of the Dosimetric Effect of
Patient Daily Setup Variations Suring
Strut-Adjusted Volume Implant (SAVI)
Breast Brachytherapy
3356
Dengwang Li
Tumor Tracking for Adaptive Radiation
Therapy System by Multi-resolution
Wavelet Deformable Registration
Framework
3345
Marco Trovo
Fiducial Markers for Image-Guided
Partial Breast Irradiation
3357
Bo Lu
A Patient Alignment Solution For Lung
SBRT Setups Based on a Deformable
Registration Technique
3346
Yingjie Zhang
A Study on the Contribution of
Respiratory and Heart-beat to the
Displacement of Mediastinal Lymph
Nodes Based on 4-D CT
3347
Yingjie Zhang
Displacement of Liver Cancer and Interested Structures During Respiration Detected by 4-D CT And
3-D CT
3358
Bernard Jones
Dosimetric and Deformation Effects
of Image Guided Interventions During
of the Prostate Using an Endorectal
Balloon
3359
George Ding
Methods to Account for Additional
Imaging Dose in the Era of IGRT
3348
Indra Das
Dosimetric Impact of Gastric and
Bowel Air Column in IMRT for Pancreatic Cancer
3360
Gabriella Pastore
Correcting Rotational Errors by Couch
Translations Can Lead Dosimetric
Uncertainties on the Dose to OARs
3349
Christie Lin
Shape Distribution-based 2-D/3-D
Registration for Fast And Accurate
6 Degrees-of-freedom Stereotactic
Patient Positioning
3361
Lindsay Jensen
Magnitude and Agreement of Cone
Beam Computed Tomography Shifts
for Patients With Intact and Post-operative Prostate Cancer
3350
Wu Liu
Feature-based Automatic Real-time
Tumor Motion Monitoring With or
Without Fiducial Markers
3362
Sean Vance
Evaluation of Breathing Excursion Variability in Lung Cancer Patients During Conventional and Hypo-fractionated Radiotherapy
3351
Hania Al-Hallaq
An Image-Guided Study of Setup
Reproducibility of Chestwall Patients
Treated With Inverse-planned IMRT
3352
Jun Lian
Influence of Patient Setup and Target
Delineation on Air Cavity Tomotherapy
Dosimetry
3353
Terence Sio
S-frame versus BodyFIX: A Comparison of Immobilization Techniques for Upper Lung Tumors
With Stereotactic Body Radiotherapy
3354
Craig Hullett
Impact Of BMI on Daily Setup Variation
With Pelvic Radiotherapy: Is Prone
Positioning a Class Solution?
3355
Sang Gyu Ju
Development of a Video Guided
Real-time Patient Motion Monitoring
System for Helical Tomotherpay
3363
Jun Zhou
Head and Neck Patient Setup Using
3-D Surface Matching: Accuracy and
Performance Analysis
3364
Ruijiang Li
Accurate Real-time Tumor Localization From Respiratory Surrogates Via Memory-Based Learning
3365
Sara Alcorn
Multi-site Assessment of the Utility of
Daily Cone Beam CT in Achieving Clinical CTV-PTV Setup Margin
3366
Tanja Langsenlehner
Role of Residual Set-up Errors and
Intrafraction Motion in the Evaluation
of Planning Target Volume Margins for
Prostate Cancer Radiotherapy
151
RADIATION PHYSICS/
continued
3367
Joo Hwan Lee
Weekly Position, Volume and Dosimetric Changes During Image
Guided Radiation Therapy With Kilovoltage CT-on-Rail for Head and
Neck Cancer
3368
Mitsuhiro Inoue
Estimation of Clinical Error With Respiratory Motion Tracking of the
Image Guided Robotic Radiosurgery
System
3369
Andrew Perkinson
Assessment of the Benefit of MRI
Immobilisation for Deformable Image
Co-registration for Head and Neck
Radiotherapy Planning
3370
Richard Speight
Assessment of Accuracy and Reproducibility of Automatic Deformable Image Registration for
Head and Neck Radiotherapy
3371
Marianne Falk
A Dosimetric Comparison of MLC
Tracking and Gated Delivery of Arc
Therapy to a Moving Target
3377
Gregory Perkins
A Novel Open Architecture Purpose
Built Phased Coil Array for Head and
Neck MR-SIM: Characterization, Protocol Optimization and Imaging
Performance Using Subjects Immobilized in the Treatment Position
3378
Dimitrios Lazos
Assessment of Fiducial -based 2d kV
Orthogonal Imaging, Fiducial-based
CBCT and Soft Tissue-based CBCT
for Prostate Cancer Patients With
Implanted Fiducial Markers
3379
Angie Hu
Time Series Analysis of Interfraction
Patient Setup in Image Guided Radiation Therapy
3380
Sarah Han-Oh
Analysis of Tumor-motion Surrogate
Signals Under Different Coaching
Conditions Using Empirical Mode
Decomposition and Hilbert-Huang
Transformation
3381
Pankaj Mishra
Fluoroscopic 3-D Images Based on 2-D
Treatment Images Using a Realistic
Modified XCAT Phantom
3372
Eduard Schreibmann
Automated Quality Assurance for IGRT-based Patient Positioning
3382
Peter Wersall
Spatial Accuracy and Visibility Studies
of a MRI Compatible Gold AnchorTM
Fiducial Marker
3373
Howard Hsu
Daily CBCT vs. Biweekly CBCT vs. Portal
Imaging for Partial Breast Irradiation
3383
Tracy Bray
Rotational Dual-energy Image-guided
Radiotherapy for Lung Tumors
3374
Rabih Hammoud
Qa Procedures for The Assessment of
Geometric Accuracy For Mri-sim Using
a Novel Large Field of View Phantom:
System Performance Tests and Validation of Clinical Protocols
3384
Cynthia Chuang
Development of a Workflow to Quantitatively Validate Various Image Fusion Algorithms in Radiation
Therapy
3375
Noam VanderWalde
A Dosimetric Study of the Effect of
Patient Positioning on the Incidental
Radiation Dose to the Larynx for
Patients Treated for Head and Neck
3376
Biniam Tesfamicael
Prediction of Lung Tumor Motion With
Measured Breathing Motion
3385
Jatinder Saini
Assessment of PTV Margins For
Exactrac-based Frameless Intracranial
Fractionated Stereotactic Radiotherapy
3386
Jing Wang
High Quality Four-dimensional Cone-beam CT by Deforming Prior
Images
3387
Juan Diego Azcona
Assessment of the Prostate Motion
During Volumetric Modulated Treatments
3388
Brian Wang
Ultrasound Image Guidance for Abdominal Tumor
3389
Xiaoli Tang
Investigation of the Immobilization
Capability of Open Masks for Head and
Neck Patient Setup and Treatment
3390
Yue Cao
MRCT: Synthetic CT imaging for
Radiation Oncology Using Magnetic
Resonance Images
3391
Luis Silva
Variability in Interpretations of
Computed Radiography Portal Images
Using Two Different Methods
3392
Haijun Song
Study of Prostate Bed Motion Using
Daily CBCT and Surgical Clips
3393
Anand Santhanam
3-D Feature Recognition-based Automated Patient Treatment
Mismatch Verification System for
Radiotherapy
3394
Jeff Olsen
Feasibility of Single and Multi-plane
Cine MR for Monitoring Tumor
Volumes and Organs at Risk (OARs)
Position During Radiotherapy
3395
Ting Chen
A Quantitative Study of the Correlations of Lung Tumor Motion to
Cardiac and Respiratory Motion
3396
Parvesh Kumar
Four-dimensional Cone Beam CT (4-D
CBCT) Significantly Improves Localization of Lung Tumors in Comparison to ExacTrac X-Ray 6-D Image Guidance (ExacTrac) in the
Delivery of Stereotactic Body Radiotherapy (SBRT)
3397
Joo Han Park
A 4-D Adaptive Approach to Improve
Pre-treatment Patient Positioning
Accuracy in Lung Cancer Radiation
Treatments
3398
Haijun Lu
The Use of 4-D CT for Radiation Treatment Planning of Esophageal
Cancer
152
3399
Yongsook Lee
Daily Localization Comparison
Between Kilovoltage Cone-beam
Computed Tomography and Electromagnetic Tracking System
(Calypso) For Intensity Modulated
Radiation Therapy-treated Prostate
Patients
3400
Anna Arns
Dose Exposure and Geometric
Accuracy of Ultrafast
Kilovoltage-Megavoltage (kV-MV)
Cone-Beam CT for Image Guided
Radiotherapy of Lung Cancer
3401
Anthony Michaud
A Retrospective Analysis of Setup
Reproducibility for Anorectal Cancer
Patients Treated Prone on a Belly Board
3402
Ilsung Cho
Feasibility Study of Using Lipiodol As
Tumor Motion Surrogate for Liver IGRT
3403
Wing Fung
To Evaluate the Advantages and Disadvantages Using 4 Degree of Freedom (DOF) vs. 6 Degree of Freedom (DOF) for Tomotherapy Treatment in Head and Neck Cancer
3404
Daniel Low
Addition of Cardiac Motion in a Breathing Motion Model
3405
Sean Tanny
Challenges in Clinical Electron Dosimetry: Over-response of Solid-state Detectors in Small Fields
3406
Caroline Olsson
The Reference for Self-reported
Complication Data: Reflections from
the Swedish Program on Atomized
Symptoms After Cancer Treatments
(SPASACT)
3407
Mehran Zaini
Temporal Analysis of Inter-fraction
in vivo 3-D Dosimetry Using DVH
Difference Curves, Based on Daily Exit
Fluence Measures and Cone-beam CT
Images
3408
Ruggero Ruggieri
Computed 88 percent TCP Dose for
SBRT of Non-small Cell Lung Cancer
(NSCLC)
3409
Masao Tanooka
Carbon-Fiber Couch Modeling Optimization for Monaco VMAT Planning and Delivery
3410
Michelle Ludwig
Implanted Intrathecal Drug Delivery
Systems and Radiation Treatment
3411
Pier-Yves Trepanier
A Prospective Model-based Approach
to Personalize Radiotherapy Treatment
Plans for Glioblastoma Multiforme
Patients
3412
Charles Shang
A New Reliable SUV Index for Evaluating Local Control Using F-18
FDG PET Following Lung SBRT
3413
Vahid Entezari
Computed Tomography-based Rigidity
Analysis Affects Treatment Plan for
Skeletal Metastasis
3414
Andrew Godley
Comparison of Reproducibility of
Manual and Automated Prostate
Contouring Using Kilovoltage Cone-beam Computed Tomography
and Diagnostic Quality Computed
Tomography
3415
Sigolene Galland-Girodet
Interest of [18F]-fluoromisonidazolepositron Emission Tomography in
Radiotherapy for Glioblastomas :
Evaluation of its Impact in a Dose
Escalation Protocol
3416
Bertrand Biritz
Three-dimensional MRT/CT Treatment
Planning for 106Ru Eye Plaques Commissioned Using Radiochromic
Film in a Solid Water Phantom
3417
Sigolene Galland
Treatment of Cervical and Cranial
Base Paragangliomas With Conformal
Fractionated Radiotherapy: A 25-year
Experience in Single Institution
3418
Samuel Park
Developing Fuzzy Contour and Fuzzy
Similarity Index to Consider Inter- and
Intra-observer Variation in Image
Segmentation
3419
Omar Chibani
CT-based Monte Carlo Dose Calculations for Prostate Implants
3420
Allison Toltz
Prediction of Excess Risks of Radiation-induced Cardiac Mortality
and Secondary Cancers After Radiotherapy for Hodgkin’s Lymphoma
3421
Apryl Mensah
Generalized Approach to Planning
Multimodality Therapy Adapted to
Periodically Obtained Maps of Tumor
Evolution Which Will be Robust to
Prediction Error
3422
Andrew Jackson
Correlation of the Dose Delivered to
the Nausea Center With Acute Onset
of Nausea and Vomiting in Oropharynx
Cancer Patients Treated With Chemoradiation
3423
Claudio Fiorino
Weekly DSH/DVH of the Bladder
Predicts a Worsening of the Ipps Value
at the End of High-dose Radiotherapy
for Localized Prostate Cancer
3424
Niranjan Bhandare
Post-radiation Otitis Media With Effusion: Modeling the
Complication Probability and
Determining the Parameters of Clinical
Significance
3425
Jenghwa Chang
Analysis of Radiation-induced Toxicity
in Patients Receiving Stereotactic Body
Radiotherapy (SBRT) for Lung Tumors
3426
Yevgeniy Vinogradskiy
Quantitative Assessment of Lung
Function in Stage I and Stage III Lung
Radiotherapy Patients Using 4-D CT-based Ventilation Imaging
3427
Ellis Ziel
Integral Dose Delivered to Normal
Brain With Conventional IMRT and
Helical Tomotherapy IMRT During
Partial Brain Radiotherapy for High
Grade Gliomas With and Without
Selective Sparing of the Hippocampus,
Limbic Circuit and Neural Stem Cell
Compartment
3428
Zhe Chen
On the Use of Biologically Effective
Dose (BED) and Iso-Effective Dose
(IED) in Radiobiological Evaluations
of Permanent Brachytherapy with
Proliferating Tumors
3429
Oana Craciunescu
Quantifying Temporal Fluctuations of
DCE-MRI Extracted Parameters in Neck
Nodal Metastases
153
RADIATION PHYSICS/
continued
3430
Yong Yue
A Novel Hybrid Multi-modal Registration for Lung Radiotherapy
Response Evaluation
3431
William Watkins
Dose Differences in ITV Planning of
Time Dependent Anatomy
3432
Jin Wang
Impact of Dose-volume Parameters
and Tumor Location on Severe Acute
Radiation Pneumonitis for Lung Cancer Patients Treated With Concurrent Chemo-radiotherapy
3433
Antonio Damato
Inter-fraction Uncertainties in Multi-fraction Gynecologic Interstitial
Brachytherapy (MGIB)
3434
Michael Snyder
Potential Gender Differences in a
Normal Tissue Complication Probability Model for Heart Toxicity
During Radiotherapy for Esophageal
Cancer
3435
Omid Nohadani
Unbiased Metrics of Dosimetric Variation in IMRT Planning
3436
Clay Holdsworth
Adaptive IMRT Using a Multiobjective
Evolutionary Algorithm Integrated
With a Diffusion-Invasion Model for
Glioblastoma
3437
Olga Green
Observation of Radiation-induced
Tissue Signal Intensity Changes With
the First Commercial MRI-guided IMRT
System
3438
Anthony Kim
Predicting Dose in the Periphery Of
Treatment Fields
3439
Tianyu Zhao
A Non-Uniform Dose Prescription
Based on Tumor Position Probabilities
for Patients With Lung Cancer
3440
Morad Nasseri
Does Pseudoprogression Occur
Beyond Three Months Following
Standard Chemoradiotherapy in
Glioblastoma Patients?
3441
William Yuh
Biological Equivalent Dose (BED) - Application of the Generalized Linear-Quadratic Model for Spinal
SBRT
3442
Tod Speer
Monte Carlo Modeling of the Metastatic Formation of a Patient
Treated With a Single Dose of Ibritumomab Tiuxetan: The Case for
Radionuclide Combinations of
Different Path Lengths
3443
Chiramana Haritha
Accuracy of Stent Based 4-D CBCT Image Guidance for Inoperable
Klatskin Tumor Treated by Chemoradiotherapy
3444
Prashantkumar Shinde
Cone Beam CT-based 3-D Dose
Verification in Head and Neck Cancers
- Validation Study
3445
Lukasz Matulewicz
Dosimetric Implications of CT Metallic
Artifacts Correction in Current Radiotherapy Treatment Planning
Systems
3446
Pengpeng Zhang
Predictive Treatment Management:
Incorporating a Predictive Tumor Response Model Into Robust Prospective Treatment Planning for
3447
Yi Wang
Comparison of Imaging Dose From
Daily Cone-beam CT to Out-of-field
Therapeutic Dose in IMRT and VMAT
Treatments of Prostate Cancer
3448
Naoki Tohyama
Validation of IMRT Postal Dosimetry
Audit Using Radiophotoluminescence
Glass Dosimeter
3449
Raj Varadhan
Testing Accuracy of Deformable Registration Studies Using Computational Modeling and Inverse
Consistency Metrics
3450
Anthony Lo
CyberKnife IGRT for Optic Nerve
Sheath Meningioma
3451
Shrikant Deshpande
An Integrated 2-D Dosimeter and
Electronic Portal Imaging Device for in
Vivo Dosimetry: A Feasibility Study
3452
Kai Ding
Air-Bellow Belt and LED Display Based
Compact Visual Biofeedback System
Improves the Respiratory Regularities
for Gated Radiation Therapy
3453
Takashi Hanada
Variation of Rectal Volumes and
Dosimetry Values Including NTCP Due
to Inter-fractional Variability Receiving
2-D Based IG-IMRT for Prostate Cancer
3454
Shichao Wang
Applied Analysis on the Biological
Effect Dose (bed) Through the Dosimetric Comparison Between the
IMRT and the VMAT Plans
3455
Pierre Graff
A Tool for the Daily Management of
Dose Guided RadioTherapy for Head
and Neck IMRT Patients
3456
Hiroyuki Okamoto
Probability of Human Errors in Operation of Treatment Planning
System (TPS)
3457
Hui Geng
The Application of Metal Artifact
Reduction Algorithm in CT Spectral
Imaging on Radiotherapy Dose
Calculation
3458
Chor-yi Ng
Dosimetric Evaluation of the Interplay
Between LINAC Movement and Tumor
Motion in Respiratory Gated VMAT of
Lung Cancer
3459
Tonnis Nuver
MVCT-Detector Based Dose Reconstruction Makes Phantom QA Measurements for Tomotherapy Prostate Treatments Redundant
3460
Xiao qin Jiang
Automatic Adaptive Inverse Planning
Optimization for Head and Neck
Cancer Radiotherapy
3461
Ivaylo Mihaylov
Dose-mass Based Inverse Optimization
for Head and Neck Cancers
154
3462
Nathalie Rochet
Multicriteria Optimization in IntensityModulated Radiation Therapy Treatment Planning for Large Target
Volumes: First Experience With Whole
Abdomen Radiotherapy
3463
Edward Obedian
The Value of Repeat Cone Beam CT
Scans in Image Guided Radiation
Therapy for Prostate Cancer
3464
Masatoshi Hashimoto
Verification of MLC Position Using
Electric Portal Imaging Device During
RapidArc Delivery
3465
Kentaro Nishioka
Interfractional Setup Error and
Intrafractional Bladder Motion During
Radiotherapy for Bladder Tumors
3466
Akira Nakamura
Fluoroscopic Lung Tumor Tracking-based on Gradient-based
Features Without Fiducial Markers
3467
Suk Lee
Development of Patient Specific 3-D
Dose Real Evaluation Systems Using
a Novel Patient-based 3-Dimensional
Dose Scanner (P3DS) in Tomotherapy
3468
Jiazhou Wang
Using Corrected Cone Beam CT Image
for Accelerated Partial Breast Irradiation Treatment Dose Verification
3469
Eileen Cirino
Using Dose Homogeneity Index and
Conformity Index to Evaluate Prostate
High-dose-rate Plan Quality and
Consistency
3470
Tatsuya Toyoda
How Much Does Field Size Become
Larger With Interfractional Computed
Tomography in Treating Gastric Malignant Lymphoma?
3471
Adam Reese
Deformable Image Registration As a
Method to Assess Motion for Pancreatic Cancer Using 4-D Computed Tomography (CT) Scans
3472
Malcolm Mattes
The Dosimetric Effects of Photon
Energy on the Quality of Prostate
Volumetric-Modulated Arc Therapy
(VMAT)
3473
Xiangrong Qi
Interfraction Patient Setup for Multiple
Volumetric-based Image Guidance
Systems for Head-and-Neck IMRT
3474
Zijie Xu
Comparison of Automatic and
User-guided Methods for Isocenter
Mapping
3475
Tomasz Piotrowski
Tomotherapy: Implications on Daily
Workload and Scheduling Patients
Based on Three Years Experience in
Poznan
3476
Roger Rice
Evaluation of Portal Dosimetry for
RapidArc Treatments
3477
Hyunjin Lee
Location of Tumors Influencing Small
Bowel Sparing in Intensity Modulated Radiation Therapy for Locally Advanced Rectal Cancer
3478
Dongwook Kim
Secondary Radiation Doses of
Intensity Modulated Radiotherapy in
Patients With Lung And Liver Cancer
3479
HongSeok Jang
Evaluation for Direct Aperture Optimization (DAO) in Intensity Modulation Radiotherapy (IMRT) Treatment Planning
3480
Tomohiro Yokoi
Development of a New Simulation
Method of Dose-distribution Changes
for an IMRT Plan by Rotational Set-up
Error
3481
Ana Cámara
Quality Assurance of the Dose
Delivered Throughout the Entire IMRT
Treatment
3482
Claus Behrens
Adaptive RT for Head and Neck Cancer:
The Usefulness of Deformable Image
Registration
3483
Daniel McDoland
Dosimetric Effects of Balloon Positioning Errors for Partial Breast
Irradiation Using Contura
3484
Mohammad Khan
Prostate Motion Is Correlated in the
Superior/Inferior (SI) and Anterior/
Posterior (AP) Direction: Use Statistical
Margin Recipes With Extreme Caution
3485
Seungjong Oh
Adaptive MRI Guided Brachytherapy of
Cervix Cancer: Impact of Reference Image Selection on Dose Accumulation
3486
Christina Skourou
Dosimetric Differences in Forward
Planned IMRT Calculated and Delivered With Dynamic Fields or With
Multiple Static Subfields: A Multimodality Comparison
3487
Pietro Mancosu
Total Marrow Irradiation With Volumetric Modulated Arc Therapy:
Technical Considerations and Early
Experience
3488
Wensha Yang
ITV Margin Definition and Deformable
Motion Assessment Using Multiple Fiducial Markers for Pancreas/Liver
SBRT
3489
Yong Hum Na
Ultra-Fast Multi-Objective Optimization of VMAT Treatment Using
Emerging Cloud Computing Platform
3490
Xiaocheng Yang
Dosimetric Validation of Respiratory
Motion Margins for Patients With
Pancreatic Cancer Using Deformable
4-D Contour Propagation
3491
Lei Ren
Can Standard Radiotherapy Quality Assurance (QA) Detect Potential Delivery Errors?
3492
Macharla A. Laviraj
A Method to Validate the Four-Dimensional Cone Beam
Computed Tomography (4-D CBCT) in
External Beam Radiotherapy
3493
Alec Block
Clinical Reduction of Daily kV Planar
Imaging Dose: An Observer Study
3494
Hongwei Liu
The Influence of Target Anatomic and
Patient’s Characteristics on the Volume
Obtained From Cone Beam CT (CBCT)
in Lung Stereotactic Body Radiation
Therapy
3495
Rafael Manon
Effect of Re-imaging Frequency in
Adaptive Radiation Therapy (ART) for
Head and Neck Patients
155
RADIATION PHYSICS/
continued
3496
Heming Zhen
Evaluation of a New Tomotherapy
Treatment Planning System Utilizing
Gpu Computing Capacity
3497
Katja Langen
Do Adaptive Radiotherapy (ART) Assessments Depend on the Employed
ART Workflow?
3498
Jingdong Li
Study of Dose Variations Induced by
Collimator Rotation for IMRT Delivery
Using EPID Dosimetry
3499
Nzhde Agazaryan
Intra-fraction Motion Management for
Prostate SBRT: Clinical Experience and
Motion Analysis
3500
An Tai
Relationship of PTV Margin with Frequency of Image-Guided Positioning
3501
Dongwook Kim
In vivo Verification of Rectal Wall Dose
Distribution for Volumetric Modulation
Arc
3502
Antonio Damato
Dosimetric Uncertainties Associated With Inter-observer
Contouring Variability in Gynecologic
Interstitial Brachytherapy (GIB)
3503
Rachit Kumar
SBRT Treatment Planning With VMAT
vs. IMRT: Impact of Duodenal Sparing
on Tumor Coverage in Patients With
Locally Advanced Pancreatic Adenocarcinoma
3504
Kiran Kumar
Evaluation of Gold Fiducial Marker Migration After Implantation in
Prostate Image Guided Radiotherapy
(IGRT)
3507
Jaegi Lee
Patient Specific Quality Assurance
Using a 4-D Programmable Motion
Platform in Respiratory-Gated Radiotherapy
3508
Christian Thieke
A New Planning Tool for Fast Online
Dose Optimization of IMRT Plans
3509
Nozomi Kitamura
The Threshold CT Value Difference
in the Deformed Volume With Good
Conformality
3510
Morten Hoyer
A Dose Accumulation Study of Adaptive Plan Selection vs. Daily
Re-optimization in Bladder
Radiotherapy
3511
Ryo Takahashi
Direct Measurement of Two-dimensional Dosimetric Leaf Gap
Distribution Using Electric Portal Imaging Device
3512
Hye Young Kim
for Multiple Brain Metastases: A More
Efficient Modality than Dynamic Arc
3513
Ugur Selek
Volumetric Arc Therapy Seems More
Promising to Spare Organ at Risk In
Adjuvant Postoperative Radiotherapy
for Pancreas Adenocarcinoma in Comparison to Step and Shoot Intensity Modulated Radiotherapy
3514
Rodney Ellis
Improved Care Delivery and Operational Work Flow by Inter-departmental Coordination of
PET/CT Exams and CT Simulations for
IGRT
3505
Shunshan Li
On The Regional Cross Correlation
Metric to Predict Displacement Errors
in Deformable Image Registration
3515
Adavikolanu Kesava Ramgopal
Conventional Two Phase vs. Simultaneous Integrated Boost
Methods of Intensity Modulated
Radiotherpy in Carcinoma Prostate - Analysis of Volumetric and
Dosimetric Parameters
3506
Henry Wang
Treatment Planning Recommendation - Compensating for
Perturbation via Prior Knowledge and
Collaborative Filtering
3516
Richard Speight
Assessing the Accuracy of Atlas-based
Automatic Segmentation of Volumes
for Adaptive Treatment in the Head
and Neck
3517
Per Poulsen
A Method of Dose Reconstruction
for Moving Targets With Dynamic
Treatments
3518
Adavikolanu Kesava Ramgopal
Dynamic and Segmental Methods of
Delivery in Head and Neck Cancer - Analysis of Volumetric and
Dosimetric Parameters
3519
Joseph Moore
Use of In-beams Structures in Shape
Relationship Driven Treatment Planning
3520
Giuseppe Roberto D’agostino
Dice Similarity Index Assessment in
Deformable Registration for Head
and Neck Cancer Patients Undergoing
Replanning Procedures
3521
Hassaan Alkhatib
A Method to Ensure Consistent
Delivery of Volumetric Modulated Arc
Therapy
3522
Daniel Nguyen
Evaluation of IMSureQA for Volumetric
Modulated Arc Therapy (VMAT) Treatment Plan Quality Assurance (QA)
in Lung SBRT and Abdomen Cancers
3523
Peter Winkler
Correlations Between Changes in
Morphology and Dose Distribution
for Adaptive Radiation Therapy in the
Head and Neck Region
3524
David Craft
Effective Multi-criteria Optimization
for Clinical IMRT Planning
3525
Xin Mei
Impact of a Definition Bladder ITV on
KV-CBCT Tailored Adaptive Radiotherapy in Bladder Cancer
3526
Georges Hobeika
How Does ITV Density and Small
Dynamic Dose Fields Affect Coverage
in Moving Targets
3527
Dengwang Li
Multi-resolution Deformable Registration Framework Using Dual-tree Complex Wavelet for Adaptive Radiation Therapy
156
3528
Ross McGurk
Pet Tumor Volume Segmentation: A
Comparison of Automated vs. Oncologist Drawn Volumes
3539
Hualiang Zhong
Region-based Correction of Deformable Image Registration Errors
for Adaptive Radiation Therapy
3529
James Wong
Beyond IGRT-daily Real-time Planning (RTP) – Treatment of Prostate
Cancer, Clinical Implementation and
Technique
3540
Mark Phillips
Optimization of Objective Functions
Used in Inverse Planning by Means
of a Multi-objective Evolutionary
Algorithm
3530
Natalya Morrow
Cumulative Dose With Organ Deformation for Cervical Cancer
Treated With Multi-fraction High-dose-rate Brachytherapy
3541
Jason Pukala
The Dosimetric Uncertainty Resulting
From Contour Variability of the Parotid
Glands and Its Application to Adaptive
Radiotherapy
3531
Nguyen Daniel
Quality Assurance (QA) of Volumetric
Modulated Arc Therapy (VMAT) Treatment Plans: Analysis of 1 000
Patients
3542
Han Liu
Investigation Discrepancy Between
the Planned and Delivered Dose Using
Weekly CBCT Images
3532
Leire Arbea
Dosimetric Predictors of Gastrointestinal Toxicity During
Concomitant With Capecitabine and
Oxaliplatin, for Locally Advanced
Rectal Cancer
3533
Fenghong Liu
Propagation of Gastroesophageal
Junction Target Contours on Respiration Correlated CT Images Using Deformable Image Registration
3534
Daniel Pak
Weighted Sum Cost Function vs.
Lexicographic Ordering for IMRT Treatment Planning
3535
Amar Kishan
Quantification of Gross Tumor Volume
Changes Between Simulation and First
Day of Radiation Therapy for Patients
With Locally Advanced Malignancies
of the Lung And Head/Neck
3536
Kihwan Choi
Iterative Optimization Using Normalized Transmission Map for IMRT
With Arbitrary Beam Profiles
3537
Fenghong Liu
Dosimetric Benefits of Respiratory
Gating for Gastroesophageal Junction
Tumors
3538
Ho Lee
Binary Moving Blocker-based Scatter
Correction for Single Scan Cone-Beam
CT System With Off-centered Detector
3543
Sara Pirozzi
Atlas-based Segmentation: Evaluation
of a Multi-atlas Approach for Prostate
Cancer
3551
Colleen Schinkel
Dose Reduction of Rectum and Bladder Utilizing an Adaptive Strategy
and Dual-Plan Superposition When
Treating Pelvic Lymph Nodes and
Prostate With IMRT
3552
Andre Minken
First Experience With IMRT Treatment
Plans Created With RayStation
3553
Louise Murray
Ultrasound and Cone Beam CT for Image Guidance in Prostate Radiotherapy
3554
Nadya Shusharina
Adaptive Proton Radiotherapy for Base
of Skull Tumors
3555
Jing Cai
Feasibility of MR-alone-based Brachytherapy Treatment Planning
Using a Titanium Tandem and Ring
Applicator for Cervical Cancer
3544
Dante Roa
Dose Measurements Outside the Treatment Field From a VMAT Technique Using an Anthropomorphic
Phantom: Preliminary Data
3556
Edward Dickerson
Quantitative Analysis of Head Scatter
and Jaw Transmission Correction
Factor for Enhanced Dynamic Wedge
Fields Using a Two-dimensional Diode
Array
3545
Song Wang
Sensitivity Calibration of a Two-dimensional Detector Array Using
Two Shifts
3557
Eric Ford
Lessons From the Nuclear Power
Industry: Using Incident Learning to
Improve Patient Safety
3546
Matthew Witten
Optimization of Affine Transformation
Parameters for Dose Matrix Warping
in Patient-Specific Quality Assuance of
Radiotherapy Dose Distribtuions Using
an Evolutionary Algorithm
3558
Ergun Ahunbay
Adaptive Replanning Considering
Previously Delivered Dose for Head
and Neck Cancers
3547
Ebbe Lorenzen
Automatic Segmentation of Heart
Evaluated With Multi-institution Inter-observer Variation
3559
Christoph Oehler
Comparison of Cone Beam CT and kV/
kV-imaging Using Fiducial Marker for
PTV Margin Definition in IGRT of Localized Prostate Cancer
3560
Silvia Chiesa
A Predictive Model of Correlation
Between Site and Diameter of Brain
Metastases and Hippocampal Sparing
Using Rotational Techniques
3548
Entesar Dalah
PET-guided Dose Escalation for Pancreatic Cancer: A Treatment Planning Study
3549
Ronald Berg
VMAT in Vivo Dose Delivery Verification
3550
Dimitrios Lazos
Dosimetry Study of the Effects of
Patient Positioning Correction in the
Treatment of Prostate Cancer Patients
With Image Guided Radiation Therapy
3561
Sook Kien Ng
Does HD120 MLC Give an Advantage
Over Millenium MLC in the Treatment
of Head and Neck Cancer (HNC)
Patients?
157
RADIATION PHYSICS/
continued
3562
Strahinja Stojadinovic
Gamma Analysis of Normalized and
Un-normalized Dose Distributions
3563
Issa Mohamad
Implementation of Intensity Modulated Radiation Therapy in a
Developing Country: Lessons for
Everyone
3564
Feng Liu
Dosimetric Benefits of Online Adaptive
Replanning for Radiotherapy of Prostate Plus Seminal Vesicle:
Evaluation-based on Cumulative Dose
3565
Penggang Bai
Evaluation of Atlas-based Auto-segmentation for Head Neck
Cancer Patient
3566
Amanda Walker
Improving Patient Safety With a Prospective Safety Tool in the Academic and Community Radiation
Oncology Setting: A Feasibility Study
and Report of Outcomes
3567
Sonali Rudra
Contouring of Breast and Axillary
Nodal Volumes Per RTOG Guidelines
Improves Dose Coverage at a Single
Institution
3568
John Kipritidis
4-D Cone-beam CT Ventilation Imaging to Facilitate Adaptive
Functional Avoidance Lung Cancer
Radiotherapy
3569
Per Munck af Rosenschold
The Transition From Conformal Photon
Radiation Therapy to Arc Therapy for
High-grade Gliomas
3570
Dengwang Li
Deformable Registration of 4-D Computed Tomography Data Using
Edge Preserving Scale Space
3571
Kurt Meyer
Including Radiographic Shrinkage of
Head and Neck Tumor in Adaptive
Radiotherapy Process: Is it a Safe
Consideration?
3572
Joo Ho Kim
Metastatic Spine Tumors: Helical Tomotherapy Achieved High Conformity for Multiple Lesions
3573
Vivek Mehta
VMAT Improves Clinical Efficiency
3574
Jessica Klaers
Evaluation of Delivered Dose Distributions and Metrics: A New
Patient Specific QA Protocol
3583
Jessica Schuster
Influence of Volumetric Change and
Tumor Motion on Inter- and Intra-fractional Positional
Variations in Frameless Stereotactic
Body Radiotherapy (SBRT) of Lung
Tumors
3584
Michael Folkert
Dosimetric Impact of Intraoperative
32P Plaque on Postoperative Stereotactic Radiation Therapy for
Treatment of Recurrent and Metastatic
Tumors of the Spine
3575
Jun Li
Dosimetric Evaluation of RTOG 0815
Compliance Criteria for Volumetric
Modulated Arc Therapy Treatment
Planning
3585
Taoran Li
Prostate SBRT in Five Fractions: Initial
Report on Dosimetric Results and IGRT
Experiences
3576
Vivian Rodriguez
MVCT-detector Data Sinograms for
in Vivo Quality Assurance of Helical
TomoTherapy Treatments of Head and
Neck Cancer Patients
3586
Olivier Blasi
A Method to Objectively Evaluate Stereotactic Radiation Surgery (SRS)
Treatments of Essential Tremor Patients
3577
Lilie Wang
Monte Carlo Dose Calculations for
IMRT Head and Neck Patients With
Dental Fillings Using the Varian Generic Phase Space Files for TrueBeam
3587
Jing Wang
Long-term Results of Gamma Ray-based Stereotactic Body Radiotherapy in Treatment of Medically Unfit or Inoperable Non-metastatic Pancreatic Adenocarcinoma
3578
Kai Ding
Ventilation Imaging for Lung Radiation
Therapy Planning: Free Breathing 4-D
CT vs. Breath-hold MRI
3579
Sunyoung Jang
Evaluation of Sequential and Simultaneously Integrated Boost IMRT
Methods in Head and Neck Cancer
3580
Jonathan Ha
Skin Flash in IMRT Plans
3581
Elisabetta Cagni
Correlation of Delivery Reproducibility
With Anatomical Modifications and
Intra-fractions Motion During Treatments Using Helical Tomotherapy
(HT) Integrated Detectors
3582
Sanath Kumar
Establishment of Benchmark CBCT/
CT Deformable Image Registration in
Radiotherapy of Prostate Cancer
3588
Javad Rahimian
Comparative Study of Internal Target
Volume (ITV) Based on PET-CT and 4-D
CT for Stereotactic Body Radiotherapy
of Non-small Cell Lung Cancer
3589
Matthew Orton
Contour Variability During Stereotactic Body Radiation Therapy
(SBRT) Treatment Planning, and the
Effect of Physician Training
3590
Guang Li
Frameless Stereotactic Radiosurgery
With IGRT Setup and Optical Surface
Imaging for Setup Verification and
Motion Monitoring
3591
Takeaki Ishihara
Hypofractionated Stereotactic
Radiotherapy for Brain Metastases:
Exploration of Adhibition and Key Factors Involved in Local Control Rate
3592
Tyler Gunter
Quantitative Assessment of Gross Tumor Volume Changes During and
After Completion of SBRT for NSCLC
158
3593
Ange Wambaka Mampuya
Interfractional Variations in Lung
Tumor Position Under Abdominal
Compression in Stereotactic Body
Radiotherapy for Lung Cancer
3605
Jinyu Xue
Dose-volume Effects on Hearing Preservation in Gamma Knife Radiosurgery of Vestibular Schwannomas
3594
Wing Kei Rebecca Wong
A Model-based Iterative Reconstruction Technique for Computer Tomography on Automated
Contour of Small and Low Contrast
Lesions
3606
Dukagjin Blakaj
Radiation Necrosis After Radiosurgery:
Correlation Of Volume and Dose
Parameters in Patients With Metastatic
Brain Lesions
3595
Yoshihiro Ueda
Calculation of Cranial and Caudal
Margins to Compensate Tumor Motion
Change in Lung SBRT Using EPID Cine
3596
Ingrig Fumagalli
Robotic Stereotactic Body Radiotherapy for Patients With Pulmonary and Hepatic Oligometastases
3597
Chuxiong Ding
To Evaluate the Dosimetric Outcomes
of Multi-stage Robotic Stereotactic Radio-surgery for Intracranial Arteriovenous Malformations Using Cyberknife
3616
Toufik Djemil
Dosimetric Effect of Implanted Hardware in Spine SBRT: Comparison
of the Actual Planned Dose Using Pencil Beam Calculation to Monte
Carlo
3607
Yun Liang
Intra-fraction Motion in Frameless
Cranial Stereotactic Radiosurgery and
Radiotherapy
3608
Siyong Kim
Can Flattening-filter-free (FFF) Beams
Be Used for Off-axis Targets in Conformal Arc Delivery Of SBRT?
3609
Grace Gwe-Ya Kim
Stereotactic Radiosurgery With FFF
Mode Photon Beams
3610
Yuichi Akino
Impact of Heterogeneity Corrections
in Stereotactic Radiotherapy Treatment of the Lung
3598
Gaurav Marwaha
Lung Lesions treated With SBRT: Does
Size Matter?
3611
John Lilley
VMAT for Lung SABR With a New 160
Leaf MLC
3599
Claudio Sole
Delivered by Helical Tomotherapy for
Early-stage Non-small Cell Lung Cancer: Dosimetric Evaluation and
Toxicity
3612
Manuela Buleteanu
Feasibility Of Using the Novel Vero
SBRT System for Radiation Therapy
and SRS of Intracranial Lesions
3600
Joao Seco
Stereotactic Body Radiotherapy, SBRT,
of Spine Lesions: Optimizing Number
of IMRT Beams and Monte Carlo Assessment of Dose Predictions
3601Withdrawn
3602
Qinghui Zhang
How Much Margin Is Adequate for
Single-fraction Stereotactic Radiosurgery Treatments?
3603Withdrawn
3604
Vimoj Janardanan Nair
Feasibility, Detectability and Experience With Platinum Seed Internal Fiducial Markers for CT-MRI
Fusion and Real-time Tumor Tracking
During Stereotactic Ablative Radiotherapy
3617
Mustafa Cengiz
Comparison of Single vs. Two
Fractions of Radiosurgery for Brain
Metastases: A Prospective Randomized Study
3618
Wilko F.A.R. Verbakel
Flattening Filter Free Beams for SBRT:
Advantages and Risks
3619
Andrew Ju
A Dosimetric and Clinical Evaluation
of Monotherapy With Hypofractionated Stereotactic Body Radiation Therapy in the Treatment of Intermediaterisk Prostate Cancer
3620
Marie Pierre Sunyach
Hypofractionated Stereotactic Radiotherapy for Symptomatic or
Recurrent Meningioma: Two French
Anticancer Center Experience
3621
Carnell Hampton
Is a Single IGRT Localization Followed
by a Planned Isocenter Shift Sufficient
to Accurately Localize Multi-isocenter
SBRT Targets?
3622
Varun Singh Thakur
Delivery Accuracy of Stereotactic
Radiosurgery (SRS) With TomoTherapy
as Compared Linear Accelerator and
Robotic Based Radiosurgery
3613
Teo Stanescu
Quantification of the Magnetic Susceptibility Effects During MRI-guided Radiosurgery of Hemorrhagic Brain Metastases
3623
Haisong Liu
Is Head Frame Still the Gold Standard
Of Fixation for Linac Stereotactic
Radiosurgery?
3614
Goldie Kurtz
Salvage Radiosurgery for Brain Metastases: Prolonged Survival With
Durable Tumor Control
3615
Mustapha Khordi
On the Clinical and Dosimetric Accuracy o Recently Released Acuros
Xb and Analytical Anisotropic Algorithm (AAA) Photon Dose
Calculation Algorithms for SBRT Lung
Treatment With Volumetric Modulated
Arctherapy (VMAT)
3624
Qianyi Xu
Study on Interfractional Liver Tumor
Volume Variations-based on Reconstructed Fiducials in Three-dimension During CyberKnife-based Stereotactic Body
Radiation Therapy (SBRT)
3625
Raj Varadhan
Dosimetric Impact of Interplay Effect
on a Single Arc VMAT Stereotactic
Lung Delivery: Validation Using a 6-D
Motion Platform
159
RADIATION PHYSICS/
continued
3626
Diane Ling
Stereotactic Body Radiotherapy in
Treatment of Adenocarcinoma of
Pancreas in Elderly Patients
3627
Claudiu Diaconu
Active Breathing Control Provides an
Accurate Method for Stereotactic Body
Radiation Therapy of Lung and Liver
Tumors
3628
Fen Wang
Validation and Reliability of Free
Breathing Cone Beam Computed
Tomography (FB-CBCT) Imaging
Guidance in Stereotactic Ablative
Radiotherapy (SABR) of Lung Tumors
3629
Rasim Meral
Side Effects of Stereotactic
Fractionated Radiotherapy for Malign
and Benign Lesions
3630
Yoonsun Chung
Intrafractional Movement During Stereotactic Body Radiotherapy in
Spine Metastasis Using Helical Tomotherapy
3631
Hong Xiang
Endorectal Balloon in CyberKnife
(SBRT) for Early-stage Prostate Cancer:
A Planning and Dosimetry Analysis
3632
Yulin Song
Investigation of 3-D Optical Image
Guided Frameless Stereotactic Radiosurgery Using Homegrown
3633
Akito Saito
Patient Clearance Simulation for Stereotactic Body Radiation Therapy
3634
Carolyn Kim
Steroid Prophylaxis Prevents Acute
Pain Flare or Swelling Sensation
Following Cervical Spine Stereotactic
Radiosurgery
3635
Mariko Kawamura
Usefulness of Vinyl Polysiloxane Dental
Impression Material as a Proton Beam
Stopper to Save Normal Tissue in Oral
Cancer Irradiation: Basic and Clinical
Verification
3636
Katrin Henkner
Dosimetric Characterization of
Scanned Ion Beam QA- and Patient
Treatment Fields
3637
Jeong-Eun Rah
Feasibility Study of Glass Dosimeter
Postal Dose Intercomparison for
Proton Beams
3638
Joao Seco
Decreased Vertebral Column Dose
in Spinal Irradiation With IMPT and
Proton Arc Techniques: Potential for
Protons to Allow for CSI Without Inducing Spinal Growth Impairment
3639
Yuanshui Zheng
Range Uncertainty in Proton Therapy:
An End-to-end Study Using Various
Animal Tissues
3647
Post-Operative Radiotherapy (RT) for
Salivary Gland Carcinoma: A Comparison of Intensity Modulated
Radiation Therapy (IMRT) and Proton
Treatment Techniques
3648
Daniel Yeung
Dosimetric Characteristics In IMPT: Impact of Optimization Techniques
and Pencil Beam Scanning Nozzle
Designs
3649
Heng Li
Automatic Dose Verification for Spot
Scanning Proton Therapy Using Recorded Spot Positions and MUs
3650
Anita Mahajan
Evaluation of Scanning Beam Proton
Therapy for Medulloblastoma Boost
Treatment
3640
Jun-ichi Saitoh
Changes of the Range of Carbon Ion
Beam During the Course of Radiation
Therapy for the Treatment of Nasal
and Paranasal Mucosal Malignant
Melanoma
3651
Yoshifumi Kamikubo
A New Clinical Dose-measuring Tool
for Electron-beam Therapy Using
Plastic Scintillator
3641
Eric Klein
Single Room Proton Radiotherapy
3652
Shinichiro Mori
Four-dimensional Treatment Planning
in Layer-stacking Boost Irradiation for
Carbon-ion Pancreatic Therapy
3642
Sandeep Dhanesar
Comparison of Skin Doses in Spot
Scanning and Passive Scattering
Proton Therapy Treatment Plans for
Pediatric Patients With Spinal Ependymomas
3643
Haruo Inokuchi
Assessment of Acute Cervical Skin Toxicity Due to Fractionated Proton
Beam Therapy for Head And Neck
Cancer
3644
Sang Gyu Ju
New Technique for Developing Proton
Range Compensator Using Three-dimensional Printer
3645
Kristofer Kainz
Plan Quality of Proton vs. Photon
IG-IMRT
3646
Wei Liu
Conventional PTV-based Optimization
Lacks Robustness For IMPT Head and
Neck (H and N) Planning
3653
Brian Yeh
Intensity Modulated Proton Therapy
Is Dosimetrically Superior to Intensity
Modulated Radiation Therapy for Head
and Neck Cancers
3654
Xun Jia
Fast Monte Carlo Dose Calculation on
GPU for Proton Therapy
3655
Masami Mukai
Proposal of the Cooperation Method
Between EMR/CPOE-RIS-TMS by Using
the IHE (integrating the Healthcare
Enterprise) - Implementation and Challenge At NIRS
3656
Ralf Schneider
High-dose, Spot Scanning Based
Proton Therapy for Sacral Neoplasms.
Toxicities of Pelvic Organs and Dose
Distribution Analysis in a Patient
Cohort
3657
Yusuke Egashira
Experimental Evaluation of the Interplay Effect of Scanning Proton-beam for Small Moving Target
in Heterogeneity Using a Four-dimensional Phantom
160
3658
Jaiteerth Avadhani
Dosimetric Analysis of Small Field 6
MeV Electrons to Replace Superficial
X-Rays for Superficial Cancers
3669
Dragan Mirkovic
Is Constant RBE Accurate Enough for
Determination of Biological Effects in
Proton Therapy?
3659
Tae Kyu Lee
Characterization of Uniform Scanning
Proton Beams With Proton Loss Model
3670
Abigail Milby
Prospective Study of Thoracic Reirradiation With Proton Beam Radiotherapy: Feasibility and Safety
Analysis
3660
Bijan Arjomandy
A Comparative Study of Single vs.
Two Field Daily Fraction for Treatment of Prostate Cancer Using
IMPT, Double-scattered and SFUD
Delivery Technique
3661
Seungtaek Choi
Comparison of Scanning Beam Proton
Therapy (SBPT) to Intensity Modulated
X-ray Therapy (IMRT) for Post-
operative Salvage Treatment of
Prostate Cancer Patients
3662
Yuanshui Zheng
Dosimetric Comparison Between IMRT
and Uniform Scanning Proton Therapy
for Prostate Cancer Treatment
3663
Quynh Nguyen
Scanning Beam Proton Therapy Reduces Dose to Normal Tissue
Compared to 3-D X-rays Or Passively-scattered Proton Therapy in
Patients With Stage I Seminoma
3664
Drosoula Giantsoudi
LET-Guided Biological Optimization in
IMPT: Implications on RBE Value
3665
Daniel Habermehl
Carbon Ion Therapy Applied In Raster
Scanning Technique For Hepatocellular Carcinoma -
First Results From the Heidelberg Ion-beam Therapy Center
3666
April Cook
Development, Implementation and
Results of an Automated Compensator
Quality Assurance Device
3667
Matthew Palmer
Dose Reduction to Small Bowel and
Other Relevant Structures in Rectal
Carcinoma With Proton Therapy
3668
Quynh Nguyen
Utilization of Constraints in the Optimization Algorithm With Scanning Beam Proton Therapy
Decreases Dose to the Rectum for
Patients With Prostate Cancer
3671
Santosh Yajnik
Proton Beam Therapy Reduces Dose
to Pelvic Bone Marrow Compared with
IMRT: A Dosimetric Study
3672
Su Yeon Park
Comparison of Different Treatment
Techniques in Radiotherapy for
Hepatocellular Carcinoma: Dosimetric
Analysis According to Tumor Location
3673
Xiaofei Song
Application of Beam Specific PTV in
Proton Therapy Treatment Planning
3674
Narayan Sahoo
Determination of Spread Out Bragg
Peak Factors and Range Shifter Factors
From Measured Depth Dose Curves for
Passively Scattered Proton Beams
3680
Mitsuhiro Nakamura
Estimation of a Tracking Margin in Surrogate Signal-based Dynamic Tumor Tracking Irradiation With Vero 4-D RT (MHI-TM2000)
3681
Nobutaka Mukumoto
Intra-fractional Tracking Accuracy
in Surrogate Signal-based Dynamic
Tumor-tracking Irradiation With Vero4DRT (MHI-TM2000)
3682
Yoshinori Miyahara
Feasibility of Direct-Conversion Flat
Panel Detector (FPD) System as Quality
Assurance (QA) Tool for 192-Ir Source
of High Dose Rate (HDR) Remote Afterloading Unit : Evaluation of Positional and Temporal Accuracy
3683
Hideo Yamamoto
A New Method of Total Body Irradiation Using a Field-In-Field Technique
3684
Eric Paulson
Feasibility of Generating Synthetic ED
and CT Images from Conventional MR
Images for Brain Radiation Treatment
Planning and Delivery
3675
Enrique W. Izaguirre
Polymer Scintillator Detector for Real
Time Proton Beam Quality Assurance
3685
Yoshitomo Ishihara
Four-dimensional Monte Carlo Dose
Calculation Method For Dynamic
Tumor Tracking Irradiation With a
Gimbaled X-ray Head
3676
John Han-Chih Chang
Dosimetric Comparisons of Uniform
Scanning Proton Beam Therapy (US
PBT) vs. Intensity Modulated Radiation
Therapy (IMRT) vs. Conformal 3-Dimensional Radiation Therapy (3-D CRT) for Mediastinal Malignancies
3686
Taro Murai
Using Static Ports of Tomotherapy
(TomoDirect): Comparison With the
TomoHelical Mode
3677
Ileana Iftimia
HDR GYN: Syed and Tandem and Ring
- Moving Forward Toward GEC-ESTRO
Protocol Implementation
3678
Dror Alezra
A New Beam and Delivery System for
Radiotherapy
3679
Waleed Mourad
Dosimetric and Biological Impacts of
Simultaneous Integrated Brachytherapy Boost (SIBB) Delivered
Via I125 Seeds Followed by External
Beam Radiotherapy (EBRT) on Prostate
Cancer
3687
Daniel Markel
A Novel Semi-automated Multi-modality Segmentation Tool for
Radiotherapy Treatment Planning in
Sarcoma Patients
3688
Robert Cormack
Locally Drug Enhanced Brachytherapy:
A Comparison of Two Approaches
Based on Biologically Effective Dose
3689
Guoqiang Cui
Delivery Efficiency and Dosimetric
Accuracy of Respiratory-gated Volumetric Modulated Arc Therapy
Using An Elekta Digital Accelerator
161
RADIATION PHYSICS/
continued
3690
Abdulmecit Canbolat
Investigation of Out-of-field Scattered
Radiation Based on Dose Rate for Sliding Window IMRT
3691
Lanchun Lu
NanoDots Dosimetry for RS 2000 X-Ray
Biological Irradiator
3692
Kin Yin Cheung
Gated VMAT Treatment of Moving
Targets Using a FFF Linear Accelerator
3693
Yun Yang
Design and Optimization of an HDR
192Ir Brachytherapy Applicator for
Skin Irradiation Using Monte Carlo-Based Dosimetry
3694
Rania Hashem
The Utilization of IMRT Planning in
Decreasing the Risk of Accelerated
Demyelination in Multiple Sclerosis
Patients Following External Beam
Radiation Therapy
3695
Mami Akimoto
Improvement of Tracking Accuracy
With Vero4-D RT(MHI-TM2000) Using
Phase Shift Correction
3696
Nancy Lee
The Immobilization Performance of a
Novel “Open-face” Mask Used for the
Setup of Claustrophobic Patients Being Treated for Head and Neck
Cancers
3700
Michael Epperly
Total Body Irradiation at High-dose-rate Using a TrueBeam Accelerator Results in Increased Survival in a Mouse Model
3701
Omar Mahmoud
A Ten-year Single Institutional Experience Using Adjuvant External
Beam Radiation Therapy for Extremity
Soft Tissue Sarcomas
3702
Evan Thomas
Improved Treatment Efficiency With
Flattening Filter Free Mode and Implications for Common Clinical
Scenarios
3711
Jian-Yue Jin
A Novel Multi-field Grid Treatment
Technique Using MLC Based IMRT
3712
Sai Subramanian
Chest Wall Radiotherapy With
Volumetric Modulated Arcs and the
Potential Role of Flattening Filter Free
Photon Beams
3713
Meng Welliver
A New Method for Total Body
Irradiation (TBI) Treatment Planning
Using an “Irregular Surface Compensator”
3703
Lakshmi Santanam
Risk Analysis of Real-time Adaptive
Planning Using the ViewRay System
3714
Wonmo Sung
Dose Perturbations Involving an
Implanted Cardiac Pacemaker in
High-dose-rate (HDR) Breast Balloon
Brachytherapy
3704
Steffi Kantz
Impact of MLC Properties and IMRT
Technique in Meningeoma and Head
and Neck
3715
Jung-in Kim
Assessment of Tracking Jaws Based
on MLC Aperture to Reduce Normal
Tissue Irradiation in VMAT
3705
Ikeda Tsuyoshi
Reduction of Patient Body Size
Dependency of CT Number Using Dual
Energy Computed Tomography
3716
Yu Ra Cho
Development of Tissue Equivalent Gel
Dosimeter for 3-Dimensional Dose
Evaluation
3706
Ho jin Jeong
A Dosimetric Effects of Four-dimensional and Monte Carlo
Calculation Methods on Treatment
Plans for Mobile Lung Cancer In Robotic Radiosurgery
3717
Magdalena Bazalova
Cost-effective Radiation Therapy With
Kilovoltage Photon Beams: A Monte
Carlo Study
3707
Ivaylo Mihaylov
Energy Minimization Approach to
Inverse Optimization for Head and
Neck Cancers
3718
Ilja Ciernik
Evaluation of Different External Radiotherapy Techniques for the Treatment of Malignant Pleural Mesothelioma After Extrapleural
Pleuropneumonectomy
3708
Laura Masi
Impact of Control Point Angular
Separation on the Dosimetric Accuracy
of VMAT Plans
3719
Hans Martin Kjer
Optimized Acquisition Parameters for
MRI Only RT Using Ultrashort Echo
Times
3698
Maria Clara Ferreira
Comparative Study of Biologic Effective Dose for the Beta Emitters
142Pr and 90Y and Their Applications
in Microsphere Brachytherapy of
Hepatocellular Carcinoma
3709
Mohammed Almaghrabi
Respiratory Gated Radiotherapy With
Hypofractionated Doses for Lung
Tumors: Four Years’ Experience of a
Single-institution
3720
Deniz Yalman
Comparison of Step-and-Shoot IMRT
and Different Volumetric Modulated
Arc Therapy (VMAT) Techniques for the
Treatment of Prostate Cancer
3699
Houari Korideck
Pre-clinical Image Guided Irradiation
of Pancreatic Cancer Transgenic Mouse
Model
3710
Qiuwen Wu
Evaluation of IMRT and VMAT for Head
and Neck Cancer With Flattening Filter
Free (FFF) Beams
3721
Jiang Xie
Breast Tangential Treatment Plan
Using Flattening Filter Free Beams: A
Planning Study
3697
Weigang Hu
Implement of a Passive Breath Gating
Equipment for Cone Beam CT guided
Volumetric Modulated Radiotherapy in
Gastric Cancer Treatment: Preliminary
Results
162
3722
Parthena Sansourekidou
Computer Vision Based Automation of
Verification of Treatment Field Parameters (Field Verification Timeout)
Prior to Radiation Therapy
3723
Lydia Handsfield
Current STAT Clinical Workflow and
Proposed 30 Minute Scan, Plan, Treat
STAT-RAD Workflow
3724
Jeffrey Kemp
Facilitating 3-D Image Guided
Treatment Planning of Shielded Tandem and Ovoid-based, Gynecological Brachytherapy Utilizing
Mvct
3725
Colin Carpenter
FDG-Cerenkov Imaging: A Molecular
Approach to Real-time Treatment
Guidance
3726
Elena Herranz
Iterative Determination of Clinical
Beam Phase Space From Dose Measurements
3727
Krishni Wijesooriya
Novel Findings on 18F-FDG PET
Uptake Distributions Within NSCLC
Tumors
3728
Ericka Wiebe
Customized Vaginal Vault Brachytherapy With CT Imaging-Derived Applicator
Prototyping
3729
John Greskovich
Improving Clinical Target Volume
(CTV) Dose Homogeneity and Normal
Tissue Maximum Dose for
Endoesophageal High-dose-rate (HDR)
Brachytherapy: One vs. Three HDR
Tube Technique
3731
Nava Paudel
Study of the Radiation Dose Enhancement at the Gold-tissue
Interface in Gold Nanoparticle-aided
Radiation Therapy With Micro-dosimetry Technique
3739
Rebecca Weinberg
Dosimetric Comparison of Treatment
Techniques for Skin Cancer Above the
Clavicle: High-dose-rate 3-Dimensional
Topographic Applicator Brachytherapy
vs. Electron Therapy
3732
Tejan Diwanji
Validation of High-resolution Multi-modality Imaging of
Pre-treatment Lung Function in Pulmonary Neoplasms
3740
Daniel Joh
A Novel ‘Theranostic’ Approach?
Polymer-coated Gold Nanoparticles
Show Durable Systemic Circulation,
are Readily Imaged, and Radiosensitize
Human Cancer Cells and Tumors
3733
Grace Gwe-Ya Kim
A comparison of Lung SBRT Using
With Static Field IMRT on TrueBeam
3734
Andre Vieira
Evaluation of Dosimetric Accuracy in
the Treatment of Multiple Brain Metastases With Volumetric Modulated Arc Therapy and Single
Isocenter.
3741
James Kavanaugh
Evaluation of Flattening Filter Free
Lung/Tissue Heterogeneity Dose
Calculations for Two Commercial Planning Systems
3742
Eric Ehler
Evaluation of Multi-isocentric VMAT
Plan Sensitivity to Setup Errors
3743
Yulin Song
A Pragmatic Approach to Assessing
Structure-Specific Dosimetric Error of
VMAT Delivery
3735
Shahram Mashouf
Optimization of Permanent Seed
Implant Dosimetry Incorporating Tissue Heterogeneity
3736
Semra Unal
Head and Neck IMRT With or Without
Flattening Filter: A Dosimetric Comparison
3737
Long Huang
Planning Quality and Delivery Accuracy Assessment of VMAT Plans
for Whole Brain Treatment With Hippocampus Avoidance
3738
Aman Anand
Dosimetric Evaluation of Tungsten
Eye-Shield In 9, 12 And 16 Mev Electron Beams Using EBT2 Gafchromic Films
3730
Pedro Guerra Gutierrez
Optimization of Monte Carlo Code for
Clinical Simulation of Electron Beams
163
NOTES
164
NOTES
165
AMERICAN SOCIE T Y FOR RADIATION ONCOLOGY
Help patients understand
their treatment options.
A diagnosis of cancer can
be overwhelming.
Help your patients understand radiation therapy as a treatment
option for their cancer by sharing ASTRO’s disease-site specific
brochures or guiding them to RTAnswers.org.
®
TAR GE TING CANCER CARE
INSIDE:
Indexes
Abstract by Author
Abstract by Topic
2012
ANNUAL MEETING
S
UPPORTERS
Special thanks to the following companies for supporting
ASTRO’s 54th Annual Meeting with an unrestricted educational grant.
PLATINUM
GOLD
SILVER
COPPER
Sun Nuclear
|
Vertual, Ltd
(as of September 2012)
|
Xstrahl, Ltd
Index by Author (Abstracts only)
A
Abazeed, Mohamed
Abazeed, Mohamed
Abbineni, Gopal
Abdel-Wahab, May
Abdel-Wahab, May
Abel, Ryan
Abelson, Jonathan
Abidin, Caitlin
Abramowitz, Matthew
Abrams, Matthew
Abuodeh, Yazan
Adams, Robert
Adams, Todd
Agarwal, Jai Prakash
Agarwal, Ankit
Agazaryan, Nzhde
Agbahiwe, Harold
Aggarwal, Aditi
Ahmed, Kamran
Ahmed, Awad
Ahmed, Safia
Ahmed, Kazi
Ahn, Peter
Ahunbay, Ergun
Aivas, Inge
Aizer, Ayal
Akasaka, Hiroaki
Akervall, Jan
Akimoto, Mami
Akino, Yuichi
Al Sulaimani, Eman
Albuquerque, Kevin
Alcorn, Sara
Alcorn, Sara
Alcorn, Sara
Aleman, Berthe
Alexander, Jesse
Alexander, Brian
Alezra, Dror
Al-Hallaq, Hania
AlHussain, Hussain
Ali, Arif
Alizadeh-Kashani, Moein
Alkhatib, Hassaan
Allen, Bryan
Allison, Ron
Almaghrabi, Mohammed
Al-Mamgani, Abrahim
Al-Omair, Ameen
Alongi, Filippo
Althaqfi, Saif
Altoos, Taghrid
Amarnath, Sudha
Anand, Aman
Anderson, Carryn
Anderson, James
Anderson, Joshua
1034
3285
3276
2326
3154
2149
1018
3259
330
2071
2182
2839
3151
1114
3185
3499
162
2260
2378
2532
396
313
2742
3558
2872
1039
3287
3313
3695
3610
276
2850
2819
2999
3365
174
1047
253
3678
3351
2821
2774
2833
3521
3288
2541
3709
53
98
2438
2629
3028
2816
3738
2818
2574
55
Anderson, Nigel
Anderson, Nigel
Ando, Yutaka
Aneja, Sanjay
Aneja, Sanjay
Aneja, Sanjay
2801
2830
3179
2124
2875
III
Barney, Brandon
Baschnagel, Andrew
Bassetti, Michael
Batth, Sukhjeet
Baumann, Brian
Bayouth, John
2551
2666
3226
199
1035
76
Bortolus, Roberto
Bowes, David
Brade, Anthony
Bradley, Julie
Bratman, Scott
Bray, Tracy 2436
2487
26
2786
7
6
Anton, Adrian
Anwar, Moshiur
Anwar, Moshiur
Aoki, Manabu
Aoki, Masahiko
Apicelli, Anthony
Appenzoller, Lindsey
Arastu, Nabeel
Arbea, Leire
Arbea, Leire
Arcangeli, Giorgio
Arcangeli, Stefano
Archambault, Jean
Ares, Carmen
Arjomandy, Bijan
Arneson, Kyle
Arns, Anna
Arora, Shruthi
Arsenault, Daniel
Arvold, Nils
Arvold, Nils
Asai, Kaori
Ashamalla, Hani
Atallah, Soha
Atsumi, Kazushige
Ausborn, Natalie
Avadhani, Jaiteerth
Aviles, Lijia
Awan, Musaddiq
Ayala-Peacock, Diandra
Azcona, Juan Diego
Aznar, Marianne
2501
2491
2517
2401
2930
2582
196
2988
244
2344
3532
364
5
2873
81
3660
2761
3400
2765
3131
1055
2195
2917
2776
2905
2235
216
3658
2616
2067
2205
3387
176
Bazalova, Magdalena
Bazalova, Magdalena
Bazan, Jose
Beadle, Beth
Becker, Nathan
Becker, Stefan
Bedi, Manpreet
Behrens, Claus
Beitler, Jonathan
Bejarano, Daniela
Bekelman, Justin
Berg, Ronald
Berlach, David
Berlach, David
Bernad, Daniel
Bernad, Daniel
Bernstein, Michael
Best, Lara
Beyer, David
Bhandare, Niranjan
Bhandare, Niranjan
Bhandari, Rahul
Bhatnagar, Ajay
Bhatt, Aashish
Bhattacharjee, Somorat
Bhavsar, Shripal
Bi, Nan
Bian, Shelly X.
Bibault, Jean-Emmanuel
Biritz, Bertrand
Bishop, Andrew
Bishop, Andrew
Bishop, Michael
Bjerre, Troels
Blacksburg, Seth
Blackstock, A. William
Blakaj, Dukagjin
Blakaj, Dukagjin
Blake, Monika
Blanchard, Miran
Blasi, Olivier
Bledsoe, Trevor
Bledsoe, Trevor
Block, Alec
Block, Alec
Blumenfeld, Philip
Bodis, Stephan
Boggs, Hunter
Boimel, Pamela
Bonavitacola, Patrick
Joseph
Bonner, James
Boo, Dorothy
3252
3717
2352
2665
1024
2208
1002
3482
13
2076
298
3549
2519
2805
2214
2341
2406
1001
1045
2794
3424
2150
340
153
2588
3002
3045
2405
2294
3416
2126
2130
2689
3334
2482
2854
3314
3606
2946
3049
3586
2690
2829
1123
3493
3306
2141
2908
3198
Bray, Tracy
Brink, Carsten
Brodin, Patrik
Brown, Aaron
Bruce, Jeff
Brunner, Thomas
Brunner, Thomas
Bryant, Curtis
Buatti, John
Buckstein, Michael
Buleteanu, Manuela
Burri, Ryan
Burt, Ashley
Burt, Ashley
Buscariollo, Daniela
Butterworth, Karl
Buzurovic, Ivan
3383
1121
158
235
60
223
2274
3150
2813
124
3612
2368
3135
3170
108
3208
3328
B
Baba, Fumiya
Baden, Craig
Badiyan, Shahed
Bahl, Gaurav
Bai, Penggang
Baine, Michael
Bakhoum, Samuel
Bakst, Richard
Balagamwala, Ehsan
Balagamwala, Ehsan
Balamucki, Christopher
Barani, Igor
Barker, Christopher
Barker, Christopher
Barnes, Carolyn
Barney, Brandon
2891
2363
1077
2841
3565
413
3190
1033
3103
3157
2888
2158
2743
3158
1083
2284
C
Cagni, Elisabetta
Cai, Gang
Cai, Jing
Cai, Yong
Cairncross, Gregory
Cámara, Ana
Camarata, Andrew
Cambeiro, Mauricio
Canbolat, Abdulmecit
Cannon, Donald
Cao, Ning
Cao, Yue
Caparrotti, Francesca
Carpenter, Colin
Carpenter, Todd
Casamassima, Franco
Cascales Garcia, Maria A.
Casey, Stephanie
Cassidy, Richard
Castle, Katherine
Cattaneo II, Richard
Catton, Charles
CaudeII, Jimmy
Cazoulat, Guillaume
Cengiz, Mustafa
Cha, Hyejung
Cha, Yong
Chadha, Manjeet
Chakravarti, Arnab
2027
Challapalli, Amar
409
Champ, Colin
2507
Champ, Colin
Chan, Annie
3581
1072
3555
2337
10
3481
2849
1011
3690
2223
3278
3390
2187
3725
3136
3100
2543
2897
2731
1009
238
345
2688
70
3617
2139
312
1057
9
1044
95
2846
375
169
Chan, Cato
3066
Chang, Jee Suk
277
Chang, Jee Suk
2325
Chang, Ji Hyun
3425
Chang, John Han-Chih
3676
Chang, Joseph Tung-Chieh 2741
Chang, Lynn
2086
Chao, Samuel
1117
Chapet, Olivier
2499
Charissoux, Marie
2503
Charpentier, Anne-Marie 2686
Chaudhry, Huma
2610
Chen, Aileen
4
Chen, Andy
2620
Chen, Helen
2575
Chen, Jenny Ling-Yu
2705
Chen, Lili
2524
Chen, Linda
18
Chen, Peter
212
Chen, Qing
3038
Chen, Shifeng
3337
Chen, Ting
3395
Chen, Viola
2419
Chen, Wenzhou
3018
Chen, Wenzhou
3020
Chen, Xiaojian
67
Chen, Xiaoming
336
Chen, Yen-Lin Evelyn
341
Chen, Yu-Jen
2562
Chen, Zhe
3428
Cheng, Yufeng
2238
Cherian, Sheen
2320
Cheung, Kin Yin
3692
Cheung, Patrick
118
Chia, David
2330
Chiang, Andrew
1111
Chibani, Omar
3419
Chiblak, Sara
3221
Chiesa, Silvia
3560
Chilukuri, Srinivas
2239
Chin, Christine
2653
Chin, Christine
2657
Chin, Michael
3320
Chinnachamy, Anand N. 2579
Chino, Junzo
2642
Cho, Ilsung
3402
Cho, Yu Ra
3716
Choi, Serah
1027
Choi, Kihwan
3536
Choi, Seungtaek
3661
Chopra, Supriya
2584
Choudhury, Ananya
2533
Chowdhry, Varun
2932
Christensen, Charlotte Birk 3129
Christenson, Eric
2064
Christensen, Eva
2585
Christensen, James
1091
Christensen, Michael
2138
Chu, Karen
2804
Chua, Melvin
262
Chuang, Cynthia
3384
Chung, Yoonsun
Chuong, Michael
Chuong, Michael
Church, Jessica
Churilla, Thomas
Churilla, Thomas
Ciernik, Ilja
Ciezki, Jay
Cigarral Garcia, Cristina
Cihoric, Nikola
Cirino, Eileen
Citrin, Deborah
Clark, Grant
Claude, Line
Clayton, Ravinder
Cohen, Dane
Cohen, Randi
Combs, Stephanie E.
Confer, Michael
Cook, April
Coolens, Catherine
Cooper, Anna
Cooper, Samuel
Cope, Frederick
Coplowitz, Shana
Cormack, Robert
Corradetti, Michael
Corso, Christopher
Cotter, Ryan
Coucke, Philippe
Cox, Brett
Cox, Brett
Craciunescu, Oana
Craft, David
Crandley, Edwin
Crandley, Edwin
Crandley, Edwin
Crehange, Gilles
Crehange, Gilles
Croke, Jennifer
Crook, Juanita
Cuaron, John
Cui, Yunfeng
Cui, Guoqiang
Cummings, Natalie
Cuneo, Kyle
Currey, Adam
Currey, Adam
Currier, Blake
Cuthbert, David
Czerminska, Maria Anna
Czito, Brian
Dabaja, Bouthaina
D’agostino, Giuseppe
Roberto
Dahele, Max
3520
2883
Chung, Alfred
Chung, Caroline
Chung, Yi Hsuan
Dai, Ying
Dai Kubicky, Charlotte
Dalah, Entesar
3300
283
3548
170
2631
189
2922
3630
29
2354
2838
2017
2018
3718
38
3144
3090
3469
2030
2565
1023
2382
240
82
1084
3110
3666
268
3164
2237
2068
2063
3688
3014
3280
2815
2089
292
2471
3429
3524
2096
2695
2909
2505
2509
2407
2424
1014
2944
3689
3295
15
2032
2061
2935
2485
325
106
D
179
D’Alimonte, Laura
Daly, Megan
Daly, Patricia
Damato, Antonio
Damato, Antonio
D’Ambrosi, Rafael
Dandapani, Savita
Dandapani, Savita
Daniel, Nguyen
Daniel, Nguyen
Dar, Abdul
Das, Indra
Das, Saikat
Das, Samayita
Das, Shiva
Dasgupta, Tina
Dawson, Laura
De Hertogh, Olivier
de Souza-Lawrence, Lana
Deasy, Joseph
Debenham, Brock
DeMarco, John
Demoor-Goldschmidt,
Charlotte
Deng, Jun
Deng, Meiling
Denniston, Kyle
Deraniyagala, Rohan
Desai, Neil
Desai, Prashant
Deshpande, Shrikant
Deviers, Alexandra
DeWees, Todd
Dhanesar, Sandeep
Dharmarajan, Kavita
Dharmarajan, Kavita
Dharmarajan, Kavita
Di, Liu
Diaconu, Claudiu
Diao, Kevin
Diaz, Dayssy
Diaz, Roberto
Dickerson, Edward
Diletto, Barbara
Dilling, Thomas
Dilworth, Joshua
Dinçbaş, Fazilet
Dinçbaş, Fazilet
Ding, Chuxiong
Ding, George
Ding, Jie
Ding, Kai
Ding, Kai
Diot, Quentin
Diwanji, Tejan
Djemil, Toufik
Doi, Yoshiko
Doll, Corinne
Dominello, Michael
Dong, Peng
Dong, Peng
Dorth, Jennifer
2513
1013
2808
3433
3502
2569
2173
3277
3522
3531
2990
3348
264
1032
2820
310
24
323
334
2004
2005
77
3084
207
3121
2041
17
3116
2785
1007
2655
3451
2140
1015
3642
12
401
3124
2907
3627
2411
278
3272
3556
2143
3013
3271
2442
3172
3597
3359
1065
3452
3578
193
3732
3616
2852
358
2392
1092
2081
3055
Dosoretz, Arie
Douglas, James
Drean, Gael
Duarte, Catherine
Dubey, Arbind
Dulaney, Caleb
Dunn, Emily
Dutta, Pinaki
Dvorak, Tomas
Dyer, Brandon
Dyk, Pawel
140
2789
2446
2413
3138
3080
239
2802
2860
3205
2597
E
Eaton, Bree
Eaton, Bree
Ebeling III, Robert
Edge, Stephen
Edson, Mark
Efstathiou, Jason
Egashira, Yusuke
Eguiguren Bastida, Mikel
Ehler, Eric
Eich, Hans Theodor
El-Bared, Nancy
Eldredge, Harriet
Eldredge, Harriet
Ellis, Rodney
Ellis, Rodney
El-Sayed, Samy
Engineer, Reena
Entezari, Vahid
Eom, Keun Yong
Epperly, Michael
Epperly, Michael
Epperly, Michael
Epperly, Michael
Epperly, Michael
Epperly, Michael
Epperly, Michael
Epstein-Peterson, Zachary
Ernst, Iris
Erpolat, Petek
Ester, Elizabeth
Esthappan, Jacqueline
Eto, Hidehiro
Evans, Suzanne
Evans, Andrew
2177
2296
2163
107
2166
297
3657
2861
3742
173
3120
185
2291
294
3514
2602
356
3413
2276
3211
3214
3222
3223
3224
3228
3700
1110
1064
2591
2496
2578
2590
2640
2904
F
Fahimian, Benjamin
Fairchild, Alysa
Fakhreddine, Mohamad
Falk, Marianne
Famiglietti, Robin
Fan, Kang-Hsing
Fareed, Muhammad
Farkas, Amy
Fasih, Aisha
Fasola, Carolina
1085
110
171
3371
247
2647
2711
2271
3292
2052
Fedewa, Stacey
Feigenberg, Steven
Felix, Armando
Feng, Felix
Feng, Wen
Feng, Yuanming
Ferraris, Gustavo
Ferreira, Maria Clara
Ferrer, Ferran
Fields, Emma
Finkelstein, Steven
Finkelstein, Steven
Fiorino, Claudio
Flickinger, John
Folkert, Michael
Folkert, Michael
Foote, Michael
Ford, Eric
Ford, Victoria
Formenti, Silvia Chiara
Fortin, Israel
Fortin, Marie Andree
Fosker, Chris
Foster, Ryan
Foster, William
Fotouhi Ghiam, Alireza
Frandsen, Jonathan
Frank, Steven
Frank, Steven
Fratamico, Robert
Freilich, Jessica
Freilich, Jessica
Fried, David
Fried, David
Fried, David
Fuhrer, Russell
Fuji, Hiroshi
Fujii, Osamu
Fujiwara, Masayuki
Fukada, Junichi
Fuller, Donald
Fumagalli, Ingrig
Fung, Wing
Funk, Ryan
Furet, Elise
Furlan, Carlo
Fuss, Martin
Fyles, Tony
295
2057
2427
1025
2983
273
3114
3698
2423
1060
2078
2369
3423
2204
2537
3584
3263
3557
3015
1030
2383
2865
127
3330
2456
3156
2622
2461
2682
2453
361
2942
2672
2744
3215
3182
3125
2885
2807
2264
368
3596
3403
2213
2016
3088
2309
353
G
Gaballa, Hani
Gabriel, Peter
Galerani, Ana Paula
Galland-Girodet, Sigolene
Gallant, Fleure
Gambacorta, Maria A.
Gamez, Mauricio
Gan, Gregory
2552
392
2490
3417
3415
2353
2345
3070
166
Gandhi, Ajeet
2684
Gandhi, Nishant
1029
Gandhidasan, Senthilkumar 394
Gao, Yunsheng
Garg, Shalini
Garsa, Adam
Gayou, Olivier
Ge, Jiajia
Gemici, Cengiz
Geneser, Sarah
Geng, Hui
Gerber, Naamit
Gerszten, Peter
Gerweck, Leo
Gewanter, Richard
Ghadessi, Mercedeh
Ghaly, Maged
Ghaly, Maged
Ghi, Maria Grazia
Giantsoudi, Drosoula
Godley, Andrew
Godley, Andrew
Goff, Julie
Goggin, Lisa
Goggin, Lisa
Golden, Daniel
Golden, Daniel
Golden, Daniel
Goldsmith, Benjamin
Goldsmith, Benjamin
Goldsmith, Tessa
Gomez, Caitlin
Gomez, Daniel
Gomez, Daniel
Gomez-Veiga, Francisco
Gong, Youling
Gore, Elizabeth
Gospodarowicz, Mary
Govers, Mieke
Graff, Pierre
Grant, Jonathan
Gray, Phillip
Greco, Carlo
Grecula, John
Green, Olga
Greer, Lester
Greskovich, John
Greskovich, John
Grew, David
Grills, Inga
Groselj, Blaz
Gross, Cary
Grover, Surbhi
Guadagnolo, B. Ashleigh
Guan, XiYin
Guarnaschelli, Jessica
Guckenberger, Matthias
Guerra Gutierrez, Pedro
Guerrero, Mariana
Guix, Benjamin
Gunn, G. Brandon
Gunter, Tyler
Guo, Susan
Gupta, Gaorav
Gupta, Pramod
Gupta, Shlok
2715
2962
2675
390
269
2281
202
3457
339
2179
3237
2422
144
2272
2457
378
3664
1129
3414
3229
2104
2116
2709
2847
3092
300
3048
154
2615
2858
2859
2489
1069
254
08
2092
3455
2997
30
2464
3027
3437
2512
3031
3729
2083
2152
3299
109
2824
303
2746
2147
1075
3730
197
2506
2660
2694
2921
346
2302
2874
Gutovich, Jordan
Guttmann, David
2835
3257
Ha, Jonathan
3580
Haas, Jonathan Andrew 2381
Habermehl, Daniel
3665
Hadziahmetovic, Mersiha 3168
Haidar, Yarah
2600
Hall, Matthew
3075
Hall, William
222
Hall, William
3312
Hallahan, Dennis
3297
Hallemeier, Christopher
301
Hallemeier, Christopher 2768
Hallman, Mark
2090
Hamilton, Sarah
3056
Hammer, Josef
2056
Hammoud, Rabih
3374
Hampton, Carnell
3621
Hamstra, Daniel
225
Han, Chengbo
3046
Han, Hee Ji
2324.5
Han, Jeannie
2184
Hanada, Takashi
3453
Hanasoge, Sheela
2358
Handsfield, Lydia
3723
Han-Oh, Sarah
3380
Hansen, Christian
2809
Hansen, Henrik
2589
Hansen, James
405
Harada, Hideyuki
2945
Harada, Satoshi
3255
Harasaki, Yasuaki
2219
Hardee, Matthew
2025
Hardee, Matthew
2156
Hardenbergh, Patricia
243
Haridass, Anoop
94
Haridass, Anoop
3332
Harima, Yoko
57
Haritha, Chiramana
3443
Harris, Timothy
2042
Hasegawa, Azusa
2748
Hasegawa, Masatoshi
3245
Hashem, Rania
43
Hashem, Rania
3694
Hashimoto, Masatoshi
3464
Hashimoto, Takayuki
2245
Hashizume, Chisa
2301
Hashizume, Chisa
2889
Hata, Masaharu
2788
Hatakenaka, Masamitsu
99
Hattangadi, Jona
93
Hattangadi, Jona
402
Hayashi, Akihiro
2462
Hayes, John
2488
Hazariwala, Ronica
3109
Hearn, Jason
3021
Hedayati, Mohammad
407
Helou, Joelle
Henderson, Randal
Henkner, Katrin
Hennequin, Christophe
Heravi, Mitra
Herde, Ryan
Herman, Michael
Heron, Dwight
Herranz, Elena
Herrera, Fernanda
Herskind, Carsten
Hertan, Lauren
Hess, Clayton
Hess, Clayton
Hess, Clayton
Heydarian, Mostafa
Higgins, Susan
Hijazi, Hussam
Hill-Kayser, Christine
Hillman, Gilda
Hillman, Gilda
Hiniker, Susan
Hinojosa Gomez, Jose
Hiraoka, Masahiro
Hirata, Kimiko
HIrata, Herbert
Hirata, Hidenari
Hjalm-Eriksson, Marie
Ho, Alice
Ho, Clement
Ho, Felix
Ho, Jennifer
Hobeika, Georges
Hofner, Peter
Holdsworth, Clay
Hollander, Andrew
Hollen, Tyler
Hollensen, Christian
Holliday, Emma
Holtzer, Nienke
Hong, Angela
Hong, Ji-Hong
Hong, Julian
Hong, Robert
Hoover, Andrew
Hoppe, Bradford
Horowitz, David
Horton, Janet
Hoskin, Peter
Hou, Ying
Housri, Nadine
Howard, Michael
Howell, David
Hoyer, Morten
Hristov, Dimitre
Hsu, Charles
Hsu, Feng-Ming
Hsu, Howard
Hu, Angie
Hu, Kenneth Shung
Hu, Man
2481
2514
3636
2393
3307
2941
2755
1036
3726
2559
3207
2318
123
1115
2844
2176
3281
2476
1116
3291
3293
2637
2408
2910
2553
2879
251
2500
2039
2131
2656
2540
3526
2654
3436
2450
2749
275
2878
69
1008
186
372
1050
2832
1119
1067
3310
LBA3
1118
2664
201
3087
3510
1122
3113
2254
3373
3379
52
377
Hegarty, Sarah
Hegde, John
Heijmen, Ben J.M.
Hu, Man
Hu, Weigang
Huang, Chun-Ming
2739
3697
2312
H
2843
2377
2735
171
Huang, Ellen Xiaoyan
Huang, Jiayi
Huang, Jing
Huang, Kitty
Huang, Kris
Huang, Long
Huang, Shao Hui
Huang, Zhibin
Huang, Zhibin
Huber, Kathryn
Huddart, Robert
Hullett, Craig
Hung, Chiwei
Hunt, Margie
Hunter, Bradley
Hunter, Grant
Hunter, Klaudia
Hunter, Klaudia
Hunter, Klaudia
Hunter, Klaudia
Hurwitz, Mark
Hutcheson, Katherine
195
1106
3203
2895
1040
3737
1100
2162
3197
410
296
3354
3251
1131
3050
2521
1101
2663
2722
2775
1109
155
I
Iftimia, Ileana
Igdem, Sefik
Ikushima, Hitoshi
Im, Jung Ho
Indelicato, Daniel
Infusino, Erminia
Ingledew, Paris-Ann
Innocente, Roberto
Inokuchi, Haruo
Inomata, Taisuke
Inoue, Kazuya
Inoue, Mitsuhiro
Inoue, Tetsuya
Iori, Mauro
Ishibashi, Naoya
Ishida, Yuichi
Ishihara, Takeaki
Ishihara, Takeaki
Ishihara, Yoshitomo
Ishikawa, Hitoshi
Ishiyama, Hiromichi
Isohashi, Fumiaki
Israel, Rebecca
Israel, Rebecca
Ito, Hitoshi
Ito, Yoshinori
Iuchi, Toshihiko
Iwabuchi, Michio
Iwata, Hiromitsu
Izaguirre, Enrique W.
3677
2703
2951
2304
3106
2060
2087
2242
3643
2466
2943
3368
2906
1120
3270
2249
2886
3591
3685
3206
2374
2299
2753
2754
2233
2234
21
3062
3243
3041
J
Jackson, James
Jackson, Andrew
Jacob, Naduparambil
Jain, Anshu
172
3161
3422
259
2409
Jain, Suneil
Janardanan Nair, Vimoj
Jang, Joanne
Jang, Joanne
Jang, Joanne
Jang, HongSeok
Jang, Sunyoung
Janko, Matthew
Jarboe, John
Jawad, Maha
Jawad, Maha
Jensen, Lindsay
Jeong, Bae Kwon
Jeong, Ho jin
Jeongshim, Lee
Jhaveri, Pavan
Jhawar, Sachin
Ji, ShengJun
Jia, Xun
Jiang, Xiaoqin
Jimenez, Rachel
Jin, Jian-Yue
Job, Mary
Joh, Daniel
Johansen, Jorgen
Johnson, Alex
Johnson, Jennifer
Johnson, Matthew
Johnson, Matthew
Johung, Kimberly
Jones, Bernard
Jones, Daniel Adam
Jones, Guy
Jones, Jennifer
Jones, Tiffanie
Joo, Jihyeon
Joshi, Chaitanya G.
Jotwani, Amit
Ju, Sang Gyu
Ju, Andrew
Ju, Sang Gyu
Julka, Pramod
Juloori, Aditya
Juloori, Aditya
Jung, Edward
Jung, Jinhong
2894
2955
3604
36
54
2692
3479
3579
3225
3324
1049
2073
3361
2606
3706
2929
307
3181
3189
3654
3460
161
3711
3097
3740
2737
2153
2862
3035
338
286
3358
2373
3077
3325
349
157
3309
2468
3355
3619
3644
2577
2630
2994
3093
2342
K
Kabarriti, Rafi
Kabolizadeh, Peyman
Kachnic, Lisa
Kagawa, Kazufumi
Kahn, Leonel
Kahn, Jenna
Kahn, Jenna
Kainz, Kristofer
Kajiya, Yoshiki
Kalakota, Kapila
Kalakota, Kapila
Kamikubo, Yoshifumi
Kaminuma, Takuya
2504
2222
2360
2777
1078
3118
3274
3645
2225
291
2550
3651
2474
Kandula, Shravan
Kane, Erin
Kang, Josephine
Kang, Josephine
Kang, Julie Jung
Kang, Ki Mun
Kannan, Neeta
Kannan, Neeta
Kantz, Steffi
Kapadia, Nirav
Kapadia, Nirav
Kapur, Ajay
Kapur, Ajay
Karakaya, Ebru
Karam, Irene
Karam, Irene
Karasawa, Kumiko
Karasawa, Katsuyuki
Kariya, Shinji
Karlin, Jeremy
Karlsson, Kristin
Kassas, Bassel
Kasuya, Goro
Kathpal, Madeera
Katoh, Norio
Katsoulakis, Evangelia
Katz, Alan
Katz, Alan
Katz, Leah
Kaufman, Isaac
Kavanaugh, James
Kawaguchi, Hideo
Kawamura, Mariko
Keall, Paul
Kehrer, Jason
Keiler, Louis
Keller, Lanea
Kelly, Douglas
Kelsey, Christopher
Kemp, Jeffrey
Ken, Soleakhena
Keole, Sameer
Kerns, Sarah
Kesarwala, Aparna
Kesarwala, Aparna
Kesarwala, Aparna
Kesava Ramgopal,
Adavikolanu
Kesava Ramgopal,
Adavikolanu
Khan, Atif
Khan, Luluel
Khan, Luluel
Khan, Mohammad
Khanuja, Jasleen
Kharofa, Jordan
Kharofa, Jordan
Kharofa, Jordan
Khodri, Mustapha
Khouri, Anton
Kiess, Ana
Kikuchi, Koyo
Kil, Whoon Jong
Kilburn, Jeremy
2172
1053
3159
3166
14
2322
2020
2567
3704
2871
3104
374
3183
2667
88
2795
2961
3023
2400
2396
79
3327
2556
2190
3342
2733
365
2380
2538
2822
3741
2730
3635
204
2796
2001
2790
2498
2933
3724
2134
2516
2486
284
2956
2966
3515
3518
350
3071
125
3484
2563
219
2898
3127
3615
2082
287
2435
2416
3025
Killoran, Joseph
Kiltie, Anne
Kiltie, Anne
Kim, Anthony
Kim, Byoung-Hyuck
Kim, Carolyn
Kim, Carolyn
Kim, Carolyn
Kim, Daniel
Kim, Dong W. Nathan Kim, Dongwook
Kim, Dongwook
Kim, Grace Gwe-Ya
Kim, Grace Gwe-Ya
Kim, Hayeon
Kim, Hye Young
Kim, In Ah
Kim, In Ah
Kim, JaYoung
Kim, Ji Hyun
Kim, Ji Hyun
Kim, Jin Hee
Kim, Joo Ho
Kim, Jun Won
Kim, Jun Won
Kim, Jun Won
Kim, Jun Won
Kim, Jung-in
Kim, Michelle
Kim, Siyong
Kim, Sung hoon
Kim, Taeho
Kim, Young Suk
Kim, Yusung
Kimple, Randall
Kimura, Tomoki
King, Benjamin
King, Christopher
King, Martin
King, Martin
Kinoshita, Rumiko
Kipritidis, John
Kirichenko, Alexander
Kirova, Youlia
Kirschner, Austin
Kishan, Amar
Kishi, Takahiro
Kitamura, Nozomi
Kjer, Hans Martin
Klaers, Jessica
Klein, Elizabeth
Klein, Eric
Klein, Thomas
Kleinberg, Lawrence
Klement, Rainer
Klepczyk, Lisa
Klopp, Ann
Knill, Cory
Ko, Eric
Koay, Eugene
Kobayashi, Noriko
Kodaira, Takeshi
Koh, Hyeon Kang
Koh, Wee Yao
2243
3218
3323
3438
2186
2526
2527
3634
2178
3322
3478
3501
3609
3733
2581
3512
184
3254
3068
237
3078
2572
3572
2315
2351
3171
3232
3715
2029
3608
2293
1128
3076
333
3279
2286
391
2448
2985
3107
2026
3568
25
2012
2636
3535
2981
3509
3719
3574
3153
3641
3194
16
121
2044
2627
2937
2492
2641
2228
2701
2122
2015
Kohutek, Zachary
Koike, Ryuta
Komaki, Ritsuko
Kong, Chi Wah
Kong, Feng-Ming
Kong, Lin
Koo, Tae Ryool
Koom, Woong Sub
Koontz, Bridget
Korah, Mariam
Korideck, Houari
Kornerup, Josefine S.
Kosaki, Katsura
Kosztyla, Robert
Koul, Rashmi
Kovalchuk, Nataliya
Kovalchuk, Nataliya
Kowalchik, Kristin
Kowalchik, Kristin
Koyfman, Shlomo
Kramkimel, Nora
Krauss, Daniel
Krengli, Marco
Kress, Marie-Adele
Krishnan, Monica
Krishnatry, Rahul
Kropp, Lauren
Krueger, Sarah
Kry, Stephen
Ku, Lichung
Kuang, Yu
Kudo, Shigehiro
Kumar, Aryavarta
Kumar, Aryavarta
Kumar, Aryavarta
Kumar, Kiran
Kumar, Parvesh
Kumar, Rachit
Kumar, Rachit
Kumar, Sanath
Kumaravelu, Azmi
Kunaprayoon, Dan
Kuo, Yuan-Chia
Kupelian, Patrick
Kuremsky, Jeffrey
Kurt, Meral
Kurtz, Goldie
Kusano, Aaron
Kuske, Robert
Kwok, Young
Kwon, Jeanny
Kwong, Stanley
90
2232
169
3343
3040
2714
2285
360
1112
84
3699
3122
2934
2137
3148
2784
271
2034
2241
2740
3160
145
2053
3086
129
2554
2803
3213
319
2900
328
2231
1061
2347
2687
3504
3396
1103
3503
3582
2767
2174
3248
389
380
2535
3614
249
214
2495
3089
3030
Laack, Nadia
Lai, Shihfan
Lally, Brian
Landry, Jerome
Lane, Sophia
1
2118
3047
357
128
Lappinen, Erik
Laser, Benjamin
Lasley, Foster
Latifi, Kujtim
Laufer, Marsha
Lauro, Christine
Lavaf, Amir
Laviraj, Macharla A.
Lavrenkov, Konstantin
Lawrence, Yaacov
Lawton, Colleen
Lazos, Dimitrios
Lazos, Dimitrios
Le, Yi
Leapman, Michael
Lecavalier-Barsoum,
Magali
Lee, Andrew
Lee, Andrew
Lee, Ann Shing
Lee, Dong Soo
Lee, Grace
Lee, Ho
Lee, Hyebin
Lee, Hyunjin
Lee, Jaegi
Lee, Jayoung
Lee, Joo Ho
Lee, Joo Hwan
Lee, Joseph
Lee, Joseph
Lee, Larissa
Lee, Larissa
Lee, Lucille
Lee, Nancy
Lee, Richard
Lee, Richard
Lee, Ryan
Lee, Sang-wook
Lee, Sangkyu
Lee, Seung Heon
Lee, Suk
Lee, Tae Kyu
Lee, Tsz Kin
Lee, Yongsook
Leeman, Jonathan
Leggett, Heather
Lei, Rachel
Leonard, Kara
Leonard, Kara
Leong, Nelson
Lescut, Nicolas
Lester-Coll, Nataniel
Letourneau, Melanie
Letourneau, Daniel
Lewis, Stephen
Leyrer, Marc
Li, BaoQing
Li, Dengwang
Li, Dengwang
Langen, Katja
Langsenlehner, Tanja
Lanni, Thomas
3497
3366
2047
Li, Dengwang
Li, Guang
Li, Hao
L
2297
404
23
2070
2346
3111
3022
3492
2335
3305
2402
3378
3550
2458
2511
3649
2624
3498
3575
2327
2310
3364
3505
3267
3585
71
3352
3217
2311
3607
2957
3147
3611
2102
2270
2367
3349
2712
3250
2706
3626
2051
1019
1004
3564
3533
3537
2265
3623
3542
3494
2437
3646
3350
1016
3344
220
327
3450
2324
2598
2530
3547
279
2189
2544
1076
3404
3357
2723
3398
1104
3691
2328
2529
2246
Ly, Bevan
Ly, Bevan
Ly, David
2389
2395
3139
2305
2201
2107
3538
2669
3477
3507
2109
2896
3367
2697
3019
236
2607
2853
3696
2266
2510
2698
3069
194
2303
3467
3659
3142
3399
2203
2113
3101
2023
2343
3316
2668
308
3112
2075
326
2127
2220
2724
3356
3527
Li, Heng
Li, Hualei
Li, Jingdong
Li, Jun
Li, Ning
Li, Ping
Li, Ruijiang
Li, Shunshan
Li, Tao
Li, Taoran
Li, X. Allen
Lian, Jun
Liang, Liping
Liang, Shixiong
Liang, Yun
Liao, Zhongxing
Likhacheva, Anna
Lilley, John
Lin, Angela
Lin, Chi
Lin, Chi
Lin, Christie
Lin, Qin
Lin, Yi-Ping
Lin, Yu-Wei
Ling, Diane
Linne, Tamara
Liriano, Melissa
Liss, Adam
Liu, Feng
Liu, Fenghong
Liu, Fenghong
Liu, Gene-Fu
Liu, Haisong
Liu, Han
Liu, Hongwei
Liu, Jerry
Liu, Wei
Liu, Wu
Liu, Yung Hsien
Liu, Zejian
Lloyd, Shane
Lo, Andrea
Lo, Anthony
Lobo, Mark
Lopez-Araujo, Javier
Lorentz, William
Lorenzen, Ebbe
Louie, Alexander
Louie, Alexander
Louie, Alexander
Lovelock, D. Michael
Low, Daniel
Lu, Bo
Lu, Haijun
Lu, Haijun
Lu, Jiade
Lu, Lanchun
Lu, NingNing
Lu, Sharon
Lu, Wei
3570
3590
206
Lucas, John
Ludwig, Michelle
Lukens, John
92
3410
152
Martin, Jeffrey
Martin, Andre
Martin, Jovita
2106
3102
2547
M
Ma, C.M. Charlie
3303
Ma, Jinli
2010
Ma, Lijun
2200
Ma, Lin
2708
Ma, Shihong
3253
MacArthur, Kelly
58
MacDonald, Shannon
281
Macdonald, Orlan
2084
Macdonald, Orlan
3007
Machtay, Mitchell
49
Macklis, Roger
3304
MacManus, Michael
2952
Macrie, Bryan
2633
Maehata, Yoshiyasu
3003
Magnan, Sindy
2515
Magnuson, William
2828
Maguire, Patrick
2021
Mahadevan, Anand
28
Mahajan, Anita
3650
Mahalingam, Sudha
2028
Mahe, Marc
2931
Mahmood, Usama
2480
Mahmoud, Omar
2356
Mahmoud, Omar
3701
Mailhot, Raymond
160
Maity, Amit
315
Mak, Kimberley
231
Mak, Raymond
33
Makita, Chiyoko
2283
Maletz, Kristina
2469
Mallarajapatna,
Govindarajan 3201
Malone, Shawn
2384
Malyapa, Robert
2745
Mampuya, Ange Wambaka 3593
Mancini, Brandon
2975
Mancini, Brandon
3000
Mancosu, Pietro
3487
Mangona, Victor
256
Manon, Rafael
3495
Mantz, Constantine
2399
Maquilan, Genevieve
2947
Maraldo, Maja Vestmoe
175
Marchan, Edward
2206
Marcus, David
2031
Marcus, Robert
3108
Margalit, Danielle
143
Maria, Ola
3227
Marina, Ovidiu
2403
Marina, Ovidiu
2414
Markel, Daniel
3687
Markovina, Stephanie
2523
Marples, Brian
265
Marshall, Richard
2426
1048
2525
3094
173
Maruyama, Katsuya
Marwaha, Gaurav
Mashouf, Shahram
Masi, Laura
Masunaga, Shin-ichiro
Mathew, Maya
Matsuo, Masayuki
Matsuo, Yukinori
Matsuyama, Tomohiko
Mattes, Malcolm
Mattes, Malcolm
Matthiesen, Chance
Matulewicz, Lukasz
Matuszak, Martha
Mayadev, Jyoti
Mayekar, Sonal
Mayr, Nina
Mazur, Lukasz
McAvoy, Sarah
McBride, Sean
McBride, William
McCloskey, Paula
McCloskey, Susan
McCormick, Beryl
McCullough, Anna
McCurdy, Matthew
McDermott, Sean
McDoland, Daniel
McGary, John
McGee, Lisa
McGee, Mackenzie
McGovern, Susan
McGurk, Ross
McKee, Andrea
Medin, Paul
Mehta, Minesh
Mehta, Niraj
Mehta, Vivek
Mei, Xin
Meier, Robert
Meier, Robert
Meier, Timothy
Mellon, Eric
Mellon, Eric
Melzig, Claudius
Membrive Conejo, Ismael
Mena, Ana Maria
Mendenhall, Nancy
Mendenhall, Nancy
Meng, Bowen
Menichelli, Claudia
Mensah, Apryl
Menzel, Paul
Meral, Rasim
Merrick, Scott
Meyer, Jeffrey
Meyer, Joshua
Meyer, Kurt
Michaelson, Evan
Michalski, Jeff
Michaud, Anthony
344
3598
3735
3708
3192
2215
3246
2887
2196
2939
3472
2729
3445
64
2586
2125
45
2836
3037
343
3302
3009
245
11
2863
101
3247
3483
3326
2443
266
1028
3528
2977
3265
2135
3165
3573
3525
366
2528
395
2048
2279
3298
2611
2035
226
2441
203
1062
3421
2159
3629
68
1063
2350
3571
3052
34
3401
Mierzwa, Michelle
Mihaylov, Ivaylo
Mihaylov, Ivaylo
2674
3461
3707
174
Mikami, Ryuji
2928
Mikell, John
1066
Miki, Yoshitaka
3163
Mikkelsen, Ross
3234
Milano, Michael
1020
Milby, Abigail
2098
Milby, Abigail
3231
Milby, Abigail
3670
Milecki, Piotr
3145
Milgrom, Sarah
2618
Miller, Robert
LBA 2
Min, Byung Jun
134
Min, Christine
2840
Min, Chul Hee
192
Minken, Andre
3552
Mirabeau-Beale, Kristina 2857
Mirkovic, Dragan
3669
Mishra, Kavita
1080
Mishra, Pankaj
3381
Mislmani, Mazen
2069
Mittal, Bharat
156
Miwa, Kazuhiro
2120
Miyahara, Yoshinori
3682
Miyakawa, Akifumi
2194
Mizoguchi, Nobutaka
2170
Mizowaki, Takashi
2379
Modesto, Anouchka
2747
Modlin, Leslie
289
Moghanaki, Drew
1046
Mohamed, Abdallah
2881
Mohamad, Issa
3563
Mohan, Radhe
2923
Mohindra, Pranshu
2696
Mok, Gary
2728
Molotievschi, Alerson
382
Moningi, Shalini
3105
Montero, Pablo H.
2652
Moore, Kevin
388
Moore, Joseph
3519
Moran, Brian
2520
Moraru, Ion
272
Moré, Jayaji
385
Morgan, Scott
230
Mori, Shinichiro
3652
Mori, Yoshimasa
2151
Morimoto, Masahiro
2376
Mornex, Francoise
221
Morris, Ann
2148
Morrow, Natalya
3530
Moskvin, Vadim
138
Mostafavi, Hassan
1130
Mou, Benjamin
2837
Mourad, Waleed
2371
Mourad, Waleed
2372
Mourad, Waleed
2508
Mourad, Waleed
2750
Mourad, Waleed
2769
Mourad, Waleed
2770
Mourad, Waleed
3079
Mourad, Waleed
3679
Moustafa, Mahmoud
3244
Msadabwe Chikuni, Susan 2596
Mueller, Sabine
114
Mukai, Masami
3655
Mukumoto, Nobutaka
3681
Mullapally, Sujith
2700
Munbodh, Reshma
2145
Munck af Rosenschold, Per 3569
Munoz Garcia, Julia Luisa 2404
Murai, Taro
3095
Murai, Taro
3686
Murakami, Ryuji
2644
Murakami, Yuji
2247
Murofushi, Keiko
2564
Murphy, James
2856
Murphy, James
126
Murphy, Rita
3016
Murray, Louise
3553
Musunuru, Hima
37
Noble, Anisha
Noel, Camille
Nohadani, Omid
Nowak, Kamila
Nowsheen, Somaira
Numasaki, Hodaka
Nuver, Tonnis
Nuyttens, Joost
Nuyttens, Joost
Nuyttens, Joost
Nwachukwu, Chika
Nygaard, Ditte Eklund
N
Obedian, Edward
Ochoa, Laura
Octave, Nadia
Oehler, Christoph
Offor, Onyi
Ogawa, Yasuhiro
Ogura, Kengo
Oguri, Mitsuhiko
Oh, Daniel
Oh, Dongryul
Oh, Dongryul
Oh, Jung Hun
Oh, RyoongJin
Oh, Seungjong
Ohga, Saiji
Ohri, Nitin
Oike, Takahiro
Ojerholm, Eric
Okamoto, Hiroyuki
Okamoto, Masahiko
Okano, Naoko
Okonogi, Noriyuki
Olsen, Jeff
Olson, Robert
Olsson, Caroline
Onimaru, Rikiya
Onishi, Hiroshi
Orcutt, Kevin
Orton, Matthew
Osa, Etin-Osa
Osinga, Julia-Maria
Ospina, Juan
Otsuka, Shinya
Otter, Sophie
Ou, Xiaomin
Ovalle, Valentina
Ovalle, Valentina
Ove, Roger
Owen, Jean
Na, Yong Hum
Nabid, Abdenour
Nagar, Himanshu
Nagar, Himanshu
Nakagawa, Akiko
Nakajima, Naomi
Nakamura, Akira
Nakamura, Mitsuhiro
Nakamura, Naoki
Nakamura, Naoki
Nakamura, Satoshi
Nakayama, Yuko
Nakayama, Masao
Nam, Jin-Min
Nam, Jiho
Narayana, Ashwatha
Nasseri, Morad
Nath, Sameer
Navarria, Pierina
Naydich, Boris
Nelson, Carl
Newcomb, Matthew
Ng, Chor-yi
Ng, John
Ng, Sook Kien
Ngan, Samuel
Nguyen, Brandon
Nguyen, Nhu Tram
Nguyen, Quynh
Nguyen, Quynh
Nguyen, Sonia
Ngwa, Wilfred
Niazi, Tamim
Nichols, Elizabeth
Nickers, Philippe
Nielsen, Tine B
Nijkamp, Jasper
Nishibuchi, Ikuno
Nishimura, Hideki
Nishimura, Takuya
Nishimura, Yasumasa
Nishioka, Akihito
3489
2415
2007
115
2568
2973
3466
3680
2003
3085
136
3034
3282
354
2117
2221
3440
2207
2959
2430
306
2671
3458
2984
3561
355
2472
2811
3663
3668
2088
332
2483
2926
2587
2986
2991
3216
2725
2473
167
2269
Nishioka, Kentaro
Nixon, Iain
Noa, Kate
3465
2670
2536
2760
66
3435
182
1026
250
3459
2359
2967
1010
3130
1017
O
3463
2160
72
3559
2522
280
2123
3005
61
2976
2980
2762
2290
3485
3065
2
3262
2210
3456
3204
2974
3260
3394
1097
3406
2949
122
3026
3589
208
133
2447
3064
148
2710
2095
2217
2267
2259
P
Paganetti, Harald
Pak, Daniel
137
3534
Palma, David
Palma, David
Palmer, Matthew
2882
3008
2693
Palmer, Matthew
Palta, Manisha
Paly, Jonathan
Pan, Hubert
Pan, Jianji
Panoff, Joseph
Papachristofilou,
Alexandros
Parashar, Bhupesh
Parekh, Arti
Parikh, Dhwani
Parikh, Parag
Parikh, Ravi
Parisi, Elisabetta
Parisi, Elisabetta
Park, Catherine
Park, Hae-jin
Park, Henry
Park, Joo Han
Park, Sang-June
Park, Samuel
Park, Su Yeon
Park, Wungki
Park, Young Hee
Parliament, Matthew
Parvathaneni, Upendra
Paryani, Nitesh
Pashtan, Itai
Pastore, Gabriella
Patel, Nisha
Patel, Nita
Patel, Samir
Patel, Shilpen
Patel, Shilpen
Patel, Shyamal
Patel, Pretesh
Patel, Vaiibhav
Patel, Vivek
Patil, Nikhilesh
Patni, Nidhi
Paudel, Nava
Paulino, Arnold
Paulson, Eric
Paulsson, Anna
Pawlicki, Todd
Paximadis, Peter
Peacock, Justin
Pelloski, Christopher
Peng, Jean
Peng, Luke
Peng, Ran
Peng, Xu
Peng, Zhang
Pennathur, Arjun
Pentimalli, Sara
Perez, Bradford
Perez, Carmen
Perez-Regadera, Jose
Perez-Romasanta, Luis
Perillo-Adamer, Florence
Perkins, Gregory
Perkins, Gregory
3667
2099
2548
2191
2704
2079
1022
2252
229
3286
329
309
379
2958
3199
2229
2180
3397
2797
3418
3672
2282
2183
3317
3098
1005
3162
2848
2192
3360
2175
2494
2673
2251
2262
2621
2759
2364
3209
2638
2036
3731
163
3684
2146
2866
408
3132
3289
3338
2339
209
2721
2718
2998
2038
1079
2968
2573
2772
3284
270
3377
Perkinson, Andrew
Peroski, Michael
Persson, Gitte
Peters, Christopher
Peterson, Carl
Peterson, David
Pfeffer, Raphael
Pfeffer, Raphael
Pham, Daniel
Pham, Ngoc
Phillips, Mark
Piotrowski, Tomasz
Pirozzi, Sara
Platta, Christopher
Plimpton, Steven
Podder, Tarun
Poettgen, Christoph
Poettgen, Christoph
Pollack, Alan
Poorvu, Philip
Popescu, Carmen
Potters, Louis
Poulsen, Per
Prabhu, Roshan
Prabhu, Roshan
Prah, Douglas
Pratx, Guillem
Prendergast, Brendan
Price, Samantha
Prieto, Isabel
Prior, Phillip
Prosnitz, Robert
Pugh, Thomas
Pukala, Jason
3369
2425
1088
2918
3012
2963
2165
2877
2545
80
3540
3475
3543
116
2062
321
381
3010
62
2601
2094
246
3517
2199
3081
3123
3196
2903
324
2798
2049
348
2439
3541
Q
Qi, Huanpeng
3032
Qi, Xiangrong
2924
Qi, Xiangrong
3473
Qiao,Xueying102
Qiao, Xueying
2884
Qin, Songbing
3339
Quero, Laurent
2226
Quirk, Sarah
2111
Quivrin, Magali
2394
Quon, Harry
1107
Quon, Harvey
367
Qureshi, Muhammad
2855
R
Raben, David
Racadot, Severine
Rah, Jeong-Eun
Rahimian, Javad
Rahn, Douglas
Rajagopalan, Malolan
Rajpara, Raj
Rakhra, Sunpreet
Rakusic, Zoran
Ramamurthy, Sindhu
386
2275
3637
3588
3133
2268
2969
218
2677
2964
Rana, Shushan
Rancati, Tiziana
Ranck, Mark
Rao, Yuan
Rao, Nikhil
Rao, Shyam
Raphael, Jomon
Rash, Dominique
Rashtian, Afshin
Rashtian, Afshin
Rashtian, Afshin
Rashtian, Afshin
Rath, Goura Kishor
Rathod, Shrinivas
Rava, Paul
Rava, Paul
Raval, Raju
Ravi, Akkamma
Reddy, Krishna
Redmond, Kristin
Reese, Adam
Refaat, Tamer
Register, Steven
Reinartz, Gabriele
Ren, Hua
Ren, Lei
Repka, Michael
Resende Salgado, Lucas
Rey, Felipe
Rey, Felipe
Riaz, Nadeem
Riaz, Nadeem
Riaz, Nadeem
Riaz, Nadeem
Ricchetti, Francesco
Rice, Roger
Riegel, Adam
Rimner, Andreas
Rineer, Justin
Riou, Olivier
Roa, Dante
Robbins, Jared
Robbins, Jared
Roberge, David
Roberts, Kenneth
Rochet, Nathalie
Rochet, Nathalie
Rodrigues, George
Rodrigues, George
Rodriguez, Vivian
Rodriguez de Dios, Nuria
Rodriguez-Ruiz, Maria E.
Roehrich, Manuel
Roenjom, Marianne Feen
Rollmann, Denise
Roman, Nicholas
Romesser, Paul
Romesser, Paul
Romesser, Paul
Romesser, Paul
Rong, Yi
Rooney, Jessica
2876
35
2454
2570
1098
74
2732
2576
2101
2114
3143
1012
2428
3146
2197
2198
3152
2132
2133
164
3471
2557
2612
177
2256
3491
2497
2757
2758
2634
2827
2680
2699
2738
2763
2662
3476
1127
2960
3033
2534
3544
2463
2193
1006
3119
2617
3462
141
1038
3576
215
2144
2825
316
149
3134
2992
2679
2764
2800
3242
1126
3167
Rosen, Lane
Rosen, Lane
Rosenberg, Stephen
Rosenberg, Jennifer
Rostom, Yousri
Roszak, Andrzej
Rottmann, Joerg
Roy, David
Royce, Trevor
Ruan, Dan
Ruby, Ashley
Rudra, Sonali
Rudra, Sonali
Rudzianskas, Viktoras
Ruggieri, Ruggero
Russell, Wesley
Russo, Andrea
Russo, Andrea
Russo, James
Rusu, Iris
Rutenberg, Michael
Rutkowski, Tomasz
2632
120
2914
3082
2298
2593
1086
2211
302
320
2643
3091
3567
2766
3408
2915
2845
178
2925
3029
2691
3311
S
Sabri, Siham
Sachsman, Suzanne
Sadek, Betro
Sahoo, Narayan
Sai, Sei
Saini, Jatinder
Saito, Akito
Saitoh, Jun-ichi
Sakata, Koh-ichi
Salem, Ahmed
Sales, Lindsay
Salguero, Francisco
Salinas, Juan
Samiee, Sara
Samuelian, Jason
Sandler, Howard
Sanfilippo, Nicholas
Sanguineti, Giuseppe
Sansourekidou, Parthena
Santanam, Lakshmi
Santhanam, Anand
Santos, Marcos
Sanuki, Naoko
Sarkar, Vikren
Sattler, Jennifer
Sattler, Margriet
Scala, L. Matthew
Schefter, Tracey
Schinkel, Colleen
Schmid, Thomas
Schmitt, Adam
Schneider, Ralf
Schoenfeld, Jonathan
Schonewolf, Caitlin
Schreibmann, Eduard
Schroyer, Daniel
Schubert, Leah
20
2361
1051
3674
3241
3385
3633
3640
3268
2100
2278
78
2417
3219
3340
7
227
2661
3722
3703
3393
168
2066
2386
3235
2103
371
39
3551
3240
3212
3656
2181
142
2316
3372
2518
387
175
Schuster, Jessica
Scorsetti, Marta
Seco, Joao
Seco, Joao
Sedlmayer, Felix
Seidel, Philipp
Sekine, Hiroshi
Selek, Ugur
Semrau, Robert
Sen, Sounok
Sen, Amarjit
Senan, Suresh
Senthi, Sashendra
Senthi, Sashendra
Serban, Monica
Sethi, Rajni
Sethi, Rajni
Sethi, Manish
Shah, Chirag
Shah, Chirag
Shah, Mira
Shah, Anand
Shang, Charles
Shankar, Vangipuram
Sharabi, Andrew
Sharabi, Andrew
Sharma, Charu
Sharma, Charu
Sharma, Daya Nand
Sharma, Daya Nand
Sharma, Kuldeep
Sharp, Hadley
Shaverdian, Narek
Sheets, Nathan
Sheldon, Thomas
Shen, Sui
Shenouda, Mina
Sheth, Nikul
Sheybani, Arshin
Shibamoto, Yuta
Shibamoto, Yuta
Shih, Helen
Shilkrut, Mark
Shimizu, Shinichi
Shinde, Prashantkumar
Shioyama, Yoshiyuki
Shipley, William
Shirai, Kiyonori
Shiraishi, Yutaka
Shirvani, Shervin
Shiue, Kevin
Shridhar, Ravi
Shridhar, Ravi
Shridhar, Ravi
Shukla, Monica
Shultz, David
Shusharina, Nadya
Shusharina, Nadya
Siedow, Michael
Siglin, Joshua
Silva, Luis
3583
27
3600
3638
2484
406
2006
3513
2683
86
2479
117
1021
2972
3176
282
2157
335
211
2024
2619
242
3412
2002
3173
3187
2050
2635
2580
398
2128
2168
2595
2869
2421
2599
89
2410
2185
1081
183
91
369
1037
3444
2995
299
3331
2387
3004
2188
105
2253
2263
2493
2940
257
3554
3296
2978
3391
Simpson, Daniel
Singh, Deepinder
Sinicki, James
Sio, Terence
Sio, Terence
Sio, Terence
Siva, Shankar
Siva, Shankar
Sjödin, Kristina
Skinner, Heath
Skinner, Heath
Skladowski, Krzysztof
Skliarenko, Julia
Skolny, Melissa
Skourou, Christina
Slomowitz, Alan
Smith, Jessica
Smith, Ryan
Smith, Wade
Sneed, Penny
Snyder, Michael
Soeder, Sherry
Soike, Mike
Sole, Claudio
Sole, Claudio
Soliman, Hany
Soliman, Hany
Soltys, Scott
Son, Christina
Song, Haijun
Song, Yeohan
Song, Yulin
Song, Yulin
Song, Xiaofei
Sood, Sumit
Sopka, Dennis
Sostin, Oleg
Spadea, Maria Francesca
Speer, Tod
Speer, Tod
Speers, Corey
Speight, Richard
Speight, Richard
Speight, Richard
Spencer, Christopher
Sperduto, Paul
Spiotto, Michael
Spira, Gregor
Spraker, Matthew
Spratt, Daniel
Stanescu, Teo
Stanic, Sinisa
Stanic, Sinisa
Stauder, Michael
Stavas, Mark Stavas
Stea, Baldassarre
Steen, Sven
Stegmaier, Petra
Stessin, Alexander
Stessin, Alexander
Stinauer, Michelle
44
3001
3184
1071
342
3353
47
337
2475
103
363
48
3053
285
3486
2097
2334
2467
393
293
3434
3149
3039
1095
3599
2224
22
1074
130
3392
2460
3632
3743
3673
3140
1099
2531
131
3308
3442
3269
2546
3370
3516
51
352
412
2418
3169
32
3613
2451
119
2880
3174
3083
2782
2756
1082
267
2313
Silveira, William
Silveira, William
Simone, Charles
2681
2979
87
Stock, Richard
Stockham, Abigail
Stojadinovic, Strahinja
2440
2834
3562
176
Stokes, William
Stone, Brandon
Stoyanova, Radka
Studer, Gabriela
Sturgeon, Jared
Su, Zhong
Subramanian, Sai
Suderman, Derek
Suh, John
Summers, Paige
Sun, Jason
Sun, Rui
Sun, Yan
Sung, Wonmo
Sunyach, Marie Pierre
Surapaneni, Aparna
Swamy, Kumara
Swisher-McClure, Samuel
Symon, Zvi
Symon, Zvi
Szeja, Sean
Szumacher, Ewa
Szumacher, Ewa
2867
2045
147
2771
2348
3115
3712
2455
3099
73
2823
3238
2720
3714
3620
2072
3200
2477
150
3647
1043
2465
2218
2008
3178
T
Taghian, Alphonse
Taguchi, Senzo
Tai, An
Tait, Lauren
Tajima, Yuu
Takahashi, Ryo
Takahashi, Shigeo
Takahashi, Shinichi
Takamatsu, Shigeyuki
Takayama, Kanako
Takemoto, Shinya
Takiar, Vinita
Takita, Cristiane
Tam, Tiffany
Tamura, Takeshi
Tandberg, Daniel
Tang, Chad
Tang, Xiaoli
Tang, Zili
Taniguchi, Cullen
Tanny, Sean
Tanooka, Masao
Tanzler, Emily
Tao, Randa
Tao, Zhen
Tatekawa, Kotoha
Taylor, Ben
Taylor, Noah
Taylor, Robert
Teckie, Sewit
Teckie, Sewit
Tejwani, Ajay
Tendulkar, Rahul
Terakedis, Breanne
Terashima, Kotaro
213
2812
3500
2212
2950
3511
2300
2391
2398
2649
2902
2431
2115
1052
2432
258
2676
3389
3294
263
3405
3409
96
373
3058
2953
2013
2093
1087
2171
2792
3180
232
2388
2375
Tesfamicael, Biniam
Tey, Jeremy
Thakur, Varun Singh
Thariat, Juliette
Thawani, Nitika
Thieke, Christian
Thirion, Pierre
Thomas, Evan
Thomas, Maria
Thomas, Tarita
Thorstad, Wade
Tian, Junqiang
Tinkle, Christopher
Tohyama, Naoki
Tokita, Kenneth
Tokumaru, Sunao
Toltz, Allison
Tonlaar, Nathan
Toramatsu, Chie
Torrecilla, Jose Lopez
Torres, Mylin
Townamchai, Kanokpis
Townsend, Natasha
Toyama, Shingo
Toyoda, Tatsuya
Trepanier, Pier-Yves
Trakul, Nicholas
Tremmel, Christoph
Tribius, Silke
Trister, Andrew
Troeller, Almut
Trovo, Marco
Trovo, Marco
Truong, Pauline
Tsai, Chiao-Ling
Tseng, Chia-Lin
Tseng, Yolanda
Tsuchiya, Kazuhiko
Tsudou, Shinji
Tsutsumi, Yurie
Tsuyoshi, Ikeda
Tsvang, Lev
Tumati, Vasu
Tumati, Vasu
Tunceroglu, Ahmet
Tundisi, Carmen
Turaka, Aruna
Turaka, Aruna
Turaka, Kiran
Turkevich, Vladimir
Turkevich, Vladimir
Tward, Jonathan
Tyagi, Neelam
Tzeng, Ching-Wei
3376
2255
3622
50
2366
3508
3011
3702
46
2817
2658
261
2583
3448
2502
2603
3420
2478
2289
2420
1058
2625
1042
2169
3470
3411
3036
331
3137
19
190
383
3345
347
2319
2161
2273
2707
2919
2121
3705
2470
2558
317
2280
2209
2916
3073
3074
2449
3096
2445
146
2338
U
Uchiyama, Kaoru
Ueda, Shinichi
Ueda, Yoshihiro
Unal, Semra
Ung, Yee
Ung, Yee
Urbanski, Bartosz
Ushjima, Hiroki
2927
3329
3595
3736
2864
3024
2046
3261
V
Vainshtein, Jeffrey
Valakh, Vladimir
Valliares, Martin
Vallinayagam,
Shanmuga S.
van Lin, Emile
van Sörnsen de Koste,
John
Vance, Sean
Vance, Sean
VanderWalde, Noam
Varadhan, Raj
Varadhan, Raj
Vargo, John
Vargo, John
Vasseur, Frederique
Vatner, Ralph
Vaughan, Andrew
Vazquez, Gonzalo
Vazquez, Gonzalo
Veeravalli, Krishna Kumar
Velec, Michael
Velker, Vikram
Venarini, Sabina
Vendrely, Veronique
Verbakel, Wilko F.A.R.
Vergalasova, Irina
Verheij, Marcel
Verma, Jonathan
Vern-Gross, Tamara
Vernon, Matthew
Vichare, Anushree
Videtic, Gregory
Vieira, Andre
Viertl, David
Vigneault, Eric
Villa, Salvador
Vineberg, Karen
Vinh-Hung, Vincent
Vinod, Shalini
Vinogradskiy, Yevgeniy
Vivekanandan, Sindu
Vlacich, Gregory
Vogel, Jennifer
Volz, Edna
Vora, Sujay
Vujaskovic, Zeljko
362
3057
1003
2594
2433
1125
2989
3362
3375
3449
3625
2779
2780
2560
2085
3188
1059
2971
2129
1090
2385
2022
2357
1096
3618
3335
1070
159
165
3054
2842
2913
3734
311
2397
2119
200
2105
2571
384
3426
2362
2787
2539
248
2444
3236
Vujovic, Olga
Vulquin, Noamie
Vuong, Te
Vyas, Shilpa
2019
2566
3273
3177
W
Wagner, Aaron
Wakatsuki, Masaru
Waldron, John
Walker, Amanda
Walker, Gary
Walker, Joshua
Wallace, Michelle
Wallace, Harold
Wang, Andrew
Wang, Brian
Wang, Chia-Chun
Wang, Chun-Chieh
Wang, Dian
Wang, Feng-Ming
Wang, Hongmei
Wang, Jin
Wang, Jin
Wang, Jin
Wang, Jing
Wang, Jingya
Wang, Kyle
Wang, Lilie
Wang, Lin
Wang, Pin-Chieh
Wang, Ping
Wang, Ping
Wang, Po-Ming
Wang, Qifeng
Wang, Qifeng
Wang, Shichao
Wang, Suzhen
Wang, Suzhen
Wang, Tao
Wang, Tony
Wang, Wei
Wang, Wei
Wang, Wei
Wang, Weili
Wang, Xin
Wang, Yan-yang
Wang, Yi
Wang, Yu-Wen
Wang, Yucai
Washington, Iman
Watanabe, Miho
Watanabe, Miho
Waters, Alexandra
Watkins, William
Weber, Damien
Wei, Lichun
Wei, Xiong
Wei, Xiong
Weinberg, Rebecca
Weinshank, Lindsay
Weiss, Elisabeth
Weksberg, David
3072
40
1102
3566
304
3239
2059
2412
3256
3388
2336
3249
2810
2230
2982
2717
3341
3432
3386
100
2826
2659
3155
3186
2936
3202
2308
2604
187
3454
2954
2037
3195
376
2054
2055
2250
170
2257
2333
3447
2713
2167
3210
2555
3126
2778
3431
2370
2561
2938
59
3739
2080
1124
3713
Welsh, James
Welsh, James
Werner-Wasik, Maria
Wernicke, A.Gabriella
Wersall, Peter
Whaley, Jonathan
Whaley, Jonathan
Whelan, Timothy
White, Evan
White, Ruth
Whitley, Alexander
Wiebe, Ericka
Wiebe, Ericka
Wijesooriya, Krishni
Wilcox, Shea
Wild, Aaron
Wild, Aaron
Wild, Aaron
Wilkinson, Ben
Wilkinson, Ben
Willers, Henning
Willey, Christopher
Williams, Jacqueline
Williams, Terence
Wilson, David
Wilson, David
Wilson, George
Wilson, Joella
Windsor, Apsara
Winkler, Peter
Witten, Matthew
Wo, Jennifer
Wobb, Jessica
Wobb, Jessica
Wojcieszynski, Andrzej
Wong, James
Wong, Jason
Wong, Michael
Wong, Philip
Wong, Rebecca
Wong, William
Wong, Wing Kei Rebecca
Woods, Charles
Woodward, Wendy
Woolley, Amy
Wright, Ato
Wright, Jean
Wu, Abraham
Wu, Cheng-Chia
Wu, Jia-Shing
Wu, Junxin
Wu, Q. Jackie
Wu, Qiuwen
Wu, Run-Ye
Wu, Szu-Yuan
Wuerschmidt, Florian
Wurstbauer, Karl
Wynn, Raymond Bernard
2452
172
2899
288
3382
2331
2920
LBA 1
2365
188
411
2639
3728
3727
2434
2277
2317
1094
255
3044
314
1031
3191
63
2719
2814
3315
3128
2459
3523
3546
2314
2033
2783
1068
3529
2429
2112
56
1073
1113
3594
2773
3321
2074
2970
2011
2244
3193
1108
2716
65
3710
180
2645
210
2009
2987
2851
X
Xiang, Hong
Xiang, Zuolin
Xie, Jiang
Xing, Ligang
Xing, Ligang
Xu, Benhua
Xu, Huimin
Xu, Li-ming
Xu, Min
Xu, Qianyi
Xu, Yaping
Xu, Zijie
Xue, Jianxin
Xue, Jinyu
Xue, Jinyu
3631
2901
3721
2248
2261
2332
3043
3063
2040
3624
3042
3474
2996
2043
3605
Y
Yajnik, Santosh
Yalman, Deniz
Yamada, Masahiro
Yamada, Yoshiya
Yamamoto, Hideo
Yamamoto, Michinori
Yamazaki, Takuya
Yamoah, Kosj
Yan, Di
Yan, Heping
Yan, Susu
Yan, Weisi
Yan, Weisi
Yanagi, Takeshi
Yang, Cungeng
Yang, Eddy
Yang, Joanna
Yang, Joanna
Yang, Joanna
Yang, Joanna
Yang, Tzu-I Jonathan
Yang, Wensha
Yang, Wensha
Yang, Xiaocheng
Yang, Xiaofeng
Yang, Xiaofeng
Yang, Yun
Yang, Zhaozhi
Yao, Min
Yap, Mei Ling
Yaparpalvi, Ravindra
Yassa, Michael
Ye, Hong
Yechieli, Raphael
Yeh, Brian
Yeh, Brian
Yeung, Rosanna
Yeung, Anamaria
Yeung, Daniel
Yi, Junlin
Yi, Sun
3671
3720
3336
97
3683
2791
2793
113
198
318
2077
85
2613
2727
274
181
397
399
403
3117
3141
2340
1093
3488
3490
75
2751
3693
2058
2650
234
2605
1041
2390
2626
139
3653
2355
2870
3648
2702
3006
177
Yin, Liangjie
Yip, Connie
Yip, Connie
Yip, Connie
Yip, Darwin
Yokoi, Tomohiro
Yondorf, Menachem
Yondorf, Menachem
Yoo, Sua
Yoon, Hannah
Yoon, Hyunsik
Yoon, Sang Min
Yorozu, Atsunori
Yoshikazu, Tsunashima
Yoshimoto, Yuya
Yoshimura, Ryo-ichi
Yoshimura, Michio
Youland, Ryan
Young, Kristina
Young, Melissa
Young, Rebekah
Yovino, Susannah
Yu, David
Yu, James
Yu, Jennifer
Yu, Jeong Il
Yu, Jinming
Yu, Naichang
Yu, Yao
Yuan, Zhi-Yong
Yue, Yong
Yuh, William
Yusoff, Sarahatul Bahiah
178
3230
2227
2240
2892
3175
3480
2136
2142
2065
233
2321
2155
370
135
3266
2646
2726
90
2202
2609
2110
2216
217
31
3275
2292
2912
2349
2651
2288
3430
3441
2014
Z
Zaccariotto, Audrey
Zaini, Mehran
Zakeri, Kaveh
Zaki, Bassem
Zaorsky, Nicholas
Zeidan, Youssef
Zelefsky, Michael
Zeng, Zhao-Chong
Zhai, Huifang Anna
Zhai, Yi Rui
Zhang, Chi
Zhang, Chi
Zhang, Chi
Zhang, Hong
Zhang, Hui
Zhang, Jeanette
Zhang, Jiandong
Zhang, Li
Zhang, Pengpeng
Zhang, Qinghui
Zhang, Ximei
Zhang, Ximei
Zhang, Ximei
Zhang, Yingjie
Zhang, Yingjie
Zhang, Zhenhuan
Zhao, Lujun
Zhao, Tianyu
Zhao, Ting
Zhen, Heming
Zhen, Heming
Zheng, Xiangpeng
Zheng, Yuanshui
Zheng, Yuanshui
Zhong, Hualiang
Zhong, Yahua
Zhou, Jessica
Zhou, Jun
Zhou, Su-Min
Zhu, Guangying
Zhu, He
Zhu, Ji
Zhu, Lihong
Zhu, Mingyao
Zhu, Shuchai
Zhu, Xuping
Zhuang, Hong-Qing
Zhuang, Hong-Qing
Zhuang, Yan
Zhung, Joanne
Zia, Yaseen
Zia, Yaseen
Ziegler, Mark
Ziel, Ellis
Zook, Jennifer
Zumsteg, Zachary
Zumsteg, Zachary
351
3407
112
3319
2154
2752
3
2287
2164
2306
228
2592
400
2734
3220
2831
2948
2258
3446
3602
3059
3060
3061
3346
3347
3233
3264
3439
3067
322
3496
2893
3639
3662
3539
1105
2614
3363
205
3283
42
2329
2628
3333
2236
132
252
2911
2993
1089
2685
2799
2323
3427
2108
1056
224
Index by Track (Abstracts only)
BREAST CANCER
McCormick, Beryl
Sperduto, Paul
Cohen, Randi
Roberts, Kenneth
Korah, Mariam
Yan, Weisi
Sen, Sounok
Simone, Charles
Karam, Irene
Shenouda, Mina
Osa, Etin-Osa
Peng, Ran
Shah, Chirag
Chen, Peter
Taghian, Alphonse
Kuske, Robert
Rodriguez de Dios, Nuria
Chang, Jee Suk
Diaz, Dayssy
Louie, Alexander
Ogawa, Yasuhiro
MacDonald, Shannon
Sethi, Rajni
Dai Kubicky, Charlotte
Kesarwala, Aparna
Skolny, Melissa
Gupta, Gaorav
Prosnitz, Robert
Jones, Tiffanie
Khan, Atif
Zaccariotto, Audrey
Fyles, Tony
Nam, Jin-Min
Jawad, Maha
Hong, Robert
Sadek, Betro
Tam, Tiffany
Kane, Erin
Weksberg, David
Arvold, Nils
Zumsteg, Zachary
Chadha, Manjeet
Torres, Mylin
Vazquez, Gonzalo
Fields, Emma
Keiler, Louis
Shankar, Vangipuram
Nakamura, Naoki
Sekine, Hiroshi
Nagar, Himanshu
Szumacher, Ewa
Ma, Jinli
Wright, Jean
Kirova, Youlia
11
52
82
83
84
85
86
87
88
89
208
209
210
211
212
213
214
215
277
278
279
280
281
282
283
284
285
347
348
349
350
351
353
354
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
Taylor, Ben
Yusoff, Sarahatul Bahiah
Koh, Wee Yao
Furet, Elise
Churilla, Thomas
Churilla, Thomas
Vujovic, Olga
Kannan, Neeta
Maguire, Patrick
Venarini, Sabina
Leonard, Kara
Shah, Chirag
Hardee, Matthew
Kinoshita, Rumiko
Bonavitacola, Patrick
Joseph
Mahalingam, Sudha
Kim, Michelle
Claes, Stefan
Marcus, David
Currey, Adam
Wobb, Jessica
Kowalchik, Kristin
Mena, Ana Maria
Patni, Nidhi
Wang, Suzhen
Pentimalli, Sara
Ho, Alice
Xu, Min
Deng, Jun
Harris, Timothy
Xue, Jinyu
Klepczyk, Lisa
Stone, Brandon
Urbanski, Bartosz
Lanni, Thomas
Mellon, Eric
Prior, Phillip
Sharma, Charu
Linne, Tamara
Fasola, Carolina
Krengli, Marco
Wang, Wei
Wang, Wei
Hammer, Josef
Feigenberg, Steven
Yang, Zhaozhi
Wallace, Michelle
Infusino, Erminia
Currey, Adam
Plimpton, Steven
Coplowitz, Shana
Christenson, Eric
Yoo, Sua
Sanuki, Naoko
Awan, Musaddiq
Cope, Frederick
Mislmani, Mazen
Latifi, Kujtim
Abrams, Matthew
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
Surapaneni, Aparna
Jawad, Maha
Woolley, Amy
Letourneau, Melanie
Bejarano, Daniela
Yan, Susu
Finkelstein, Steven
Panoff, Joseph
Weinshank, Lindsay
Dong, Peng
Khouri, Anton
Grew, David
Macdonald, Orlan
Vatner, Ralph
Chang, Lynn
Ingledew, Paris-Ann
Nguyen, Sonia
Coucke, Philippe
Hallman, Mark
Ravi, Akkamma
Govers, Mieke
Taylor, Noah
Popescu, Carmen
Ovalle, Valentina
Crandley, Edwin
Slomowitz, Alan
Milby, Abigail
Palta, Manisha
Salem, Ahmed
Rashtian, Afshin
Lin, Angela
Sattler, Margriet
Goggin, Lisa
Vinh-Hung, Vincent
Ly, Bevan
Lee, Grace
Zook, Jennifer
Lee, Jayoung
Young, Rebekah
Quirk, Sarah
Wong, Michael
Leggett, Heather
Rashtian, Afshin
Takita, Cristiane
Goggin, Lisa
Nam, Jiho
Lai, Shihfan
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
CENTRAL NERVOUS SYSTEM
Chakravarti, Arnab
Laack, Nadia
Cairncross, Gregory
Kang, Julie Jung
Cuneo, Kyle
Kleinberg, Lawrence
Deng, Meiling
Chen, Linda
Trister, Andrew
Sabri, Siham
9
1
10
14
15
16
17
18
19
20
Iuchi, Toshihiko
Youland, Ryan
Shih, Helen
Lucas, John
Hattangadi, Jona
Haridass, Anoop
Champ, Colin
Tanzler, Emily
Yamada, Yoshiya
Al-Omair, Ameen
Johung, Kimberly
Kiess, Ana
Wernicke, A. Gabriella
Modlin, Leslie
Kohutek, Zachary
Kalakota, Kapila
Cox, Brett
Sneed, Penny
Wong, Rebecca
Soltys, Scott
Guckenberger, Matthias
Lovelock, D. Michael
Badiyan, Shahed
Kahn, Leonel
Perez, Bradford
Shibamoto, Yuta
Stessin, Alexander
Barnes, Carolyn
Combs, Stephanie E.
Villa, Salvador
Miwa, Kazuhiro
Tsutsumi, Yurie
Koh, Hyeon Kang
Ogura, Kengo
Aneja, Sanjay
Mayekar, Sonal
Bishop, Andrew
Lewis, Stephen
Sharma, Kuldeep
Veeravalli, Krishna Kumar
Bishop, Andrew
Ho, Clement
Reddy, Krishna
Reddy, Krishna
Ken, Soleakhena
Mehta, Minesh
Yondorf, Menachem
Kosztyla, Robert
Christensen, Michael
Cha, Hyejung
Deviers, Alexandra
Bodis, Stephan
Yondorf, Menachem
Diletto, Barbara
Munbodh, Reshma
Paulsson, Anna
Guarnaschelli, Jessica
Morris, Ann
Abel, Ryan
21
90
91
92
93
94
95
96
97
98
286
287
288
289
290
291
292
293
1073
1074
1075
1076
1077
1078
1079
1081
1082
1083
1084
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
179
Bhandari, Rahul
Mori, Yoshimasa
Grills, Inga
Johnson, Alex
Zaorsky, Nicholas
Yoon, Sang Min
Hardee, Matthew
Sethi, Rajni
Barani, Igor
Menzel, Paul
Ochoa, Laura
Tseng, Chia-Lin
Huang, Zhibin
Ebeling III, Robert
Zhai, Huifang Anna
Pfeffer, Raphael
Edson, Mark
Wang, Yucai
Sharp, Hadley
Toyama, Shingo
Mizoguchi, Nobutaka
Teckie, Sewit
Kandula, Shravan
Dandapani, Savita
Kunaprayoon, Dan
Patel, Nisha
Heydarian, Mostafa
Eaton, Bree
Kim, Daniel
Gerszten, Peter
Park, Henry
Abuodeh, Yazan
Park, Young Hee
Han, Jeannie
Sheybani, Arshin
Kim, Byoung-Hyuck
Caparrotti, Francesca
Shiue, Kevin
Louie, Alexander
Kathpal, Madeera
Pan, Hubert
Pashtan, Itai
Roberge, David
Miyakawa, Akifumi
Arvold, Nils
Matsuyama, Tomohiko
Rava, Paul
Rava, Paul
Prabhu, Roshan
Ma, Lijun
Lee, Dong Soo
Young, Kristina
Leeman, Jonathan
Flickinger, John
Ayala-Peacock, Diandra
Marchan, Edward
Nath, Sameer
Becker, Stefan
Tundisi, Carmen
Ojerholm, Eric
Roy, David
Tait, Lauren
Funk, Ryan
180
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
Bernad, Daniel
Mathew, Maya
Yovino, Susannah
Ovalle, Valentina
Szeja, Sean
Harasaki, Yasuaki
Leyrer, Marc
Narayana, Ashwatha
Kabolizadeh, Peyman
Cannon, Donald
Soliman, Hany
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
GASTROINTESTINAL
CANCER Soliman, Hany
Lasley, Foster
Dawson, Laura
Kirichenko, Alexander
Brade, Anthony
Scorsetti, Marta
Mahadevan, Anand
Chuong, Michael
Hatakenaka, Masamitsu
Wang, Jingya
McCurdy, Matthew
Qiao, Xueying
Skinner, Heath
Shridhar, Ravi
Czito, Brian
Ausborn, Natalie
Yu, David
Rakhra, Sunpreet
Kharofa, Jordan
Lloyd, Shane
Mornex, Francoise
Hall, William
Brunner, Thomas
Ngan, Samuel
Engineer, Reena
Landry, Jerome
Doll, Corinne
Koom, Woong Sub
Freilich, Jessica
Vainshtein, Jeffrey
Kumar, Aryavarta
Menichelli, Claudia
Meyer, Jeffrey
Ernst, Iris
Ding, Jie
Mikell, John
Horowitz, David
Wojcieszynski, Andrzej
Gong, Youling
Verheij, Marcel
Sio, Terence
Cai, Gang
Kajiya, Yoshiki
Quero, Laurent
Yip, Connie
Kobayashi, Noriko
Park, Hae-jin
Wang, Feng-Ming
Kudo, Shigehiro
22
23
24
25
26
27
28
29
99
100
101
102
103
105
106
216
217
218
219
220
221
222
223
355
356
357
358
360
361
362
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
2225
2226
2227
2228
2229
2230
2231
Koike, Ryuta
Ito, Hitoshi
Ito, Yoshinori
Atsumi, Kazushige
Zhu, Shuchai
Cooper, Samuel
Cheng, Yufeng
Chilukuri, Srinivas
Yip, Connie
Kowalchik, Kristin
Innocente, Roberto
Killoran, Joseph
Wu, Abraham
Hashimoto, Takayuki
Lu, Wei
Murakami, Yuji
Xing, Ligang
Ishida, Yuichi
Wang, Wei
Patel, Shilpen
Parashar, Bhupesh
Shridhar, Ravi
Hsu, Feng-Ming
Tey, Jeremy
Ren, Hua
Wang, Xin
Zhang, Li
Owen, Jean
Aggarwal, Aditi
Xing, Ligang
Patel, Shilpen
Shridhar, Ravi
Fukada, Junichi
Liu, Gene-Fu
Lee, Richard
Ove, Roger
Rajagopalan, Malolan
Nishioka, Akihito
Lin, Chi
Farkas, Amy
Ghaly, Maged
Tseng, Yolanda
Brunner, Thomas
Racadot, Severine
Eom, Keunyong
Wild, Aaron
Sales, Lindsay
Mellon, Eric
Tunceroglu, Ahmet
Gemici, Cengiz
Park, Wungki
Makita, Chiyoko
Barney, Brandon
Koo, Tae Ryool
Kimura, Tomoki
Zeng, Zhao-Chong
Yuan, Zhi-Yong
Toramatsu, Chie
Oh, RyoongJin
Eldredge, Harriet
Yu, Jeong Il
Kim, Sung hoon
Bibault, Jean-Emmanuel
Eaton, Bree
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2296
Lappinen, Erik
Rostom, Yousri
Isohashi, Fumiaki
Takahashi, Shigeo
Hashizume, Chisa
Gupta, Pramod
Lee, Seung Heon
Im, Jung Ho
Lee, Ann Shing
Zhai, Yi Rui
Wang, Po-Ming
Fuss, Martin
Li, Ping
Liang, Shixiong
Huang, Chun-Ming
Stinauer, Michelle
Wo, Jennifer
Kim, Jun Won
Schonewolf, Caitlin
Wild, Aaron
Hertan, Lauren
Tsai, Chiao-Ling
Cherian, Sheen
Yoon, Hyunsik
Kang, Ki Mun
Ziegler, Mark
Lobo, Mark
Han, Hee Ji
Chang, Jee Suk
Abdel-Wahab, May
Li, Ning
Zhu, Ji
Chia, David
Whaley, Jonathan
Xu, Benhua
Wang, Yan-yang
Smith, Jessica
Lavrenkov, Konstantin
Wang, Chia-Chun
Cai, Yong
Tzeng, Ching-Wei
Peng, Luke
Bernad, Daniel
Jung, Jinhong
Leonard, Kara
Arbea, Leire
Gambacorta, Maria
Antonietta
Laufer, Marsha
Kumar, Aryavarta
Sturgeon, Jared
Yu, Naichang
Meyer, Joshua
Kim, Jun Won
Bazan, Jose
Gallant, Fleure
Chuong, Michael
Yeung, Rosanna
Mahmoud, Omar
Vendrely, Veronique
Hanasoge, Sheela
Nuyttens, Joost
Kachnic, Lisa
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2324.5
2325
2326
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
Sachsman, Suzanne
Vivekanandan, Sindu
Baden, Craig
Patel, Vaiibhav
White, Evan
Thawani, Nitika
Lin, Chi
2361
2362
2363
2364
2365
2366
2367
GENITOURINARY CANCER
Zelefsky, Michael
Sandler, Howard
Gospodarowicz, Mary
Gray, Phillip
Yu, James
Spratt, Daniel
Mak, Raymond
Michalski, Jeff
Rancati, Tiziana
Jang, Joanne
Musunuru, Hima
Ciezki, Jay
Dosoretz, Arie
Rodrigues, George
Margalit, Danielle
Ghadessi, Mercedeh
Krauss, Daniel
Tyagi, Neelam
Stoyanova, Radka
Zumsteg, Zachary
Hamstra, Daniel
Mendenhall, Nancy
Sanfilippo, Nicholas
Zhang, Chi
Parekh, Arti
Morgan, Scott
Mak, Kimberley
Tendulkar, Rahul
Ellis, Rodney
Fedewa, Stacey
Huddart, Robert
Efstathiou, Jason
Bekelman, Justin
Shipley, William
Goldsmith, Benjamin
Skinner, Heath
Arcangeli, Giorgio
Katz, Alan
Meier, Robert
Quon, Harvey
Fuller, Donald
Shilkrut, Mark
Yorozu, Atsunori
Shimizu, Shinichi
Rodrigues, George
Aizer, Ayal
Huang, Kris
Yassa, Michael
Townsend, Natasha
Symon, Zvi
Challapalli, Amar
3
7
8
30
31
32
33
34
35
36
37
38
140
141
142
143
144
145
146
147
224
225
226
227
228
229
230
231
232
294
295
296
297
298
299
300
301
363
364
365
366
367
368
369
370
1037
1038
1039
1040
1041
1042
1043
1044
Beyer, David
Moghanaki, Drew
Alexander, Jesse
Martin, Jeffrey
Burri, Ryan
Finkelstein, Steven
Weber, Damien
Mourad, Waleed
Mourad, Waleed
Jones, Daniel Adam
Ishiyama, Hiromichi
Terashima, Kotaro
Morimoto, Masahiro
Hegde, John
Ahmed, Kamran
Mizowaki, Takashi
Katz, Alan
Haas, Jonathan Andrew
Clayton, Ravinder
Fortin, Israel
Malone, Shawn
Velker, Vikram
Sato, Hiraku
Shiraishi, Yutaka
Terakedis, Breanne
Lecavalier-Barsoum,
Magali
Ye, Hong
Takahashi, Shinichi
Dominello, Michael
Hennequin, Christophe
Quivrin, Magali
Karlin, Jeremy
Vigneault, Eric
Takamatsu, Shigeyuki
Mantz, Constantine
Kariya, Shinji
Aoki, Manabu
Lawton, Colleen
Marina, Ovidiu
Munoz Garcia, Julia Luisa
Bian, Shelly X.
Bernstein, Michael
Croke, Jennifer
Hinojosa Gomez, Jose
Jain, Anshu
Sheth, Nikul
Diao, Kevin
Wallace, Harold
Duarte, Catherine
Marina, Ovidiu
Nabid, Abdenour
Kil, Whoon Jong
Salinas, Juan
Spira, Gregor
Chen, Viola
Torrecilla, Jose Lopez
Sheldon, Thomas
Gewanter, Richard
Ferrer, Ferran
Crook, Juanita
Peroski, Michael
Marshall, Richard
Felix, Armando
1045
1046
1047
1048
2368
2369
2370
2371
2372
2373
2374
2375
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
Rath, Goura Kishor
Wong, Jason
Naydich, Boris
Takiar, Vinita
Tamura, Takeshi
van Lin, Emile
Wilcox, Shea
Kikuchi, Koyo
Bortolus, Roberto
Liu, Jerry
Alongi, Filippo
Pugh, Thomas
Stock, Richard
Mendenhall, Nancy
Dincbas, Fazilet
McGee, Lisa
Vora, Sujay
Tward, Jonathan
Drean, Gael
Ospina, Juan
King, Christopher
Turkevich, Vladimir
Hollander, Andrew
Stanic, Sinisa
Welsh, James
Fratamico, Robert
Ranck, Mark
Suderman, Derek
Foster, William
Ghaly, Maged
Le, Yi
Windsor, Apsara
Song, Yeohan
Frank, Steven
Hayashi, Akihiro
Robbins, Jared
Greco, Carlo
Symon, Zvi
Inomata, Taisuke
Smith, Ryan
Jotwani, Amit
Maletz, Kristina
Tsvang, Lev
Cox, Brett
Nguyen, Brandon
Nishimura, Takuya
Kaminuma, Takuya
Sjödin, Kristina
Hijazi, Hussam
Tonlaar, Nathan
Sen, Amarjit
Mahmood, Usama
Helou, Joelle
Blacksburg, Seth
Niazi, Tamim
Sedlmayer, Felix
Cuthbert, David
Kerns, Sarah
Bowes, David
Hayes, John
Gomez-Veiga, Francisco
Galerani, Ana Paula
Anwar, Moshiur
2428
2429
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
2441
2442
2443
2444
2445
2446
2447
2448
2449
2450
2451
2452
2453
2454
2455
2456
2457
2458
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
Ko, Eric
Shukla, Monica
Patel, Nita
Kwok, Young
Ester, Elizabeth
Repka, Michael
Kelly, Douglas
Chapet, Olivier
Hjalm-Eriksson, Marie
Anton, Adrian
Tokita, Kenneth
Charissoux, Marie
Kabarriti, Rafi
Crehange, Gilles
Guix, Benjamin
Boo, Dorothy
Mourad, Waleed
Crehange, Gilles
Lee, Richard
Leapman, Michael
Greer, Lester
D’Alimonte, Laura
Henderson, Randal
Agnan, Sindy
Keole, Sameer
Anwar, Moshiur
Schroyer, Daniel
Berlach, David
Moran, Brian
Hunter, Grant
Offor, Onyi
Markovina, Stephanie
Chen, Lili
Martin, Andre
Kim, Carolyn
Kim, Carolyn
Meier, Robert
Lu, Sharon
Lorentz, William
Sostin, Oleg
Ahmed, Awad
Choudhury, Ananya
Riou, Olivier
Kurt, Meral
Noa, Kate
Folkert, Michael
Katz, Leah
Vogel, Jennifer
Ho, Jennifer
Allison, Ron
Cascales Garcia, Maria
Almudena
Louie, Alexander
Pham, Daniel
Speight, Richard
Ly, David
Paly, Jonathan
Zhang, Chi
Kalakota, Kapila
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2543
2544
2545
2546
2547
2548
2549
2550
181
GYNECOLOGICAL CANCER
Schefter, Tracey
Wakatsuki, Masaru
Gandhi, Ajeet
Zhu, He
Hashem, Rania
Simpson, Daniel
Mayr, Nina
Thomas, Maria
Siva, Shankar
Yoon, Hannah
Yap, Mei Ling
Brown, Aaron
Lee, Larissa
Kim, Ji Hyun
Cattaneo II, Richard
Dunn, Emily
Cohen, Dane
Robbins, Jared
Barney, Brandon
Gaballa, Hani
Hirata, Kimiko
Krishnatry, Rahul
Watanabe, Miho
Kasuya, Goro
Refaat, Tamer
Tumati, Vasu
Herrera, Fernanda
Vasseur, Frederique
Wei, Lichun
Chen, Yu-Jen
Khanuja, Jasleen
Murofushi, Keiko
Clark, Grant
Vulquin, Noamie
Kannan, Neeta
Nakagawa, Akiko
D’Ambrosi, Rafael
Rao, Yuan
Vinod, Shalini
Kim, Jin Hee
Perez-Regadera, Jose
Anderson, James
Chen, Helen
Rash, Dominique
Julka, Pramod
Esthappan, Jacqueline
Chinnachamy, Anand
Narayan
Sharma, Daya Nand
Kim, Hayeon
Apicelli, Anthony
Tinkle, Christopher
Chopra, Supriya
Christensen, Eva
Mayadev, Jyoti
Nickers, Philippe
Bhattacharjee, Somorat
Hansen, Henrik
Eto, Hidehiro
Erpolat, Petek
Zhang, Ying
Roszak, Andrzej
182
39
40
41
42
43
44
45
46
47
233
234
235
236
237
238
239
240
241
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
Vallinayagam, S.
Subramanian
Shaverdian, Narek
Msadabwe Chikuni, Susan
Dyk, Pawel
Lopez-Araujo, Javier
Shen, Sui
Haidar, Yarah
Poorvu, Philip
Eng, Tony
Tokumaru, Sunao
Wang, Qifeng
Yaparpalvi, Ravindra
Jeong, Bae Kwon
Lee, Larissa
Young, Melissa
Chaudhry, Huma
Membrive Conejo, Ismael
Register, Steven
Yan, Weisi
Zhou, Jessica
Gomez, Caitlin
Aviles, Lijia
Rochet, Nathalie
Milgrom, Sarah
Shah, Mira
Chen, Andy
Patel, Shyamal
Frandsen, Jonathan
Nagar, Himanshu
Li, Hualei
Townamchai, Kanokpis
Yechieli, Raphael
Klopp, Ann
Zhu, Lihong
Althaqfi, Saif
Juloori, Aditya
Chung, Alfred
Rosen, Lane
Macrie, Bryan
Rey, Felipe
Sharma, Charu
Kirschner, Austin
Hiniker, Susan
Patil, Nikhilesh
Wiebe, Ericka
Evans, Suzanne
Koay, Eugene
Chino, Junzo
Ruby, Ashley
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2609
2610
2611
2612
2613
2614
2615
2616
2617
2618
2619
2620
2621
2622
2623
2624
2625
2626
2627
2628
2629
2630
2631
2632
2633
2634
2635
2636
2637
2638
2639
2640
2641
2642
2643
HEAD AND NECK CANCER
Beitler, Jonathan
Skladowski, Krzysztof
Machtay, Mitchell
Thariat, Juliette
Spencer, Christopher
Hu, Kenneth Shung
Al-Mamgani, Abrahim
Jang, Joanne
Otter, Sophie
Roenjom, Marianne Feen
13
48
49
50
51
52
53
54
148
149
150
Lukens, John
Bhatt, Aashish
Goldsmith, Tessa
Hutcheson, Katherine
Mittal, Bharat
Scala, L. Matthew
Hong, Julian
Tao, Randa
Kapur, Ajay
Chan, Annie
Wang, Tony
Hu, Man
Ghi, Maria Grazia
Olson, Robert
Rao, Nikhil
Sopka, Dennis
Huang, Shao Hui
Hunter, Klaudia
Waldron, John
Kumar, Rachit
Lu, Jiade
Zhong, Yahua
Huang, Jiayi
Quon, Harry
Wu, Jia-Shing
Murakami, Ryuji
Wu, Szu-Yuan
Yoshimura, Ryo-ichi
Fan, Kang-Hsing
Wang, Lilie
Takayama, Kanako
Yao, Min
Yu, Yao
Montero, Pablo H.
Chin, Christine
Hofner, Peter
Desai, Prashant
Ho, Felix
Chin, Christine
Thorstad, Wade
Wang, Tony
Gunn, G. Brandon
Sanguineti, Giuseppe
Ricchetti, Francesco
Hunter, Klaudia
Housri, Nadine
Beadle, Beth
Baschnagel, Andrew
Karakaya, Ebru
Lescut, Nicolas
Lee, Hyebin
Nixon, Lain
Newcomb, Matthew
Fried, David
Patel, Samir
Mierzwa, Michelle
Garsa, Adam
Tang, Chad
Rakusic, Zoran
Romesser, Paul
Riaz, Nadeem
Silveira, William
Frank, Steven
Semrau, Robert
152
153
154
155
156
371
372
373
374
375
376
377
378
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
2644
2645
2646
2647
2648
2649
2650
2651
2652
2653
2654
2655
2656
2657
2658
2659
2660
2661
2662
2663
2664
2665
2666
2667
2668
2669
2670
2671
2672
2673
2674
2675
2676
2677
2679
2680
2681
2682
2683
Ajeet Gandhi
Zia, Yaseen
Charpentier, Anne-Marie
Kumar, Aryavarta
Caudell, Jimmy
Bishop, Michael
Bledsoe, Trevor
Rutenberg, Michael
Jang, Joanne
Palmer, Matthew
Guo, Gordon
Crandley, Edwin
Mohindra, Pranshu
Lee, Joseph
Lee, Ryan
Riaz, Nadeem
Mullapally, Sujith
Kodaira, Takeshi
Yi, Junlin
Igdem, Sefik
Pan, Jianji
Chen, Jenny Ling-Yu
Lin, Yu-Wei
Tsuchiya, Kazuhiko
Ma, Lin
Golden, Daniel
Ou, Xiaomin
Fareed, Muhammad
Lin, Qin
Wang, Yu-Wen
Kong, Lin
Gao, Yunsheng
Wu, Junxin
Wang, Jin
Peng, Zhang
Wilson, David
Sun, Yan
Peng, Xu
Hunter, Klaudia
Lu, Haijun
Li, BaoQing
Nishimura, Hideki
Yoshimura, Michio
Yanagi, Takeshi
Mok, Gary
Matthiesen, Chance
Kawaguchi, Hideo
Cassidy, Richard
Raphael, Jomon
Katsoulakis, Evangelia
Zhang, Hong
Heijmen, Ben J.M.
Johansen, Jorgen
Riaz, Nadeem
Hu, Man
Koyfman, Shlomo
Chang, Joseph
Tung-Chieh
Ahn, Peter
Barker, Christopher
Fried, David
Malyapa, Robert
Modesto, Anouchka
Hasegawa, Azusa
2684
2685
2686
2687
2688
2689
2690
2691
2692
2693
2694
2695
2696
2697
2698
2699
2700
2701
2702
2703
2704
2705
2706
2707
2708
2709
2710
2711
2712
2713
2714
2715
2716
2717
2718
2719
2720
2721
2722
2723
2724
2725
2726
2727
2728
2729
2730
2731
2732
2733
2734
2735
2737
2738
2739
2740
2741
2742
2743
2744
2746
2747
2748
Hollen, Tyler
Mourad, Waleed
Yang, Xiaofeng
Zeidan, Youssef
Israel, Rebecca
Israel, Rebecca
Herman, Michael
Stegmaier, Petra
Patel, Pretesh
Noble, Anisha
Arneson, Kyle
Oh, Jung Hun
Riaz, Nadeem
Romesser, Paul
Arora, Shruthi
Rudzianskas, Viktoras
Kumaravelu, Azmi
Mourad, Waleed
Mourad, Waleed
Studer, Gabriela
Perez-Romasanta, Luis
Woods, Charles
Ali, Arif
Hunter, Klaudia
Ashamalla, Hani
Kagawa, Kazufumi
Waters, Alexandra
Vargo, John
Vargo, John
Balamucki, Christopher
Steen, Sven
Wobb, Jessica
Kovalchuk, Nataliya
Deraniyagala, Rohan
Bradley, Julie
Vlacich, Gregory
Hata, Masaharu
Douglas, James
Keller, Lanea
Yamamoto, Michinori
Teckie, Sewit
Yamazaki, Takuya
Bhandare, Niranjan
Karam, Irene
Kehrer, Jason
Park, Sang-June
Prieto, Isabel
Zia, Yaseen
Romesser, Paul
Anderson, Nigel
Dutta, Pinaki
Kropp, Lauren
Chu, Karen
Berlach, David
El-Sayed, Samy
Fujiwara, Masayuki
Daly, Patricia
Hansen, Christian
Wang, Dian
Nguyen, Nhu Tram
Taguchi, Senzo
2749
2750
2751
2752
2753
2754
2755
2756
2757
2758
2759
2760
2761
2762
2763
2764
2765
2766
2767
2768
2769
2770
2771
2772
2773
2774
2775
2776
2777
2778
2779
2780
2781
2782
2783
2784
2785
2786
2787
2788
2789
2790
2791
2792
2793
2794
2795
2796
2797
2798
2799
2800
2801
2802
2803
2804
2805
2806
2807
2808
2809
2810
2811
2812
Buatti, John
Wilson, David
Cotter, Ryan
Amarnath, Sudha
Thomas, Tarita
Anderson, Carryn
Alcorn, Sara
Das, Shiva
AlHussain, Hussain
Kaufman, Isaac
Sun, Jason
Grover, Surbhi
Wang, Kyle
Rey, Felipe
Magnuson, William
Bledsoe, Trevor
Anderson, Nigel
Zhang, Jeanette
Hoover, Andrew
Alizadeh-Kashani, Moein
2813
2814
2815
2816
2817
2818
2819
2820
2821
2822
2823
2824
2825
2826
2827
2828
2829
2830
2831
2832
2833
HEALTH SERVICES RESEARCH
Ohri, Nitin
Fairchild, Alysa
Edge, Stephen
Buscariollo, Daniela
Gross, Cary
Aneja, Sanjay
Zakeri, Kaveh
Yamoah, Kosj
Mueller, Sabine
Shah, Anand
Hardenbergh, Patricia
McCloskey, Susan
Potters, Louis
Famiglietti, Robin
Volz, Edna
Kusano, Aaron
Numasaki, Hodaka
Royce, Trevor
Guadagnolo, B. Ashleigh
Walker, Gary
Mackley, Heath
Nelson, Carl
Jhaveri, Pavan
Parikh, Ravi
Stockham, Abigail
Gutovich, Jordan
Mazur, Lukasz
Mou, Benjamin
Church, Jessica
Adams, Robert
Min, Christine
Bahl, Gaurav
Vichare, Anushree
Hegarty, Sarah
Hess, Clayton
Russo, Andrea
Champ, Colin
Golden, Daniel
Paryani, Nitesh
2
110
107
108
109
111
112
113
114
242
244
245
246
247
248
249
250
302
303
304
305
306
307
308
309
2834
2835
2836
2837
2838
2839
2840
2841
2842
2843
2844
2845
2846
2847
2848
Camarata, Andrew
Albuquerque, Kevin
Wynn, Raymond Bernard
Doi, Yoshiko
Lee, Lucille
Blackstock, A. William
Qureshi, Muhammad
Murphy, James
Mirabeau-Beale, Kristina
Gomez, Daniel
Gomez, Daniel
Dvorak, Tomas
Eguiguren Bastida, Mikel
Johnson, Jennifer
McCullough, Anna
Ung, Yee
Fortin, Marie Andree
Pawlicki, Todd
Stokes, William
Sheets, Nathan
Yeung, Anamaria
Kapadia, Nirav
Aivas, Inge
Archambault, Jean
Gupta, Shlok
2849
2850
2851
2852
2853
2854
855
2856
2857
2858
2859
2860
2861
2862
2863
2864
2865
2866
2867
2869
2870
2871
2872
2873
2874
HISTORY
Aneja, Sanjay
Rana, Shushan
Pfeffer, Raphael
Holliday, Emma
Torres, Herbert
2875
2876
2877
2878
2879
LUNG CANCER
Nagata, Yasushi
Platta, Christopher
Senan, Suresh
Cheung, Patrick
Stanic, Sinisa
Rosen, Lane
Klement, Rainer
Onishi, Hiroshi
Gan, Gregory
Nishimura, Yasumasa
Santos, Marcos
Komaki, Ritsuko
Wang, Weili
Fakhreddine, Mohamad
Welsh, James
Zhuang, Hongqing
Alexander, Brian
Gore, Elizabeth
Wilkinson, Ben
Mangona, Victor
Shusharina, Nadya
Tandberg, Daniel
Parisi, Elisabetta
Kuremsky, Jeffrey
Poettgen, Christoph
Molotievschi, Alerson
Trovo, Marco
115
116
117
118
119
120
121
122
166
167
168
169
170
171
251
252
253
254
255
256
257
258
379
380
381
382
383
384
Moré, Jayaji
Raben, David
Daly, Megan
Cuaron, John
DeWees, Todd
Liu, Yung Hsien
Nygaard, Ditte Eklund
Abelson, Jonathan
Liriano, Melissa
Milano, Michael
Senthi, Sashendra
Papachristofilou,
Alexandros
Claude, Line
Stauder, Michael
Mohamed, Abdallah
Palma, David
Dahele, Max
Qiao, Xueying
Fujii, Osamu
Ishihara, Takeaki
Matsuo, Yukinori
Bar Ad, Voichita
Hashizume, Chisa
Chang, Ji Hyun
Baba, Fumiya
Yip, Connie
Zheng, Xiangpeng
Jain, Suneil
Huang, Kitty
Lee, Joo Ho
Casey, Stephanie
Kharofa, Jordan
Werner-Wasik, Maria
Ku, Lichung
Xiang, Zuolin
Takemoto, Shinya
Prendergast, Brendan
Evans, Andrew
Atallah, Soha
Inoue, Tetsuya
Di, Liu
Boggs, Hunter
Crandley, Edwin
Hiraoka, Masahiro
Zhuang, Hong-Qing
Yu, Jinming
Videtic, Gregory
Rosenberg, Stephen
Russell, Wesley
Turaka, Aruna
Asai, Kaori
Peters, Christopher
Tsudou, Shinji
Whaley, Jonathan
Guo, Susan
Chung, Yi Hsuan
Mohan, Radhe
Qi, Xiangrong
Russo, James
Nichols, Elizabeth
Chiyama, Kaoru
Mikami, Ryuji
Jeongshim, Lee
385
386
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
2880
2881
2882
2883
2884
2885
2886
2887
2888
2889
2890
2891
2892
2893
2894
2895
2896
2897
2898
2899
2900
2901
2902
2903
2904
2905
2906
2907
2908
2909
2910
2911
2912
2913
2914
2915
2916
2917
2918
2919
2920
2921
2922
2923
2924
2925
2926
2927
2928
2929
183
Aoki, Masahiko
Mahe, Marc
Chowdhry, Varun
Kelsey, Christopher
Kosaki, Katsura
Currier, Blake
Wang, Ping
Knill, Cory
Wei, Xiong
Mattes, Malcolm
Shultz, David
Herde, Ryan
Freilich, Jessica
Inoue, Kazuya
Cui, Yunfeng
Harada, Hideyuki
Blake, Monika
Maquilan, Genevieve
Zhang, Jiandong
Onimaru, Rikiya
Tajima, Yuu
Ikushima, Hitoshi
MacManus, Michael
Tatekawa, Kotoha
Wang, Suzhen
Kesarwala, Aparna
Liao, Zhongxing
Parisi, Elisabetta
Navarria, Pierina
Rimner, Andreas
Karasawa, Kumiko
Garg, Shalini
Peterson, David
Ramamurthy, Sindhu
Kesarwala, Aparna
Nuyttens, Joost
Perez, Carmen
Rajpara, Raj
Wright, Ato
Vazquez, Gonzalo
Senthi, Sashendra
Nakajima, Naomi
Okano, Naoko
Mancini, Brandon
Oh, Dongryul
McKee, Andrea
Siglin, Joshua
Silveira, William
Oh, Dongryul
Kishi, Takahiro
Wang, Hongmei
Feng, Wen
Ng, John
King, Martin
Nielsen, Tine B.
Wurstbauer, Karl
Vance, Sean
Dar, Abdul
Nijkamp, Jasper
Roman, Nicholas
Zhuang, Yan
Juloori, Aditya
184
2930
2931
2932
2933
2934
2935
2936
2937
2938
2939
2940
2941
2942
2943
2944
2945
2946
2947
2948
2949
2950
2951
2952
2953
2954
2955
2956
2957
2958
2959
2960
2961
2962
2963
2964
2966
2967
2968
2969
2970
2971
2972
2973
2974
2975
2976
2977
2978
2979
2980
2981
2982
2983
2984
2985
2986
2987
2988
2989
2990
2991
2992
2993
2994
Shioyama, Yoshiyuki
Xue, Jianxin
Grant, Jonathan
Pennathur, Arjun
Alcorn, Sara
Mancini, Brandon
Singh, Deepinder
Bhavsar, Shripal
Maehata, Yoshiyasu
Shirvani, Shervin
Oguri, Mitsuhiko
Yi, Sun
Macdonald, Orlan
Palma, David
McCloskey, Paula
Poettgen, Christoph
Thirion, Pierre
Peterson, Carl
Dilling, Thomas
Corradetti, Michael
Ford, Victoria
Murphy, Rita
Sarkar, Vikren
Chen, Wenzhou
Lee, Joseph
Chen, Wenzhou
Hearn, Jason
Lavaf, Amir
Karasawa, Katsuyuki
Kilburn, Jeremy
Orcutt, Kevin
Grecula, John
Altoos, Taghrid
Rusu, Iris
Kwong, Stanley
Greskovich, John
Qi, Huanpeng
Rineer, Justin
Nakayama, Yuko
Johnson, Matthew
Trakul, Nicholas
McAvoy, Sarah
Chen, Qing
Soike, Mike
Kong, Feng-Ming
Jabbour, Salma
Xu, Yaping
Xu, Huimin
Wilkinson, Ben
Bi, Nan
Han, Chengbo
Lally, Brian
2995
2996
2997
2998
2999
3000
3001
3002
3003
3004
3005
3006
3007
3008
3009
3010
3011
3012
3013
3014
3015
3016
3017
3018
3019
3020
3021
3022
3024
3025
3026
3027
3028
3029
3030
3031
3032
3033
3034
3035
3036
3037
3038
3039
3040
3041
3042
3043
3044
3045
3046
3047
LYMPHOMA
Eich, Hans Theodor
Aleman, Berthe
Maraldo, Maja Vestmoe
Aznar, Marianne
Reinartz, Gabriele
Russo, Andrea
Dabaja, Bouthaina
Wu, Run-Ye
Goldsmith, Benjamin
173
174
175
176
177
178
179
180
3048
Blanchard, Miran
Hunter, Bradley
Michaelson, Evan
Skliarenko, Julia
Vernon, Matthew
Dorth, Jennifer
Hamilton, Sarah
Valakh, Vladimir
Tao, Zhen
Zhang, Ximei
Zhang, Ximei
Zhang, Ximei
Iwabuchi, Michio
Xu, Li-ming
Otsuka, Shinya
Ohga, Saiji
Chan, Cato
Zhao, Ting
Kim, JaYoung
Lee, Sang-wook
Gamez, Mauricio
Khan, Luluel
Wagner, Aaron
Turaka, Aruna
Hall, Matthew
Kim, Young Suk
Jones, Guy
Kim, Ji Hyun
3049
3050
3052
3053
3054
3055
3056
3057
3058
3059
3060
3061
3062
3063
3064
3065
3066
3067
3068
3069
3070
3071
3072
3074
3075
3076
3077
3078
NONMALIGNANT DISEASE
Mourad, Waleed
Dulaney, Caleb
Prabhu, Roshan
Rosenberg, Jennifer
Stea, Baldassarre
3079
3080
3081
3082
3083
PALLIATIVE CARE
Chen, Aileen
Khan, Luluel
Murphy, James
Fosker, Chris
Palma, David
Krishnan, Monica
Hurwitz, Mark
Epstein-Peterson,
Zachary
Chiang, Andrew
Chao, Samuel
Debenham, Brock
Nakamura, Naoki
Kress, Marie-Adele
Howell, David
Furlan, Carlo
Kwon, Jeanny
Cihoric, Nikola
Rudra, Sonali
Golden, Daniel
Jung, Edward
Martin, Jovita
Murai, Taro
Turkevich, Vladimir
Job, Mary
4
125
126
127
128
129
1109
1110
1111
1117
3084
3085
3086
3087
3088
3089
3090
3091
3092
3093
3094
3095
3096
3097
Suh, John
Casamassima, Franco
Lei, Rachel
Ly, Bevan
Balagamwala, Ehsan
3098
3099
3100
3101
3102
3103
PEDIATRIC CANCER
Dharmarajan, Kavita
12
Joo, Jihyeon
157
Brodin, Patrik
158
Verma, Jonathan
159
Mailhot, Raymond
160
Jimenez, Rachel
161
Agbahiwe, Harold
162
Paulino, Arnold
163
Redmond, Kristin
164
Vern-Gross, Tamara
165
Ahmed, Safia
396
Yang, Joanna
397
Sharma, Daya Nand
398
Yang, Joanna
399
Zhang, Chi
400
Dharmarajan, Kavita
401
Hattangadi, Jona
402
Yang, Joanna
403
Laser, Benjamin
404
Kapadia, Nirav
3105
Indelicato, Daniel
3106
King, Martin
3107
Marcus, Robert
3108
Hazariwala, Ronica
3109
Confer, Michael
3110
Lauro, Christine
3111
3112
Hsu, Charles
3113
Ferraris, Gustavo
3114
Su, Zhong
3115
Denniston, Kyle
3116
Yang, Joanna
3117
Kahn, Jenna
3118
Roca, Monica
3119
El-Bared, Nancy
3120
Demoor-Goldschmidt,
Charlotte
3121
Kornerup, Josefine S.
3122
Prah, Douglas
3123
Dharmarajan, Kavita
3124
Fuji, Hiroshi
3125
Watanabe, Miho
3126
Kharofa, Jordan
3127
Wilson, Joella
3128
Christensen, Charlotte Birk 3129
Nwachukwu, Chika
3130
Arsenault, Daniel
3131
Peacock, Justin
3132
Rahn, Douglas
3133
QUALITY OF LIFE
Hess, Clayton
Buckstein, Michael
Son, Christina
123
124
130
Koontz, Bridget
Wong, William
Agarwal, Jai Prakash
Hess, Clayton
Hill-Kayser, Christine
Hou, Ying
Hoppe, Bradford
Rollmann, Denise
Burt, Ashley
Carpenter, Todd
Tribius, Silke
Dubey, Arbind
Lee, Andrew
Sood, Sumit
Lee, Tsz Kin
Rashtian, Afshin
Cigarral Garcia, Cristina
Milecki, Piotr
Rathod, Shrinivas
Likhacheva, Anna
Koul, Rashmi
Soeder, Sherry
Bryant, Curtis
Adams, Todd
Raval, Raju
Klein, Elizabeth
Abdel-Wahab, May
Wang, Lin
Fotouhi Ghiam, Alireza
Balagamwala, Ehsan
1112
1113
1114
1115
1116
1118
1119
3134
3135
3136
3137
3138
3139
3140
3141
3142
3143
3144
3145
3146
3147
3148
3149
3150
3151
3152
3153
3154
3155
3156
3157
SARCOMA AND CUTANEOUS
TUMORS
Siva, Shankar
Johnson, Matthew
Gerber, Naamit
Bhatnagar, Ajay
Chen, Yen-Lin Evelyn
Sio, Terence
McBride, Sean
Maruyama, Katsuya
Catton, Charles
Best, Lara
Bedi, Manpreet
Valliares, Martin
Liss, Adam
Roberge, David
Desai, Neil
Hong, Angela
Castle, Katherine
Nuyttens, Joost
Cambeiro, Mauricio
Rashtian, Afshin
Barker, Christopher
Kang, Josephine
Kramkimel, Nora
Jackson, James
Miki, Yoshitaka
Cooper, Anna
Mehta, Niraj
337
338
339
340
341
342
343
344
345
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
3158
3159
3160
3161
3162
3163
3164
3165
Kang, Josephine
Rooney, Jessica
Hadziahmetovic, Mersiha
Spraker, Matthew
Burt, Ashley
Kim, Jun Won
Dinçbaş, Fazilet
Sharabi, Andrew
Stavas, Mark Stavas
Yip, Darwin
Serban, Monica
Vyas, Shilpa
3166
3167
3168
3169
3170
3171
3172
3173
3174
3175
3176
3177
BIOLOGY
Anderson, Joshua
55
Wong, Philip
56
Harima, Yoko
57
MacArthur, Kelly
58
Wei, Xiong
59
Bruce, Jeff
60
Oh, Daniel
61
Pollack, Alan
62
Williams, Terence
63
Wu, Q. Jackie
65
Yang, Eddy
181
Nowak, Kamila
182
Shibamoto, Yuta
183
Kim, In Ah
184
Eldredge, Harriet
185
Hong, Ji-Hong
186
Wang, Qifeng
187
White, Ruth
188
Chung, Caroline
189
196
DeMarco, John
207
Jacob, Naduparambil
259
Citrin, Deborah
260
Tian, Junqiang
261
Chua, Melvin
262
Taniguchi, Cullen
263
Das, Saikat
264
Marples, Brian
265
McGee, Mackenzie
266
Stessin, Alexander
267
Dasgupta, Tina
310
Viertl, David
311
Cha, Yong
312
Ahmed, Kazi
313
Willers, Henning
314
Maity, Amit
315
Roehrich, Manuel
316
Tumati, Vasu
317
Yan, Heping
318
Schubert, Leah
387
Moore, Kevin
388
Kupelian, Patrick
389
Gayou, Olivier
390
King, Benjamin
391
Gabriel, Peter
392
Smith, Wade
393
Gandhidasan, Senthilkumar 394
Meier, Timothy
395
Hansen, James
Seidel, Philipp
Hedayati, Mohammad
Paximadis, Peter
Bonner, James
Huber, Kathryn
Whitley, Alexander
Spiotto, Michael
Baine, Michael
Feng, Felix
Nowsheen, Somaira
405
406
407
408
409
410
411
412
413
1025
1026
Choi, Serah
McGovern, Susan
Gandhi, Nishant
Formenti, Silvia Chiara
Willey, Christopher
Das, Samayita
Bakst, Richard
Abazeed, Mohamed
Baumann, Brian
Heron, Dwight
Szumacher, Ewa
Ando, Yutaka
Tejwani, Ajay
Jhawar, Sachin
Fuhrer, Russell
Kapur, Ajay
Sinicki, James
Agarwal, Ankit
Wang, Pin-Chieh
Sharabi, Andrew
Vaughan, Andrew
Ji, ShengJun
Bakhoum, Samuel
Williams, Jacqueline
Masunaga, Shin-ichiro
Wu, Cheng-Chia
Klein, Thomas
Wang, Tao
Pratx, Guillem
Huang, Zhibin
Boimel, Pamela
Park, Catherine
Swamy, Kumara
Mallarajapatna,
Govindarajan
Wang, Ping
Huang, Jing
Okamoto, Masahiko
Dyer, Brandon
Ishikawa, Hitoshi
Herskind, Carsten
Butterworth, Karl
Washington, Iman
Epperly, Michael
Schmitt, Adam
Krueger, Sarah
Epperly, Michael
Fried, David
Nishibuchi, Ikuno
Liang, Liping
Kiltie, Anne
Samiee, Sara
Zhang, Hui
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
3178
3179
3180
3181
3182
3183
3184
3185
3186
3187
3188
3189
3190
3191
3192
3193
3194
3195
3196
3197
3198
3199
3200
Chiblak, Sara
Epperly, Michael
Epperly, Michael
Epperly, Michael
Janko, Matthew
Bassetti, Michael
Maria, Ola
Epperly, Michael
Goff, Julie
Yin, Liangjie
Milby, Abigail
Kim, Jun Won
Zhang, Zhenhuan
Mikkelsen, Ross
Sattler, Jennifer
Vujaskovic, Zeljko
Gerweck, Leo
Sun, Rui
Walker, Joshua
Schmid, Thomas
Sai, Sei
Romesser, Paul
Iwata, Hiromitsu
Hasegawa, Masatoshi
Matsuo, Masayuki
McDermott, Sean
Kuo, Yuan-Chia
Wang, Chun-Chieh
Lin, Yi-Ping
Hung, Chiwei
Bazalova, Magdalena
Ma, Shihong
Kim, In Ah
Harada, Satoshi
Wang, Andrew
Guttmann, David
Abidin, Caitlin
Okonogi, Noriyuki
Ushjima, Hiroki
Oike, Takahiro
Foote, Michael
Zhao, Lujun
Medin, Paul
Yoshimoto, Yuya
Li, Tao
Sakata, Koh-ichi
Speers, Corey
Ishibashi, Naoya
Dilworth, Joshua
Diaz, Roberto
Vuong, Te
Kahn, Jenna
Yu, Jennifer
Abbineni, Gopal
Dandapani, Savita
Cao, Ning
Kimple, Randall
Corso, Christopher
Higgins, Susan
Nakayama, Masao
Zhu, Guangying
Perillo-Adamer, Florence
Abazeed, Mohamed
Parikh, Dhwani
3221
3222
3223
3224
3225
3226
3227
3228
3229
3230
3231
3232
3233
3234
3235
3236
3237
3238
3239
3240
3241
3242
3243
3245
3246
3247
3248
3249
3250
3251
3252
3253
3254
3255
3256
3257
3259
3260
3261
3262
3263
3264
3265
3266
3267
3268
3269
3270
3271
3272
3273
3274
3275
3276
3277
3278
3279
3280
3281
3282
3283
3284
3285
3286
185
3201
3202
3203
3204
3205
3206
3207
3209
3210
3211
3212
3213
3214
3215
3216
3217
3218
3219
3220
Akasaka, Hiroaki
Allen, Bryan
Pelloski, Christopher
Hillman, Gilda
Fasih, Aisha
Hillman, Gilda
Tang, Zili
Cummings, Natalie
Siedow, Michael
Hallahan, Dennis
Melzig, Claudius
Groselj, Blaz
Dai, Ying
McBride, William
Ma, C.M. Charlie
Macklis, Roger
Lawrence, Yaacov
Blumenfeld, Philip
Heravi, Mitra
Speer, Tod
G.Joshi, Chaitanya
Horton, Janet
Rutkowski, Tomasz
Hall, William
Akervall, Jan
Blakaj, Dukagjin
Wilson, George
Leong, Nelson
Parliament, Matthew
Bratman, Scott
Zaki, Bassem
Chin, Michael
Woodward, Wendy
Kim, Dong Wook Nathan
Kiltie, Anne
Jarboe, John
Jones, Jennifer
3287
3288
3289
3291
3292
3293
3294
3295
3296
3297
3298
3299
3300
3302
3303
3304
3305
3306
3307
3308
3309
3310
3311
3312
3313
3314
3315
3316
3317
3318
3319
3320
3321
3322
3323
3324
3325
PHYSICS
Arcangeli, Stefano
Bray, Tracy
Matuszak, Martha
Noel, Camille
Chen, Xiaojian
Merrick, Scott
Holtzer, Nienke
Cazoulat, Guillaume
Li, X. Allen
Octave, Nadia
Summers, Paige
Rao, Shyam
Yang, Xiaofeng
Bayouth, John
Deasy, Joseph
Salguero, Francisco
Karlsson, Kristin
Pham, Ngoc
Ares, Carmen
Spadea, Maria Francesca
Zhu, Xuping
Osinga, Julia-Maria
Min, Byung Jun
186
5
6
64
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
131
132
133
134
Yoshikazu, Tsunashima
Nakamura, Satoshi
Paganetti, Harald
Moskvin, Vadim
Yeh, Brian
Troeller, Almut
Min, Chul Hee
Diot, Quentin
Lee, Sangkyu
Huang, Ellen Xiaoyan
Guerrero, Mariana
Yan, Di
Batth, Sukhjeet
Vineberg, Karen
Howard, Michael
Geneser, Sarah
Meng, Bowen
Keall, Paul
Zhou, Su-Min
Li, Hao
Coolens, Catherine
Ge, Jiajia
Perkins, Gregory
Kovalchuk, Nataliya
Moraru, Ion
Feng, Yuanming
Yang, Cungeng
Hollensen, Christian
Al Sulaimani, Eman
Kry, Stephen
Ruan, Dan
Podder, Tarun
Zhen, Heming
De Hertogh, Olivier
Price, Samantha
Czerminska, Maria Anna
Letourneau, Daniel
Lo, Andrea
Kuang, Yu
Parikh, Parag
Abramowitz, Matthew
Tremmel, Christoph
Ngwa, Wilfred
Kim, Yusung
Sethi, Manish
Chen, Xiaoming
Becker, Nathan
Mishra, Kavita
Fahimian, Benjamin
Rottmann, Joerg
Taylor, Robert
Persson, Gitte
Zhung, Joanne
Velec, Michael
Christensen, James
Dong, Peng
Yang, Wensha
Wild, Aaron
Sole, Claudio
Iori, Mauro
Brink, Carsten
Hristov, Dimitre
135
136
137
138
139
190
192
193
194
195
197
198
199
200
201
202
203
204
205
206
268
269
270
271
272
273
274
275
276
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
1024
1080
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1120
1121
1122
Block, Alec
Weiss, Elisabeth
van Sornsen de Koste,
John
Rong, Yi
Riegel, Adam
Kim, Taeho
Godley, Andrew
Mostafavi, Hassan
Hunt, Margie
McGary, John
Kassas, Bassel
Buzurovic, Ivan
Ueda, Shinichi
Foster, Ryan
Shirai, Kiyonori
Haridass, Anoop
Zhu, Mingyao
Bjerre, Troels
Vergalasova, Irina
Yamada, Masahiro
Chen, Shifeng
Peng, Jean
Qin, Songbing
Samuelian, Jason
Wang, Jin
Katoh, Norio
Kong, Chi Wah
Liu, Zejian
Trovo, Marco
Zhang, Yingjie
Zhang, Yingjie
Das, Indra
Lin, Christie
Liu, Wu
Al-Hallaq, Hania
Lian, Jun
Sio, Terence
Hullett, Craig
Ju, Sang Gyu
Li, Dengwang
Lu, Bo
Jones, Bernard
Ding, George
Pastore, Gabriella
Jensen, Lindsay
Vance, Sean
Zhou, Jun
Li, Ruijiang
Alcorn, Sara
Langsenlehner, Tanja
Lee, Joo Hwan
Noue, Mitsuhiro
Perkinson, Andrew
Speight, Richard
Falk, Marianne
Schreibmann, Eduard
Hsu, Howard
Hammoud, Rabih
VanderWalde, Noam
Tesfamicael, Biniam
Perkins, Gregory
Lazos, Dimitrios
Hu, Angie
1123
1124
1125
1126
1127
1128
1129
1130
1131
3326
3327
3328
3329
3330
3331
3332
3333
3334
3335
3336
3337
3338
3339
3340
3341
3342
3343
3344
3345
3346
3347
3348
3349
3350
3351
3352
3353
3354
3355
3356
3357
3358
3359
3360
3361
3362
3363
3364
3365
3366
3367
3368
3369
3370
3371
3372
3373
3374
3375
3376
3377
3378
3379
Han-Oh, Sarah
Mishra, Pankaj
Wersall, Peter
Bray, Tracy
Chuang, Cynthia
Saini, Jatinder
Wang, Jing
Azcona, Juan Diego
Wang, Brian
Tang, Xiaoli
Cao, Yue
Silva, Luis
Song, Haijun
Santhanam, Anand
Olsen, Jeff
Chen, Ting
Kumar, Parvesh
Park, Joo Han
Lu, Haijun
Lee, Yongsook
Arns, Anna
Michaud, Anthony
Cho, Ilsung
Fung, Wing
Low, Daniel
Tanny, Sean
Olsson, Caroline
Zaini, Mehran
Ruggieri, Ruggero
Tanooka, Masao
Ludwig, Michelle
Trepanier, Pierre-Yves
Shang, Charles
Entezari, Vahid
Godley, Andrew
Biritz, Bertrand
Galland, Sigolene
Park, Samuel
Chibani, Omar
Toltz, Allison
Mensah, Apryl
Jackson, Andrew
Fiorino, Claudio
Bhandare, Niranjan
Chang, Jenghwa
Ziel, Ellis
Chen, Zhe
Craciunescu, Oana
Yue, Yong
Watkins, William
Damato, Antonio
Snyder, Michael
Nohadani, Omid
Holdsworth, Clay
Green, Olga
Kim, Anthony
Zhao, Tianyu
Nasseri, Morad
Yuh, William
Haritha, Chiramana
Shinde, Prashantkumar
Matulewicz, Lukasz
3380
3381
3382
3383
3384
3385
3386
3387
3388
3389
3390
3391
3392
3393
3394
3395
3396
3397
3398
3399
3400
3401
3402
3403
3404
3405
3406
3407
3408
3409
3410
3411
3412
3413
3414
3415
3416
3417
3418
3419
3420
3421
3422
3423
3424
3425
3426
3427
3428
3429
3430
3432
3433
3434
3435
3436
3437
3438
3439
3440
3442
3443
3444
3445
Zhang, Pengpeng
Wang, Yi
Tohyama, Naoki
Varadhan, Raj
Lo, Anthony
Deshpande, Shrikant
Ding, Kai
Hanada, Takashi
Wang, Shichao
Graff, Pierre
Okamoto, Hiroyuki
Geng, Hui
Ng, Chor-yi
Nuver, Tonnis
Jiang, Xiaoqin
Mihaylov, Ivaylo
Rochet, Nathalie
Obedian, Edward
Hashimoto, Masatoshi
Nishioka, Kentaro
Nakamura, Akira
Lee, Suk
Wang, Jiazhou
Cirino, Eileen
Toyoda, Tatsuya
Reese, Adam
Mattes, Malcolm
Qi, Xiangrong
Xu, Zijie
Piotrowski, Tomasz
Rice, Roger
Lee, Hyunjin
Kim, Dongwook
Jang, HongSeok
Yokoi, Tomohiro
Cámara, Ana
Behrens, Claus
McDoland, Daniel
Khan, Mohammad
Oh, Seungjong
Skourou, Christina
Mancosu, Pietro
Yang, Wensha
Na, Yong Hum
Yang, Xiaocheng
Ren, Lei
Laviraj, Macharla
Anjaneyulu
Block, Alec
Liu, Hongwei
Manon, Rafael
Zhen, Heming
Langen, Katja
Li, Jingdong
Agazaryan, Nzhde
Tai, An
Kim, Dongwook
Damato, Antonio
Kumar, Rachit
Kumar, Kiran
Li, Shunshan
Wang, Henry
Lee, Jaegi
Thieke, Christian
3446
3447
3448
3449
3450
3451
3452
3453
3454
3455
3456
3457
3458
3459
3460
3461
3462
3463
3464
3465
3466
3467
3468
3469
3470
3471
3472
3473
3474
3475
3476
3477
3478
3479
3480
3481
3482
3483
3484
3485
3486
3487
3488
3489
3490
3491
3492
3493
3494
3495
3496
3497
3498
3499
3500
3501
3502
3503
3504
3505
3506
3507
3508
Kitamura, Nozomi
3509
Hoyer, Morten
3510
Takahashi, Ryo
3511
Kim, Hye Young
3512
Selek, Ugur
3513
Ellis, Rodney
3514
Kesava Ramgopal,
Adavikolanu
3515
Speight, Richard
3516
Poulsen, Per
3517
Kesava Ramgopal,
Adavikolanu
3518
Moore, Joseph
3519
D’agostino, Giuseppe
Roberto
3520
Alkhatib, Hassaan
3521
Daniel, Nguyen
3522
Winkler, Peter
3523
Craft, David
3524
Mei, Xin
3525
Hobeika, Georges
3526
Li, Dengwang
3527
McGurk, Ross
3528
Wong, James
3529
Morrow, Natalya
3530
Daniel, Nguyen
3531
Arbea, Leire
3532
Liu, Fenghong
3533
Pak, Daniel
3534
Kishan, Amar
3535
Choi, Kihwan
3536
Liu, Fenghong
3537
Lee, Ho
3538
Zhong, Hualiang
3539
Phillips, Mark
3540
Pukala, Jason
3541
Liu, Han
3542
Pirozzi, Sara
3543
Roa, Dante
3544
Wang, Song
3545
Witten, Matthew
3546
Lorenzen, Ebbe
3547
Dalah, Entesar
3548
Berg, Ronald
3549
Lazos, Dimitrios
3550
Schinkel, Colleen
3551
Minken, Andre
3552
Murray, Louise
3553
Shusharina, Nadya
3554
Cai, Jing
3555
Dickerson, Edward
3556
Ford, Eric
3557
Ahunbay, Ergun
3558
Oehler, Christoph
3559
Chiesa, Silvia
3560
Ng, Sook Kien
3561
Stojadinovic, Strahinja
3562
Mohamad, Issa
3563
Liu, Feng
3564
Bai, Penggang
3565
Walker, Amanda
3566
Rudra, Sonali
3567
Kipritidis, John
3568
Munck af Rosenschold, Per 3569
Li, Dengwang
3570
Meyer, Kurt
Kim, Joo Ho
Mehta, Vivek
Klaers, Jessica
Li, Jun
Rodriguez, Vivian
Wang, Lilie
Ding, Kai
Jang, Sunyoung
Ha, Jonathan
Cagni, Elisabetta
Kumar, Sanath
Schuster, Jessica
Folkert, Michael
Li, Taoran
Blasi, Olivier
Wang, Jing
Rahimian, Javad
Orton, Matthew
Ishihara, Takeaki
Gunter, Tyler
Mampuya, Ange
Wambaka
Wong, Wing Kei Rebecca
Ueda, Yoshihiro
Fumagalli, Ingrig
Ding, Chuxiong
Marwaha, Gaurav
Sole, Claudio
Seco, Joao
Zhang, Qinghui
Xue, Jinyu
Blakaj, Dukagjin
Liang, Yun
Kim, Siyong
Kim, Grace Gwe-Ya
Akino, Yuichi
Lilley, John
Buleteanu, Manuela
Stanescu, Teo
Kurtz, Goldie
Khodri, Mustapha
Djemil, Toufik
Cengiz, Mustafa
Ju, Andrew
Sunyach, Marie Pierre
Hampton, Carnell
Thakur, Varun Singh
Liu, Haisong
Xu, Qianyi
Varadhan, Raj
Ling, Diane
Diaconu, Claudiu
Wang, Fen
Meral, Rasim
Chung, Yoonsun
Xiang, Hong
Song, Yulin
Saito, Akito
Kim, Carolyn
Kawamura, Mariko
Henkner, Katrin
3571
3572
3573
3574
3575
3576
3577
3578
3579
3580
3581
3582
3583
3584
3585
3586
3587
3588
3590
3591
3592
3593
3594
3595
3596
3597
3598
3599
3600
3602
3604
3605
3606
3607
3608
3609
3610
3611
3612
3613
3614
3615
3616
3617
3618
3619
3620
3621
3622
3623
3624
3625
3626
3627
3628
3629
3630
3631
3632
3633
3634
3635
3636
Rah, Jeong-Eun
Seco, Joao
Zheng, Yuanshui
Saitoh, Jun-ichi
Klein, Eric
Dhanesar, Sandeep
Inokuchi, Haruo
Ju, Sang Gyu
Kainz, Kristofer
Liu, Wei
Yeung, Daniel
Li, Heng
Mahajan, Anita
Kamikubo, Yoshifumi
Mori, Shinichiro
Yeh, Brian
Jia, Xun
Mukai, Masami
Schneider, Ralf
Egashira, Yusuke
Avadhani, Jaiteerth
Lee, Tae Kyu
Arjomandy, Bijan
Choi, Seungtaek
Zheng, Yuanshui
Nguyen, Quynh
Giantsoudi, Drosoula
Habermehl, Daniel
Cook, April
Palmer, Matthew
Nguyen, Quynh
Mirkovic, Dragan
Milby, Abigail
Yajnik, Santosh
Park, Su Yeon
Song, Xiaofei
Sahoo, Narayan
Izaguirre, Enrique W.
Chang, John Han-Chih
Iftimia, Ileana
Alezra, Dror
Mourad, Waleed
Nakamura, Mitsuhiro
Mukumoto, Nobutaka
Miyahara, Yoshinori
Yamamoto, Hideo
Paulson, Eric
Ishihara, Yoshitomo
Murai, Taro
Markel, Daniel
Cormack, Robert
Cui, Guoqiang
Canbolat, Abdulmecit
Lu, Lanchun
Cheung, Kin Yin
Yang, Yun
Hashem, Rania
Akimoto, Mami
Lee, Nancy
Hu, Weigang
Ferreira, Maria Clara
Korideck, Houari
Epperly, Michael
3637
3638
3639
3640
3641
3642
3643
3644
3645
3646
3647
3648
3649
3650
3651
3652
3653
3654
3655
3656
3657
3658
3659
3660
3661
3662
3663
3664
3665
3666
3667
3668
3669
3670
3671
3672
3673
3674
3675
3676
3677
3678
3679
3680
3681
3682
3683
3684
3685
3686
3687
3688
3689
3690
3691
3692
3693
3694
3695
3696
3697
3698
3699
3700
187
Mahmoud, Omar
Thomas, Evan
Santanam, Lakshmi
Kantz, Steffi
Tsuyoshi, Ikeda
Jeong, Ho Jin
Mihaylov, Ivaylo
Masi, Laura
Almaghrabi, Mohammed
Wu, Qiuwen
Jin, Jian-Yue
Subramanian, Sai
Welliver, Meng
Sung, Wonmo
Kim, Jung-in
Cho, Yu Ra
Bazalova, Magdalena
Ciernik, Ilja
Kjer, Hans Martin
Yalman, Deniz
Xie, Jiang
Sansourekidou, Parthena
Handsfield, Lydia
Kemp, Jeffrey
Carpenter, Colin
Herranz, Elena
Wijesooriya, Krishni
Wiebe, Ericka
Greskovich, John
Guerra Gutierrez, Pedro
Paudel, Nava
Diwanji, Tejan
Kim, Grace Gwe-Ya
Vieira, Andre
Mashouf, Shahram
Unal, Semra
Huang, Long
Anand, Aman
Weinberg, Rebecca
Joh, Daniel
Kavanaugh, James
Ehler, Eric
Song, Yulin
188
3701
3702
3703
3704
3705
3706
3707
3708
3709
3710
3711
3712
3713
3714
3715
3716
3717
3718
3719
3720
3721
3722
3723
3724
3725
3726
3727
3728
3729
3730
3731
3732
3733
3734
3735
3736
3737
3738
3739
3740
3741
3742
3743
INSIDE:
Exhibitor List
Exhibitor List by Product/Service
Floor Plan
INDUSTRY-EXPERT THEATER
Front of Hall A, Exhibit Hall
This activity allows companies to present their noteworthy products and
services through a live presentation in the Industry-Expert Theater
located in the Exhibit Hall.
Seating is available on a first-come, first-served basis.
A box lunch will be provided.
The Industry-Expert Theater content and views expressed therein are those of the Exhibitor and not of ASTRO.
Sunday
Monday
Tuesday
12:45 p.m. - 1:45 p.m.
12:30 p.m. - 1:30 p.m.
12:00 p.m. - 1:00 p.m.
October 28, 2012
Clinical Trial Update: Anchored
Transponder in Lung Cancer
Patients
Goals and Objectives of the
Trial, Current Status and Future
Potential
Presented by Varian Medical Systems
Contact: Shari Huffine
Phone: 650-424-5938
October 29, 2012
Accuray Showcases Leading-edge
Treatment Solutions at ASTRO
2012 with New Clinical
Advancements in the Field of
Radiosurgery and Radiation
Therapy
Presented by Accuray
Contact: Sales@accuray.com
October 30, 2012
The Role of Zevalin in the
Treatment of Low Grade
or Follicular Lymphoma
Presented by Spectrum
Pharmaceuticals Inc.
Contact: Linda Azarbal
Phone: 949-743-9347
Thank you
Recognizing ASTRO’s 2012 Corporate Members
.decimal
a-fabco Inc.
Acceletronics/Rad Parts
Accuray
Advanced Particle Therapy
Aktina Corporation
Alliance Oncology
AMAC
Amgen Inc.
BARD Medical Division
Bayer Healthcare Pharmaceuticals
The Bergendahl Institute
Biocompatibles Inc.
Bionix Radiation Therapy
Boehringer Ingelheim
Pharmaceuticals
Bogardus Medical Systems Inc.
Brainlab
Bristol-Myers Squibb
Cancer CarePoint Inc.
Cianna Medical
CIVCO Medical Solutions
CompHealth Locum Tenens
D3 Radiation Planning
Diacor Inc.
Eckert & Ziegler Bebig
Elekta
Equicare Health Inc.
Gammex Inc.
GE Healthcare
Genomic Health
Hologic Inc.
IBA
IntraOp Medical Corporation
IsoRay Medical Inc.
James L. Davis Inc.
Klarity Medical Products
Landauer Inc.
LAP of America LLC
Leighton McGinn
MedTech Billing Services Inc.
Mevion Medical Systems
Mick Radio-Nuclear Instruments Inc.
MIM Software Inc.
Modus Medical Devices Inc.
MRP Inc.
NELCO
New Bedford Corporation
Nuclear Shielding Supplies & Service
Oncology Services International
Oncura Inc.
Oncure Medical Corporation
Philips Healthcare
Pitts Little Corporation
ProNova Solutions LLC
ProTom International Inc.
Prowess Inc.
PTW
Qfix
RAD Technology Medical Systems
CO R P O R AT E
M E M B E R
RadiaDyne
Radiation Business Solutions
Radiation Oncology Resources
Radiation Products Design Inc.
Radiological Imaging
Technology (RIT)
RADMAX Ltd.
RaySearch Laboratories
RC Billing
Revenue Cycle Inc.
Scandi Dos
Sensus Healthcare
Siemens Healthcare
Spectrum Pharmaceuticals
Standard Imaging
Sun Nuclear Corporation
TGM2
Theragenics Corporation
TRG Oncology Equipment
US Radiosurgery
Vantage Oncology
Varian Medical Systems
Veritas Medical Solutions
Veriteq Corporation
Vertual Ltd.
ViewRay Inc.
Vision RT
VisionTree
Weatherby Healthcare
Xoft Inc.
Xstrahl
Exhibitor List
EXHIBITOR NAME
BOOTH#
.decimal
7003
121 Central Park Place
Sanford, FL 32771
Phone: 1-800-255-1613
Email: contact@dotdecimal.com
Website: www.dotdecimal.com
6055
2270 Colonial Boulevard
Fort Myers, FL 33907
Phone: 239-931-7333
Email: jhobaugh@rtsx.com
Website: www.21stcenturyoncology.com
A2J Laser America Corporation
11085
Parc d’Activité des Vallières, 5 allée des Rousselets
Thorigny sur Marne, 77 77400
France
Phone: 0033-0-160-9422-99
Email: export@a2jlaser.com
Website: www.a2jlaser.com
Acceletronics/RadParts11013
602 Gordon Drive
Exton, PA 19341
Phone: 1-800-543-5144
Email: info@acceletronics.com
Website: www.acceletronics.com
R
AccuBoost3055
1 Industrial Way
Tyngsboro, MA 01879
Phone: 978-649-0007
Email: ryan.flynn@accuboost.com
Website: www.accuboost.com
R
Accuray Inc.
1310 Chesapeake Terrace
Sunnyvale, CA 94089
Phone: 408-716-4757, ext. 226
Email: sales@accuray.com
Website: www.accuray.com
A R Advanced Radiation Inc. Measurements
601 NE Emerson Street
Port St. Lucie, FL 34983
Phone: 772-340-3279
Email: armx2000@aol.com
Website: www.armx2000.com
LEGEND
A
Ambassador
P Platinum Sponsor
G Gold Sponsor
S
B
Silver Sponsor
Bronze Sponsor
C Copper Sponsor
R Enhanced RO MarketPlace
Listing
Corporate members in bold.
7101
7011
EXHIBITOR NAME
BOOTH#
Advanced Shielding Technologies Inc.
11059
23355 L&N Turnpike, Building F
West Point, KY 40177
Phone: 502-922-3009
Email: svantilburg@advancedshieldingtech.com
Website: www.advancedshieldingtechnologies.com
Advanced Technology and Co. Ltd. Materials 7096
Zone C. No. 10 Youngcheng Beilu, Young Feng
Industrial Base, Haidium
Beijing, 100096
China
Phone: 86-587-173-0180-08
Email: wangweidick@yahoo.com.ch
Aktina Medical Corporation
4077
360 Route 9W North
Congers, NY 10920
Phone: 888-433-3380
Email: info@aktina.com
Website: www.aktina.com
R
ALATRO9097
C/ Castelló 128 1º Madrid, 28006
Spain
Phone: 51-142-295-94
Email: secretaria@alatro.com
Website: www.alatro.org
Algeta11062
210 Broadway Street, 4th Floor
Cambridge, MA 02139
Phone: 617-225-2301
Email: jessica.stifel@algeta.com
Website: www.algeta.com
Alphatron Linac
8008
5 Penn Plaza, 23rd Floor
New York, NY 10001
Phone: 646-845-1914
Website: www.alphatronlinac.com
R
American Association of Medical Dosimetrists 8011 2201 Cooperative Way, Suite 600
Herndon, VA 20171
Phone: 703-677-8071
Email: aamd@medicaldosimetry.org
Website: www.medicaldosimetry.org
American College of Radiology
7092
1891 Preston White Drive
Reston, VA 20191
Phone: 703-648-8900
Email: bmonzon@acr.org
Website: www.acr.org
R
AMAC
8014
2864 Johnson Ferry Boulevard
Suite 150
Marietta, GA 30062
Phone: 770-693-6031
Email: info@amac-usa.com Website: www.amac-usa.com
R
EXHIBITOR NAME
BOOTH#
American Radium Society
6056
11300 West Olympic Boulevard
Suite 600
Los Angeles, CA 90064
Phone: 310-437-0581
Email: info@americanradiumsociety.org
Website: www.americanradiumsociety.org
ASTRO Resource Center
8043
8280 Willow Oaks Corporate Drive, Suite 500
Fairfax, VA 22031
Phone: 1-800-962-7876
Email: membership@astro.org
Website: www.astro.org
American Society of Clinical Oncology
10118
2318 Mill Road, Suite 800
Alexandria, VA 22314
Phone: 703-299-0158
Email: membermail@asco.org
Website: www.asco.org
American Society of Radiologic Technologists 7006
15000 Central Avenue SE
Albuquerque, NM 87123-3909
Phone: 505-298-4500
Email: marketing@asrt.org
Website: www.asrt.org
Anatom-e XRT Information Systems Ltd.
6107 2047 University Boulevard
Houston, TX 77030
Phone: 713-382-3638
Email: bill@anatom-e.com
Website: www.anatom-e.com
AQUILAB7095
Parc Eurasante 250, rue Salvador Allende
Loos Les Lille, 59120
France
Phone: 00-333-696-1515-1
Email: info@aquilab.com
Website: www.aquilab.com
R
architection10073
425 W. Market Street
Louisville, KY 40202
Phone: 502-561-1024
Email: ptorp@architection.com
Website: www.architection.com
R
Augmenix2023
204 2nd Avenue, Lower Level
Waltham, MA 02451
Phone: 781-902-1625
Email: egardner@augmenix.com
Website: www.augmenix.com
Azimuth Therapy
2021
68 B Amal Street
Petach Tikva, 49513
Israel
Phone: 972-3-927-8111
Email: info@azimutherapy.com
Website: www.azimutherapy.com
191
EXHIBITOR NAME
BOOTH#
Bard, Rao + Athanas Consulting Engineer LLC 7062
311 Arsenal Street
Watertown, MA 02472
Phone: 617-925-8374
Email: dlt@brplusa.com
Website: www.brplusa.com
Bayer HealthCare
4055
6 West Belt
Wayne, NJ 07470
Phone: 973-305-5000
Email: jerry.samuels@bayer.com
Website: www.bayerus.com
G
Best Medical International Inc. 4005, 6003, 9079,10031
7643 Fullerton Road
Springfield, VA 22153
Phone: 703-451-2378
Email: christina@teambest.com
Website: www.teambest.com
R
Biocompatibles Inc.
8037
115 Hurley Road, Building 3
Oxford, CT 06478
Phone: 203-262-4198
Email: lindsey.raymond@biocompatibles.com
Website: www.biocompatiblesinc.com
R
9067
5154 Enterprise Boulevard
Toledo, OH 43612
Phone: 419-727-8421, ext. 222
Email: rmasters@bionix.com
Website: www.bionixrt.com
BK Medical
6013
BK Medical, 8 Centennial Drive
Peabody, MA 01960
Phone: 978-326-1300
Email: info@us.bkmed.com
Website: www.bkmed.com
5055
3555 N. W. 58th Street, Suite 500
Oklahoma City, OK 73112
Phone: 405-917-0500
Email: jcarlin@oncochart.com
Website: www.oncochart.com
R
LEGEND
A
Ambassador
P
G
S
Platinum Sponsor
Gold Sponsor
Silver Sponsor
B Bronze Sponsor
C Copper Sponsor
Listing
EXHIBITOR NAME
Cangene Corporation
920 Cassatt Rd., Suite 100
Berwyn, PA 19312
Email: dsamphir@cangene.com
Website: www.cangene.com
Carl Zeiss Meditec Inc.
5160 Hacienda Drive
Dublin, CA 94568
Phone: 925-557-4100
Email: info@meditec.zeiss.com
Website: www.meditec.zeiss.com
CDR Systems Inc.
#33, 235105 Wrangler Drive, SE
Calgary, AB T1X 0K3
Canada
Phone: 403-850-7035
Email: carldenis@cdrsys.ca
Website: www.cdrsys.ca
R
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Phone: 202-690-8267
192
BOOTH#
Brainlab5037
3 Westbrook Corporate Center, Suite 400
Westchester, IL 60154
Phone: 708-409-1343
Email: anna.bliss@brainlab.com
Website: www.brainlab.com
A R
BSD Medical Corp.
6007
2188 W 2200 S
Salt Lake City, UT 84119
Phone: 801-972-5555
Email: dstancill@bsdmc.com
Website: www.bsdmedical.com
R
Business Services International Inc.
13045
22 East Church Street
Martinsville, VA 24112
Phone: 1-866-768-6886
Email: bizserv@gmail.com
Website: www.bizservint.com
8015
17 Executive Park Drive, Suite 520
Atlanta, GA 30329
Phone: 1-800-998-5859
Email: jlux@cancercarepoint.com
Website: www.cancercarepoint.com
R
Cancer Treatment Centers of America
10063
2610 Sheridan Road
Zion, IL 60099
Phone: 847-746-4441
Email: jeanette.krimmer@ctca-hope.com
Website: www.cancercenter.com
3030
2049
3063
3060
EXHIBITOR NAME
BOOTH#
Cholangiocarcinoma Foundation, The
13009
10 West Broadway, Suite 700
Phone: 707-481-8045
Website: www.cholangiocarcinoma.org
Churchill Consulting Inc.
7012
384 Route 148
Killingworth, CT 06419
Phone: 860-663-5630
Email: deb@churchillconsulting.com
Website: www.churchillconsulting.com
R
Cianna Medical
7002
6 Journey, Suite 125
Aliso Viejo, CA 92656
Phone: 949-360-0059
Email: customercare@ciannamedical.com
Website: www.ciannamedical.com
CIRS5101
2428 Almeda Avenue, Suite 316
Norfolk, VA 23513
Phone: 757-855-2765
Email: info@cirsinc.com
Website: www.cirsinc.com
R
10003
1401 8th Street SE
Orange City, IA 51041
Phone: 712-737-8688
Email: info@civco.com
Website: www.civco.com
S R
ClinicMax9062
20271 Goldenrod Lane, Suite 2045
Germantown, MD 20876
Phone: 240-668-4825
Email: info@clinicmax.com
Website: www.clinicmax.com
Cold Shot Chillers
12062
14020 Interdrive West
Houston, TX 77032
Phone: 281-227-8400
Email: vleger@waterchillers.com
Website: www.waterchillers.com
R
Computerized Radiation Scanners Inc.
9006
140 Sopwith Drive
Vero Beach, FL 32968
Phone: 772-562-0405
Email: crs7@bellsouth.net
Website: www.beamscanners.com
CR Bard Inc.
11054
13183 Harland Drive
Covington, GA 30014
Phone: 770-784-6399
Email: rebecca.pierucci@crbard.com
Website: www.bardbiopsy.com
EXHIBITOR NAME
BOOTH#
C-RAD Incorporated
3077
8059 Rose Marie Avenue East
Boynton Beach, FL 33472
Phone: 561-742-9260
Email: martin.clay@c-rad.se
Website: www.c-rad.se
R
D3 Oncology Solutions
13031
5750 Centre Avenue, Suite 500
Pittsburgh, PA 15206
Phone: 412-365-0719
Email: briggsla2@d3onc.com
Website: www.d3onc.com
R
Dana-Farber/ Brigham and Women’s
7009
Cancer Center 450 Brookline Avenue
Boston, MA 02215
Phone: 617-632-5859
Email: kwooten@parnters.org
Dansko’s by Alexanders
13067
999 Pontiac Avenue
Cranston, RI 02920
Phone: 401-490-2910
Demos Medical Publishing
8005
11 West 42nd Street, 15th Floor
New York, NY 10036
Phone: 212-683-0072, ext. 217
Email: thastings@demosmedpub.com
Website: www.demosmedpub.com
Department of Veterans Affairs (HRRO)
13010
1555 Poydras Street, Suite 1971
New Orleans, LA 70112
Phone: 504-565-4844
Email: susan.montelius@va.gov
Website: www.vacareers.va.gov
R
Destiny Educational Services Inc.
2019
15 Noble Avenue
Pittsburgh, PA 15205
Phone: 412-875-5992
Email: tom@destinyeducates.com
Website: www.destinyeducates.com
R
DIACOR4031
2550 Decker Lake Boulevard, Suite #26
Phone: 763-227-2256
Email: tpierson@diacorinc.com
Website: www.diacorinc.com
R
DOSIsoft8092
45-47 Avenue Carnot
Cachan, 94230
France
Phone: 33-141-242-626
EXHIBITOR NAME
BOOTH#
e+CancerCare9055
104 Woodmont Boulevard, Suite 500
Nashville, TN 37205
Phone: 615-467-7407
Email: jjohnson@epluscancercare.com
Website: www.epluscancercare.com
e2v8006
520 White Plains Road, Suite 450
Tarrytown, NY 10591
Phone: 914-592-6050
Email: vijay.patel@e2v.com
Website: www.e2v.com
Eckert & Ziegler BEBIG
8094
Robert-Rössle-Strasse 10
Berlin, 13125
Germany
Phone: 49-30-941084-272
Email: dorota.tkaczyk@bebig.eu
Website: www.bebig.eu
El Dorado Metals Inc.
12029
122 Pellizzari Place
El Dorado, AR 71730
Phone: 870-863-5757
Email: pholsinger@eldomet.com
Website: www.eldomet.com
R
Elekta 5067
4775 Peachtree Industrial Boulevard
Norcross, GA 30092
Phone: 770-670-2592
Email: doris.aubuchon@elekta.com
Website: www.elekta.com
A R
Elsevier9002
1600 JFK Boulevard
Philadelphia, PA 19103
Phone: 215-239-3490
Email: j.hayes@elsevier.com
Website: www.us.elsevierhealth.com
Enterade USA LLC
9119
14407 SW 2nd Place, Building F-2
Newberry, FL 32669
Phone: 1-855-ENTERADE
Email: enterade@enterade.com
Website: www.enterade.com
Equal-Estro Inc.
185 Alewife Brook Parkway, #40
Cambridge, MA 02138
Phone: 32-277-681-53
Website: www.equal-estro.org
Everson Tesla Inc.
615 Daniels Road
Nazareth, PA 18064
Phone: 610-216-6279
Email: tstenulis@eversontesla.com
Website: www.eversontesla.com
Foss Therapy Services Inc.
5938 Satsuma Avenue
North Hollywood, CA 91601
Phone: 626-818-3880
Email: ftsinc12@gmail.com
Website: www.fosstherapyservices.net
12015
11072
12013
EXHIBITOR NAME
BOOTH#
Gamma Basics
3032
175 Strafford Avenue, Suite 1 #509
Wayne, PA 19087
Phone: 1-888-980-0077
Email: mkijewski@gammabasics.com
Website: www.gammabasics.com
Gammex Inc.
9037
7600 Discovery Drive
Middleton, WI 53562
Phone: 608-828-7000
Email: sales@gammex.com
Website: www.gammex.com
R
GE Healthcare
4036
P.O. Box 414
Milwaukee, WI 53201
Phone: 414-788-1880
Email: jkohlmann@med.ge.com
Website: www.gehealthcare.com
A Genomic Health Inc.
8059
301 Penobscot Drive
Redwood City, CA 94063
Phone: 866-ONCOTYPE
Email: CustomerService@genomichealth.com
Website: www.OncotypeDX.com
Global Physics Solutions
13019
2 Science Road
Glenwood, IL 60425
Phone: 1-877-476-8433
Email: info@landauermp.com
Website: www.landauermp.com
GMV6101
Isaac Newton, 11
Tres Cantos, Madrid 28760
Spain
Phone: 34-918-072-100
Email: cillana@gmv.com
Website: www.gmv.com
R
Gold Anchor
6061
Vassvagen 21
Huddinge, 14139
Sweden
Phone: 46-706-105-411
Email: info@fineneedlemarker.com
Website: www.fineneedlemarker.com
Grensuny Medical Technology Stock Co. Ltd. 11049
Room 2110 Profit Yinglong Plaza
No. 76, West Huangpu Road
Guangzhou, Guangdong 510623
China
Phone: 86-203-839-1505 /38391508
Email: renfu@renfumed.com
Website: www.grensuny.com
H & H Design-Build
5054
130 East Main Street
New Albany, IN 47150
Phone: 812-944-2396
Email: frank.heinz@hhdesignbuild.com
Website: www.hhdesignbuild.com
R
193
EXHIBITOR NAME
BOOTH#
Healthcare Administrative Partners
12054
112 Chesley Drive
Media, PA 19063
Phone: 610-892-8889
Email: bconrad@hapusa.com
Website: www.hapusa.com
R
Healthcare Global Enterprises
7093
# 8, P Kalinga Rao Road, Tower IV, HCG,
Sampaniramnagar
Bangalore, Karnataka 560027
India
Phone: 91-804-020-6058
Website: www.hcgoncology.com
Hermes Medical Solutions Inc.
7007
710 Cromwell Drive, Suite A
Greenville, NC 27858
Phone: 866-437-6372
Email: info@hermesmedical.com
Website: www.hermesmedical.com
Hitachi Aloka Medical
4088
10 Fairfield Boulevard
Wallingford, CT 06492
Phone: 1-800-872-5652
Email: inquiry@hitachi-aloka.com
Website: www.hitachi-aloka.com
Hitachi America Ltd.
4084
50 Prospect Avenue
Tarrytown, NY 10591
Phone: 914-332-5800
Email: protonbeam@hal.hitachi.com
Website: www.hitachi-america.us
Hologic Inc.
3049
35 Crosby Drive
Bedford, MA 01730
Phone: 781-999-7300
Website: www.hologic.com
R
IBA3019
Chemin du Cyclotron, 3
Louvain-la-Neuve, 1348
Belgium
Phone: 32-470-048-622
Email: daniel.ernult@iba-group.com
Website: www.iba-worldwide.com
A
LEGEND
A
Ambassador
P
G
S
Platinum Sponsor
Gold Sponsor
Silver Sponsor
B Bronze Sponsor
C Copper Sponsor
Listing
EXHIBITOR NAME
Imaging Technology News
3030 West Salt Creek Lane, Suite 201
Arlington Heights, IL 60005
Phone: 847-391-1000
Email: sreilly@sgcmail.com
Website: www.itnonline.com
ImpediMed Inc.
2850 Clover Street
Pittsford, NY 14534
Phone: 1-877-247-0111
Website: www.impedimed.com
R
InSightec Ltd.
5 Nachum Heth Street
Tirat Carmel, 39120
Israel
Phone: 972-54-6374738
Email: nicolef@insightec.com
Website: www.insightec.com
Integrated Oncology Network
2865 E. Coast Highway, Suite 210
Corona del Mar, CA 92625
Phone: 949-208-3111
Email: gingersoll@ion-llc.com
Website: www.ion-llc.com
IntraOp Medical Corporation
570 Del Rey Avenue
Sunnyvale, CA 94085
Phone: 408-636-1020
Website: www.intraopmedical.com
R
IOP Publishing
150 S. Independence Mall W., Suite 929
Phone: 215-627-0880
Email: info@ioppubusa.com
Website: publishing.iop.org
Iron Medical Systems Inc.
3104 E. Camelback Road #562
Phoenix, AZ 85016
Phone: 602-343-6440
Email: mary@ironmedicalsystems.com
Website: www.ironmedicalsystems.com
IsoAid LLC
7824 Clark Moody Boulevard
Port Richey, FL 34668
Phone: 727-207-5973
Email: jgibson@isoaid.com
Website: www.isoaid.com
R
IsoRay Medical Inc.
350 Hills Street, Suite 106
Richland, WA 99354
Phone: 520-240-4840
Email: dbabcock@isoray.com
Website: www.isoray.com
194
BOOTH#
7010
2048
3033
11091
7094
8010
8013
6060
10055
EXHIBITOR NAME
BOOTH#
IZI Medical Products a Landauer Company
9059
5 Easter Court, Suite J
Owings Mills, MD 21117
Phone: 410-594-9403
Email: barbara.woodward@izimed.com
Website: www.izimed.com
James L. Davis
7015
13521 Walsingham Road
Largo, FL 33774
Phone: 727-596-0408
Email: tracy@jld-radcon.com
Website: www.jld-radcon.com
R
Karger Publishers Inc.
8003
26 West Avon Road, P.O. Box 529
Unionville, CT 06085
Phone: 860-675-7834
Email: karger.susan@snet.net
Website: www.karger.com
Klarity7063
80 Westgate Drive
Newark, OH 43055
Phone: 740-788-8107
Email: peter@klaritymedical.com
Website: www.klaritymedical.com
R
KOS Systems
1217 Floribunda Avenue, #4
Burlingame, CA 94010
Phone: 714-655-3152
Website: www.kossystems.com
Kyoto Kagaku Co. Ltd.
3109 Lomita Boulevard
Torrance, CA 90505
Phone: 310-325-8860
Email: f_kawamoto@kyotokagaku.co.jp
Website: www.kyotokagaku.com
2 Science Road
Glenwood, IL 60425
Phone: 1-877-476-8433
Email: info@landauermp.com
Website: www.landauermp.com
LAP of America LLC
1701 Avenda del Sol
Boca Raton, FL 33432
Phone: 561-416-9250
Email: tava@lap-laser.com
Website: www.lap-laser.com
R
Liberty Medical Inc.
22135 Davis Drive #112
Sterling, VA 20164
Phone: 1-888-257-2408
Email: rwittmer@libertymedicalinc.com
Website: www.libertymedicalinc.com
R
3058
11055
13019
3001
6100
EXHIBITOR NAME
BOOTH#
LifeLine Software Inc.
8119
2407 Pemberton Place
Austin, TX 78703
Phone: 866-592-1343, ext. 1
Email: sales@lifelinesoftware.com
Website: www.lifelinesoftware.com
R
LinaTech LLC
8086
1294 Kifer Road, Suite 705
Sunnyvale, CA 94086
Phone: 408-733-2051
Email: corynorris@linatech.com
Website: www.linatech.com
R
Linbeck Group LLC
3031
3900 Essex Lane, Suite 1200
Houston, TX 77027
Phone: 832-922-0244
Email: dpitzenberger@linbeck.com
Website: www.linbeck.com
Lippincott Williams and Wilkins/WKH
4028
Two Commerce Square 2001 Market Street
Phone: 215-521-8300
Email: joey-rose.jester@wolterskluwer.com
Website: www.lww.com
Locumtenens.com
5105
2655 Northwinds Parkway
Alpharetta, GA 30009-2280
Phone: 770-643-5559
Email: ccru@locumtenens.com
Website: www.locumtenens.com
Logos Systems Int’l
175 El Pueblo Road
Scotts Valley, CA 95066
Phone: 831-439-9440
Email: brett@logovisionsystem.com
Website: www.logosvisionsystem.com
MASEP Infini
17870 Castleton Street, Suite 395
Industry, CA 92509
Phone: 626-965-3200
Email: wendyj@masepinfini.com
Website: www.masepinfini.com
3062
11079
Math Resolutions LLC
1019
5975 Gales Lane
Columbia, MD 21045
Website: www.mathresolutions.com
Maxim Government Services
12060
7227 Lee DeForest Drive
Columbia, MD 21046
Phone: 1-877-306-4429
Email: alwilliam@maxhealth.com
Website: www.maximgov.com
Medical Business Systems
6011
59 Damonte Ranch Parkway, B-185
Reno, NV 89521
Phone: 775-453-3193
Email: susan@iridiumsuite.com
Website: www.iridiumsuite.com
EXHIBITOR NAME
BOOTH#
Medical Dosimetrist Certification Board (MDCB)9058
15000 Commerce Parkway, Suite C
Mt. Laurel, NJ 08054
Phone: 856-642-4430
Email: flembesis@ahint.com
Website: www.mdcb.org
Medical Mediation Services LLC
13073
P.O. Box 2409
Pearland, TX 77588
Phone: 225-439-2977
Email: info@medicalmediationservices.com
Medspira11060
2718 Summer Street NE
Minneapolis, MN 55413
Phone: 612-789-0013
Website: www.medspira.com
MEI Healthcare Group
4091
11772 West Sample Road
Coral Springs, FL 33065
Phone: 954-341-3302
Email: ksmyth@mei.com
Website: www.mei.com
R
12037
300 Foster Street
Littleton, MA 01460
Phone: 978-540-1500
Email: info@mevion.com
Website: www.mevion.com
G R
MGS Research
6103
1 Orchard Park Road, Suite 6
Madison, CT 06443
Phone: 203-245-3251
Email: jhknapp@mgsresearch.com
Website: www.mgsresearch.com
Miaderm at Aiden Industries
6054
2412 Calle San Miguel
Encinitas, CA 92024
Phone: 617-461-5959
Email: plinson@post.harvard.edu
Website: www.miaderm.com
Mick Radio Nuclear-Instruments Inc. 9036
521 Homestead Avenue
Mount Vernon, NY 10550
Phone: 914-667-3999
Website: www.micknuclear.com
R
Micropos Medical AB
4073
Stena Center 1
Gothenburg, 41292
Sweden
Phone: 46-31-772-8099
Email: info@micropos.se
Website: www.micropos.se
R
EXHIBITOR NAME
BOOTH#
MIM Software
25200 Chagrin Boulevard, Suite #200
Cleveland, OH 44122
Phone: 216-455-0600
Email: info@mimsoftware.com
Website: www.mimsoftware.com
R
Mirada Medical
999 18th Street, Suite 2025N
Denver, CO 89292
Phone: 1-877-872-2617
Email: support@mirada-medical.com
Website: www.mirada-medical.com
3013
5109
Mission Search
5072
2203 N. Lois Avenue, Suite 1225
Tampa, FL 33607
Phone: 1-800-410-2009
Email: info@missionsearchusa.com
Website: www.missionsearchusa.com
Mitsubishi Electric
8061
2-7-3 Marunouchi Chiyoda-ku
Tokyo, 100-8310
Japan
Phone: 81-3-3218-9780
Email: kobayashi.yuji@eb.mitsubishielectric.co.jp
Website: www.mitsubishielectric.com/bu/
particlebeam
R
Mobius Medical Systems LP
13037
512 Tamarisk Street
Bellaire, TX 77401
Phone: 1-888-263-8541
Email: elizabeth@mobiusmed.com
Website: www.mobiusmed.com
5059
1570 North Routledge Park
London, ON N6H 5L6
Canada
Phone: 519-438-2409
Email: marketing@modusmed.com
Website: www.modusmed.com
MPM Medical Inc.
3029
2301 Crown Court
Irving, TX 75038
Phone: 972-893-4090
Website: www.mpmmed.com
R
MuCheck-Oncology Data Systems
5090
1601 SW 89th Street E-100
Oklahoma City, OK 73159
Phone: 405-680-5222
Email: mail@mucheck.com
Website: www.mucheck.com
Multidata Systems International Corp.
6102
10816 Indian Head Industrial Boulevard
St Louis, MO 63132
Phone: 314-968-6880
Email: wroestel@multidata-systems.com
Website: www.multidata-systems.com
195
EXHIBITOR NAME
BOOTH#
National Medical Professional RRG Inc. 10096
P.O. Box 50933
Fort Myers, FL 33994
Phone: 1-888-804-9556
Email: nlutz@nmpinsurance.com
Website: www.nmpinsurance.com
R
NELCO9085
2 Burlington Woods Drive, Suite 300
Burlington, MA 01803
Phone: 781-933-1940
Email: cmiller@nelcoworldwide.com
Website: www.nelcoworldwide.com
R
Niigata Mechatronics Co. Ltd.
7091
3268-18, Shimami-cho, Kita-ku
Niigata-city, 950-3102 JP
Japan
Phone: 81-25-255-3932
Email: nimonji@niigata-kiden.co.jp
Website: www.niigata-kiden.co.jp
Oncolink-University of Pennsylvania 10056
Perleman Center for Advanced Medicine
3400 Civic Center Boulevard
Radiation Oncology Admin Offices
Suite 2338
Phone: 215-349-8895
Email: hampshire@uphs.upenn.edu
Website: www.oncolink.org
Oncology Interactive Navigator (OIN)
301-645 King Street West
Toronto, Ontario
Canada M5V 1M5
Phone: 416-504-7506
Website: www.oncologyinteractive.com
400 Rella Boulevard, Suite 123
Montebello, NY 10901
Phone: 845-357-6560
Email: trichardson@thinkosi.com
Website: www.thinkosi.com
R
Oncology Systems Limited
14 Longbow Professional Centre
Shrewsbury, Shropshire SY1 3GZ
United Kingdom
Phone: 44-017-434-6269-4
Email: enquiry@osl.uk.com
Website: www.osl.uk.com
LEGEND
A
Ambassador
P
G
Platinum Sponsor
Gold Sponsor
S Silver Sponsor
B Bronze Sponsor
C Copper Sponsor
Listing
4097
9073
5127
EXHIBITOR NAME
196
BOOTH#
Oncura Inc.
4049
3350 North Ridge Avenue
Arlington Heights, IL 60004
Phone: 1-800-228-0126
Email: lory.bradley@ge.com
Website: www.oncura.com
Oncure Medical Corp
9008
188 Inverness Drive West, Suite 650
Englewood, CO 80112
Phone: 303-643-6510
Email: khime@oncure.com
Website: www.oncure.com
R
Onics Direct
9063
P.O. Box 53
Hornell, NY 14843
Phone: 607-968-1220
Website: www.i-notz.com
Orfit Industries America
12077
350 Jericho Turnpike, Suite 101
Jericho, NY 11753
Phone: 516-935-8500
Email: martinj.ratner@orfit.com
Website: www.orfit.com
R
Oxford Instruments Service
1031
64 Union Way
Vacaville, CA 95687
Phone: 1-888-673-5151
Email: michaelle.serrano@oxinst.com
Website: www.oxford-instruments.com/ct-mr
P-Cure Ltd.
13043
500 Lake Cook Road
Deerfield, IL 60015
Phone: 847-874-7771
Email: israel.raz@p-cure.com
Website: www.p-cure.com
Phantom Laboratory, The
10054
P.O. Box 511
Salem, NY 12865
Phone: 518-692-1190
Email: levy@phantomab.com
Website: www.phantomlab.com
Philips Healthcare
10037
3000 Minuteman Road
Andover, MA 01810
Phone: 1-800-229-6417
Email: healthcare@philips.com
Website: www.philips.com/healthcare
A Pitts Little Corp.
6015
2711 Alton Road
Birmingham, AL 35210
Phone: 205-833-5911
Email: sales@pittslittle.com
Website: www.pittslittle.com
P
EXHIBITOR NAME
BOOTH#
Precise Construction Inc.
8097
5026 Trenton Street
Tampa, FL 33619
Phone: 813-241-2403, ext. 14
Email: scott.johnson@preciseconstruction.com
Website: www.preciseconstruction.com
Precision X-Ray 5096
15 Commerce Drive, Unit 1
North Branford, CT 06471
Phone: 203-484-2011
Email: bdermott@pxinc.com
Website: www.pxinc.com
12019
1100 Parker Square, Suite 230
Flower Mound, TX 75028
Phone: 972-410-3551
Email: jfrank@protominternational.com
Website: www.protominternational.com
R
Prowess Inc.
10093
1844 Clayton Road
Concord, CA 94520
Phone: 925-356-0360
Email: sharon.springorum@prowess.com
Website: www.prowess.com
PTW-New York
5117
205 Park Avenue
Hicksville, NY 11801
Phone: 516-827-3181
Email: john@ptwny.com
Website: www.ptwny.com
R
Qfix7037
440 Church Road
Avondale, PA 19311
Phone: 610-268-0585
Email: damon.kirk@qfix.com
Website: www.qfix.com
R
QLRAD11061
80 South West 8th Street, Suite 2000
Miami, FL 33130
Phone: 770-335-5601
Email: awinkel@qlrad.com
Website: www.qlrad.com
QUALIFORMED Sarl
7060
14 Rue de la Vieille Horloge
La Roche Sur Yon, 85000
France
Phone: 33-9-77-00-91-29
Email: margit.villing@qualiformed.com
Website: www.qualiformed.com
10077
20801 Biscayne Boulevard, Suite 403
Aventura, FL 33180
Phone: 305-898-2544
Email: info@rad-technology.com
Website: www.rad-technology.com
EXHIBITOR NAME
BOOTH#
RadiaDyne6087
11931 Wickchester Lane, Suite 360
Houston, TX 77043
Phone: 281-759-9600
Email: info@radiadyne.com
Website: www.radiadyne.com
Radia-Guard3004
419 Erin Drive, Suite 5
Knoxville, TN 37919
Phone: 1-866-400-8080
Email: info@radiaguard.com
Website: www.radiaguard.com
Radialogica LLC
12073
114 N. Gay Avenue, Suite A
Clayton, MO 63105
Phone: 1-800-515-9132
Email: andy@radialogica.com
Website: www.radialogica.com
5012
1044 Jackson Felts Road
Joelton, TN 37080
Phone: 615-746-4711
Email: dan@radiationbilling.com
Website: www.radiationbusiness.com
S Radiation Oncology Resources
8055
P.O. Box 76
Goshen, IN 46527
Phone: 1-866-312-3499
Email: tpugliese@roresources.com
Website: www.roresources.com
R
12099
5218 Barthel Industrial Drive
Albertville, MN 55301
Phone: 1-800-497-2071
Email: sales@rpdinc.com
Website: www.rpdinc.com
R
Radiation Therapy Oncology Group
9060
1818 Market Street, Suite 1600
Phone: 215-717-0843
Email: shartson@acr.org
Website: www.rtog.org
Radiological Imaging Technology
10085
5065 List Drive
Colorado Springs, CO 80919-3321
Phone: 719-590-1077
Email: danritt@radimage.com
Website: www.radimage.com
Radiology Oncology Systems Inc. 10049
6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
Phone: 858-454-8100
Email: info@oncologysystems.com
Website: www.oncologysystems.com
EXHIBITOR NAME
BOOTH#
RADMAX Ltd.
8002
3304 S. Broadway Avenue, Suite 200
Tyler, TX 75701
Phone: 903-531-2371
Email: kevin.ewalt@radmaxonline.com
Website: www.radmaxonline.com
R
RaySearch Laboratories AB
3067
401 Franklin Avenue, Suite 100A
Garden City
New York, NY 11530
Phone: 1-877-778-3849
Email: sales@raysearchlabs.com
Website: www.raysearchlabs.com
G Red Journal/PRO
9004
1600 JFK Boulevard
Phone: 702-260-4628
Website: www.us.elsevierhealth.com
R
Remetronix13032
2190 NW Reserve Park Trace
Port Saint Lucie, FL 34986
Phone: 1-800-875-0856
Website: www.remetronix.com
Revenue Cycle Inc.
10058
1817 West Braker Lane
Building F, Suite 200
Austin, TX 78758
Phone: 512-583-2000
Email: info@revenuecycleinc.com
Website: www.revenuecycleinc.com
R
RS & A Inc.
4094
465 Forum Parkway
Rural Hall, NC 27045
Phone: 336-969-0583
Email: bginas@rsainc.net
Website: www.rsa-inc.com
RTI Electronics Inc.
4059
33 Jacksonville Road, Building 1
Towaco, NJ 07082
Phone: 973-439-0242
Email: margaret.garza@rtielectronics.com
Website: www.rtielectronics.com
S+S Par Scientific
7008
10625 Telge Road
Houston, TX 77095
Phone: 281-815-1300
Email: tj@ParScientific.com
Website: www.ParScientific.com
ScandiDos7055
Uppsala Science Park
Uppsala, SE-751 83
Sweden
Phone: 46-018-472-3030
Email: info@scandidos.com
Website: www.scandidos.com
EXHIBITOR NAME
BOOTH#
SciMedix Co. Ltd.
12055
8 Fl. B-dong, Samho Building 275-6
Yangjae-dong, Seocho-gu 137-941
Korea
Phone: 82-258-907-75
Sensus Healthcare
9054
851 Broken Sound Parkway #215
Boca Raton, FL 33487
Phone: 1-800-324-9890
Email: info@sensushealthcare.com
Website: www.sensushealthcare.com
R
Shandong Xinhua Medical Instruments Co. Ltd. 1001
No.7 Taimei Road, Zibo New and Hi-Tech Zone
Shandong, 255086, China
Phone: 86-533-358-7719
Email: xhliping@hotmail.com Website: www.shinva.com
Shielding Construction Solutions Inc. 10013
4620 South Coach Drive
Tucson, AZ 85714
Phone: 520-917-0661
Email: info@shieldingconstruction.com
Website: www.shieldingconstruction.com
R
Siemens Medical Solutions USA Inc. 10019
51 Valley Stream Parkway
Malvern, PA 19355
Phone: 610-448-4252
Email: lisa.richard@siemens.com
Website: www.medical.siemens.com
A
Skin Clinical
P.O. Box 5005 #69
16921-C Via de Santa Fe
Rancho Santa Fe, CA 92067
Phone: 858-756-0467
Email: niv@truenorthinv.com
Website: www.skinclinicallabs.com
Sky Factory
801 N. 18th Street, PO 1177
Fairfield, IA 52556
Phone: 641-472-1747
Email: Info@skyfactory.com
Website: www.skyfactory.com
Source Production & Equipment
113 Teal Street
St. Rose, LA 70087
Phone: 504-464-9471
Email: kevin@spec150.com
Website: www.spec-med.com
Spectrum Pharmaceuticals Inc.
157 Technology Drive
Irvine, CA 92618
Phone: 949-788-6700
Email: linda.azarbal@sppirx.com
Website: www.sppirx.com
R A 6105
6063
8090
2013
197
EXHIBITOR NAME
BOOTH#
Springer8007
233 Spring Street
New York, NY 10013
Phone: 212-460-1500
Email: exhibits-ny@springer.com
Website: www.springer.com
Staff Care Inc.
10122
5001 Statesman Drive
Irving, TX 75063
Phone: 1-800-685-2272
Email: tania.cotter@staffcare.com
Website: www.staffcare.com
Standard Imaging
7045
3120 Deming Way
Middleton, WI 53562
Phone: 1-800-261-4446
Email: dwasha@standardimaging.com
Website: www.standardimaging.com
R
Sumitomo Heavy Industries Ltd.
11067
Think Park Tower 1-1, Osaki 2-chome, Shinagawa
Tokyo, 141-6025
Japan
Phone: 61-079-167-16
Email: shn_masui@shi.co.jp
Website: www.shi.co.jp/english/
R
425-A Pineda Court
Melbourne, FL 32940
Phone: 321-259-6862-275
Email: insidesales@sunnuclear.com
Website: www.sunnuclear.com
C superDimension Inc.
161 Cheshire Lane, Suite 100
Plymouth, MN 55441
Phone: 763-210-4013
Email: kobrien@superdimension.com
Website: www.superdimension.com
Suremark Company, The
4645 Industrial Street, 2C
Simi Valley, CA 93063
Phone: 1-800-406-3399
Email: customerservice@suremark.com
Website: www.suremark.com
12000
Teva
41 Moores Road
Frazer, PA 19355
Phone: 1-800-782-3656
Website: www.tevapharm.com
TGM2 Inc.
15375 Roosevelt Boulevard, Suite 300
Clearwater, FL 33760
Phone: 727-507-8500
Email: sales@tgm2.com
Website: www.tgm2.com
R
7119
198
3000
6058
4013
EXHIBITOR NAME
BOOTH#
10067
5203 Bristol Industrial Way
Buford, GA 30518
Phone: 770-831-5151
Email: mahoneys@theragenics.com
R
Top Grade Medical Equipment Co. Ltd.
6111
No. 11 Yongchang North Road, BDA
Beijing, P.R.C. 10076
China
Phone: 86-10-6788-5599-398
Email: pengcheng.zhang@topgradehc.com
Website: www.topgradehc.com
9012
5318 E. 2nd Street, #682
Long Beach, CA 90803
Phone: 949-622-0022
Email: John@trgoe.com
Website: www.oncologyequipment.com
Tsoi/Kobus and Associates
12027
One Brattle Square P.O. Box 9114
Cambridge, MA 02238
Phone: 617-475-4312
Email: emiller@tka-architects.com Website: www.tka-architects.com US Radiosurgery
7087
40 Burton Hills Boulevard, Suite 220
Nashville, TN 37215
Phone: 615-263-7888
Email: cmarks@allianceoncology.com
Website: www.usradiosurgery.com
R
Vantage Oncology
5095
1500 Rosecrans Avenue, Suite 400
Manhattan Beach, CA 90266
Phone: 310-335-4000
Email: info@vantageoncology.com
Website: www.vantageoncology.com
5019
3100 Hansen Way
Palo Alto, CA 94304
Phone: 650-424-5927
Email: robert.capuzelo@varian.com
Website: www.varian.com
A R
Velocity Medical Solutions
11073
1350 Spring Street, Suite 275
Atlanta, GA 30309
Phone: 404-920-1966
Email: thomas.brunson@velocitymedical.com
Website: www.velocitymedical.com
2037
5 Great Valley Parkway, Suite 210
Malvern, PA 19355
Phone: 1-888-242-6760
Email: info@veritas-medicalsolutions.com
Website: www.veritas-medicalsolutions.com
R
EXHIBITOR NAME
BOOTH#
Vertual Ltd.
4085
Logistics Institute
Hull, UK HU6 7RX
United Kingdom
Phone: 44-148-234-7572
Email: sales@vertual.co.uk
Website: www.vertual.co.uk
C ViewRay Inc.
12067
2 Thermo Fisher Way
Oakwood Village, OH 44146
Phone: 440-703-3210
Email: msaracen@viewray.com
Website: www.viewray.com
S
Vision RT Ltd.
12047
Dove House, Arcadia Avenue
London, UK N3 2JU
United Kingdom
Phone: 00-44-771-432-7781
Email: jturner@visionrt.com
Website: www.visionrt.com
R
VisionTree Software Inc.
3054
8885 Rio San Diego Drive #220
San Diego, CA 92108
Phone: 619-295-2800
Website: www.visiontree.com
Water-Jel Technologies
4063
50 Broad Street
Carlstadt, NJ 07072
Phone: 201-507-8300
Email: jstempkowski@WaterJel.com
Website: www.Radiaderm.com
R
Wells Fargo Equipment Finance Inc.
5062
608 Second Avenue South, N9303-116, 11th Floor
Minneapolis, MN 55402
Phone: 612-667-0855
Email: vita.taormina@wellsfargo.com
Website: www.wellsfargo.com/healthcarefinancing
Xecan8012
275 Grove Street, Building 2, Suite 400
Newton, MA 02466
Phone: 617-686-9953
Xoft-a subsidiary of iCAD Inc.
345 Potrero Avenue
Sunnyvale, CA 94085
Phone: 408-419-2300
Email: mfees@icadmed.com
Website: www.xoftinc.com
Xstrahl Ltd.
480 Brogdon Road, Suite 100
Suwanee, GA 30024
Phone: 678-482-6800
Email: support@xstrahl.com
Website: www.xstrahl.com
C
5087
4067
Exhibitor Listing by Product/Service
ACCELERATOR
DOSIMETRY/DETECTORS
IMAGING PRODUCTS
A2J Laser America
11085
Brainlab5037
Gamma Basics
3032
4084
IBA
3019
LAP of America L.C.
3001
MEIHealthcare Group
4091
Mitsubishi Electric
8061
9073
12019
Radiology Oncology Systems Inc.
10049
RS & A Inc.
4094
Shielding Construction Solutions Inc.
10013
Siemens Medical Solutions USA Inc.
10019
11067
TGM2 Inc.
4013
9012
5019
ViewRay Inc.
12067
6107
Best Medical
4005, 6003 9079, 10031
International Inc.
CIRS5101
Gammex Inc.
9037
IBA
3019
MGS Research
6103
Micropos Medical AB
4073
6102
10054
PTW-New York
5117
QLRAD11061
12009
10085
4059
ScandiDos7055
Standard Imaging
7045
12000
5019
11073
A2J Laser America
11085
6107
AQUILAB7095
Best Medical
4005, 6003 9079, 10031
International Inc.
Biocompatibles Inc.
8037
BK Medical
6013
Brainlab5037
C-RAD Incorporated
3077
Gamma Basics
3032
Gammex Inc.
9037
7007
4088
Hologic Inc.
3049
IBA
3019
9059
Kyoto Kagaku Co. Ltd.
11055
LAP of America L.C.
3001
4091
MGS Research
6103
MIM Software
3013
5127
1031
P-Cure Ltd.
13043
10054
Philips Healthcare
10037
12009
10085
10049
10019
6058
TGM2 Inc.
4013
6111
11073
ViewRay Inc.
12067
Vision RT Ltd.
12047
5087
Xstrahl Ltd.
4067
BRACHYTHERAPY
ELECTRONIC MEDICAL RECORDS
6055
AccuBoost3055
Best Medical
4005, 6003 9079, 10031
International Inc.
Biocompatibles Inc.
8037
BK Medical
6013
Cianna Medical
7002
CIRS5101
10003
Dana-Farber/Brigham and Women’s
Cancer Center
7009
DIACOR4031
Eckert and Ziegler BEBIG
8094
Elekta5067
Gamma Basics
3032
Hologic Inc.
3049
IsoAid LLC
6060
IsoRay Medical Inc.
10055
6100
8119
MEIHealthcare Group
4091
Mick Radio Nuclear-Instruments Inc.
9036
MIM Software
3013
5090
Oncura Inc.
4049
Prowess Inc.
10093
PTW-New York
5117
QLRAD11061
12009
10019
Source Production and Equipment
8090
Standard Imaging
7045
10067
5019
5087
6107
5055
7012
ClinicMax9062
Elekta5067
6011
4091
Onics Direct
9063
10019
5019
3054
FACILITY CONSTRUCTION AND DESIGN
architection10073
Bard, Rao + Athanas Consulting Engineers LLC 7062
H & H Design-Build
5054
IBA
3019
James L. Davis
7015
Linbeck Group LLC
3031
MEIHealthcare Group
4091
NELCO9085
Precise Construction Inc.
8097
10077
5012
10013
Sky Factory
6063
TGM2 Inc.
4013
Tsoi/Kobus & Associates
12027
2037
FINANCIAL SERVICES
US Radiosurgery
Wells Fargo Equipment Finance Inc.
13045
7012
4091
10077
5012
10019
7087
5062
INFORMATION/TECHNOLOGY
6107
AQUILAB7095
5055
7012
ClinicMax9062
2019
Gamma Basics
3032
7007
Iron Medical Systems Inc.
8013
6011
4091
MIM Software
3013
5090
Onics Direct
9063
Philips Healthcare
10037
Radialogica LLC
12073
10019
5019
3054
199
INSURANCE PROVIDER
National Medical Professional RRG Inc.
13045
10096
MEDICAL DEVICE
.decimal7003
A2J Laser America
11085
Accuray Inc.
7101
6107
AQUILAB7095
Augmenix2023
Azimuth Therapy
2021
Best Medical
4005, 6003, 9079, 10031
International Inc.
Biocompatibles Inc.
8037
BK Medical
6013
Brainlab5037
Carl Zeiss Meditec Inc.
2049
DIACOR4031
e2v
8006
8094
Elekta5067
12013
Gammex Inc.
9037
Gold Anchor
6061
4088
4084
Hologic Inc.
3049
InSightec Ltd.
3033
IsoAid LLC
6060
Klarity7063
LAP of America L.C.
3001
6100
LinaTech LLC
8086
Medspira11060
MEIHealthcare Group
4091
12037
MGS Research
6103
9036
Micropos Medical AB
4073
MIM Software
3013
MPM Medical Inc.
3029
7091
9073
Oncura Inc.
4049
1031
P-Cure Ltd.
13043
Philips Healthcare
10037
12019
Qfix
7037
QLRAD11061
12009
RS & A Inc.
4094
Sensus Healthcare
9054
Source Production & Equipment
8090
Standard Imaging
7045
11067
12000
superDimension Inc.
3000
TGM2 Inc.
4013
10067
5019
Vision RT Ltd.
12047
Xstrahl Ltd.
4067
200
OTHER
PRACTICE MANAGEMENT
Alphatron Linac
8008
AMAC8014
6056
6107
BK Medical
6013
BSD Medical Corp.
6007
CDR Systems Inc.
3063
7012
10003
Cold Shot Chillers
12062
13031
Dana-Farber/Brigham and Women’s Cancer 7009
Center
12013
Gammex Inc.
9037
Genomic Health Inc.
8059
13019
12054
7007
InSightec Ltd.
3033
13019
MIM Software
3013
7091
9073
9060
RADMAX Ltd.
8002
Revenue Cycle Inc.
10058
Sky Factory
6063
US Radiosurgery
7087
Vertual Ltd.
4085
Water-Jel Technologies
4063
6055
6107
7012
ClinicMax9062
2019
e+CancerCare9055
12054
Integrated Oncology Network
11091
6011
Mission Search
5072
Oncure Medical Corp
9008
Onics Direct
9063
5012
Vantage Oncology
5095
3054
PATIENT HANDLING/POSITIONING
A2J Laser America
11085
4077
Best Medical
4005, 6003 9079, 10031
International Inc.
9067
Brainlab5037
CDR Systems Inc.
3063
10003
C-RAD Incorporated
3077
DIACOR4031
Elekta5067
Gold Anchor
6061
Klarity7063
LAP of America L.C.
3001
Micropos Medical AB
4073
Philips Healthcare
10037
Qfix
7037
QLRAD11061
12009
10049
S+S Par Scientific
7008
Vision RT Ltd.
12047
PHARMACEUTICAL
Algeta11062
Bayer HealthCare
4055
6054
Radia-Guard3004
Spectrum Pharmaceuticals Inc.
2013
PROFESSIONAL SOCIETY
ALATRO9097
American Association of Medical Dosimetrists 8011
American College of Radiology
7092
6056
American Society of Clinical Oncology
10118
American Society of Radiologic Technologists 7006
ASTRO Resource Center
8043
PUBLISHER
6107
Demos Medical Publishing
8005
Elsevier9002
Imaging Technology News
7010
IOP Publishing
8010
Karger Publishers Inc.
8003
Lippincott Williams and Wilkins/WKH
4028
Red Journal/PRO
9004
Springer8007
QUALITY ASSURANCE
4077
AMAC8014
AQUILAB7095
7012
CIRS5101
10003
9006
13031
12013
Gammex Inc.
9037
7007
IBA
3019
LAP of America L.C.
3001
8119
Math Resolutions LLC
1019
MGS Research
6103
9036
Micropos Medical AB
4073
Mission Search
5072
13037
5059
5090
6102
10054
PTW-New York
5117
QUALIFORMED Sarl
7060
12009
9060
10085
4059
ScandiDos7055
Standard Imaging
7045
12000
TGM2 Inc.
4013
RADIATION PROTECTION/SHIELDING
architection10073
Brainlab5037
El Dorado Metals Inc.
12029
Enterade USA LLC
9119
Gamma Basics
3032
James L. Davis
7015
NELCO9085
Pitts Little Corp.
6015
10077
12009
10013
10019
2037
RADIATION THERAPY
6055
A2J Laser America
11085
Accuray Inc.
7101
Advanced Radiation Measurements Inc.
7011
ALATRO9097
6107
Azimuth Therapy
2021
Best Medical
4005, 6003 9079, 10031
International Inc.
Biocompatibles Inc.
8037
9067
Brainlab5037
CDR Systems Inc.
3063
Cianna Medical
7002
CIRS5101
10003
9006
Dana-Farber/Brigham and Women’s Cancer
7009
Center
2019
DIACOR4031
e2v
8006
8094
Elekta5067
Enterade USA LLC
9119
12013
13019
GMV6101
Hologic Inc.
3049
IBA
3019
IsoAid LLC
6060
9059
Klarity7063
13019
LAP of America L.C.
3001
8119
MASEP Infini
11079
Medspira11060
12037
MGS Research
6103
6054
Micropos Medical AB
4073
MIM Software
3013
Mirada Medical
5109
Mitsubishi Electric
8061
13037
5059
5090
6102
Oncolink-University of Pennsylvania
10056
9073
5127
Orfit Industries America
12077
1031
P-Cure Ltd.
13043
10054
Philips Healthcare
10037
Precision X-Ray
5096
PTW-New York
5117
Qfix
7037
QLRAD11061
QUALIFORMED Sarl
7060
RadiaDyne6087
8055
12009
9060
10085
10049
3067
RS & A Inc.
4094
S+S Par Scientific
7008
ScandiDos7055
Sensus Healthcare
9054
10019
Sky Factory
6063
Standard Imaging
7045
11067
12000
TGM2 Inc.
4013
6111
9012
US Radiosurgery
7087
Vantage Oncology
5095
5019
Vertual Ltd.
4085
ViewRay Inc.
12067
5087
Xstrahl Ltd.
4067
RADIOISOTOPE SOURCE MANUFACTURER
Biocompatibles Inc.
IBA
IsoAid LLC
8037
3019
6060
10067
SEARCH FIRM/STAFFING/RECRUITMENT
8015
Cancer Treatment Centers of America
10063
Department of Veterans Affairs (HRRO)
13010
13019
13019
Locumtenens.com5105
Maxim Government Services
12060
Mission Search
5072
Staff Care Inc.
13009
TREATMENT ACCESSORIES
A2J Laser America
11085
4077
Alphatron Linac
8008
Best Medical
4005, 6003 9079, 10031
International Inc.
Biocompatibles Inc.
8037
Brainlab5037
BSD Medical Corp.
6007
CDR Systems Inc.
3063
DIACOR4031
Eckert and Ziegler BEBIG
8094
Hitachi America Ltd
4084
IsoAid LLC
6060
6100
Medspira11060
6054
Micropos Medical AB
4073
MIM Software
3013
Mitsubishi Electric
8061
QLRAD11061
Radia-Guard3004
10049
S+S Par Scientific
7008
Sky Factory
6063
6058
TREATMENT PLANNING
Accuray Inc.
7101
6107
AQUILAB7095
Azimuth Therapy
2021
Best Medical
4005, 6003 9079, 10031
International Inc.
Brainlab5037
CIRS5101
10003
13031
Dana-Farber/Brigham and Women’s Cancer
7009
Center
8094
Elekta5067
GMV6101
IsoAid LLC
6060
LAP of America L.C.
3001
8119
LinaTech LLC
8086
Medspira11060
MIM Software
3013
Mirada Medical
5109
13037
Oncolink-University of Pennsylvania
10056
1031
10054
Philips Healthcare
10037
Precision X-Ray
5096
Prowess Inc.
10093
QUALIFORMED Sarl
7060
8055
3067
ScandiDos7055
TGM2 Inc.
4013
6111
5019
11073
ViewRay Inc.
12067
2012 ASTRO Annual Meeting | Boston Convention
Posters beyond this point in Hall C.
Concession Area
Concession Area
Cyber Cafe
202
and Exhibition Center | Halls A-B
Exhibitor Service
Center
ASTRO
Resource
Center
Industry-Expert Theater
Exhibitor Sales Office
and Lounge
EXHIBIT H
ALL HOUR
S
:00 p.m.
:00 a.m. – 5
Sunday: 10
5:00 p.m.
0:00 a.m. –
Monday: 1
5:00 p.m.
0:00 a.m. –
Tuesday: 1
203
NOTES
204
NOTES
205
A S T R O 5 4 TH A N N U A L M E E T I N G
through iNNOVATiON
Stop by the ASTRO Resource Center – Booth #8043
2012
CIRCLSURVIVOR
E
VISIT THE RESOURCE CENTER TO:
 See a demonstration of the new PQRIwizard, an easy online
tool for the Medicare PQRS program.
 Check out ROhub, the new ASTRO online community—have
your picture taken for the ASTRO membership directory and
set up your profile.
 Pick up free patient brochures and browse our patient
website RTAnswers.org.
 Purchase the ASTRO/ACR Guide to Radiation Oncology
Coding and multi-year Web subscription.
 Download the new Journals’ app to your smart phone
for full text access.
Stop b
y the S
urvivo
in the
r Circle
Resou
r
c
e Cent
more a
er. Lea
bout t
rn
his yea
Circle A
r
’s
Surviv
ward w
or
inner a
Surviv
nd the
or Circ
2
le
012
Grant
the va
recipie
luable
nts an
service
cancer
d
s they
patien
offer to
ts. Plus
drop o
, don’t
ff your
forget
stamp
for a ch
to
ed Pas
ance to
sport
win gr
eat priz
es.
ANNUAL MEE TING
A M E R I C A N S O C I E T Y F O R R A D I AT I O N O N C O LO G Y
meetings2013
STAY ON TOP OF WHAT’S NEW IN CANCER CARE
Cancer Imaging and Radiation Therapy Symposium:
A Multidisciplinary Approach
February 8-9, 2013
Hilton Lake Buena Vista in the Walt Disney World Resort | Orlando
Spring Refresher Course
March 22-24, 2013
JW Marriott Chicago | Chicago
State of the Art Techniques Symposium
May 17-19, 2013
San Antonio Marriott Rivercenter | San Antonio
ASTRO/AAPM/NCI Workshop:
Technology for Innovation in Radiation Oncology
June 13-14, 2013
NIH Campus | Bethesda, Md.
ASTRO’s 55th Annual Meeting
September 22-25, 2013
Georgia World Congress Center | Atlanta
Best of ASTRO
November 8-9, 2013
Hilton Bayfront San Diego | San Diego
TA R G E T I N G C A N C E R C A R E
www.astro.org
Free yourself from hours of tedious contouring.
Are you tired of spending hours manually contouring for each treatment plan? Philips
Pinnacle 3 Auto-Segmentation with SPICE streamlines the process to just a few
fast clicks. It provides consistent contours in minutes that require little or no editing.
Plus, it automatically identifies challenging structures
like head and neck nodes. Experience the freedom at
www.philips.com/SPICE.

Final Program - American Society for Radiation Oncology

Transcription

Similar documents

merrell moc speed streak

Program

2016 World Congress of Brachytherapy, San Francisco, CA

patients

- isott 2016

Journal 2260 - Patents Office

1 V erzeichnis der wissenschaftlichen Arbeiten 1974